primaryid,caseid,drug_seq,role_cod,drugname,prod_ai,val_vbm,route,dose_vbm,cum_dose_chr,cum_dose_unit,dechal,rechal,lot_num,exp_dt,nda_num,dose_amt,dose_unit,dose_form,dose_freq,year_x,quarter_x,pt,drug_rec_act,year_y,quarter_y,caseversion,i_f_code,event_dt,mfr_dt,init_fda_dt,fda_dt,rept_cod,auth_num,mfr_num,mfr_sndr,lit_ref,age,age_cod,age_grp,sex,e_sub,wt,wt_cod,rept_dt,to_mfr,occp_cod,reporter_country,occr_country,year,quarter,age_group
128582696,12858269,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Asthma,,2020,Q1,6,F,20160312.0,20200203.0,20161018,20200211,EXP,,JP-JNJFOC-20161013100,JOHNSON AND JOHNSON,,39.0,YR,,F,Y,86.0,KG,20200211.0,,MD,JP,JP,2020,Q1,Adult
128582696,12858269,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Borderline personality disorder,,2020,Q1,6,F,20160312.0,20200203.0,20161018,20200211,EXP,,JP-JNJFOC-20161013100,JOHNSON AND JOHNSON,,39.0,YR,,F,Y,86.0,KG,20200211.0,,MD,JP,JP,2020,Q1,Adult
128582696,12858269,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Facial paralysis,,2020,Q1,6,F,20160312.0,20200203.0,20161018,20200211,EXP,,JP-JNJFOC-20161013100,JOHNSON AND JOHNSON,,39.0,YR,,F,Y,86.0,KG,20200211.0,,MD,JP,JP,2020,Q1,Adult
130398446,13039844,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Atrial fibrillation,,2020,Q1,6,F,20160813.0,20200228.0,20161219,20200312,EXP,,JP-JNJFOC-20161201691,JOHNSON AND JOHNSON,,60.0,YR,,M,Y,85.0,KG,20200312.0,,MD,JP,JP,2020,Q1,Adult
130398446,13039844,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Prostatitis,,2020,Q1,6,F,20160813.0,20200228.0,20161219,20200312,EXP,,JP-JNJFOC-20161201691,JOHNSON AND JOHNSON,,60.0,YR,,M,Y,85.0,KG,20200312.0,,MD,JP,JP,2020,Q1,Adult
130398446,13039844,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Atrial fibrillation,,2020,Q1,6,F,20160813.0,20200228.0,20161219,20200312,EXP,,JP-JNJFOC-20161201691,JOHNSON AND JOHNSON,,60.0,YR,,M,Y,85.0,KG,20200312.0,,MD,JP,JP,2020,Q1,Adult
130398446,13039844,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Prostatitis,,2020,Q1,6,F,20160813.0,20200228.0,20161219,20200312,EXP,,JP-JNJFOC-20161201691,JOHNSON AND JOHNSON,,60.0,YR,,M,Y,85.0,KG,20200312.0,,MD,JP,JP,2020,Q1,Adult
141501506,14150150,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",17400.0,MG,U,,,,,100.0,MG,,QD,2020,Q1,Hyperglycaemia,,2020,Q1,6,F,20171017.0,20200313.0,20171101,20200318,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-096699,BRISTOL MYERS SQUIBB,,64.0,YR,,M,Y,66.67,KG,20200318.0,,HP,US,US,2020,Q1,Adult
141904254,14190425,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Aspartate aminotransferase increased,,2020,Q1,4,F,20151127.0,20200207.0,20171115,20200220,EXP,,JP-JNJFOC-20171109793,JOHNSON AND JOHNSON,,52.0,YR,,M,Y,96.0,KG,20200220.0,,HP,JP,JP,2020,Q1,Adult
141904254,14190425,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Blood alkaline phosphatase increased,,2020,Q1,4,F,20151127.0,20200207.0,20171115,20200220,EXP,,JP-JNJFOC-20171109793,JOHNSON AND JOHNSON,,52.0,YR,,M,Y,96.0,KG,20200220.0,,HP,JP,JP,2020,Q1,Adult
141904254,14190425,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Blood triglycerides increased,,2020,Q1,4,F,20151127.0,20200207.0,20171115,20200220,EXP,,JP-JNJFOC-20171109793,JOHNSON AND JOHNSON,,52.0,YR,,M,Y,96.0,KG,20200220.0,,HP,JP,JP,2020,Q1,Adult
141904254,14190425,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Muscle disorder,,2020,Q1,4,F,20151127.0,20200207.0,20171115,20200220,EXP,,JP-JNJFOC-20171109793,JOHNSON AND JOHNSON,,52.0,YR,,M,Y,96.0,KG,20200220.0,,HP,JP,JP,2020,Q1,Adult
141904254,14190425,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Urine ketone body present,,2020,Q1,4,F,20151127.0,20200207.0,20171115,20200220,EXP,,JP-JNJFOC-20171109793,JOHNSON AND JOHNSON,,52.0,YR,,M,Y,96.0,KG,20200220.0,,HP,JP,JP,2020,Q1,Adult
145779323,14577932,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Decreased appetite,,2020,Q1,3,F,20170112.0,20191225.0,20180227,20200212,EXP,,JP-JNJFOC-20180234242,JOHNSON AND JOHNSON,,52.0,YR,,F,Y,75.0,KG,20200212.0,,MD,JP,JP,2020,Q1,Adult
145779323,14577932,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Dizziness,,2020,Q1,3,F,20170112.0,20191225.0,20180227,20200212,EXP,,JP-JNJFOC-20180234242,JOHNSON AND JOHNSON,,52.0,YR,,F,Y,75.0,KG,20200212.0,,MD,JP,JP,2020,Q1,Adult
145779323,14577932,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Gastrooesophageal reflux disease,,2020,Q1,3,F,20170112.0,20191225.0,20180227,20200212,EXP,,JP-JNJFOC-20180234242,JOHNSON AND JOHNSON,,52.0,YR,,F,Y,75.0,KG,20200212.0,,MD,JP,JP,2020,Q1,Adult
145779323,14577932,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Urine ketone body,,2020,Q1,3,F,20170112.0,20191225.0,20180227,20200212,EXP,,JP-JNJFOC-20180234242,JOHNSON AND JOHNSON,,52.0,YR,,F,Y,75.0,KG,20200212.0,,MD,JP,JP,2020,Q1,Adult
145779323,14577932,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Vertigo,,2020,Q1,3,F,20170112.0,20191225.0,20180227,20200212,EXP,,JP-JNJFOC-20180234242,JOHNSON AND JOHNSON,,52.0,YR,,F,Y,75.0,KG,20200212.0,,MD,JP,JP,2020,Q1,Adult
158382182,15838218,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Dyslipidaemia,,2020,Q1,2,F,201608.0,20200228.0,20190117,20200312,EXP,,JP-JNJFOC-20190120752,JOHNSON AND JOHNSON,,55.0,YR,,M,Y,83.0,KG,20200312.0,,MD,JP,JP,2020,Q1,Adult
158382182,15838218,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Thyroid cancer,,2020,Q1,2,F,201608.0,20200228.0,20190117,20200312,EXP,,JP-JNJFOC-20190120752,JOHNSON AND JOHNSON,,55.0,YR,,M,Y,83.0,KG,20200312.0,,MD,JP,JP,2020,Q1,Adult
160430154,16043015,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Diarrhoea,,2020,Q1,4,F,201708.0,20200109.0,20190306,20200122,EXP,,JP-JNJFOC-20180316192,JOHNSON AND JOHNSON,,44.0,YR,,F,Y,,,20200122.0,,MD,JP,JP,2020,Q1,Adult
160430154,16043015,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Intervertebral disc protrusion,,2020,Q1,4,F,201708.0,20200109.0,20190306,20200122,EXP,,JP-JNJFOC-20180316192,JOHNSON AND JOHNSON,,44.0,YR,,F,Y,,,20200122.0,,MD,JP,JP,2020,Q1,Adult
160430154,16043015,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Low density lipoprotein increased,,2020,Q1,4,F,201708.0,20200109.0,20190306,20200122,EXP,,JP-JNJFOC-20180316192,JOHNSON AND JOHNSON,,44.0,YR,,F,Y,,,20200122.0,,MD,JP,JP,2020,Q1,Adult
160430154,16043015,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Neurogenic bladder,,2020,Q1,4,F,201708.0,20200109.0,20190306,20200122,EXP,,JP-JNJFOC-20180316192,JOHNSON AND JOHNSON,,44.0,YR,,F,Y,,,20200122.0,,MD,JP,JP,2020,Q1,Adult
160430154,16043015,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Pain in extremity,,2020,Q1,4,F,201708.0,20200109.0,20190306,20200122,EXP,,JP-JNJFOC-20180316192,JOHNSON AND JOHNSON,,44.0,YR,,F,Y,,,20200122.0,,MD,JP,JP,2020,Q1,Adult
160430154,16043015,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Urinary incontinence,,2020,Q1,4,F,201708.0,20200109.0,20190306,20200122,EXP,,JP-JNJFOC-20180316192,JOHNSON AND JOHNSON,,44.0,YR,,F,Y,,,20200122.0,,MD,JP,JP,2020,Q1,Adult
161483832,16148383,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,300.0,MG,FILM-COATED TABLET,,2020,Q1,Fournier's gangrene,,2020,Q1,2,F,20180709.0,20200311.0,20190402,20200313,EXP,GB-MHRA-EYC 00196667,GB-JNJFOC-20190342411,JOHNSON AND JOHNSON,,64.0,YR,,M,Y,123.0,KG,20200313.0,,MD,GB,GB,2020,Q1,Adult
161913334,16191333,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204042.0,100.0,MG,TABLET,QD,2020,Q1,Cystitis,,2020,Q1,4,F,20160122.0,20200121.0,20190412,20200131,EXP,,JP-JNJFOC-20170703763,JOHNSON AND JOHNSON,,74.0,YR,,F,Y,76.0,KG,20200131.0,,MD,JP,JP,2020,Q1,Elderly
161913334,16191333,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204042.0,100.0,MG,TABLET,QD,2020,Q1,Dementia Alzheimer's type,,2020,Q1,4,F,20160122.0,20200121.0,20190412,20200131,EXP,,JP-JNJFOC-20170703763,JOHNSON AND JOHNSON,,74.0,YR,,F,Y,76.0,KG,20200131.0,,MD,JP,JP,2020,Q1,Elderly
162057364,16205736,6,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,"300 MILLIGRAM, ONCE A DAY",,,U,U,,,,300.0,MG,,QD,2020,Q1,Acute kidney injury,,2020,Q1,4,F,,20200207.0,20190417,20200218,EXP,,CA-AUROBINDO-AUR-APL-2019-019847,AUROBINDO,,37.0,YR,,F,Y,158.0,KG,20200218.0,,PH,CA,CA,2020,Q1,Adult
162057364,16205736,6,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,"300 MILLIGRAM, ONCE A DAY",,,U,U,,,,300.0,MG,,QD,2020,Q1,Sepsis,,2020,Q1,4,F,,20200207.0,20190417,20200218,EXP,,CA-AUROBINDO-AUR-APL-2019-019847,AUROBINDO,,37.0,YR,,F,Y,158.0,KG,20200218.0,,PH,CA,CA,2020,Q1,Adult
164110213,16411021,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Interstitial lung disease,,2020,Q1,3,F,20160514.0,20200310.0,20190610,20200324,EXP,,JP-JNJFOC-20190314109,JOHNSON AND JOHNSON,,68.0,YR,,M,Y,,,20200324.0,,MD,JP,JP,2020,Q1,Elderly
164110213,16411021,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Lung neoplasm malignant,,2020,Q1,3,F,20160514.0,20200310.0,20190610,20200324,EXP,,JP-JNJFOC-20190314109,JOHNSON AND JOHNSON,,68.0,YR,,M,Y,,,20200324.0,,MD,JP,JP,2020,Q1,Elderly
164146003,16414600,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Chronic hepatic failure,,2020,Q1,3,F,2017.0,20200225.0,20190611,20200306,EXP,,JP-JNJFOC-20190612408,JOHNSON AND JOHNSON,,71.0,YR,,F,Y,,,20200306.0,,MD,JP,JP,2020,Q1,Elderly
164833193,16483319,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Atrial fibrillation,,2020,Q1,3,F,20171204.0,20200212.0,20190627,20200221,EXP,,JP-JNJFOC-20190629283,JOHNSON AND JOHNSON,,59.0,YR,,M,Y,,,20200221.0,,MD,JP,JP,2020,Q1,Adult
165715843,16571584,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Diplegia,,2020,Q1,3,F,20180612.0,20200130.0,20190715,20200207,EXP,,JP-JNJFOC-20190712323,JOHNSON AND JOHNSON,,49.0,YR,,M,Y,,,20200207.0,,MD,JP,JP,2020,Q1,Adult
166605262,16660526,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",90400.0,MG,,,,,204042.0,100.0,MG,TABLET,QD,2020,Q1,Gastric cancer,,2020,Q1,2,F,20180705.0,20200122.0,20190802,20200131,EXP,,JP-JNJFOC-20190800134,JOHNSON AND JOHNSON,,66.0,YR,,M,Y,,,20200131.0,,MD,JP,JP,2020,Q1,Elderly
166770712,16677071,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",75300.0,MG,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Subdural haematoma,,2020,Q1,2,F,20180224.0,20200106.0,20190807,20200114,EXP,,JP-JNJFOC-20190806795,JOHNSON AND JOHNSON,,95.0,YR,,M,Y,,,20200114.0,,MD,JP,JP,2020,Q1,Elderly
167244262,16724426,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Bronchitis,,2020,Q1,2,F,20190111.0,20200205.0,20190821,20200214,EXP,,JP-JNJFOC-20190811690,JOHNSON AND JOHNSON,,70.0,YR,,,Y,,,20200214.0,,MD,JP,JP,2020,Q1,Elderly
167244262,16724426,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Cataract,,2020,Q1,2,F,20190111.0,20200205.0,20190821,20200214,EXP,,JP-JNJFOC-20190811690,JOHNSON AND JOHNSON,,70.0,YR,,,Y,,,20200214.0,,MD,JP,JP,2020,Q1,Elderly
167244262,16724426,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Herpes zoster,,2020,Q1,2,F,20190111.0,20200205.0,20190821,20200214,EXP,,JP-JNJFOC-20190811690,JOHNSON AND JOHNSON,,70.0,YR,,,Y,,,20200214.0,,MD,JP,JP,2020,Q1,Elderly
168347762,16834776,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Hypertension,,2020,Q1,2,F,20170531.0,20200206.0,20190920,20200218,EXP,,JP-JNJFOC-20180514939,JOHNSON AND JOHNSON,,79.0,YR,,F,Y,52.0,KG,20200218.0,,MD,JP,JP,2020,Q1,Elderly
168347762,16834776,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Myocardial infarction,,2020,Q1,2,F,20170531.0,20200206.0,20190920,20200218,EXP,,JP-JNJFOC-20180514939,JOHNSON AND JOHNSON,,79.0,YR,,F,Y,52.0,KG,20200218.0,,MD,JP,JP,2020,Q1,Elderly
168977066,16897706,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2020,Q1,Acute kidney injury,,2020,Q1,6,F,,20200110.0,20191009,20200120,EXP,,PT-AUROBINDO-AUR-APL-2019-064795,AUROBINDO,,76.0,YR,,M,Y,,,20200120.0,,HP,PT,PT,2020,Q1,Elderly
168977066,16897706,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2020,Q1,Blood bicarbonate decreased,,2020,Q1,6,F,,20200110.0,20191009,20200120,EXP,,PT-AUROBINDO-AUR-APL-2019-064795,AUROBINDO,,76.0,YR,,M,Y,,,20200120.0,,HP,PT,PT,2020,Q1,Elderly
168977066,16897706,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2020,Q1,Blood lactic acid increased,,2020,Q1,6,F,,20200110.0,20191009,20200120,EXP,,PT-AUROBINDO-AUR-APL-2019-064795,AUROBINDO,,76.0,YR,,M,Y,,,20200120.0,,HP,PT,PT,2020,Q1,Elderly
168977066,16897706,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2020,Q1,Dyspnoea,,2020,Q1,6,F,,20200110.0,20191009,20200120,EXP,,PT-AUROBINDO-AUR-APL-2019-064795,AUROBINDO,,76.0,YR,,M,Y,,,20200120.0,,HP,PT,PT,2020,Q1,Elderly
168977066,16897706,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2020,Q1,Emotional distress,,2020,Q1,6,F,,20200110.0,20191009,20200120,EXP,,PT-AUROBINDO-AUR-APL-2019-064795,AUROBINDO,,76.0,YR,,M,Y,,,20200120.0,,HP,PT,PT,2020,Q1,Elderly
168977066,16897706,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2020,Q1,Fatigue,,2020,Q1,6,F,,20200110.0,20191009,20200120,EXP,,PT-AUROBINDO-AUR-APL-2019-064795,AUROBINDO,,76.0,YR,,M,Y,,,20200120.0,,HP,PT,PT,2020,Q1,Elderly
168977066,16897706,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2020,Q1,Hyperhidrosis,,2020,Q1,6,F,,20200110.0,20191009,20200120,EXP,,PT-AUROBINDO-AUR-APL-2019-064795,AUROBINDO,,76.0,YR,,M,Y,,,20200120.0,,HP,PT,PT,2020,Q1,Elderly
168977066,16897706,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2020,Q1,Hypotension,,2020,Q1,6,F,,20200110.0,20191009,20200120,EXP,,PT-AUROBINDO-AUR-APL-2019-064795,AUROBINDO,,76.0,YR,,M,Y,,,20200120.0,,HP,PT,PT,2020,Q1,Elderly
168977066,16897706,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2020,Q1,Lactic acidosis,,2020,Q1,6,F,,20200110.0,20191009,20200120,EXP,,PT-AUROBINDO-AUR-APL-2019-064795,AUROBINDO,,76.0,YR,,M,Y,,,20200120.0,,HP,PT,PT,2020,Q1,Elderly
168977066,16897706,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2020,Q1,Metabolic acidosis,,2020,Q1,6,F,,20200110.0,20191009,20200120,EXP,,PT-AUROBINDO-AUR-APL-2019-064795,AUROBINDO,,76.0,YR,,M,Y,,,20200120.0,,HP,PT,PT,2020,Q1,Elderly
168977066,16897706,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2020,Q1,Pallor,,2020,Q1,6,F,,20200110.0,20191009,20200120,EXP,,PT-AUROBINDO-AUR-APL-2019-064795,AUROBINDO,,76.0,YR,,M,Y,,,20200120.0,,HP,PT,PT,2020,Q1,Elderly
168977066,16897706,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2020,Q1,Palpitations,,2020,Q1,6,F,,20200110.0,20191009,20200120,EXP,,PT-AUROBINDO-AUR-APL-2019-064795,AUROBINDO,,76.0,YR,,M,Y,,,20200120.0,,HP,PT,PT,2020,Q1,Elderly
168977066,16897706,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2020,Q1,Vomiting,,2020,Q1,6,F,,20200110.0,20191009,20200120,EXP,,PT-AUROBINDO-AUR-APL-2019-064795,AUROBINDO,,76.0,YR,,M,Y,,,20200120.0,,HP,PT,PT,2020,Q1,Elderly
169004802,16900480,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2020,Q1,Acute kidney injury,,2020,Q1,2,F,,20200104.0,20191009,20200109,EXP,,PT-MYLANLABS-2019M1094528,MYLAN,"SANTOS M. B., GARCA M., COTA P., AVILA P, SANTOS A.. LACTIC ACIDOSIS ASSOCIATED TO METFORMIN, WITH ACUTE RENAL INJURY BY IATROGENIC HYPOTENSION. THE ENDOCRINE AND METABOLIC DISEASES. 2019",76.0,YR,,M,Y,,,20200109.0,,HP,PT,PT,2020,Q1,Elderly
169004802,16900480,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2020,Q1,Blood bicarbonate decreased,,2020,Q1,2,F,,20200104.0,20191009,20200109,EXP,,PT-MYLANLABS-2019M1094528,MYLAN,"SANTOS M. B., GARCA M., COTA P., AVILA P, SANTOS A.. LACTIC ACIDOSIS ASSOCIATED TO METFORMIN, WITH ACUTE RENAL INJURY BY IATROGENIC HYPOTENSION. THE ENDOCRINE AND METABOLIC DISEASES. 2019",76.0,YR,,M,Y,,,20200109.0,,HP,PT,PT,2020,Q1,Elderly
169004802,16900480,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2020,Q1,Blood lactic acid increased,,2020,Q1,2,F,,20200104.0,20191009,20200109,EXP,,PT-MYLANLABS-2019M1094528,MYLAN,"SANTOS M. B., GARCA M., COTA P., AVILA P, SANTOS A.. LACTIC ACIDOSIS ASSOCIATED TO METFORMIN, WITH ACUTE RENAL INJURY BY IATROGENIC HYPOTENSION. THE ENDOCRINE AND METABOLIC DISEASES. 2019",76.0,YR,,M,Y,,,20200109.0,,HP,PT,PT,2020,Q1,Elderly
169004802,16900480,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2020,Q1,Dyspnoea,,2020,Q1,2,F,,20200104.0,20191009,20200109,EXP,,PT-MYLANLABS-2019M1094528,MYLAN,"SANTOS M. B., GARCA M., COTA P., AVILA P, SANTOS A.. LACTIC ACIDOSIS ASSOCIATED TO METFORMIN, WITH ACUTE RENAL INJURY BY IATROGENIC HYPOTENSION. THE ENDOCRINE AND METABOLIC DISEASES. 2019",76.0,YR,,M,Y,,,20200109.0,,HP,PT,PT,2020,Q1,Elderly
169004802,16900480,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2020,Q1,Emotional distress,,2020,Q1,2,F,,20200104.0,20191009,20200109,EXP,,PT-MYLANLABS-2019M1094528,MYLAN,"SANTOS M. B., GARCA M., COTA P., AVILA P, SANTOS A.. LACTIC ACIDOSIS ASSOCIATED TO METFORMIN, WITH ACUTE RENAL INJURY BY IATROGENIC HYPOTENSION. THE ENDOCRINE AND METABOLIC DISEASES. 2019",76.0,YR,,M,Y,,,20200109.0,,HP,PT,PT,2020,Q1,Elderly
169004802,16900480,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2020,Q1,Fatigue,,2020,Q1,2,F,,20200104.0,20191009,20200109,EXP,,PT-MYLANLABS-2019M1094528,MYLAN,"SANTOS M. B., GARCA M., COTA P., AVILA P, SANTOS A.. LACTIC ACIDOSIS ASSOCIATED TO METFORMIN, WITH ACUTE RENAL INJURY BY IATROGENIC HYPOTENSION. THE ENDOCRINE AND METABOLIC DISEASES. 2019",76.0,YR,,M,Y,,,20200109.0,,HP,PT,PT,2020,Q1,Elderly
169004802,16900480,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2020,Q1,Hyperhidrosis,,2020,Q1,2,F,,20200104.0,20191009,20200109,EXP,,PT-MYLANLABS-2019M1094528,MYLAN,"SANTOS M. B., GARCA M., COTA P., AVILA P, SANTOS A.. LACTIC ACIDOSIS ASSOCIATED TO METFORMIN, WITH ACUTE RENAL INJURY BY IATROGENIC HYPOTENSION. THE ENDOCRINE AND METABOLIC DISEASES. 2019",76.0,YR,,M,Y,,,20200109.0,,HP,PT,PT,2020,Q1,Elderly
169004802,16900480,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2020,Q1,Hypotension,,2020,Q1,2,F,,20200104.0,20191009,20200109,EXP,,PT-MYLANLABS-2019M1094528,MYLAN,"SANTOS M. B., GARCA M., COTA P., AVILA P, SANTOS A.. LACTIC ACIDOSIS ASSOCIATED TO METFORMIN, WITH ACUTE RENAL INJURY BY IATROGENIC HYPOTENSION. THE ENDOCRINE AND METABOLIC DISEASES. 2019",76.0,YR,,M,Y,,,20200109.0,,HP,PT,PT,2020,Q1,Elderly
169004802,16900480,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2020,Q1,Lactic acidosis,,2020,Q1,2,F,,20200104.0,20191009,20200109,EXP,,PT-MYLANLABS-2019M1094528,MYLAN,"SANTOS M. B., GARCA M., COTA P., AVILA P, SANTOS A.. LACTIC ACIDOSIS ASSOCIATED TO METFORMIN, WITH ACUTE RENAL INJURY BY IATROGENIC HYPOTENSION. THE ENDOCRINE AND METABOLIC DISEASES. 2019",76.0,YR,,M,Y,,,20200109.0,,HP,PT,PT,2020,Q1,Elderly
169004802,16900480,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2020,Q1,Metabolic acidosis,,2020,Q1,2,F,,20200104.0,20191009,20200109,EXP,,PT-MYLANLABS-2019M1094528,MYLAN,"SANTOS M. B., GARCA M., COTA P., AVILA P, SANTOS A.. LACTIC ACIDOSIS ASSOCIATED TO METFORMIN, WITH ACUTE RENAL INJURY BY IATROGENIC HYPOTENSION. THE ENDOCRINE AND METABOLIC DISEASES. 2019",76.0,YR,,M,Y,,,20200109.0,,HP,PT,PT,2020,Q1,Elderly
169004802,16900480,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2020,Q1,Pallor,,2020,Q1,2,F,,20200104.0,20191009,20200109,EXP,,PT-MYLANLABS-2019M1094528,MYLAN,"SANTOS M. B., GARCA M., COTA P., AVILA P, SANTOS A.. LACTIC ACIDOSIS ASSOCIATED TO METFORMIN, WITH ACUTE RENAL INJURY BY IATROGENIC HYPOTENSION. THE ENDOCRINE AND METABOLIC DISEASES. 2019",76.0,YR,,M,Y,,,20200109.0,,HP,PT,PT,2020,Q1,Elderly
169004802,16900480,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2020,Q1,Palpitations,,2020,Q1,2,F,,20200104.0,20191009,20200109,EXP,,PT-MYLANLABS-2019M1094528,MYLAN,"SANTOS M. B., GARCA M., COTA P., AVILA P, SANTOS A.. LACTIC ACIDOSIS ASSOCIATED TO METFORMIN, WITH ACUTE RENAL INJURY BY IATROGENIC HYPOTENSION. THE ENDOCRINE AND METABOLIC DISEASES. 2019",76.0,YR,,M,Y,,,20200109.0,,HP,PT,PT,2020,Q1,Elderly
169004802,16900480,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2020,Q1,Vomiting,,2020,Q1,2,F,,20200104.0,20191009,20200109,EXP,,PT-MYLANLABS-2019M1094528,MYLAN,"SANTOS M. B., GARCA M., COTA P., AVILA P, SANTOS A.. LACTIC ACIDOSIS ASSOCIATED TO METFORMIN, WITH ACUTE RENAL INJURY BY IATROGENIC HYPOTENSION. THE ENDOCRINE AND METABOLIC DISEASES. 2019",76.0,YR,,M,Y,,,20200109.0,,HP,PT,PT,2020,Q1,Elderly
169160322,16916032,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Eczema,,2020,Q1,2,F,20190303.0,20200106.0,20191014,20200114,EXP,,JP-JNJFOC-20191018377,JOHNSON AND JOHNSON,,63.0,YR,,F,Y,,,20200114.0,,MD,JP,JP,2020,Q1,Adult
169160322,16916032,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Facial paralysis,,2020,Q1,2,F,20190303.0,20200106.0,20191014,20200114,EXP,,JP-JNJFOC-20191018377,JOHNSON AND JOHNSON,,63.0,YR,,F,Y,,,20200114.0,,MD,JP,JP,2020,Q1,Adult
170115303,17011530,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Albumin urine present,,2020,Q1,3,F,20170208.0,20200107.0,20191108,20200115,EXP,,JP-JNJFOC-20170613392,JOHNSON AND JOHNSON,,76.0,YR,,M,Y,83.0,KG,20200115.0,,HP,JP,JP,2020,Q1,Elderly
170115303,17011530,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Blood ketone body increased,,2020,Q1,3,F,20170208.0,20200107.0,20191108,20200115,EXP,,JP-JNJFOC-20170613392,JOHNSON AND JOHNSON,,76.0,YR,,M,Y,83.0,KG,20200115.0,,HP,JP,JP,2020,Q1,Elderly
170115303,17011530,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Blood pressure increased,,2020,Q1,3,F,20170208.0,20200107.0,20191108,20200115,EXP,,JP-JNJFOC-20170613392,JOHNSON AND JOHNSON,,76.0,YR,,M,Y,83.0,KG,20200115.0,,HP,JP,JP,2020,Q1,Elderly
170115303,17011530,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Constipation,,2020,Q1,3,F,20170208.0,20200107.0,20191108,20200115,EXP,,JP-JNJFOC-20170613392,JOHNSON AND JOHNSON,,76.0,YR,,M,Y,83.0,KG,20200115.0,,HP,JP,JP,2020,Q1,Elderly
170115303,17011530,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Lumbar spinal stenosis,,2020,Q1,3,F,20170208.0,20200107.0,20191108,20200115,EXP,,JP-JNJFOC-20170613392,JOHNSON AND JOHNSON,,76.0,YR,,M,Y,83.0,KG,20200115.0,,HP,JP,JP,2020,Q1,Elderly
170115303,17011530,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Albumin urine present,,2020,Q1,3,F,20170208.0,20200107.0,20191108,20200115,EXP,,JP-JNJFOC-20170613392,JOHNSON AND JOHNSON,,76.0,YR,,M,Y,83.0,KG,20200115.0,,HP,JP,JP,2020,Q1,Elderly
170115303,17011530,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Blood ketone body increased,,2020,Q1,3,F,20170208.0,20200107.0,20191108,20200115,EXP,,JP-JNJFOC-20170613392,JOHNSON AND JOHNSON,,76.0,YR,,M,Y,83.0,KG,20200115.0,,HP,JP,JP,2020,Q1,Elderly
170115303,17011530,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Blood pressure increased,,2020,Q1,3,F,20170208.0,20200107.0,20191108,20200115,EXP,,JP-JNJFOC-20170613392,JOHNSON AND JOHNSON,,76.0,YR,,M,Y,83.0,KG,20200115.0,,HP,JP,JP,2020,Q1,Elderly
170115303,17011530,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Constipation,,2020,Q1,3,F,20170208.0,20200107.0,20191108,20200115,EXP,,JP-JNJFOC-20170613392,JOHNSON AND JOHNSON,,76.0,YR,,M,Y,83.0,KG,20200115.0,,HP,JP,JP,2020,Q1,Elderly
170115303,17011530,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Lumbar spinal stenosis,,2020,Q1,3,F,20170208.0,20200107.0,20191108,20200115,EXP,,JP-JNJFOC-20170613392,JOHNSON AND JOHNSON,,76.0,YR,,M,Y,83.0,KG,20200115.0,,HP,JP,JP,2020,Q1,Elderly
170690192,17069019,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD (EVERY MORNING BEFORE FIRST MEAL OF THE DAY) (30 TABLETS, 11 REFILLS)",,,U,,,,,300.0,MG,TABLET,QD,2020,Q1,Asthenia,,2020,Q1,2,F,20191002.0,20200103.0,20191124,20200106,EXP,,NVSC2019US042298,NOVARTIS,,71.0,YR,,M,Y,84.8,KG,20200106.0,,CN,COUNTRY NOT SPECIFIED,US,2020,Q1,Elderly
170690192,17069019,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD (EVERY MORNING BEFORE FIRST MEAL OF THE DAY) (30 TABLETS, 11 REFILLS)",,,U,,,,,300.0,MG,TABLET,QD,2020,Q1,Ill-defined disorder,,2020,Q1,2,F,20191002.0,20200103.0,20191124,20200106,EXP,,NVSC2019US042298,NOVARTIS,,71.0,YR,,M,Y,84.8,KG,20200106.0,,CN,COUNTRY NOT SPECIFIED,US,2020,Q1,Elderly
170690192,17069019,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD (EVERY MORNING BEFORE FIRST MEAL OF THE DAY) (30 TABLETS, 11 REFILLS)",,,U,,,,,300.0,MG,TABLET,QD,2020,Q1,Immunodeficiency,,2020,Q1,2,F,20191002.0,20200103.0,20191124,20200106,EXP,,NVSC2019US042298,NOVARTIS,,71.0,YR,,M,Y,84.8,KG,20200106.0,,CN,COUNTRY NOT SPECIFIED,US,2020,Q1,Elderly
170690192,17069019,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD (EVERY MORNING BEFORE FIRST MEAL OF THE DAY) (30 TABLETS, 11 REFILLS)",,,U,,,,,300.0,MG,TABLET,QD,2020,Q1,Lethargy,,2020,Q1,2,F,20191002.0,20200103.0,20191124,20200106,EXP,,NVSC2019US042298,NOVARTIS,,71.0,YR,,M,Y,84.8,KG,20200106.0,,CN,COUNTRY NOT SPECIFIED,US,2020,Q1,Elderly
170690192,17069019,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD (EVERY MORNING BEFORE FIRST MEAL OF THE DAY) (30 TABLETS, 11 REFILLS)",,,U,,,,,300.0,MG,TABLET,QD,2020,Q1,Malaise,,2020,Q1,2,F,20191002.0,20200103.0,20191124,20200106,EXP,,NVSC2019US042298,NOVARTIS,,71.0,YR,,M,Y,84.8,KG,20200106.0,,CN,COUNTRY NOT SPECIFIED,US,2020,Q1,Elderly
170690192,17069019,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD (EVERY MORNING BEFORE FIRST MEAL OF THE DAY) (30 TABLETS, 11 REFILLS)",,,U,,,,,300.0,MG,TABLET,QD,2020,Q1,Movement disorder,,2020,Q1,2,F,20191002.0,20200103.0,20191124,20200106,EXP,,NVSC2019US042298,NOVARTIS,,71.0,YR,,M,Y,84.8,KG,20200106.0,,CN,COUNTRY NOT SPECIFIED,US,2020,Q1,Elderly
170690192,17069019,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD (EVERY MORNING BEFORE FIRST MEAL OF THE DAY) (30 TABLETS, 11 REFILLS)",,,U,,,,,300.0,MG,TABLET,QD,2020,Q1,Nausea,,2020,Q1,2,F,20191002.0,20200103.0,20191124,20200106,EXP,,NVSC2019US042298,NOVARTIS,,71.0,YR,,M,Y,84.8,KG,20200106.0,,CN,COUNTRY NOT SPECIFIED,US,2020,Q1,Elderly
171418332,17141833,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Interstitial lung disease,,2020,Q1,2,F,201404.0,20200203.0,20191211,20200211,EXP,,JP-JNJFOC-20191210697,JOHNSON AND JOHNSON,,69.0,YR,,M,Y,,,20200211.0,,PH,JP,JP,2020,Q1,Elderly
171427572,17142757,4,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,U,,,,100.0,MG,,QD,2020,Q1,Acute kidney injury,,2020,Q1,2,F,,20200120.0,20191211,20200122,EXP,,NVSC2019PT057912,NOVARTIS,,76.0,YR,,M,Y,,,20200122.0,,HP,PT,PT,2020,Q1,Elderly
171427572,17142757,4,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,U,,,,100.0,MG,,QD,2020,Q1,Blood bicarbonate decreased,,2020,Q1,2,F,,20200120.0,20191211,20200122,EXP,,NVSC2019PT057912,NOVARTIS,,76.0,YR,,M,Y,,,20200122.0,,HP,PT,PT,2020,Q1,Elderly
171427572,17142757,4,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,U,,,,100.0,MG,,QD,2020,Q1,Blood lactic acid increased,,2020,Q1,2,F,,20200120.0,20191211,20200122,EXP,,NVSC2019PT057912,NOVARTIS,,76.0,YR,,M,Y,,,20200122.0,,HP,PT,PT,2020,Q1,Elderly
171427572,17142757,4,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,U,,,,100.0,MG,,QD,2020,Q1,Dyspnoea,,2020,Q1,2,F,,20200120.0,20191211,20200122,EXP,,NVSC2019PT057912,NOVARTIS,,76.0,YR,,M,Y,,,20200122.0,,HP,PT,PT,2020,Q1,Elderly
171427572,17142757,4,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,U,,,,100.0,MG,,QD,2020,Q1,Emotional distress,,2020,Q1,2,F,,20200120.0,20191211,20200122,EXP,,NVSC2019PT057912,NOVARTIS,,76.0,YR,,M,Y,,,20200122.0,,HP,PT,PT,2020,Q1,Elderly
171427572,17142757,4,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,U,,,,100.0,MG,,QD,2020,Q1,Fatigue,,2020,Q1,2,F,,20200120.0,20191211,20200122,EXP,,NVSC2019PT057912,NOVARTIS,,76.0,YR,,M,Y,,,20200122.0,,HP,PT,PT,2020,Q1,Elderly
171427572,17142757,4,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,U,,,,100.0,MG,,QD,2020,Q1,Hyperhidrosis,,2020,Q1,2,F,,20200120.0,20191211,20200122,EXP,,NVSC2019PT057912,NOVARTIS,,76.0,YR,,M,Y,,,20200122.0,,HP,PT,PT,2020,Q1,Elderly
171427572,17142757,4,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,U,,,,100.0,MG,,QD,2020,Q1,Hypotension,,2020,Q1,2,F,,20200120.0,20191211,20200122,EXP,,NVSC2019PT057912,NOVARTIS,,76.0,YR,,M,Y,,,20200122.0,,HP,PT,PT,2020,Q1,Elderly
171427572,17142757,4,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,U,,,,100.0,MG,,QD,2020,Q1,Lactic acidosis,,2020,Q1,2,F,,20200120.0,20191211,20200122,EXP,,NVSC2019PT057912,NOVARTIS,,76.0,YR,,M,Y,,,20200122.0,,HP,PT,PT,2020,Q1,Elderly
171427572,17142757,4,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,U,,,,100.0,MG,,QD,2020,Q1,Metabolic acidosis,,2020,Q1,2,F,,20200120.0,20191211,20200122,EXP,,NVSC2019PT057912,NOVARTIS,,76.0,YR,,M,Y,,,20200122.0,,HP,PT,PT,2020,Q1,Elderly
171427572,17142757,4,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,U,,,,100.0,MG,,QD,2020,Q1,Pallor,,2020,Q1,2,F,,20200120.0,20191211,20200122,EXP,,NVSC2019PT057912,NOVARTIS,,76.0,YR,,M,Y,,,20200122.0,,HP,PT,PT,2020,Q1,Elderly
171427572,17142757,4,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,U,,,,100.0,MG,,QD,2020,Q1,Palpitations,,2020,Q1,2,F,,20200120.0,20191211,20200122,EXP,,NVSC2019PT057912,NOVARTIS,,76.0,YR,,M,Y,,,20200122.0,,HP,PT,PT,2020,Q1,Elderly
171427572,17142757,4,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,U,,,,100.0,MG,,QD,2020,Q1,Vomiting,,2020,Q1,2,F,,20200120.0,20191211,20200122,EXP,,NVSC2019PT057912,NOVARTIS,,76.0,YR,,M,Y,,,20200122.0,,HP,PT,PT,2020,Q1,Elderly
171598122,17159812,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Angina pectoris,,2020,Q1,2,F,20161214.0,20200106.0,20191216,20200109,EXP,,JP-JNJFOC-20170203702,JOHNSON AND JOHNSON,,49.0,YR,,M,Y,81.0,KG,20200109.0,,MD,JP,JP,2020,Q1,Adult
171598122,17159812,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Blood glucose increased,,2020,Q1,2,F,20161214.0,20200106.0,20191216,20200109,EXP,,JP-JNJFOC-20170203702,JOHNSON AND JOHNSON,,49.0,YR,,M,Y,81.0,KG,20200109.0,,MD,JP,JP,2020,Q1,Adult
171695792,17169579,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",48300.0,MG,U,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Anxiety disorder,,2020,Q1,2,F,20171106.0,20200212.0,20191218,20200220,EXP,,JP-JNJFOC-20191226571,JOHNSON AND JOHNSON,,42.0,YR,,F,Y,,,20200220.0,,MD,JP,JP,2020,Q1,Adult
171695792,17169579,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",48300.0,MG,U,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Gastric ulcer,,2020,Q1,2,F,20171106.0,20200212.0,20191218,20200220,EXP,,JP-JNJFOC-20191226571,JOHNSON AND JOHNSON,,42.0,YR,,F,Y,,,20200220.0,,MD,JP,JP,2020,Q1,Adult
171695792,17169579,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",48300.0,MG,U,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Insomnia,,2020,Q1,2,F,20171106.0,20200212.0,20191218,20200220,EXP,,JP-JNJFOC-20191226571,JOHNSON AND JOHNSON,,42.0,YR,,F,Y,,,20200220.0,,MD,JP,JP,2020,Q1,Adult
171695792,17169579,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,48300.0,MG,U,U,,,204042.0,1.0,DF,FILM-COATED TABLET,QD,2020,Q1,Anxiety disorder,,2020,Q1,2,F,20171106.0,20200212.0,20191218,20200220,EXP,,JP-JNJFOC-20191226571,JOHNSON AND JOHNSON,,42.0,YR,,F,Y,,,20200220.0,,MD,JP,JP,2020,Q1,Adult
171695792,17169579,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,48300.0,MG,U,U,,,204042.0,1.0,DF,FILM-COATED TABLET,QD,2020,Q1,Gastric ulcer,,2020,Q1,2,F,20171106.0,20200212.0,20191218,20200220,EXP,,JP-JNJFOC-20191226571,JOHNSON AND JOHNSON,,42.0,YR,,F,Y,,,20200220.0,,MD,JP,JP,2020,Q1,Adult
171695792,17169579,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,48300.0,MG,U,U,,,204042.0,1.0,DF,FILM-COATED TABLET,QD,2020,Q1,Insomnia,,2020,Q1,2,F,20171106.0,20200212.0,20191218,20200220,EXP,,JP-JNJFOC-20191226571,JOHNSON AND JOHNSON,,42.0,YR,,F,Y,,,20200220.0,,MD,JP,JP,2020,Q1,Adult
172162862,17216286,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",51800.0,MG,D,,,,204042.0,100.0,MG,TABLET,QD,2020,Q1,Atrial fibrillation,,2020,Q1,2,F,20161026.0,20200129.0,20191230,20200207,EXP,,JP-JNJFOC-20191246449,JOHNSON AND JOHNSON,,41.0,YR,,M,Y,,,20200207.0,,MD,JP,JP,2020,Q1,Adult
172162862,17216286,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",51800.0,MG,D,,,,204042.0,100.0,MG,TABLET,QD,2020,Q1,Hepatic function abnormal,,2020,Q1,2,F,20161026.0,20200129.0,20191230,20200207,EXP,,JP-JNJFOC-20191246449,JOHNSON AND JOHNSON,,41.0,YR,,M,Y,,,20200207.0,,MD,JP,JP,2020,Q1,Adult
172162862,17216286,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",51800.0,MG,D,,,,204042.0,100.0,MG,TABLET,QD,2020,Q1,Hypoglycaemia,,2020,Q1,2,F,20161026.0,20200129.0,20191230,20200207,EXP,,JP-JNJFOC-20191246449,JOHNSON AND JOHNSON,,41.0,YR,,M,Y,,,20200207.0,,MD,JP,JP,2020,Q1,Adult
172164552,17216455,6,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q1,Bradycardia,,2020,Q1,2,F,,20200302.0,20191230,20200312,EXP,,PL-AUROBINDO-AUR-APL-2019-108573,AUROBINDO,,74.0,YR,,F,Y,,,20200312.0,,HP,PL,PL,2020,Q1,Elderly
172164552,17216455,6,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q1,Drug interaction,,2020,Q1,2,F,,20200302.0,20191230,20200312,EXP,,PL-AUROBINDO-AUR-APL-2019-108573,AUROBINDO,,74.0,YR,,F,Y,,,20200312.0,,HP,PL,PL,2020,Q1,Elderly
172164552,17216455,6,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q1,Hypotension,,2020,Q1,2,F,,20200302.0,20191230,20200312,EXP,,PL-AUROBINDO-AUR-APL-2019-108573,AUROBINDO,,74.0,YR,,F,Y,,,20200312.0,,HP,PL,PL,2020,Q1,Elderly
172247581,17224758,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2020,Q1,Acute kidney injury,,2020,Q1,1,I,,20191223.0,20200102,20200102,EXP,,PT-EMD SERONO-E2B_90073609,EMD SERONO INC,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. THE METFORMINE-RELATED LACTIC ACIDOSIS WITH THE ACUTE RENAL INJURY BY HYDROGEN HYPOTENSION. THE ENDOCRINE AND METABOLIC DISEASES. 2019;.",76.0,YR,,M,Y,,,20200102.0,,HP,PT,PT,2020,Q1,Elderly
172247581,17224758,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2020,Q1,Blood bicarbonate decreased,,2020,Q1,1,I,,20191223.0,20200102,20200102,EXP,,PT-EMD SERONO-E2B_90073609,EMD SERONO INC,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. THE METFORMINE-RELATED LACTIC ACIDOSIS WITH THE ACUTE RENAL INJURY BY HYDROGEN HYPOTENSION. THE ENDOCRINE AND METABOLIC DISEASES. 2019;.",76.0,YR,,M,Y,,,20200102.0,,HP,PT,PT,2020,Q1,Elderly
172247581,17224758,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2020,Q1,Blood lactic acid increased,,2020,Q1,1,I,,20191223.0,20200102,20200102,EXP,,PT-EMD SERONO-E2B_90073609,EMD SERONO INC,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. THE METFORMINE-RELATED LACTIC ACIDOSIS WITH THE ACUTE RENAL INJURY BY HYDROGEN HYPOTENSION. THE ENDOCRINE AND METABOLIC DISEASES. 2019;.",76.0,YR,,M,Y,,,20200102.0,,HP,PT,PT,2020,Q1,Elderly
172247581,17224758,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2020,Q1,Dyspnoea,,2020,Q1,1,I,,20191223.0,20200102,20200102,EXP,,PT-EMD SERONO-E2B_90073609,EMD SERONO INC,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. THE METFORMINE-RELATED LACTIC ACIDOSIS WITH THE ACUTE RENAL INJURY BY HYDROGEN HYPOTENSION. THE ENDOCRINE AND METABOLIC DISEASES. 2019;.",76.0,YR,,M,Y,,,20200102.0,,HP,PT,PT,2020,Q1,Elderly
172247581,17224758,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2020,Q1,Emotional distress,,2020,Q1,1,I,,20191223.0,20200102,20200102,EXP,,PT-EMD SERONO-E2B_90073609,EMD SERONO INC,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. THE METFORMINE-RELATED LACTIC ACIDOSIS WITH THE ACUTE RENAL INJURY BY HYDROGEN HYPOTENSION. THE ENDOCRINE AND METABOLIC DISEASES. 2019;.",76.0,YR,,M,Y,,,20200102.0,,HP,PT,PT,2020,Q1,Elderly
172247581,17224758,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2020,Q1,Fatigue,,2020,Q1,1,I,,20191223.0,20200102,20200102,EXP,,PT-EMD SERONO-E2B_90073609,EMD SERONO INC,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. THE METFORMINE-RELATED LACTIC ACIDOSIS WITH THE ACUTE RENAL INJURY BY HYDROGEN HYPOTENSION. THE ENDOCRINE AND METABOLIC DISEASES. 2019;.",76.0,YR,,M,Y,,,20200102.0,,HP,PT,PT,2020,Q1,Elderly
172247581,17224758,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2020,Q1,Hyperhidrosis,,2020,Q1,1,I,,20191223.0,20200102,20200102,EXP,,PT-EMD SERONO-E2B_90073609,EMD SERONO INC,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. THE METFORMINE-RELATED LACTIC ACIDOSIS WITH THE ACUTE RENAL INJURY BY HYDROGEN HYPOTENSION. THE ENDOCRINE AND METABOLIC DISEASES. 2019;.",76.0,YR,,M,Y,,,20200102.0,,HP,PT,PT,2020,Q1,Elderly
172247581,17224758,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2020,Q1,Hypotension,,2020,Q1,1,I,,20191223.0,20200102,20200102,EXP,,PT-EMD SERONO-E2B_90073609,EMD SERONO INC,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. THE METFORMINE-RELATED LACTIC ACIDOSIS WITH THE ACUTE RENAL INJURY BY HYDROGEN HYPOTENSION. THE ENDOCRINE AND METABOLIC DISEASES. 2019;.",76.0,YR,,M,Y,,,20200102.0,,HP,PT,PT,2020,Q1,Elderly
172247581,17224758,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2020,Q1,Lactic acidosis,,2020,Q1,1,I,,20191223.0,20200102,20200102,EXP,,PT-EMD SERONO-E2B_90073609,EMD SERONO INC,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. THE METFORMINE-RELATED LACTIC ACIDOSIS WITH THE ACUTE RENAL INJURY BY HYDROGEN HYPOTENSION. THE ENDOCRINE AND METABOLIC DISEASES. 2019;.",76.0,YR,,M,Y,,,20200102.0,,HP,PT,PT,2020,Q1,Elderly
172247581,17224758,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2020,Q1,Metabolic acidosis,,2020,Q1,1,I,,20191223.0,20200102,20200102,EXP,,PT-EMD SERONO-E2B_90073609,EMD SERONO INC,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. THE METFORMINE-RELATED LACTIC ACIDOSIS WITH THE ACUTE RENAL INJURY BY HYDROGEN HYPOTENSION. THE ENDOCRINE AND METABOLIC DISEASES. 2019;.",76.0,YR,,M,Y,,,20200102.0,,HP,PT,PT,2020,Q1,Elderly
172247581,17224758,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2020,Q1,Pallor,,2020,Q1,1,I,,20191223.0,20200102,20200102,EXP,,PT-EMD SERONO-E2B_90073609,EMD SERONO INC,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. THE METFORMINE-RELATED LACTIC ACIDOSIS WITH THE ACUTE RENAL INJURY BY HYDROGEN HYPOTENSION. THE ENDOCRINE AND METABOLIC DISEASES. 2019;.",76.0,YR,,M,Y,,,20200102.0,,HP,PT,PT,2020,Q1,Elderly
172247581,17224758,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2020,Q1,Palpitations,,2020,Q1,1,I,,20191223.0,20200102,20200102,EXP,,PT-EMD SERONO-E2B_90073609,EMD SERONO INC,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. THE METFORMINE-RELATED LACTIC ACIDOSIS WITH THE ACUTE RENAL INJURY BY HYDROGEN HYPOTENSION. THE ENDOCRINE AND METABOLIC DISEASES. 2019;.",76.0,YR,,M,Y,,,20200102.0,,HP,PT,PT,2020,Q1,Elderly
172247581,17224758,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2020,Q1,Vomiting,,2020,Q1,1,I,,20191223.0,20200102,20200102,EXP,,PT-EMD SERONO-E2B_90073609,EMD SERONO INC,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. THE METFORMINE-RELATED LACTIC ACIDOSIS WITH THE ACUTE RENAL INJURY BY HYDROGEN HYPOTENSION. THE ENDOCRINE AND METABOLIC DISEASES. 2019;.",76.0,YR,,M,Y,,,20200102.0,,HP,PT,PT,2020,Q1,Elderly
172254783,17225478,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Dehydration,,2020,Q1,3,F,20191219.0,20200205.0,20200102,20200214,EXP,,JP-JNJFOC-20191246681,JOHNSON AND JOHNSON,,87.0,YR,,F,Y,,,20200214.0,,MD,JP,JP,2020,Q1,Elderly
172254783,17225478,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Hypernatraemia,,2020,Q1,3,F,20191219.0,20200205.0,20200102,20200214,EXP,,JP-JNJFOC-20191246681,JOHNSON AND JOHNSON,,87.0,YR,,F,Y,,,20200214.0,,MD,JP,JP,2020,Q1,Elderly
172328281,17232828,22,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"UNK UNK, QD",,,,,,,,,,,QD,2020,Q1,Pruritus,,2020,Q1,1,I,20191211.0,20191224.0,20200103,20200103,PER,,US-IGSA-SR10009649,GRIFOLS,,46.0,YR,,F,Y,78.0,KG,20200103.0,,HP,US,US,2020,Q1,Adult
172328281,17232828,22,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"UNK UNK, QD",,,,,,,,,,,QD,2020,Q1,Rash,,2020,Q1,1,I,20191211.0,20191224.0,20200103,20200103,PER,,US-IGSA-SR10009649,GRIFOLS,,46.0,YR,,F,Y,78.0,KG,20200103.0,,HP,US,US,2020,Q1,Adult
172368291,17236829,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Arthralgia,,2020,Q1,1,I,,20191225.0,20200106,20200106,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20200106.0,,HP,CA,CA,2020,Q1,Adult
172368291,17236829,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Bronchitis,,2020,Q1,1,I,,20191225.0,20200106,20200106,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20200106.0,,HP,CA,CA,2020,Q1,Adult
172368291,17236829,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Constipation,,2020,Q1,1,I,,20191225.0,20200106,20200106,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20200106.0,,HP,CA,CA,2020,Q1,Adult
172368291,17236829,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Cough,,2020,Q1,1,I,,20191225.0,20200106,20200106,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20200106.0,,HP,CA,CA,2020,Q1,Adult
172368291,17236829,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Dyspnoea,,2020,Q1,1,I,,20191225.0,20200106,20200106,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20200106.0,,HP,CA,CA,2020,Q1,Adult
172368291,17236829,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Ear disorder,,2020,Q1,1,I,,20191225.0,20200106,20200106,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20200106.0,,HP,CA,CA,2020,Q1,Adult
172368291,17236829,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Ear infection,,2020,Q1,1,I,,20191225.0,20200106,20200106,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20200106.0,,HP,CA,CA,2020,Q1,Adult
172368291,17236829,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Eyelid infection,,2020,Q1,1,I,,20191225.0,20200106,20200106,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20200106.0,,HP,CA,CA,2020,Q1,Adult
172368291,17236829,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Heart rate increased,,2020,Q1,1,I,,20191225.0,20200106,20200106,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20200106.0,,HP,CA,CA,2020,Q1,Adult
172368291,17236829,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Hypotension,,2020,Q1,1,I,,20191225.0,20200106,20200106,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20200106.0,,HP,CA,CA,2020,Q1,Adult
172368291,17236829,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Influenza,,2020,Q1,1,I,,20191225.0,20200106,20200106,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20200106.0,,HP,CA,CA,2020,Q1,Adult
172368291,17236829,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Localised infection,,2020,Q1,1,I,,20191225.0,20200106,20200106,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20200106.0,,HP,CA,CA,2020,Q1,Adult
172368291,17236829,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Malaise,,2020,Q1,1,I,,20191225.0,20200106,20200106,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20200106.0,,HP,CA,CA,2020,Q1,Adult
172368291,17236829,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Musculoskeletal pain,,2020,Q1,1,I,,20191225.0,20200106,20200106,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20200106.0,,HP,CA,CA,2020,Q1,Adult
172368291,17236829,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Neck pain,,2020,Q1,1,I,,20191225.0,20200106,20200106,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20200106.0,,HP,CA,CA,2020,Q1,Adult
172368291,17236829,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Neuralgia,,2020,Q1,1,I,,20191225.0,20200106,20200106,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20200106.0,,HP,CA,CA,2020,Q1,Adult
172368291,17236829,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Pain in extremity,,2020,Q1,1,I,,20191225.0,20200106,20200106,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20200106.0,,HP,CA,CA,2020,Q1,Adult
172368291,17236829,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Paranasal cyst,,2020,Q1,1,I,,20191225.0,20200106,20200106,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20200106.0,,HP,CA,CA,2020,Q1,Adult
172368291,17236829,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Polyp,,2020,Q1,1,I,,20191225.0,20200106,20200106,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20200106.0,,HP,CA,CA,2020,Q1,Adult
172368291,17236829,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Sinusitis,,2020,Q1,1,I,,20191225.0,20200106,20200106,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20200106.0,,HP,CA,CA,2020,Q1,Adult
172368291,17236829,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Tinnitus,,2020,Q1,1,I,,20191225.0,20200106,20200106,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20200106.0,,HP,CA,CA,2020,Q1,Adult
172368291,17236829,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Tympanic membrane perforation,,2020,Q1,1,I,,20191225.0,20200106,20200106,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20200106.0,,HP,CA,CA,2020,Q1,Adult
172368291,17236829,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Viral infection,,2020,Q1,1,I,,20191225.0,20200106,20200106,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20200106.0,,HP,CA,CA,2020,Q1,Adult
172368291,17236829,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Weight increased,,2020,Q1,1,I,,20191225.0,20200106,20200106,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20200106.0,,HP,CA,CA,2020,Q1,Adult
172482001,17248200,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,FILM-COATED TABLET,,2020,Q1,Acute kidney injury,,2020,Q1,1,I,20191219.0,20200103.0,20200108,20200108,EXP,GB-MHRA-EYC 00215209,GB-JNJFOC-20200104941,JOHNSON AND JOHNSON,,70.0,YR,,M,Y,86.0,KG,20200108.0,,MD,GB,GB,2020,Q1,Elderly
172482001,17248200,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,FILM-COATED TABLET,,2020,Q1,Diabetic ketoacidosis,,2020,Q1,1,I,20191219.0,20200103.0,20200108,20200108,EXP,GB-MHRA-EYC 00215209,GB-JNJFOC-20200104941,JOHNSON AND JOHNSON,,70.0,YR,,M,Y,86.0,KG,20200108.0,,MD,GB,GB,2020,Q1,Elderly
172482001,17248200,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,FILM-COATED TABLET,,2020,Q1,Respiratory distress,,2020,Q1,1,I,20191219.0,20200103.0,20200108,20200108,EXP,GB-MHRA-EYC 00215209,GB-JNJFOC-20200104941,JOHNSON AND JOHNSON,,70.0,YR,,M,Y,86.0,KG,20200108.0,,MD,GB,GB,2020,Q1,Elderly
172550141,17255014,13,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2020,Q1,Completed suicide,,2020,Q1,1,I,,20200102.0,20200109,20200109,EXP,,US-SUNOVION-2020SUN000059,SUNOVION,"GUMMIN, DAVID D,; MOWRY, JAMES B.; SPYKER, DANIEL A.; BROOKS, DANIEL E.; BEUHLER, MICHAEL C.; RIVERS, LAURA J.; HASHEM, HEBA, A.; RYAN, MARK L.. 2018 ANNUAL REPORT OF THE AMERICAN ASSOCIATION OF POISON CONTROL CENTERS^ NATIONAL POISON DATA SYSTEM (NPDS): 36TH ANNUAL REPORT. CLINICAL TOXICOLOGY. 2019;57:12:1220-1413",47.0,YR,,M,Y,,,20200109.0,,MD,US,US,2020,Q1,Adult
172584081,17258408,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20200106.0,20200110,20200110,EXP,,US-EMD SERONO-9139556,EMD SERONO INC,"LEYS L, OTENG E, MALLIPEDDI V, BERHANE F, PODDAR V. SEVERE EUGLYCEMIC DIABETIC KETOACIDOSIS ASSOCIATED WITH USE OF CANAGLIFLOZIN. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 2019 MAY 01;199(9):.",46.0,YR,,M,Y,,,20200110.0,,MD,US,US,2020,Q1,Adult
172584101,17258410,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,1QD,154.0,DF,,, UNKNOWN,,,,,,,2020,Q1,Pruritus genital,,2020,Q1,1,I,20190926.0,20200102.0,20200110,20200110,EXP,GB-MHRA-TPP14354070C1517899YC1576159877758,GB-NOVOPROD-705195,NOVO NORDISK,,57.0,YR,,M,Y,119.0,KG,20200110.0,,HP,GB,GB,2020,Q1,Adult
172722762,17272276,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"UNK, UNKNOWN",,,D,,,,,,,,,2020,Q1,Completed suicide,,2020,Q1,2,F,2018.0,20200106.0,20200115,20200117,EXP,,US-APOTEX-2020AP005955,APOTEX,"GUMMIN DD, MOWRYJB, SPYKER DA, BROOKS DE, BEUHLER MC, RIVERS LJ, HASHEM HA, RYAN ML. 2018 ANNUAL REPORT OF THE AMERICAN ASSOCIATION OF POISON CONTROL CENTERS? NATIONAL POISON DATA SYSTEM (NPDS): 36TH ANNUAL REPORT. DOI: 10.1080/15563650.2019.1677022. CLINICAL TOXICOLOGY. 2019;57 (12):1220-1413",47.0,YR,,M,Y,,,20200117.0,,MD,US,US,2020,Q1,Adult
172736891,17273689,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,300.0,MG,FILM-COATED TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20200108.0,20200115,20200115,EXP,,US-JNJFOC-20200117276,JOHNSON AND JOHNSON,"LAU-SWISHER W, MATTAR Z, WAGNER C. AN UNSUSPECTED CASE OF EUGLYCEMIC DKA IN A PATIENT WITH SUBDURAL HEMATOMA. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 2019;199:A6647.",65.0,YR,,M,Y,,,20200115.0,,MD,US,US,2020,Q1,Elderly
172736891,17273689,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,300.0,MG,FILM-COATED TABLET,,2020,Q1,Subdural haematoma,,2020,Q1,1,I,,20200108.0,20200115,20200115,EXP,,US-JNJFOC-20200117276,JOHNSON AND JOHNSON,"LAU-SWISHER W, MATTAR Z, WAGNER C. AN UNSUSPECTED CASE OF EUGLYCEMIC DKA IN A PATIENT WITH SUBDURAL HEMATOMA. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 2019;199:A6647.",65.0,YR,,M,Y,,,20200115.0,,MD,US,US,2020,Q1,Elderly
172765281,17276528,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Haemangioma of liver,,2020,Q1,1,I,201705.0,20180510.0,20200116,20200116,EXP,,JP-JNJFOC-20180522014,JOHNSON AND JOHNSON,,59.0,YR,,M,Y,76.0,KG,20200116.0,,MD,JP,JP,2020,Q1,Adult
172765281,17276528,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Large intestine polyp,,2020,Q1,1,I,201705.0,20180510.0,20200116,20200116,EXP,,JP-JNJFOC-20180522014,JOHNSON AND JOHNSON,,59.0,YR,,M,Y,76.0,KG,20200116.0,,MD,JP,JP,2020,Q1,Adult
172765311,17276531,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,,,FILM-COATED TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20200107.0,20200116,20200116,EXP,,US-JNJFOC-20200117170,JOHNSON AND JOHNSON,"LEYS L, MALLIPEDDI V, BERHANE F, PODDAR V, OTENG E. SEVERE EUGLYCEMIC DIABETIC KETOACIDOSIS ASSOCIATED WITH USE OF CANAGLIFLOZIN. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 2019;199:.",46.0,YR,,M,Y,,,20200116.0,,HP,US,US,2020,Q1,Adult
172772991,17277299,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK (INGESTION),,,D,,,,,,,,,2020,Q1,Completed suicide,,2020,Q1,1,I,2018.0,20200111.0,20200116,20200116,EXP,,US-PFIZER INC-2020018228,PFIZER,"GUMMIN, D.. 2018 ANNUAL REPORT OF THE AMERICAN ASSOCIATION OF POISON CONTROL CENTERS^ NATIONAL POISON DATA SYSTEM (NPDS): 36TH ANNUAL REPORT. CLINICAL TOXICOLOGY. 2019;57 (12):10.1080/15563650.2019.1677022",47.0,YR,,M,Y,,,20200116.0,,MD,US,US,2020,Q1,Adult
172830191,17283019,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Fanconi syndrome,,2020,Q1,1,I,,20200107.0,20200117,20200117,EXP,,US-JNJFOC-20200117194,JOHNSON AND JOHNSON,"KHAN N, BROUSSARD J, DZIUBA M, TSO K. CANAGLIFLOZIN-INDUCED FANCONI SYNDROME IN A PATIENT WITH PREVIOUSLY UNRECOGNIZED TYPE 1 DIABETES. AM J HEALTH SYST PHARM. 2019 NOV 13;76 (23):1930-1933.",32.0,YR,,F,Y,59.0,KG,20200117.0,,MD,US,US,2020,Q1,Young Adult
172830191,17283019,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Product prescribing error,,2020,Q1,1,I,,20200107.0,20200117,20200117,EXP,,US-JNJFOC-20200117194,JOHNSON AND JOHNSON,"KHAN N, BROUSSARD J, DZIUBA M, TSO K. CANAGLIFLOZIN-INDUCED FANCONI SYNDROME IN A PATIENT WITH PREVIOUSLY UNRECOGNIZED TYPE 1 DIABETES. AM J HEALTH SYST PHARM. 2019 NOV 13;76 (23):1930-1933.",32.0,YR,,F,Y,59.0,KG,20200117.0,,MD,US,US,2020,Q1,Young Adult
172834772,17283477,16,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 DF,,,Y,,,,,1.0,DF,TABLET,,2020,Q1,Hyperglycaemia,,2020,Q1,2,F,20190327.0,20200217.0,20200117,20200225,EXP,,PHJP2019JP012389,NOVARTIS,,37.0,YR,,F,Y,,,20200225.0,,,JP,JP,2020,Q1,Adult
172884591,17288459,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Cervix carcinoma,,2020,Q1,1,I,201904.0,20200106.0,20200120,20200120,EXP,,JP-JNJFOC-20200128577,JOHNSON AND JOHNSON,,59.0,YR,,F,Y,,,20200120.0,,MD,JP,JP,2020,Q1,Adult
172894001,17289400,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2020,Q1,Anxiety disorder,,2020,Q1,1,I,20160807.0,20170703.0,20200120,20200120,EXP,,JP-JNJFOC-20170707471,JOHNSON AND JOHNSON,,57.0,YR,,M,Y,,,20200120.0,,MD,JP,JP,2020,Q1,Adult
172894001,17289400,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2020,Q1,Back pain,,2020,Q1,1,I,20160807.0,20170703.0,20200120,20200120,EXP,,JP-JNJFOC-20170707471,JOHNSON AND JOHNSON,,57.0,YR,,M,Y,,,20200120.0,,MD,JP,JP,2020,Q1,Adult
172894001,17289400,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2020,Q1,Blepharitis,,2020,Q1,1,I,20160807.0,20170703.0,20200120,20200120,EXP,,JP-JNJFOC-20170707471,JOHNSON AND JOHNSON,,57.0,YR,,M,Y,,,20200120.0,,MD,JP,JP,2020,Q1,Adult
172894001,17289400,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2020,Q1,Blood pressure inadequately controlled,,2020,Q1,1,I,20160807.0,20170703.0,20200120,20200120,EXP,,JP-JNJFOC-20170707471,JOHNSON AND JOHNSON,,57.0,YR,,M,Y,,,20200120.0,,MD,JP,JP,2020,Q1,Adult
172894001,17289400,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2020,Q1,Dizziness,,2020,Q1,1,I,20160807.0,20170703.0,20200120,20200120,EXP,,JP-JNJFOC-20170707471,JOHNSON AND JOHNSON,,57.0,YR,,M,Y,,,20200120.0,,MD,JP,JP,2020,Q1,Adult
172894001,17289400,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2020,Q1,Haematocrit increased,,2020,Q1,1,I,20160807.0,20170703.0,20200120,20200120,EXP,,JP-JNJFOC-20170707471,JOHNSON AND JOHNSON,,57.0,YR,,M,Y,,,20200120.0,,MD,JP,JP,2020,Q1,Adult
172894001,17289400,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2020,Q1,Hepatic function abnormal,,2020,Q1,1,I,20160807.0,20170703.0,20200120,20200120,EXP,,JP-JNJFOC-20170707471,JOHNSON AND JOHNSON,,57.0,YR,,M,Y,,,20200120.0,,MD,JP,JP,2020,Q1,Adult
172894001,17289400,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2020,Q1,Hypertriglyceridaemia,,2020,Q1,1,I,20160807.0,20170703.0,20200120,20200120,EXP,,JP-JNJFOC-20170707471,JOHNSON AND JOHNSON,,57.0,YR,,M,Y,,,20200120.0,,MD,JP,JP,2020,Q1,Adult
172894001,17289400,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2020,Q1,Motion sickness,,2020,Q1,1,I,20160807.0,20170703.0,20200120,20200120,EXP,,JP-JNJFOC-20170707471,JOHNSON AND JOHNSON,,57.0,YR,,M,Y,,,20200120.0,,MD,JP,JP,2020,Q1,Adult
172894001,17289400,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2020,Q1,Muscle spasms,,2020,Q1,1,I,20160807.0,20170703.0,20200120,20200120,EXP,,JP-JNJFOC-20170707471,JOHNSON AND JOHNSON,,57.0,YR,,M,Y,,,20200120.0,,MD,JP,JP,2020,Q1,Adult
172894001,17289400,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2020,Q1,Neuralgia,,2020,Q1,1,I,20160807.0,20170703.0,20200120,20200120,EXP,,JP-JNJFOC-20170707471,JOHNSON AND JOHNSON,,57.0,YR,,M,Y,,,20200120.0,,MD,JP,JP,2020,Q1,Adult
172894001,17289400,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2020,Q1,Penile haemorrhage,,2020,Q1,1,I,20160807.0,20170703.0,20200120,20200120,EXP,,JP-JNJFOC-20170707471,JOHNSON AND JOHNSON,,57.0,YR,,M,Y,,,20200120.0,,MD,JP,JP,2020,Q1,Adult
172894001,17289400,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2020,Q1,Platelet count decreased,,2020,Q1,1,I,20160807.0,20170703.0,20200120,20200120,EXP,,JP-JNJFOC-20170707471,JOHNSON AND JOHNSON,,57.0,YR,,M,Y,,,20200120.0,,MD,JP,JP,2020,Q1,Adult
172894001,17289400,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2020,Q1,Rhinitis allergic,,2020,Q1,1,I,20160807.0,20170703.0,20200120,20200120,EXP,,JP-JNJFOC-20170707471,JOHNSON AND JOHNSON,,57.0,YR,,M,Y,,,20200120.0,,MD,JP,JP,2020,Q1,Adult
172897332,17289733,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2020,Q1,Diabetes mellitus,,2020,Q1,2,F,20191227.0,20200127.0,20200120,20200203,EXP,,US-JAZZ-2020-US-000544,JAZZ,,60.0,YR,,F,Y,,,20200203.0,,,US,US,2020,Q1,Adult
172897332,17289733,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2020,Q1,Diabetic foot,,2020,Q1,2,F,20191227.0,20200127.0,20200120,20200203,EXP,,US-JAZZ-2020-US-000544,JAZZ,,60.0,YR,,F,Y,,,20200203.0,,,US,US,2020,Q1,Adult
172897332,17289733,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2020,Q1,Osteomyelitis,,2020,Q1,2,F,20191227.0,20200127.0,20200120,20200203,EXP,,US-JAZZ-2020-US-000544,JAZZ,,60.0,YR,,F,Y,,,20200203.0,,,US,US,2020,Q1,Adult
172968311,17296831,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Acute kidney injury,,2020,Q1,1,I,,20200110.0,20200121,20200121,EXP,,PT-MYLANLABS-2020M1004988,MYLAN,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A.. ACIDOSE LATICA A METFORMINAS, COM LESAO RENAL AGUDA POR HIPOTENSAO IATROGENICA.. MEDICINA INTERNA - CONGRESSOS NACIONAIS 25CNMI19. 2019",76.0,YR,,M,Y,,,20200121.0,,MD,PT,PT,2020,Q1,Elderly
172968311,17296831,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Lactic acidosis,,2020,Q1,1,I,,20200110.0,20200121,20200121,EXP,,PT-MYLANLABS-2020M1004988,MYLAN,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A.. ACIDOSE LATICA A METFORMINAS, COM LESAO RENAL AGUDA POR HIPOTENSAO IATROGENICA.. MEDICINA INTERNA - CONGRESSOS NACIONAIS 25CNMI19. 2019",76.0,YR,,M,Y,,,20200121.0,,MD,PT,PT,2020,Q1,Elderly
173010363,17301036,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Cellulitis,,2020,Q1,3,F,20170906.0,20200225.0,20200122,20200306,EXP,,JP-JNJFOC-20200128660,JOHNSON AND JOHNSON,"N K, R Y, S I, M M, PRIVACY. 2-C-17 A CASE OF PROLONGED KETOSIS NOTED DURING TREATMENT FOR EUGLYCAEMIC KETOACIDOSIS DUE TO SGLT2 INHIBITORS. JAPAN DIABETES SOCIETY THE 57TH ANNUAL MEETING OF CHUGOKU SHIKOKU REGION ASSOCIATION. 2019;12.6,7;89:.",64.0,YR,,M,Y,,,20200306.0,,MD,JP,JP,2020,Q1,Adult
173010363,17301036,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,3,F,20170906.0,20200225.0,20200122,20200306,EXP,,JP-JNJFOC-20200128660,JOHNSON AND JOHNSON,"N K, R Y, S I, M M, PRIVACY. 2-C-17 A CASE OF PROLONGED KETOSIS NOTED DURING TREATMENT FOR EUGLYCAEMIC KETOACIDOSIS DUE TO SGLT2 INHIBITORS. JAPAN DIABETES SOCIETY THE 57TH ANNUAL MEETING OF CHUGOKU SHIKOKU REGION ASSOCIATION. 2019;12.6,7;89:.",64.0,YR,,M,Y,,,20200306.0,,MD,JP,JP,2020,Q1,Adult
173253981,17325398,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Intradermal,"100 MG, UNK",,,U,,,,,100.0,MG,,,2020,Q1,Acute kidney injury,,2020,Q1,1,I,,20200123.0,20200127,20200127,EXP,,NVSC2020PT018156,NOVARTIS,,76.0,YR,,M,Y,,,20200127.0,,HP,COUNTRY NOT SPECIFIED,PT,2020,Q1,Elderly
173253981,17325398,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Intradermal,"100 MG, UNK",,,U,,,,,100.0,MG,,,2020,Q1,Lactic acidosis,,2020,Q1,1,I,,20200123.0,20200127,20200127,EXP,,NVSC2020PT018156,NOVARTIS,,76.0,YR,,M,Y,,,20200127.0,,HP,COUNTRY NOT SPECIFIED,PT,2020,Q1,Elderly
173299551,17329955,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"UNKNOWN, UNKNOWN",,,D,, UNKNOWN,,,,,,,2020,Q1,Death,,2020,Q1,1,I,,20200120.0,20200128,20200128,EXP,,US-PERRIGO-20US000938,PERRIGO,,47.0,YR,,M,Y,,,20200128.0,,PH,US,US,2020,Q1,Adult
173351992,17335199,61,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2020,Q1,Cholelithiasis,,2020,Q1,2,F,201901.0,20200218.0,20200128,20200220,EXP,,US-JAZZ-2020-US-001204,JAZZ,,36.0,YR,,F,Y,,,20200220.0,,,US,US,2020,Q1,Adult
173359631,17335963,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,300 MG,,,,, UNKNOWN,,,300.0,MG,TABLET,,2020,Q1,Asthenia,,2020,Q1,1,I,201907.0,20200120.0,20200128,20200128,EXP,GB-MHRA-EYC 00215589,GB-TEVA-2020-GB-1173639,TEVA,,82.0,YR,,M,Y,86.9,KG,20200128.0,,PH,GB,GB,2020,Q1,Elderly
173359631,17335963,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,300 MG,,,,, UNKNOWN,,,300.0,MG,TABLET,,2020,Q1,Blood creatine phosphokinase increased,,2020,Q1,1,I,201907.0,20200120.0,20200128,20200128,EXP,GB-MHRA-EYC 00215589,GB-TEVA-2020-GB-1173639,TEVA,,82.0,YR,,M,Y,86.9,KG,20200128.0,,PH,GB,GB,2020,Q1,Elderly
173359631,17335963,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,300 MG,,,,, UNKNOWN,,,300.0,MG,TABLET,,2020,Q1,Dyspepsia,,2020,Q1,1,I,201907.0,20200120.0,20200128,20200128,EXP,GB-MHRA-EYC 00215589,GB-TEVA-2020-GB-1173639,TEVA,,82.0,YR,,M,Y,86.9,KG,20200128.0,,PH,GB,GB,2020,Q1,Elderly
173359631,17335963,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,300 MG,,,,, UNKNOWN,,,300.0,MG,TABLET,,2020,Q1,Flatulence,,2020,Q1,1,I,201907.0,20200120.0,20200128,20200128,EXP,GB-MHRA-EYC 00215589,GB-TEVA-2020-GB-1173639,TEVA,,82.0,YR,,M,Y,86.9,KG,20200128.0,,PH,GB,GB,2020,Q1,Elderly
173359631,17335963,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,300 MG,,,,, UNKNOWN,,,300.0,MG,TABLET,,2020,Q1,Gastrooesophageal reflux disease,,2020,Q1,1,I,201907.0,20200120.0,20200128,20200128,EXP,GB-MHRA-EYC 00215589,GB-TEVA-2020-GB-1173639,TEVA,,82.0,YR,,M,Y,86.9,KG,20200128.0,,PH,GB,GB,2020,Q1,Elderly
173359631,17335963,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,300 MG,,,,, UNKNOWN,,,300.0,MG,TABLET,,2020,Q1,Hypersensitivity,,2020,Q1,1,I,201907.0,20200120.0,20200128,20200128,EXP,GB-MHRA-EYC 00215589,GB-TEVA-2020-GB-1173639,TEVA,,82.0,YR,,M,Y,86.9,KG,20200128.0,,PH,GB,GB,2020,Q1,Elderly
173359631,17335963,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,300 MG,,,,, UNKNOWN,,,300.0,MG,TABLET,,2020,Q1,Myalgia,,2020,Q1,1,I,201907.0,20200120.0,20200128,20200128,EXP,GB-MHRA-EYC 00215589,GB-TEVA-2020-GB-1173639,TEVA,,82.0,YR,,M,Y,86.9,KG,20200128.0,,PH,GB,GB,2020,Q1,Elderly
173359631,17335963,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,300 MG,,,,, UNKNOWN,,,300.0,MG,TABLET,,2020,Q1,Rash,,2020,Q1,1,I,201907.0,20200120.0,20200128,20200128,EXP,GB-MHRA-EYC 00215589,GB-TEVA-2020-GB-1173639,TEVA,,82.0,YR,,M,Y,86.9,KG,20200128.0,,PH,GB,GB,2020,Q1,Elderly
173447372,17344737,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2020,Q1,Suspected suicide,,2020,Q1,2,F,2018.0,20200127.0,20200129,20200204,EXP,,US-SHIRE-US202002815,SHIRE,"GUMMIN, D.D.; MOWRY, J.B.; SPYKER, A.A.; BROOKS, D.E.; BEUHLER, M.C.; ET AL.. 2018 ANNUAL REPORT OF THE AMERICAN ASSOCIATION OF POISON DATA SYSTEM (NPDS): 36TH ANNUAL REPORT. CLINICAL TOXICOLOGY. 2019;57(12):1220-1413",47.0,YR,,M,Y,,,20200204.0,,MD,US,US,2020,Q1,Adult
173452891,17345289,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,INGESTED,,,D,,,,,,,,,2020,Q1,Completed suicide,,2020,Q1,1,I,,20200117.0,20200129,20200129,EXP,,US-BAUSCH-BL-2020-001791,BAUSCH AND LOMB,"GUMMIN D, MOWRY J, SPYKER D, BROOKS D, BEUHLER M, RIVERS L, HASHEM H, RYAN M. 2018 ANNUAL REPORT OF THE AMERICAN ASSOCIATION OF POISON CONTROL CENTERS^ NATIONAL POISON DATA SYSTEM (NPDS): 36TH ANNUAL REPORT. CLINICAL TOXICOLOGY. 2019 NOV 21;57(12):1220-1413. DOI:10.1080/15563650.2019.1677022",47.0,YR,,M,Y,,,20200129.0,,MD,US,US,2020,Q1,Adult
173552801,17355280,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",1300.0,MG,Y,,,,204042.0,100.0,MG,TABLET,QD,2020,Q1,Erythema multiforme,,2020,Q1,1,I,20190127.0,20200121.0,20200131,20200131,EXP,,JP-JNJFOC-20200148227,JOHNSON AND JOHNSON,,86.0,YR,,F,Y,,,20200131.0,,MD,JP,JP,2020,Q1,Elderly
173655321,17365532,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,,,,,,2020,Q1,Completed suicide,Completed suicide,2020,Q1,1,I,,20200122.0,20200204,20200204,EXP,,US-ALVOGEN-2020-ALVOGEN-102527,ALVOGEN,"GUMMIN DD, MOWRY JB, SPYKER DA, BROOKS DE, BEUHLER MC, RIVERS LJ, ET AL. 2018 ANNUAL REPORT OF THE AMERICAN ASSOCIATION OF POISON CONTROL CENTERS^ NATIONAL POISON DATA SYSTEM (NPDS): 36TH ANNUAL REPORT. CLIN TOXICOL (PHILA). 2019 DEC;57(12):1220-1413.",47.0,YR,,M,Y,,,20200204.0,,MD,US,US,2020,Q1,Adult
173661421,17366142,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,DURATION OF THERAPY 14 DAYS,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Erythema multiforme,,2020,Q1,1,I,20190127.0,20191211.0,20200204,20200204,EXP,,JP-JNJFOC-20191229315,JOHNSON AND JOHNSON,,86.0,YR,,F,Y,49.0,KG,20200204.0,,MD,JP,JP,2020,Q1,Elderly
173664961,17366496,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Gangrene,,2020,Q1,1,I,20200107.0,20200124.0,20200204,20200204,EXP,,JP-JNJFOC-20200201217,JOHNSON AND JOHNSON,,7.0,DEC,,,Y,,,20200204.0,,MD,JP,JP,2020,Q1,Child
173664961,17366496,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Leg amputation,,2020,Q1,1,I,20200107.0,20200124.0,20200204,20200204,EXP,,JP-JNJFOC-20200201217,JOHNSON AND JOHNSON,,7.0,DEC,,,Y,,,20200204.0,,MD,JP,JP,2020,Q1,Child
173669911,17366991,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, UNK",,,,,,,,300.0,MG,,,2020,Q1,Asthenia,,2020,Q1,1,I,201907.0,20200128.0,20200204,20200204,EXP,GB-MHRA-EYC 00215589,GB-PFIZER INC-2020040772,PFIZER,,82.0,YR,,M,Y,86.9,KG,20200204.0,,PH,GB,GB,2020,Q1,Elderly
173669911,17366991,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, UNK",,,,,,,,300.0,MG,,,2020,Q1,Blood creatine phosphokinase increased,,2020,Q1,1,I,201907.0,20200128.0,20200204,20200204,EXP,GB-MHRA-EYC 00215589,GB-PFIZER INC-2020040772,PFIZER,,82.0,YR,,M,Y,86.9,KG,20200204.0,,PH,GB,GB,2020,Q1,Elderly
173669911,17366991,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, UNK",,,,,,,,300.0,MG,,,2020,Q1,Dyspepsia,,2020,Q1,1,I,201907.0,20200128.0,20200204,20200204,EXP,GB-MHRA-EYC 00215589,GB-PFIZER INC-2020040772,PFIZER,,82.0,YR,,M,Y,86.9,KG,20200204.0,,PH,GB,GB,2020,Q1,Elderly
173669911,17366991,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, UNK",,,,,,,,300.0,MG,,,2020,Q1,Flatulence,,2020,Q1,1,I,201907.0,20200128.0,20200204,20200204,EXP,GB-MHRA-EYC 00215589,GB-PFIZER INC-2020040772,PFIZER,,82.0,YR,,M,Y,86.9,KG,20200204.0,,PH,GB,GB,2020,Q1,Elderly
173669911,17366991,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, UNK",,,,,,,,300.0,MG,,,2020,Q1,Gastrooesophageal reflux disease,,2020,Q1,1,I,201907.0,20200128.0,20200204,20200204,EXP,GB-MHRA-EYC 00215589,GB-PFIZER INC-2020040772,PFIZER,,82.0,YR,,M,Y,86.9,KG,20200204.0,,PH,GB,GB,2020,Q1,Elderly
173669911,17366991,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, UNK",,,,,,,,300.0,MG,,,2020,Q1,Hypersensitivity,,2020,Q1,1,I,201907.0,20200128.0,20200204,20200204,EXP,GB-MHRA-EYC 00215589,GB-PFIZER INC-2020040772,PFIZER,,82.0,YR,,M,Y,86.9,KG,20200204.0,,PH,GB,GB,2020,Q1,Elderly
173669911,17366991,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, UNK",,,,,,,,300.0,MG,,,2020,Q1,Myalgia,,2020,Q1,1,I,201907.0,20200128.0,20200204,20200204,EXP,GB-MHRA-EYC 00215589,GB-PFIZER INC-2020040772,PFIZER,,82.0,YR,,M,Y,86.9,KG,20200204.0,,PH,GB,GB,2020,Q1,Elderly
173669911,17366991,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, UNK",,,,,,,,300.0,MG,,,2020,Q1,Rash,,2020,Q1,1,I,201907.0,20200128.0,20200204,20200204,EXP,GB-MHRA-EYC 00215589,GB-PFIZER INC-2020040772,PFIZER,,82.0,YR,,M,Y,86.9,KG,20200204.0,,PH,GB,GB,2020,Q1,Elderly
173681502,17368150,3,SS,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2020,Q1,Bacteraemia,,2020,Q1,2,F,201908.0,20200131.0,20200204,20200211,EXP,,JP-NOVOPROD-710411,NOVO NORDISK,,49.0,YR,,F,Y,84.0,KG,20200211.0,,MD,JP,JP,2020,Q1,Adult
173681502,17368150,3,SS,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2020,Q1,Pyelonephritis,,2020,Q1,2,F,201908.0,20200131.0,20200204,20200211,EXP,,JP-NOVOPROD-710411,NOVO NORDISK,,49.0,YR,,F,Y,84.0,KG,20200211.0,,MD,JP,JP,2020,Q1,Adult
173681502,17368150,3,SS,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2020,Q1,Urinary tract infection,,2020,Q1,2,F,201908.0,20200131.0,20200204,20200211,EXP,,JP-NOVOPROD-710411,NOVO NORDISK,,49.0,YR,,F,Y,84.0,KG,20200211.0,,MD,JP,JP,2020,Q1,Adult
173694451,17369445,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2020,Q1,Completed suicide,,2020,Q1,1,I,,20200120.0,20200130,20200130,EXP,,US-GLENMARK PHARMACEUTICALS-2020GMK045599,GLENMARK,"GUMMIN DD, MOWRY JB, SPYKER DA, BROOKS DE, OSTERTHALER KM, BANNER W. 2018 ANNUAL REPORT OF THE AMERICAN ASSOCIATION OF POISON CONTROL CENTERS^ NATIONAL POISON DATA SYSTEM (NPDS): 36TH ANNUAL REPORT. CLINICAL TOXICOLOGY. 2019",47.0,YR,,M,Y,,,20200130.0,,MD,US,US,2020,Q1,Adult
173882021,17388202,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Polycythaemia vera,,2020,Q1,1,I,,20200129.0,20200207,20200207,EXP,,JP-JNJFOC-20200206751,JOHNSON AND JOHNSON,,6.0,DEC,,M,Y,,,20200207.0,,MD,JP,JP,2020,Q1,Child
173969451,17396945,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"UNK UNKNOWN, UNKNOWN",,,D,,,,,,,,,2020,Q1,Completed suicide,,2020,Q1,1,I,2018.0,20200114.0,20200210,20200210,EXP,,US-ENDO PHARMACEUTICALS INC-2020-001249,ENDO,,47.0,YR,,M,Y,,,20200210.0,,MD,US,US,2020,Q1,Adult
174015901,17401590,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Abdominal discomfort,,2020,Q1,1,I,,20200204.0,20200211,20200211,EXP,,ES-MYLANLABS-2020M1014226,MYLAN,,59.0,YR,,M,Y,,,20200211.0,,CN,ES,ES,2020,Q1,Adult
174015901,17401590,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Asthenia,,2020,Q1,1,I,,20200204.0,20200211,20200211,EXP,,ES-MYLANLABS-2020M1014226,MYLAN,,59.0,YR,,M,Y,,,20200211.0,,CN,ES,ES,2020,Q1,Adult
174015901,17401590,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Blood glucose increased,,2020,Q1,1,I,,20200204.0,20200211,20200211,EXP,,ES-MYLANLABS-2020M1014226,MYLAN,,59.0,YR,,M,Y,,,20200211.0,,CN,ES,ES,2020,Q1,Adult
174015901,17401590,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Diabetic ketoacidosis,,2020,Q1,1,I,,20200204.0,20200211,20200211,EXP,,ES-MYLANLABS-2020M1014226,MYLAN,,59.0,YR,,M,Y,,,20200211.0,,CN,ES,ES,2020,Q1,Adult
174015901,17401590,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Glycosylated haemoglobin increased,,2020,Q1,1,I,,20200204.0,20200211,20200211,EXP,,ES-MYLANLABS-2020M1014226,MYLAN,,59.0,YR,,M,Y,,,20200211.0,,CN,ES,ES,2020,Q1,Adult
174015901,17401590,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Ketonuria,,2020,Q1,1,I,,20200204.0,20200211,20200211,EXP,,ES-MYLANLABS-2020M1014226,MYLAN,,59.0,YR,,M,Y,,,20200211.0,,CN,ES,ES,2020,Q1,Adult
174015901,17401590,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Metabolic acidosis,,2020,Q1,1,I,,20200204.0,20200211,20200211,EXP,,ES-MYLANLABS-2020M1014226,MYLAN,,59.0,YR,,M,Y,,,20200211.0,,CN,ES,ES,2020,Q1,Adult
174015901,17401590,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Metabolic disorder,,2020,Q1,1,I,,20200204.0,20200211,20200211,EXP,,ES-MYLANLABS-2020M1014226,MYLAN,,59.0,YR,,M,Y,,,20200211.0,,CN,ES,ES,2020,Q1,Adult
174015901,17401590,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Nausea,,2020,Q1,1,I,,20200204.0,20200211,20200211,EXP,,ES-MYLANLABS-2020M1014226,MYLAN,,59.0,YR,,M,Y,,,20200211.0,,CN,ES,ES,2020,Q1,Adult
174015901,17401590,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Vomiting,,2020,Q1,1,I,,20200204.0,20200211,20200211,EXP,,ES-MYLANLABS-2020M1014226,MYLAN,,59.0,YR,,M,Y,,,20200211.0,,CN,ES,ES,2020,Q1,Adult
174095622,17409562,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 * DAY RESTART MEDICATION TWO DAYS POSTOPERATIVELY AFTER MAJOR CARDIAC SURGERY WITH INSUFFICIENT,,,,,,,204042.0,,,FILM-COATED TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,2,F,20200120.0,20200206.0,20200212,20200212,EXP,BE-FAMHP-DHH-N2020-74122,BE-JNJFOC-20200210201,JOHNSON AND JOHNSON,,61.0,YR,,M,Y,95.0,KG,20200212.0,,MD,BE,BE,2020,Q1,Adult
174162192,17416219,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",900.0,MG,N,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Cerebral infarction,,2020,Q1,2,F,20200202.0,20200207.0,20200213,20200218,EXP,,JP-JNJFOC-20200216298,JOHNSON AND JOHNSON,,65.0,YR,,M,Y,,,20200218.0,,MD,JP,JP,2020,Q1,Elderly
174186941,17418694,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q1,Bradycardia,,2020,Q1,1,I,,20200210.0,20200214,20200214,EXP,,PL-MYLANLABS-2020M1016114,MYLAN,"WORON J, SIWEK M, GOROSTOWICZ A. ADVERSE EFFECTS OF INTERACTIONS BETWEEN ANTIDEPRESSANTS AND MEDICATIONS USED IN TREATMENT OF CARDIOVASCULAR DISORDERS. PSYCHIATRIA POLSKA. 2019;53(5):977-995",74.0,YR,,F,Y,,,20200214.0,,MD,PL,PL,2020,Q1,Elderly
174186941,17418694,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q1,Drug interaction,,2020,Q1,1,I,,20200210.0,20200214,20200214,EXP,,PL-MYLANLABS-2020M1016114,MYLAN,"WORON J, SIWEK M, GOROSTOWICZ A. ADVERSE EFFECTS OF INTERACTIONS BETWEEN ANTIDEPRESSANTS AND MEDICATIONS USED IN TREATMENT OF CARDIOVASCULAR DISORDERS. PSYCHIATRIA POLSKA. 2019;53(5):977-995",74.0,YR,,F,Y,,,20200214.0,,MD,PL,PL,2020,Q1,Elderly
174186941,17418694,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q1,Hypotension,,2020,Q1,1,I,,20200210.0,20200214,20200214,EXP,,PL-MYLANLABS-2020M1016114,MYLAN,"WORON J, SIWEK M, GOROSTOWICZ A. ADVERSE EFFECTS OF INTERACTIONS BETWEEN ANTIDEPRESSANTS AND MEDICATIONS USED IN TREATMENT OF CARDIOVASCULAR DISORDERS. PSYCHIATRIA POLSKA. 2019;53(5):977-995",74.0,YR,,F,Y,,,20200214.0,,MD,PL,PL,2020,Q1,Elderly
174193371,17419337,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20200205.0,20200214,20200214,EXP,,JP-JNJFOC-20200220939,JOHNSON AND JOHNSON,"PRIVACY, OTOKOZAWA H, OKAMOTO K, UNO K, MORITA K, UCHINO T, ISHIWATA C. O-025 A CASE OF LACTIC ACIDOSIS WITH SUSPECTED EUGLYCAEMIC DIABETIC KETOACIDOSIS (EDKA). 2020;1.18:74.",59.0,YR,,F,Y,,,20200214.0,,MD,JP,JP,2020,Q1,Adult
174193371,17419337,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Lactic acidosis,,2020,Q1,1,I,,20200205.0,20200214,20200214,EXP,,JP-JNJFOC-20200220939,JOHNSON AND JOHNSON,"PRIVACY, OTOKOZAWA H, OKAMOTO K, UNO K, MORITA K, UCHINO T, ISHIWATA C. O-025 A CASE OF LACTIC ACIDOSIS WITH SUSPECTED EUGLYCAEMIC DIABETIC KETOACIDOSIS (EDKA). 2020;1.18:74.",59.0,YR,,F,Y,,,20200214.0,,MD,JP,JP,2020,Q1,Adult
174199011,17419901,3,C,Canagliflozin,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM,,,,,,,,100.0,MG,UNKNOWN,QD,2020,Q1,Malignant neoplasm progression,,2020,Q1,1,I,20200106.0,20200207.0,20200214,20200214,EXP,,JP-CELGENEUS-JPN-20200203718,CELGENE,,68.0,YR,,M,Y,73.4,KG,20200214.0,,MD,US,JP,2020,Q1,Elderly
174291671,17429167,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,D,,,20200229.0,,100.0,MG,,QD,2020,Q1,Acute kidney injury,,2020,Q1,1,I,20200212.0,,20200214,20200214,DIR,,,FDA-CTU,,43.0,YR,,F,N,100.0,KG,20200214.0,N,PH,US,US,2020,Q1,Adult
174291671,17429167,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,D,,,20200229.0,,100.0,MG,,QD,2020,Q1,Biliary tract disorder,,2020,Q1,1,I,20200212.0,,20200214,20200214,DIR,,,FDA-CTU,,43.0,YR,,F,N,100.0,KG,20200214.0,N,PH,US,US,2020,Q1,Adult
174291671,17429167,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,D,,,20200229.0,,100.0,MG,,QD,2020,Q1,Blood potassium increased,,2020,Q1,1,I,20200212.0,,20200214,20200214,DIR,,,FDA-CTU,,43.0,YR,,F,N,100.0,KG,20200214.0,N,PH,US,US,2020,Q1,Adult
174291671,17429167,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,D,,,20200229.0,,100.0,MG,,QD,2020,Q1,Dehydration,,2020,Q1,1,I,20200212.0,,20200214,20200214,DIR,,,FDA-CTU,,43.0,YR,,F,N,100.0,KG,20200214.0,N,PH,US,US,2020,Q1,Adult
174291671,17429167,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,D,,,20200229.0,,100.0,MG,,QD,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,20200212.0,,20200214,20200214,DIR,,,FDA-CTU,,43.0,YR,,F,N,100.0,KG,20200214.0,N,PH,US,US,2020,Q1,Adult
174291671,17429167,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,D,,,20200229.0,,100.0,MG,,QD,2020,Q1,Flank pain,,2020,Q1,1,I,20200212.0,,20200214,20200214,DIR,,,FDA-CTU,,43.0,YR,,F,N,100.0,KG,20200214.0,N,PH,US,US,2020,Q1,Adult
174291671,17429167,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,D,,,20200229.0,,100.0,MG,,QD,2020,Q1,Gastritis,,2020,Q1,1,I,20200212.0,,20200214,20200214,DIR,,,FDA-CTU,,43.0,YR,,F,N,100.0,KG,20200214.0,N,PH,US,US,2020,Q1,Adult
174291671,17429167,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,D,,,20200229.0,,100.0,MG,,QD,2020,Q1,Infrequent bowel movements,,2020,Q1,1,I,20200212.0,,20200214,20200214,DIR,,,FDA-CTU,,43.0,YR,,F,N,100.0,KG,20200214.0,N,PH,US,US,2020,Q1,Adult
174291671,17429167,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,D,,,20200229.0,,100.0,MG,,QD,2020,Q1,Lactic acidosis,,2020,Q1,1,I,20200212.0,,20200214,20200214,DIR,,,FDA-CTU,,43.0,YR,,F,N,100.0,KG,20200214.0,N,PH,US,US,2020,Q1,Adult
174291671,17429167,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,D,,,20200229.0,,100.0,MG,,QD,2020,Q1,Leukocytosis,,2020,Q1,1,I,20200212.0,,20200214,20200214,DIR,,,FDA-CTU,,43.0,YR,,F,N,100.0,KG,20200214.0,N,PH,US,US,2020,Q1,Adult
174291671,17429167,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,D,,,20200229.0,,100.0,MG,,QD,2020,Q1,Myalgia,,2020,Q1,1,I,20200212.0,,20200214,20200214,DIR,,,FDA-CTU,,43.0,YR,,F,N,100.0,KG,20200214.0,N,PH,US,US,2020,Q1,Adult
174291671,17429167,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,D,,,20200229.0,,100.0,MG,,QD,2020,Q1,Nausea,,2020,Q1,1,I,20200212.0,,20200214,20200214,DIR,,,FDA-CTU,,43.0,YR,,F,N,100.0,KG,20200214.0,N,PH,US,US,2020,Q1,Adult
174291671,17429167,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,D,,,20200229.0,,100.0,MG,,QD,2020,Q1,Pancreatitis,,2020,Q1,1,I,20200212.0,,20200214,20200214,DIR,,,FDA-CTU,,43.0,YR,,F,N,100.0,KG,20200214.0,N,PH,US,US,2020,Q1,Adult
174291671,17429167,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,D,,,20200229.0,,100.0,MG,,QD,2020,Q1,Pneumonia,,2020,Q1,1,I,20200212.0,,20200214,20200214,DIR,,,FDA-CTU,,43.0,YR,,F,N,100.0,KG,20200214.0,N,PH,US,US,2020,Q1,Adult
174291671,17429167,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,D,,,20200229.0,,100.0,MG,,QD,2020,Q1,Retching,,2020,Q1,1,I,20200212.0,,20200214,20200214,DIR,,,FDA-CTU,,43.0,YR,,F,N,100.0,KG,20200214.0,N,PH,US,US,2020,Q1,Adult
174291671,17429167,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,D,,,20200229.0,,100.0,MG,,QD,2020,Q1,Vomiting,,2020,Q1,1,I,20200212.0,,20200214,20200214,DIR,,,FDA-CTU,,43.0,YR,,F,N,100.0,KG,20200214.0,N,PH,US,US,2020,Q1,Adult
174348951,17434895,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Abdominal pain,,2020,Q1,1,I,,20200217.0,20200219,20200219,EXP,,NVSC2020JP045081,NOVARTIS,"FUKUDA M, NABETA M, MUTA T, FUKAMI K, TAKASU O. EUGLYCEMIC DIABETIC KETOACIDOSIS CAUSED BY CANAGLIFLOZIN: A CASE REPORT. INTERNATIONAL JOURNAL OF EMERGENCY MEDICINE. 2020;13(2):1-4",71.0,YR,,F,Y,,,20200219.0,,HP,JP,JP,2020,Q1,Elderly
174348951,17434895,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Abdominal tenderness,,2020,Q1,1,I,,20200217.0,20200219,20200219,EXP,,NVSC2020JP045081,NOVARTIS,"FUKUDA M, NABETA M, MUTA T, FUKAMI K, TAKASU O. EUGLYCEMIC DIABETIC KETOACIDOSIS CAUSED BY CANAGLIFLOZIN: A CASE REPORT. INTERNATIONAL JOURNAL OF EMERGENCY MEDICINE. 2020;13(2):1-4",71.0,YR,,F,Y,,,20200219.0,,HP,JP,JP,2020,Q1,Elderly
174348951,17434895,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Decreased appetite,,2020,Q1,1,I,,20200217.0,20200219,20200219,EXP,,NVSC2020JP045081,NOVARTIS,"FUKUDA M, NABETA M, MUTA T, FUKAMI K, TAKASU O. EUGLYCEMIC DIABETIC KETOACIDOSIS CAUSED BY CANAGLIFLOZIN: A CASE REPORT. INTERNATIONAL JOURNAL OF EMERGENCY MEDICINE. 2020;13(2):1-4",71.0,YR,,F,Y,,,20200219.0,,HP,JP,JP,2020,Q1,Elderly
174348951,17434895,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Diabetic ketoacidosis,,2020,Q1,1,I,,20200217.0,20200219,20200219,EXP,,NVSC2020JP045081,NOVARTIS,"FUKUDA M, NABETA M, MUTA T, FUKAMI K, TAKASU O. EUGLYCEMIC DIABETIC KETOACIDOSIS CAUSED BY CANAGLIFLOZIN: A CASE REPORT. INTERNATIONAL JOURNAL OF EMERGENCY MEDICINE. 2020;13(2):1-4",71.0,YR,,F,Y,,,20200219.0,,HP,JP,JP,2020,Q1,Elderly
174348951,17434895,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Dry mouth,,2020,Q1,1,I,,20200217.0,20200219,20200219,EXP,,NVSC2020JP045081,NOVARTIS,"FUKUDA M, NABETA M, MUTA T, FUKAMI K, TAKASU O. EUGLYCEMIC DIABETIC KETOACIDOSIS CAUSED BY CANAGLIFLOZIN: A CASE REPORT. INTERNATIONAL JOURNAL OF EMERGENCY MEDICINE. 2020;13(2):1-4",71.0,YR,,F,Y,,,20200219.0,,HP,JP,JP,2020,Q1,Elderly
174348951,17434895,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Malaise,,2020,Q1,1,I,,20200217.0,20200219,20200219,EXP,,NVSC2020JP045081,NOVARTIS,"FUKUDA M, NABETA M, MUTA T, FUKAMI K, TAKASU O. EUGLYCEMIC DIABETIC KETOACIDOSIS CAUSED BY CANAGLIFLOZIN: A CASE REPORT. INTERNATIONAL JOURNAL OF EMERGENCY MEDICINE. 2020;13(2):1-4",71.0,YR,,F,Y,,,20200219.0,,HP,JP,JP,2020,Q1,Elderly
174348951,17434895,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Nausea,,2020,Q1,1,I,,20200217.0,20200219,20200219,EXP,,NVSC2020JP045081,NOVARTIS,"FUKUDA M, NABETA M, MUTA T, FUKAMI K, TAKASU O. EUGLYCEMIC DIABETIC KETOACIDOSIS CAUSED BY CANAGLIFLOZIN: A CASE REPORT. INTERNATIONAL JOURNAL OF EMERGENCY MEDICINE. 2020;13(2):1-4",71.0,YR,,F,Y,,,20200219.0,,HP,JP,JP,2020,Q1,Elderly
174348951,17434895,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Peripheral coldness,,2020,Q1,1,I,,20200217.0,20200219,20200219,EXP,,NVSC2020JP045081,NOVARTIS,"FUKUDA M, NABETA M, MUTA T, FUKAMI K, TAKASU O. EUGLYCEMIC DIABETIC KETOACIDOSIS CAUSED BY CANAGLIFLOZIN: A CASE REPORT. INTERNATIONAL JOURNAL OF EMERGENCY MEDICINE. 2020;13(2):1-4",71.0,YR,,F,Y,,,20200219.0,,HP,JP,JP,2020,Q1,Elderly
174348951,17434895,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Tachypnoea,,2020,Q1,1,I,,20200217.0,20200219,20200219,EXP,,NVSC2020JP045081,NOVARTIS,"FUKUDA M, NABETA M, MUTA T, FUKAMI K, TAKASU O. EUGLYCEMIC DIABETIC KETOACIDOSIS CAUSED BY CANAGLIFLOZIN: A CASE REPORT. INTERNATIONAL JOURNAL OF EMERGENCY MEDICINE. 2020;13(2):1-4",71.0,YR,,F,Y,,,20200219.0,,HP,JP,JP,2020,Q1,Elderly
174381991,17438199,12,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,UNK,,,D,, UNK,,,,,,,2020,Q1,Suspected suicide,,2020,Q1,1,I,,20200213.0,20200220,20200220,EXP,,US-NOVAST LABORATORIES LTD.-2020NOV000060,NOVAST,,47.0,YR,,M,Y,,,20200220.0,,HP,US,US,2020,Q1,Adult
174395371,17439537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Aphonia,,2020,Q1,1,I,,20200212.0,20200220,20200220,EXP,,CA-TEVA-2020-CA-1185915,TEVA,,67.0,YR,,F,Y,71.0,KG,20200220.0,,HP,CA,CA,2020,Q1,Elderly
174395371,17439537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Arthralgia,,2020,Q1,1,I,,20200212.0,20200220,20200220,EXP,,CA-TEVA-2020-CA-1185915,TEVA,,67.0,YR,,F,Y,71.0,KG,20200220.0,,HP,CA,CA,2020,Q1,Elderly
174395371,17439537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Blood glucose increased,,2020,Q1,1,I,,20200212.0,20200220,20200220,EXP,,CA-TEVA-2020-CA-1185915,TEVA,,67.0,YR,,F,Y,71.0,KG,20200220.0,,HP,CA,CA,2020,Q1,Elderly
174395371,17439537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Blood pressure increased,,2020,Q1,1,I,,20200212.0,20200220,20200220,EXP,,CA-TEVA-2020-CA-1185915,TEVA,,67.0,YR,,F,Y,71.0,KG,20200220.0,,HP,CA,CA,2020,Q1,Elderly
174395371,17439537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Blood pressure systolic increased,,2020,Q1,1,I,,20200212.0,20200220,20200220,EXP,,CA-TEVA-2020-CA-1185915,TEVA,,67.0,YR,,F,Y,71.0,KG,20200220.0,,HP,CA,CA,2020,Q1,Elderly
174395371,17439537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,C-reactive protein increased,,2020,Q1,1,I,,20200212.0,20200220,20200220,EXP,,CA-TEVA-2020-CA-1185915,TEVA,,67.0,YR,,F,Y,71.0,KG,20200220.0,,HP,CA,CA,2020,Q1,Elderly
174395371,17439537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Cough,,2020,Q1,1,I,,20200212.0,20200220,20200220,EXP,,CA-TEVA-2020-CA-1185915,TEVA,,67.0,YR,,F,Y,71.0,KG,20200220.0,,HP,CA,CA,2020,Q1,Elderly
174395371,17439537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Diabetes mellitus,,2020,Q1,1,I,,20200212.0,20200220,20200220,EXP,,CA-TEVA-2020-CA-1185915,TEVA,,67.0,YR,,F,Y,71.0,KG,20200220.0,,HP,CA,CA,2020,Q1,Elderly
174395371,17439537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Diarrhoea,,2020,Q1,1,I,,20200212.0,20200220,20200220,EXP,,CA-TEVA-2020-CA-1185915,TEVA,,67.0,YR,,F,Y,71.0,KG,20200220.0,,HP,CA,CA,2020,Q1,Elderly
174395371,17439537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Dizziness,,2020,Q1,1,I,,20200212.0,20200220,20200220,EXP,,CA-TEVA-2020-CA-1185915,TEVA,,67.0,YR,,F,Y,71.0,KG,20200220.0,,HP,CA,CA,2020,Q1,Elderly
174395371,17439537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Drug ineffective,,2020,Q1,1,I,,20200212.0,20200220,20200220,EXP,,CA-TEVA-2020-CA-1185915,TEVA,,67.0,YR,,F,Y,71.0,KG,20200220.0,,HP,CA,CA,2020,Q1,Elderly
174395371,17439537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Dry mouth,,2020,Q1,1,I,,20200212.0,20200220,20200220,EXP,,CA-TEVA-2020-CA-1185915,TEVA,,67.0,YR,,F,Y,71.0,KG,20200220.0,,HP,CA,CA,2020,Q1,Elderly
174395371,17439537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Dyspepsia,,2020,Q1,1,I,,20200212.0,20200220,20200220,EXP,,CA-TEVA-2020-CA-1185915,TEVA,,67.0,YR,,F,Y,71.0,KG,20200220.0,,HP,CA,CA,2020,Q1,Elderly
174395371,17439537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Ear infection viral,,2020,Q1,1,I,,20200212.0,20200220,20200220,EXP,,CA-TEVA-2020-CA-1185915,TEVA,,67.0,YR,,F,Y,71.0,KG,20200220.0,,HP,CA,CA,2020,Q1,Elderly
174395371,17439537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Feeling hot,,2020,Q1,1,I,,20200212.0,20200220,20200220,EXP,,CA-TEVA-2020-CA-1185915,TEVA,,67.0,YR,,F,Y,71.0,KG,20200220.0,,HP,CA,CA,2020,Q1,Elderly
174395371,17439537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Hyperhidrosis,,2020,Q1,1,I,,20200212.0,20200220,20200220,EXP,,CA-TEVA-2020-CA-1185915,TEVA,,67.0,YR,,F,Y,71.0,KG,20200220.0,,HP,CA,CA,2020,Q1,Elderly
174395371,17439537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Infection,,2020,Q1,1,I,,20200212.0,20200220,20200220,EXP,,CA-TEVA-2020-CA-1185915,TEVA,,67.0,YR,,F,Y,71.0,KG,20200220.0,,HP,CA,CA,2020,Q1,Elderly
174395371,17439537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Inflammation,,2020,Q1,1,I,,20200212.0,20200220,20200220,EXP,,CA-TEVA-2020-CA-1185915,TEVA,,67.0,YR,,F,Y,71.0,KG,20200220.0,,HP,CA,CA,2020,Q1,Elderly
174395371,17439537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Infusion related reaction,,2020,Q1,1,I,,20200212.0,20200220,20200220,EXP,,CA-TEVA-2020-CA-1185915,TEVA,,67.0,YR,,F,Y,71.0,KG,20200220.0,,HP,CA,CA,2020,Q1,Elderly
174395371,17439537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Joint swelling,,2020,Q1,1,I,,20200212.0,20200220,20200220,EXP,,CA-TEVA-2020-CA-1185915,TEVA,,67.0,YR,,F,Y,71.0,KG,20200220.0,,HP,CA,CA,2020,Q1,Elderly
174395371,17439537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Malaise,,2020,Q1,1,I,,20200212.0,20200220,20200220,EXP,,CA-TEVA-2020-CA-1185915,TEVA,,67.0,YR,,F,Y,71.0,KG,20200220.0,,HP,CA,CA,2020,Q1,Elderly
174395371,17439537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Musculoskeletal stiffness,,2020,Q1,1,I,,20200212.0,20200220,20200220,EXP,,CA-TEVA-2020-CA-1185915,TEVA,,67.0,YR,,F,Y,71.0,KG,20200220.0,,HP,CA,CA,2020,Q1,Elderly
174395371,17439537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Myocardial infarction,,2020,Q1,1,I,,20200212.0,20200220,20200220,EXP,,CA-TEVA-2020-CA-1185915,TEVA,,67.0,YR,,F,Y,71.0,KG,20200220.0,,HP,CA,CA,2020,Q1,Elderly
174395371,17439537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Respiratory rate increased,,2020,Q1,1,I,,20200212.0,20200220,20200220,EXP,,CA-TEVA-2020-CA-1185915,TEVA,,67.0,YR,,F,Y,71.0,KG,20200220.0,,HP,CA,CA,2020,Q1,Elderly
174395371,17439537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Sneezing,,2020,Q1,1,I,,20200212.0,20200220,20200220,EXP,,CA-TEVA-2020-CA-1185915,TEVA,,67.0,YR,,F,Y,71.0,KG,20200220.0,,HP,CA,CA,2020,Q1,Elderly
174395371,17439537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Vomiting,,2020,Q1,1,I,,20200212.0,20200220,20200220,EXP,,CA-TEVA-2020-CA-1185915,TEVA,,67.0,YR,,F,Y,71.0,KG,20200220.0,,HP,CA,CA,2020,Q1,Elderly
174395371,17439537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Weight increased,,2020,Q1,1,I,,20200212.0,20200220,20200220,EXP,,CA-TEVA-2020-CA-1185915,TEVA,,67.0,YR,,F,Y,71.0,KG,20200220.0,,HP,CA,CA,2020,Q1,Elderly
174494211,17449421,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"1 DF, QD",302.042,DF,,,,,,1.0,DF,,QD,2020,Q1,Hyperthyroidism,,2020,Q1,1,I,20200128.0,20200214.0,20200224,20200224,EXP,GB-MHRA-TPP14269898C304213YC1580833586008,GB-NOVOPROD-712934,NOVO NORDISK,,56.0,YR,,F,Y,104.0,KG,20200224.0,,HP,GB,GB,2020,Q1,Adult
174630881,17463088,12,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2020,Q1,Suspected suicide,,2020,Q1,1,I,,20200213.0,20200226,20200226,EXP,,US-TARO-2020TAR00361,TARO,"GUMMIN DD, MOWRY JB, SPYKER DA, BROOKS DE, BEUHLER MC, RIVERS LJ ET.AL. 2018 ANNUAL REPORT OF THE AMERICAN ASSOCIATION OF POISON CONTROL CENTERS^ NATIONAL POISON DATA SYSTEM (NPDS): 36TH ANNUAL REPORT. CLIN TOXICOL (PHILA). 2019;57 (12):1220-1413",47.0,YR,,M,Y,,,20200226.0,,MD,US,US,2020,Q1,Adult
174630881,17463088,12,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2020,Q1,Toxicity to various agents,,2020,Q1,1,I,,20200213.0,20200226,20200226,EXP,,US-TARO-2020TAR00361,TARO,"GUMMIN DD, MOWRY JB, SPYKER DA, BROOKS DE, BEUHLER MC, RIVERS LJ ET.AL. 2018 ANNUAL REPORT OF THE AMERICAN ASSOCIATION OF POISON CONTROL CENTERS^ NATIONAL POISON DATA SYSTEM (NPDS): 36TH ANNUAL REPORT. CLIN TOXICOL (PHILA). 2019;57 (12):1220-1413",47.0,YR,,M,Y,,,20200226.0,,MD,US,US,2020,Q1,Adult
174644801,17464480,12,SS,canagliflozin,CANAGLIFLOZIN,1,Oral,UNKNOWN,,,D,,,,,,,,,2020,Q1,Completed suicide,,2020,Q1,1,I,,20200218.0,20200226,20200226,EXP,,US-TORRENT-00009752,TORRENT,,47.0,YR,A,M,Y,,,20200226.0,,MD,US,US,2020,Q1,Adult
174644801,17464480,12,SS,canagliflozin,CANAGLIFLOZIN,1,Oral,UNKNOWN,,,D,,,,,,,,,2020,Q1,Toxicity to various agents,,2020,Q1,1,I,,20200218.0,20200226,20200226,EXP,,US-TORRENT-00009752,TORRENT,,47.0,YR,A,M,Y,,,20200226.0,,MD,US,US,2020,Q1,Adult
174724683,17472468,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,Bradycardia,,2020,Q1,3,F,,20200318.0,20200228,20200320,EXP,,NVSC2020PL055047,NOVARTIS,,69.0,YR,,M,Y,,,20200320.0,,HP,PL,PL,2020,Q1,Elderly
174724683,17472468,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,Dizziness,,2020,Q1,3,F,,20200318.0,20200228,20200320,EXP,,NVSC2020PL055047,NOVARTIS,,69.0,YR,,M,Y,,,20200320.0,,HP,PL,PL,2020,Q1,Elderly
174724683,17472468,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,Drug interaction,,2020,Q1,3,F,,20200318.0,20200228,20200320,EXP,,NVSC2020PL055047,NOVARTIS,,69.0,YR,,M,Y,,,20200320.0,,HP,PL,PL,2020,Q1,Elderly
174724683,17472468,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,Hypotension,,2020,Q1,3,F,,20200318.0,20200228,20200320,EXP,,NVSC2020PL055047,NOVARTIS,,69.0,YR,,M,Y,,,20200320.0,,HP,PL,PL,2020,Q1,Elderly
174731451,17473145,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Bradycardia,,2020,Q1,1,I,,20200224.0,20200228,20200228,EXP,,NVSC2020PL055027,NOVARTIS,,74.0,YR,,F,Y,,,20200228.0,,HP,PL,PL,2020,Q1,Elderly
174731451,17473145,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Drug interaction,,2020,Q1,1,I,,20200224.0,20200228,20200228,EXP,,NVSC2020PL055027,NOVARTIS,,74.0,YR,,F,Y,,,20200228.0,,HP,PL,PL,2020,Q1,Elderly
174731451,17473145,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Hypotension,,2020,Q1,1,I,,20200224.0,20200228,20200228,EXP,,NVSC2020PL055027,NOVARTIS,,74.0,YR,,F,Y,,,20200228.0,,HP,PL,PL,2020,Q1,Elderly
174793761,17479376,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",80400.0,MG,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Rectal cancer metastatic,,2020,Q1,1,I,20180322.0,20200218.0,20200228,20200228,EXP,,JP-JNJFOC-20200238600,JOHNSON AND JOHNSON,,65.0,YR,,M,Y,,,20200228.0,,MD,JP,JP,2020,Q1,Elderly
174841571,17484157,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,Bradycardia,,2020,Q1,1,I,,20200221.0,20200302,20200302,EXP,,PL-MYLANLABS-2020M1022619,MYLAN,,74.0,YR,,F,Y,,,20200302.0,,HP,PL,PL,2020,Q1,Elderly
174841571,17484157,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,Drug interaction,,2020,Q1,1,I,,20200221.0,20200302,20200302,EXP,,PL-MYLANLABS-2020M1022619,MYLAN,,74.0,YR,,F,Y,,,20200302.0,,HP,PL,PL,2020,Q1,Elderly
174841571,17484157,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,Hypotension,,2020,Q1,1,I,,20200221.0,20200302,20200302,EXP,,PL-MYLANLABS-2020M1022619,MYLAN,,74.0,YR,,F,Y,,,20200302.0,,HP,PL,PL,2020,Q1,Elderly
174848951,17484895,4,SS,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,"100 MG, QD",,,,,,,,100.0,MG,,QD,2020,Q1,Keratitis fungal,,2020,Q1,1,I,,20200220.0,20200302,20200302,EXP,,JP-NOVOPROD-715485,NOVO NORDISK,,69.0,YR,,M,Y,61.0,KG,20200302.0,,MD,JP,JP,2020,Q1,Elderly
174929191,17492919,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",74800.0,MG,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Metastases to central nervous system,,2020,Q1,1,I,20181115.0,20200221.0,20200303,20200303,EXP,,JP-JNJFOC-20200300189,JOHNSON AND JOHNSON,,64.0,YR,,F,Y,,,20200303.0,,MD,JP,JP,2020,Q1,Adult
174932921,17493292,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,300.0,MG,FILM-COATED TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20200219.0,20200303,20200303,EXP,,GR-JNJFOC-20200232680,JOHNSON AND JOHNSON,"ELISAF M, ARAPI C, PAPADAKIS G. ELECTROLYTE DISORDERS IN DIABETIC PATIENTS IN CLINICAL PRACTICE. NUTRITION IN THE PREVENTION AND TREATMENT OF DIABETES MELLITUS. 2020 FEB;10-14.",65.0,YR,,,Y,,,20200303.0,,MD,GR,GR,2020,Q1,Elderly
174959081,17495908,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Abdominal discomfort,,2020,Q1,1,I,,20200228.0,20200304,20200304,EXP,,NVSC2020ES058209,NOVARTIS,,59.0,YR,,M,Y,,,20200304.0,,HP,ES,ES,2020,Q1,Adult
174959081,17495908,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Asthenia,,2020,Q1,1,I,,20200228.0,20200304,20200304,EXP,,NVSC2020ES058209,NOVARTIS,,59.0,YR,,M,Y,,,20200304.0,,HP,ES,ES,2020,Q1,Adult
174959081,17495908,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Blood glucose increased,,2020,Q1,1,I,,20200228.0,20200304,20200304,EXP,,NVSC2020ES058209,NOVARTIS,,59.0,YR,,M,Y,,,20200304.0,,HP,ES,ES,2020,Q1,Adult
174959081,17495908,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Diabetic ketoacidosis,,2020,Q1,1,I,,20200228.0,20200304,20200304,EXP,,NVSC2020ES058209,NOVARTIS,,59.0,YR,,M,Y,,,20200304.0,,HP,ES,ES,2020,Q1,Adult
174959081,17495908,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Glycosylated haemoglobin increased,,2020,Q1,1,I,,20200228.0,20200304,20200304,EXP,,NVSC2020ES058209,NOVARTIS,,59.0,YR,,M,Y,,,20200304.0,,HP,ES,ES,2020,Q1,Adult
174959081,17495908,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Ketonuria,,2020,Q1,1,I,,20200228.0,20200304,20200304,EXP,,NVSC2020ES058209,NOVARTIS,,59.0,YR,,M,Y,,,20200304.0,,HP,ES,ES,2020,Q1,Adult
174959081,17495908,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Metabolic acidosis,,2020,Q1,1,I,,20200228.0,20200304,20200304,EXP,,NVSC2020ES058209,NOVARTIS,,59.0,YR,,M,Y,,,20200304.0,,HP,ES,ES,2020,Q1,Adult
174959081,17495908,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Metabolic disorder,,2020,Q1,1,I,,20200228.0,20200304,20200304,EXP,,NVSC2020ES058209,NOVARTIS,,59.0,YR,,M,Y,,,20200304.0,,HP,ES,ES,2020,Q1,Adult
174959081,17495908,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Nausea,,2020,Q1,1,I,,20200228.0,20200304,20200304,EXP,,NVSC2020ES058209,NOVARTIS,,59.0,YR,,M,Y,,,20200304.0,,HP,ES,ES,2020,Q1,Adult
174959081,17495908,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,U,,,,100.0,MG,,QD,2020,Q1,Vomiting,,2020,Q1,1,I,,20200228.0,20200304,20200304,EXP,,NVSC2020ES058209,NOVARTIS,,59.0,YR,,M,Y,,,20200304.0,,HP,ES,ES,2020,Q1,Adult
175013371,17501337,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2020,Q1,Completed suicide,,2020,Q1,1,I,,20200224.0,20200305,20200305,EXP,,US-STRIDES ARCOLAB LIMITED-2020SP002183,STRIDES,"GUMMIN DD, MOWRY JB, SPYKER DA, BROOKS DE, BEUHLER MC, RIVERS LJ, ET AL.. 2018 ANNUAL REPORT OF THE AMERICAN ASSOCIATION OF POISON CONTROL CENTERS^ NATIONAL POISON DATA SYSTEM (NPDS): 36TH ANNUAL REPORT.. CLINICAL TOXICOLOGY. 2019;57(12):1220-1413",47.0,YR,,M,Y,,,20200305.0,,MD,US,US,2020,Q1,Adult
175080081,17508008,6,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q1,Bradycardia,,2020,Q1,1,I,,20200221.0,20200306,20200306,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-239476,RANBAXY,,74.0,YR,,F,Y,,,20200306.0,,HP,PL,PL,2020,Q1,Elderly
175080081,17508008,6,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q1,Drug interaction,,2020,Q1,1,I,,20200221.0,20200306,20200306,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-239476,RANBAXY,,74.0,YR,,F,Y,,,20200306.0,,HP,PL,PL,2020,Q1,Elderly
175080081,17508008,6,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q1,Hypotension,,2020,Q1,1,I,,20200221.0,20200306,20200306,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-239476,RANBAXY,,74.0,YR,,F,Y,,,20200306.0,,HP,PL,PL,2020,Q1,Elderly
175091861,17509186,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q1,Palpitations,,2020,Q1,1,I,20191115.0,20200225.0,20200306,20200306,EXP,GB-MHRA-ADR 24466010,GB-NOVOPROD-715025,NOVO NORDISK,,65.0,YR,,M,Y,98.0,KG,20200306.0,,CN,GB,GB,2020,Q1,Elderly
175112852,17511285,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNKNOWN,,2020,Q1,Blood creatinine decreased,,2020,Q1,2,F,,20200306.0,20200306,20200318,EXP,,CA-JNJFOC-20200240192,JOHNSON AND JOHNSON,,47.0,YR,,F,Y,,,20200318.0,,MD,CA,CA,2020,Q1,Adult
175112852,17511285,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNKNOWN,,2020,Q1,Blood uric acid decreased,,2020,Q1,2,F,,20200306.0,20200306,20200318,EXP,,CA-JNJFOC-20200240192,JOHNSON AND JOHNSON,,47.0,YR,,F,Y,,,20200318.0,,MD,CA,CA,2020,Q1,Adult
175112852,17511285,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNKNOWN,,2020,Q1,Drug ineffective,,2020,Q1,2,F,,20200306.0,20200306,20200318,EXP,,CA-JNJFOC-20200240192,JOHNSON AND JOHNSON,,47.0,YR,,F,Y,,,20200318.0,,MD,CA,CA,2020,Q1,Adult
175112852,17511285,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNKNOWN,,2020,Q1,Gastrointestinal haemorrhage,,2020,Q1,2,F,,20200306.0,20200306,20200318,EXP,,CA-JNJFOC-20200240192,JOHNSON AND JOHNSON,,47.0,YR,,F,Y,,,20200318.0,,MD,CA,CA,2020,Q1,Adult
175112852,17511285,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNKNOWN,,2020,Q1,Hepatic cirrhosis,,2020,Q1,2,F,,20200306.0,20200306,20200318,EXP,,CA-JNJFOC-20200240192,JOHNSON AND JOHNSON,,47.0,YR,,F,Y,,,20200318.0,,MD,CA,CA,2020,Q1,Adult
175112852,17511285,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNKNOWN,,2020,Q1,Hepatosplenomegaly,,2020,Q1,2,F,,20200306.0,20200306,20200318,EXP,,CA-JNJFOC-20200240192,JOHNSON AND JOHNSON,,47.0,YR,,F,Y,,,20200318.0,,MD,CA,CA,2020,Q1,Adult
175112852,17511285,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNKNOWN,,2020,Q1,Liver disorder,,2020,Q1,2,F,,20200306.0,20200306,20200318,EXP,,CA-JNJFOC-20200240192,JOHNSON AND JOHNSON,,47.0,YR,,F,Y,,,20200318.0,,MD,CA,CA,2020,Q1,Adult
175112852,17511285,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNKNOWN,,2020,Q1,Low density lipoprotein increased,,2020,Q1,2,F,,20200306.0,20200306,20200318,EXP,,CA-JNJFOC-20200240192,JOHNSON AND JOHNSON,,47.0,YR,,F,Y,,,20200318.0,,MD,CA,CA,2020,Q1,Adult
175112852,17511285,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNKNOWN,,2020,Q1,Nonalcoholic fatty liver disease,,2020,Q1,2,F,,20200306.0,20200306,20200318,EXP,,CA-JNJFOC-20200240192,JOHNSON AND JOHNSON,,47.0,YR,,F,Y,,,20200318.0,,MD,CA,CA,2020,Q1,Adult
175112852,17511285,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNKNOWN,,2020,Q1,Psoriasis,,2020,Q1,2,F,,20200306.0,20200306,20200318,EXP,,CA-JNJFOC-20200240192,JOHNSON AND JOHNSON,,47.0,YR,,F,Y,,,20200318.0,,MD,CA,CA,2020,Q1,Adult
175112852,17511285,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNKNOWN,,2020,Q1,Psoriatic arthropathy,,2020,Q1,2,F,,20200306.0,20200306,20200318,EXP,,CA-JNJFOC-20200240192,JOHNSON AND JOHNSON,,47.0,YR,,F,Y,,,20200318.0,,MD,CA,CA,2020,Q1,Adult
175112852,17511285,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNKNOWN,,2020,Q1,Rheumatoid arthritis,,2020,Q1,2,F,,20200306.0,20200306,20200318,EXP,,CA-JNJFOC-20200240192,JOHNSON AND JOHNSON,,47.0,YR,,F,Y,,,20200318.0,,MD,CA,CA,2020,Q1,Adult
175112852,17511285,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNKNOWN,,2020,Q1,Type 2 diabetes mellitus,,2020,Q1,2,F,,20200306.0,20200306,20200318,EXP,,CA-JNJFOC-20200240192,JOHNSON AND JOHNSON,,47.0,YR,,F,Y,,,20200318.0,,MD,CA,CA,2020,Q1,Adult
175112852,17511285,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNKNOWN,,2020,Q1,Varices oesophageal,,2020,Q1,2,F,,20200306.0,20200306,20200318,EXP,,CA-JNJFOC-20200240192,JOHNSON AND JOHNSON,,47.0,YR,,F,Y,,,20200318.0,,MD,CA,CA,2020,Q1,Adult
175189531,17518953,6,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Bradycardia,,2020,Q1,1,I,,20200302.0,20200310,20200310,EXP,,PL-TEVA-2020-PL-1196664,TEVA,"WORON J, SIWEK M.",74.0,YR,,F,Y,,,20200310.0,,HP,PL,PL,2020,Q1,Elderly
175189531,17518953,6,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Drug interaction,,2020,Q1,1,I,,20200302.0,20200310,20200310,EXP,,PL-TEVA-2020-PL-1196664,TEVA,"WORON J, SIWEK M.",74.0,YR,,F,Y,,,20200310.0,,HP,PL,PL,2020,Q1,Elderly
175189531,17518953,6,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Hypotension,,2020,Q1,1,I,,20200302.0,20200310,20200310,EXP,,PL-TEVA-2020-PL-1196664,TEVA,"WORON J, SIWEK M.",74.0,YR,,F,Y,,,20200310.0,,HP,PL,PL,2020,Q1,Elderly
175233481,17523348,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",300.0,MG,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Toxic epidermal necrolysis,,2020,Q1,1,I,20200131.0,20200226.0,20200310,20200310,EXP,,JP-JNJFOC-20200303902,JOHNSON AND JOHNSON,,87.0,YR,,F,Y,,,20200310.0,,PH,JP,JP,2020,Q1,Elderly
175258781,17525878,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,FOR THE PAST 2 YEARS,,,U,,,,,,,,,2020,Q1,Acute kidney injury,,2020,Q1,1,I,,20200303.0,20200310,20200310,PER,,US-009507513-2003USA001386,MERCK,"SHRIVASTAVA S, SRIVASTAVA N, ALFANSO-JAUME M.. ACUTE RENAL FAILURE WITH COCAINE AND SGLT-2 INHIBITOR. AMERICAN JOURNAL OF THERAPEUTICS. 2018;26 (6):E762-3",52.0,YR,,F,Y,,,20200310.0,,MD,US,US,2020,Q1,Adult
175266611,17526661,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",70300.0,MG,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Cervix carcinoma,,2020,Q1,1,I,20180502.0,20200227.0,20200311,20200311,EXP,,JP-JNJFOC-20200303820,JOHNSON AND JOHNSON,,45.0,YR,,F,Y,,,20200311.0,,MD,JP,JP,2020,Q1,Adult
175376812,17537681,7,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q1,Bradycardia,,2020,Q1,2,F,,20200311.0,20200313,20200323,EXP,,PL-AUROBINDO-AUR-APL-2020-012366,AUROBINDO,,74.0,YR,,F,Y,,,20200323.0,,HP,PL,PL,2020,Q1,Elderly
175376812,17537681,7,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q1,Dizziness,,2020,Q1,2,F,,20200311.0,20200313,20200323,EXP,,PL-AUROBINDO-AUR-APL-2020-012366,AUROBINDO,,74.0,YR,,F,Y,,,20200323.0,,HP,PL,PL,2020,Q1,Elderly
175376812,17537681,7,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q1,Drug interaction,,2020,Q1,2,F,,20200311.0,20200313,20200323,EXP,,PL-AUROBINDO-AUR-APL-2020-012366,AUROBINDO,,74.0,YR,,F,Y,,,20200323.0,,HP,PL,PL,2020,Q1,Elderly
175376812,17537681,7,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q1,Hypotension,,2020,Q1,2,F,,20200311.0,20200313,20200323,EXP,,PL-AUROBINDO-AUR-APL-2020-012366,AUROBINDO,,74.0,YR,,F,Y,,,20200323.0,,HP,PL,PL,2020,Q1,Elderly
175376812,17537681,7,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q1,Toxicity to various agents,,2020,Q1,2,F,,20200311.0,20200313,20200323,EXP,,PL-AUROBINDO-AUR-APL-2020-012366,AUROBINDO,,74.0,YR,,F,Y,,,20200323.0,,HP,PL,PL,2020,Q1,Elderly
175379221,17537922,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK, (STARTED-PAST 2 YEAR)",,,U,,,,,,,,,2020,Q1,Acute kidney injury,,2020,Q1,1,I,,20200303.0,20200313,20200313,PER,,US-APOTEX-2020AP008585,APOTEX,"SHRIVASTAVA S, SRIVASTAVA N, ALFANSO-JAUME M.. ACUTE RENAL FAILURE WITH COCAINE AND SGLT-2 INHIBITOR.. AMERICAN JOURNAL OF THERAPEUTICS. 2019;26 (6):E762-E763",52.0,YR,,F,Y,,,20200313.0,,MD,US,US,2020,Q1,Adult
175442591,17544259,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,204042.0,,,FILM-COATED TABLET,,2020,Q1,Product dose omission,,2020,Q1,1,I,201912.0,20200303.0,20200316,20200316,PER,,US-JNJFOC-20200307126,JOHNSON AND JOHNSON,,71.0,YR,,F,Y,,,20200316.0,,CN,US,US,2020,Q1,Elderly
175472551,17547255,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2020,Q1,Diabetic ketoacidosis,,2020,Q1,1,I,20200109.0,20200303.0,20200316,20200316,EXP,GB-MHRA-EYC 00216503,GB-JNJFOC-20200305947,JOHNSON AND JOHNSON,,62.0,YR,,F,Y,91.0,KG,20200316.0,,HP,GB,GB,2020,Q1,Adult
175472551,17547255,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2020,Q1,Influenza,,2020,Q1,1,I,20200109.0,20200303.0,20200316,20200316,EXP,GB-MHRA-EYC 00216503,GB-JNJFOC-20200305947,JOHNSON AND JOHNSON,,62.0,YR,,F,Y,91.0,KG,20200316.0,,HP,GB,GB,2020,Q1,Adult
175472551,17547255,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2020,Q1,Sepsis,,2020,Q1,1,I,20200109.0,20200303.0,20200316,20200316,EXP,GB-MHRA-EYC 00216503,GB-JNJFOC-20200305947,JOHNSON AND JOHNSON,,62.0,YR,,F,Y,91.0,KG,20200316.0,,HP,GB,GB,2020,Q1,Adult
175472551,17547255,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,300.0,MG,FILM-COATED TABLET,,2020,Q1,Diabetic ketoacidosis,,2020,Q1,1,I,20200109.0,20200303.0,20200316,20200316,EXP,GB-MHRA-EYC 00216503,GB-JNJFOC-20200305947,JOHNSON AND JOHNSON,,62.0,YR,,F,Y,91.0,KG,20200316.0,,HP,GB,GB,2020,Q1,Adult
175472551,17547255,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,300.0,MG,FILM-COATED TABLET,,2020,Q1,Influenza,,2020,Q1,1,I,20200109.0,20200303.0,20200316,20200316,EXP,GB-MHRA-EYC 00216503,GB-JNJFOC-20200305947,JOHNSON AND JOHNSON,,62.0,YR,,F,Y,91.0,KG,20200316.0,,HP,GB,GB,2020,Q1,Adult
175472551,17547255,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,300.0,MG,FILM-COATED TABLET,,2020,Q1,Sepsis,,2020,Q1,1,I,20200109.0,20200303.0,20200316,20200316,EXP,GB-MHRA-EYC 00216503,GB-JNJFOC-20200305947,JOHNSON AND JOHNSON,,62.0,YR,,F,Y,91.0,KG,20200316.0,,HP,GB,GB,2020,Q1,Adult
175532381,17553238,3,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q1,Acute kidney injury,,2020,Q1,1,I,,20200303.0,20200318,20200318,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-240367,RANBAXY,"SHRIVASTAVA S, SRIVASTAVA N, ALFANSO-JAUME M.. ACUTE RENAL FAILURE WITH COCAINE AND SGLT-2 INHIBITOR. AM J THER. 2018;26(6):E762-E763",52.0,YR,,F,Y,,,20200318.0,,MD,US,US,2020,Q1,Adult
175534661,17553466,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,204042.0,300.0,MG,FILM-COATED TABLET,,2020,Q1,International normalised ratio increased,,2020,Q1,1,I,20200214.0,20200304.0,20200317,20200317,EXP,GB-MHRA-ADR 24478185,GB-JNJFOC-20200306684,JOHNSON AND JOHNSON,,67.0,YR,,M,Y,110.0,KG,20200317.0,,PH,GB,GB,2020,Q1,Elderly
175582611,17558261,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Acute kidney injury,,2020,Q1,1,I,,20200309.0,20200319,20200319,EXP,,US-TEVA-2020-US-1204143,TEVA,"SHRIVASTAVA S, SRIVASTAVA N, ALFANSO-JAUME M. ACUTE RENAL FAILURE WITH COCAINE AND SGLT-2 INHIBITOR. AM-J-THER 2019;26(6):E762-E763.",52.0,YR,,F,Y,,,20200319.0,,MD,US,US,2020,Q1,Adult
175582611,17558261,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Anuria,,2020,Q1,1,I,,20200309.0,20200319,20200319,EXP,,US-TEVA-2020-US-1204143,TEVA,"SHRIVASTAVA S, SRIVASTAVA N, ALFANSO-JAUME M. ACUTE RENAL FAILURE WITH COCAINE AND SGLT-2 INHIBITOR. AM-J-THER 2019;26(6):E762-E763.",52.0,YR,,F,Y,,,20200319.0,,MD,US,US,2020,Q1,Adult
175582611,17558261,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q1,Hyperkalaemia,,2020,Q1,1,I,,20200309.0,20200319,20200319,EXP,,US-TEVA-2020-US-1204143,TEVA,"SHRIVASTAVA S, SRIVASTAVA N, ALFANSO-JAUME M. ACUTE RENAL FAILURE WITH COCAINE AND SGLT-2 INHIBITOR. AM-J-THER 2019;26(6):E762-E763.",52.0,YR,,F,Y,,,20200319.0,,MD,US,US,2020,Q1,Adult
175612311,17561231,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,, N/A,,204042.0,100.0,MG,FILM-COATED TABLET,,2020,Q1,Diabetic ketoacidosis,,2020,Q1,1,I,,20200309.0,20200319,20200319,EXP,GB-MHRA-EYC 00219150,GB-JNJFOC-20200314860,JOHNSON AND JOHNSON,,41.0,YR,,M,Y,134.0,KG,20200319.0,,HP,GB,GB,2020,Q1,Adult
175640611,17564061,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Endocervical,UNK,,,U,,,,,,,,,2020,Q1,Acute kidney injury,,2020,Q1,1,I,,20200310.0,20200320,20200320,EXP,,US-AUROBINDO-AUR-APL-2020-014003,AUROBINDO,,52.0,YR,,F,Y,,,20200320.0,,MD,US,US,2020,Q1,Adult
175663861,17566386,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2020,Q1,Diabetic ketoacidosis,,2020,Q1,1,I,20190801.0,20200311.0,20200320,20200320,EXP,GB-MHRA-EYC 00219479,GB-JNJFOC-20200319467,JOHNSON AND JOHNSON,,75.0,YR,,F,Y,91.0,KG,20200320.0,,PH,GB,GB,2020,Q1,Elderly
175759631,17575963,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,300.0,MG,TABLET,,2020,Q1,Rash,,2020,Q1,1,I,20200204.0,20200316.0,20200324,20200324,EXP,GB-MHRA-ADR 24481767,GB-ACCORD-176367,ACCORD,,73.0,YR,,M,Y,,,20200324.0,,CN,GB,GB,2020,Q1,Elderly
175759631,17575963,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,300.0,MG,TABLET,,2020,Q1,Skin disorder,,2020,Q1,1,I,20200204.0,20200316.0,20200324,20200324,EXP,GB-MHRA-ADR 24481767,GB-ACCORD-176367,ACCORD,,73.0,YR,,M,Y,,,20200324.0,,CN,GB,GB,2020,Q1,Elderly
175759631,17575963,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,300.0,MG,TABLET,,2020,Q1,Skin ulcer,,2020,Q1,1,I,20200204.0,20200316.0,20200324,20200324,EXP,GB-MHRA-ADR 24481767,GB-ACCORD-176367,ACCORD,,73.0,YR,,M,Y,,,20200324.0,,CN,GB,GB,2020,Q1,Elderly
175759631,17575963,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,300.0,MG,TABLET,,2020,Q1,Swelling,,2020,Q1,1,I,20200204.0,20200316.0,20200324,20200324,EXP,GB-MHRA-ADR 24481767,GB-ACCORD-176367,ACCORD,,73.0,YR,,M,Y,,,20200324.0,,CN,GB,GB,2020,Q1,Elderly
175837751,17583775,4,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,300 MILLIGRAM,,,U,,,,,300.0,MG,TABLET,,2020,Q1,Rash,,2020,Q1,1,I,20200204.0,20200316.0,20200326,20200326,EXP,GB-MHRA-EYC 00219887,GB-AUROBINDO-AUR-APL-2020-015084,AUROBINDO,,73.0,YR,,M,Y,,,20200326.0,,CN,GB,GB,2020,Q1,Elderly
175837751,17583775,4,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,300 MILLIGRAM,,,U,,,,,300.0,MG,TABLET,,2020,Q1,Skin disorder,,2020,Q1,1,I,20200204.0,20200316.0,20200326,20200326,EXP,GB-MHRA-EYC 00219887,GB-AUROBINDO-AUR-APL-2020-015084,AUROBINDO,,73.0,YR,,M,Y,,,20200326.0,,CN,GB,GB,2020,Q1,Elderly
175837751,17583775,4,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,300 MILLIGRAM,,,U,,,,,300.0,MG,TABLET,,2020,Q1,Skin ulcer,,2020,Q1,1,I,20200204.0,20200316.0,20200326,20200326,EXP,GB-MHRA-EYC 00219887,GB-AUROBINDO-AUR-APL-2020-015084,AUROBINDO,,73.0,YR,,M,Y,,,20200326.0,,CN,GB,GB,2020,Q1,Elderly
175837751,17583775,4,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,300 MILLIGRAM,,,U,,,,,300.0,MG,TABLET,,2020,Q1,Swelling,,2020,Q1,1,I,20200204.0,20200316.0,20200326,20200326,EXP,GB-MHRA-EYC 00219887,GB-AUROBINDO-AUR-APL-2020-015084,AUROBINDO,,73.0,YR,,M,Y,,,20200326.0,,CN,GB,GB,2020,Q1,Elderly
175837901,17583790,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,300 MG,,,,, UNKNOWN,,,300.0,MG,TABLET,,2020,Q1,Rash,,2020,Q1,1,I,20200204.0,20200318.0,20200326,20200326,EXP,GB-MHRA-EYC 00219887,GB-TEVA-2020-GB-1209826,TEVA,,73.0,YR,,M,Y,,,20200326.0,,CN,GB,GB,2020,Q1,Elderly
175837901,17583790,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,300 MG,,,,, UNKNOWN,,,300.0,MG,TABLET,,2020,Q1,Skin disorder,,2020,Q1,1,I,20200204.0,20200318.0,20200326,20200326,EXP,GB-MHRA-EYC 00219887,GB-TEVA-2020-GB-1209826,TEVA,,73.0,YR,,M,Y,,,20200326.0,,CN,GB,GB,2020,Q1,Elderly
175837901,17583790,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,300 MG,,,,, UNKNOWN,,,300.0,MG,TABLET,,2020,Q1,Skin ulcer,,2020,Q1,1,I,20200204.0,20200318.0,20200326,20200326,EXP,GB-MHRA-EYC 00219887,GB-TEVA-2020-GB-1209826,TEVA,,73.0,YR,,M,Y,,,20200326.0,,CN,GB,GB,2020,Q1,Elderly
175837901,17583790,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,300 MG,,,,, UNKNOWN,,,300.0,MG,TABLET,,2020,Q1,Swelling,,2020,Q1,1,I,20200204.0,20200318.0,20200326,20200326,EXP,GB-MHRA-EYC 00219887,GB-TEVA-2020-GB-1209826,TEVA,,73.0,YR,,M,Y,,,20200326.0,,CN,GB,GB,2020,Q1,Elderly
175838801,17583880,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,300 MILLIGRAM,,,U,,,,,300.0,MG,,,2020,Q1,Rash,,2020,Q1,1,I,20200204.0,20200316.0,20200326,20200326,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-023160,BRISTOL MYERS SQUIBB,,73.0,YR,,M,Y,,,20200326.0,,CN,GB,GB,2020,Q1,Elderly
175838801,17583880,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,300 MILLIGRAM,,,U,,,,,300.0,MG,,,2020,Q1,Skin disorder,,2020,Q1,1,I,20200204.0,20200316.0,20200326,20200326,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-023160,BRISTOL MYERS SQUIBB,,73.0,YR,,M,Y,,,20200326.0,,CN,GB,GB,2020,Q1,Elderly
175838801,17583880,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,300 MILLIGRAM,,,U,,,,,300.0,MG,,,2020,Q1,Skin ulcer,,2020,Q1,1,I,20200204.0,20200316.0,20200326,20200326,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-023160,BRISTOL MYERS SQUIBB,,73.0,YR,,M,Y,,,20200326.0,,CN,GB,GB,2020,Q1,Elderly
175838801,17583880,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,300 MILLIGRAM,,,U,,,,,300.0,MG,,,2020,Q1,Swelling,,2020,Q1,1,I,20200204.0,20200316.0,20200326,20200326,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-023160,BRISTOL MYERS SQUIBB,,73.0,YR,,M,Y,,,20200326.0,,CN,GB,GB,2020,Q1,Elderly
175928571,17592857,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,,,FILM-COATED TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20180731.0,20200327,20200327,EXP,,US-JNJFOC-20180801300,JOHNSON AND JOHNSON,"BOLLIMUNTA P, NAHA S, PANGINIKKOD S, JOHN S. THE MISLEADING BLOOD GLUCOSE LEVEL-AVOID DIAGNOSTIC DELAYS. ENDOCRINE REVIEWS 2018;39 (2 SUPPLEMENT 1).",57.0,YR,,M,Y,,,20200327.0,,MD,US,US,2020,Q1,Adult
175928581,17592858,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20180904.0,20200327,20200327,EXP,,TH-JNJFOC-20180903642,JOHNSON AND JOHNSON,"THEWJITCHAROEN Y, WANOTHAYAROJ E, TAMMAWIWAT C, MALIDAENG A, YENSEUNG N, NAKASATIEN S, ET AL. A SINGLE CENTER RETROSPECTIVE ANALYSIS OF SGLT2I-ASSOCIATED DIABETIC KETOACIDOSIS IN BANGKOK: THE ROLE OF POINT-OF-CARE BLOOD KETONE TESTING. JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY: CASE REPORTS 2018;10:8-10.",22.0,YR,,F,Y,,,20200327.0,,HP,TH,TH,2020,Q1,Youth
175928581,17592858,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Off label use,,2020,Q1,1,I,,20180904.0,20200327,20200327,EXP,,TH-JNJFOC-20180903642,JOHNSON AND JOHNSON,"THEWJITCHAROEN Y, WANOTHAYAROJ E, TAMMAWIWAT C, MALIDAENG A, YENSEUNG N, NAKASATIEN S, ET AL. A SINGLE CENTER RETROSPECTIVE ANALYSIS OF SGLT2I-ASSOCIATED DIABETIC KETOACIDOSIS IN BANGKOK: THE ROLE OF POINT-OF-CARE BLOOD KETONE TESTING. JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY: CASE REPORTS 2018;10:8-10.",22.0,YR,,F,Y,,,20200327.0,,HP,TH,TH,2020,Q1,Youth
175928581,17592858,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q1,Product use in unapproved indication,,2020,Q1,1,I,,20180904.0,20200327,20200327,EXP,,TH-JNJFOC-20180903642,JOHNSON AND JOHNSON,"THEWJITCHAROEN Y, WANOTHAYAROJ E, TAMMAWIWAT C, MALIDAENG A, YENSEUNG N, NAKASATIEN S, ET AL. A SINGLE CENTER RETROSPECTIVE ANALYSIS OF SGLT2I-ASSOCIATED DIABETIC KETOACIDOSIS IN BANGKOK: THE ROLE OF POINT-OF-CARE BLOOD KETONE TESTING. JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY: CASE REPORTS 2018;10:8-10.",22.0,YR,,F,Y,,,20200327.0,,HP,TH,TH,2020,Q1,Youth
175928591,17592859,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,SINCE 3 YEARS,,,,,,,204042.0,300.0,MG,FILM-COATED TABLET,QD,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20180605.0,20200327,20200327,EXP,,US-JNJFOC-20180608336,JOHNSON AND JOHNSON,"SHRESTHA P, KHAN MZ, MALLA S, CHWIECKO B. SEVERE EUGLYCEMIC DIABETIC KETOACIDOSIS ASSOCIATED WITH CANAGLIFLOZIN (INVOKANA): ^A BLACK BOX WARNING. JOURNAL OF GENERAL INTERNAL MEDICINE 2018;33 (2 SUPPLEMENT 1):617.",71.0,YR,,M,Y,,,20200327.0,,MD,US,US,2020,Q1,Elderly
175928701,17592870,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,,,FILM-COATED TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20181127.0,20200327,20200327,EXP,,GB-JNJFOC-20181139524,JOHNSON AND JOHNSON,,6.0,DEC,,M,Y,,,20200327.0,,MD,GB,GB,2020,Q1,Child
175928751,17592875,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,ADMINISTRATION PREFERABLY BEFORE BREAKFAST,,,Y,,,,204042.0,300.0,MG,FILM-COATED TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20181129.0,20200327,20200327,EXP,GB-MHRA-MIDB-40C62543-02FF-4044-B1DC-FFE8E74051AE,GB-JNJFOC-20181141574,JOHNSON AND JOHNSON,,52.0,YR,,F,Y,,,20200327.0,,PH,GB,GB,2020,Q1,Adult
175928751,17592875,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,ADMINISTRATION PREFERABLY BEFORE BREAKFAST,,,Y,,,,204042.0,300.0,MG,FILM-COATED TABLET,,2020,Q1,Urinary tract infection,,2020,Q1,1,I,,20181129.0,20200327,20200327,EXP,GB-MHRA-MIDB-40C62543-02FF-4044-B1DC-FFE8E74051AE,GB-JNJFOC-20181141574,JOHNSON AND JOHNSON,,52.0,YR,,F,Y,,,20200327.0,,PH,GB,GB,2020,Q1,Adult
175928761,17592876,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,,,FILM-COATED TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20181204.0,20200327,20200327,EXP,,US-JNJFOC-20181204862,JOHNSON AND JOHNSON,"PACE DJ, DUKLESKA K, PHILLIPS S, GLEASON V, YEO CJ. EUGLYCEMIC DIABETIC KETOACIDOSIS DUE TO SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITOR USE IN TWO PATIENTS UNDERGOING PANCREATECTOMY. JOURNAL OF PANCREATIC CANCER 01-NOV-2018;4/1:95-99.",66.0,YR,,F,Y,,,20200327.0,,HP,US,US,2020,Q1,Elderly
175930791,17593079,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,,,FILM-COATED TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20181112.0,20200327,20200327,EXP,,GR-JNJFOC-20181116173,JOHNSON AND JOHNSON,"PRODROMIADOU E, KONTRAFOURI P, KOURTI E, TSAKANIKAS A, KARAOLIA M, NTZIORA F, ET AL. EUGLYCEMIC DIABETIC KETOACIDOSIS IN PATIENT WITH DIABETES MELLITUS DURING ADMINISTRATION OF SODIUM-GLUCOSE CO-TRANSPORTER 2 (SGLT2) INHIBITORS. 2018.",65.0,YR,,F,Y,,,20200327.0,,MD,GR,GR,2020,Q1,Elderly
175931081,17593108,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2020,Q1,Balance disorder,,2020,Q1,1,I,20200228.0,20200317.0,20200327,20200327,EXP,GB-MHRA-EYC 00219785,GB-JNJFOC-20200326009,JOHNSON AND JOHNSON,,75.0,YR,,M,Y,82.0,KG,20200327.0,,CN,GB,GB,2020,Q1,Elderly
175931081,17593108,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2020,Q1,Limb discomfort,,2020,Q1,1,I,20200228.0,20200317.0,20200327,20200327,EXP,GB-MHRA-EYC 00219785,GB-JNJFOC-20200326009,JOHNSON AND JOHNSON,,75.0,YR,,M,Y,82.0,KG,20200327.0,,CN,GB,GB,2020,Q1,Elderly
175931081,17593108,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2020,Q1,Nausea,,2020,Q1,1,I,20200228.0,20200317.0,20200327,20200327,EXP,GB-MHRA-EYC 00219785,GB-JNJFOC-20200326009,JOHNSON AND JOHNSON,,75.0,YR,,M,Y,82.0,KG,20200327.0,,CN,GB,GB,2020,Q1,Elderly
175931081,17593108,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2020,Q1,Pollakiuria,,2020,Q1,1,I,20200228.0,20200317.0,20200327,20200327,EXP,GB-MHRA-EYC 00219785,GB-JNJFOC-20200326009,JOHNSON AND JOHNSON,,75.0,YR,,M,Y,82.0,KG,20200327.0,,CN,GB,GB,2020,Q1,Elderly
175931081,17593108,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2020,Q1,Somnolence,,2020,Q1,1,I,20200228.0,20200317.0,20200327,20200327,EXP,GB-MHRA-EYC 00219785,GB-JNJFOC-20200326009,JOHNSON AND JOHNSON,,75.0,YR,,M,Y,82.0,KG,20200327.0,,CN,GB,GB,2020,Q1,Elderly
176016931,17601693,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,FILM-COATED TABLET,,2020,Q1,Diabetic ketoacidosis,,2020,Q1,1,I,,20200318.0,20200330,20200330,EXP,GB-MHRA-EYC 00219824,GB-JNJFOC-20200327626,JOHNSON AND JOHNSON,,80.0,YR,,M,Y,,,20200330.0,,MD,GB,GB,2020,Q1,Elderly
111936022,11193602,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",,,Y,,,,,100.0,MG,TABLET,QD,2020,Q2,Abdominal pain upper,,2020,Q2,2,F,,20200424.0,20150616,20200430,EXP,,PHHY2015GB067909,NOVARTIS,,69.0,YR,,M,Y,,,20200430.0,,HP,GB,GB,2020,Q2,Elderly
111936022,11193602,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",,,Y,,,,,100.0,MG,TABLET,QD,2020,Q2,Pyrexia,,2020,Q2,2,F,,20200424.0,20150616,20200430,EXP,,PHHY2015GB067909,NOVARTIS,,69.0,YR,,M,Y,,,20200430.0,,HP,GB,GB,2020,Q2,Elderly
139845607,13984560,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2020,Q2,Acute kidney injury,,2020,Q2,7,F,,20200617.0,20170918,20200623,EXP,,PHHY2017AT137108,NOVARTIS,,71.0,YR,,M,Y,,,20200623.0,,HP,AT,AT,2020,Q2,Elderly
139845607,13984560,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2020,Q2,Anion gap increased,,2020,Q2,7,F,,20200617.0,20170918,20200623,EXP,,PHHY2017AT137108,NOVARTIS,,71.0,YR,,M,Y,,,20200623.0,,HP,AT,AT,2020,Q2,Elderly
139845607,13984560,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2020,Q2,Base excess decreased,,2020,Q2,7,F,,20200617.0,20170918,20200623,EXP,,PHHY2017AT137108,NOVARTIS,,71.0,YR,,M,Y,,,20200623.0,,HP,AT,AT,2020,Q2,Elderly
139845607,13984560,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2020,Q2,Blood bicarbonate decreased,,2020,Q2,7,F,,20200617.0,20170918,20200623,EXP,,PHHY2017AT137108,NOVARTIS,,71.0,YR,,M,Y,,,20200623.0,,HP,AT,AT,2020,Q2,Elderly
139845607,13984560,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2020,Q2,Blood lactic acid increased,,2020,Q2,7,F,,20200617.0,20170918,20200623,EXP,,PHHY2017AT137108,NOVARTIS,,71.0,YR,,M,Y,,,20200623.0,,HP,AT,AT,2020,Q2,Elderly
139845607,13984560,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2020,Q2,Blood pH decreased,,2020,Q2,7,F,,20200617.0,20170918,20200623,EXP,,PHHY2017AT137108,NOVARTIS,,71.0,YR,,M,Y,,,20200623.0,,HP,AT,AT,2020,Q2,Elderly
139845607,13984560,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2020,Q2,Body temperature decreased,,2020,Q2,7,F,,20200617.0,20170918,20200623,EXP,,PHHY2017AT137108,NOVARTIS,,71.0,YR,,M,Y,,,20200623.0,,HP,AT,AT,2020,Q2,Elderly
139845607,13984560,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2020,Q2,Diabetic ketoacidosis,,2020,Q2,7,F,,20200617.0,20170918,20200623,EXP,,PHHY2017AT137108,NOVARTIS,,71.0,YR,,M,Y,,,20200623.0,,HP,AT,AT,2020,Q2,Elderly
139845607,13984560,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2020,Q2,Hyperventilation,,2020,Q2,7,F,,20200617.0,20170918,20200623,EXP,,PHHY2017AT137108,NOVARTIS,,71.0,YR,,M,Y,,,20200623.0,,HP,AT,AT,2020,Q2,Elderly
139845607,13984560,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2020,Q2,Hypotension,,2020,Q2,7,F,,20200617.0,20170918,20200623,EXP,,PHHY2017AT137108,NOVARTIS,,71.0,YR,,M,Y,,,20200623.0,,HP,AT,AT,2020,Q2,Elderly
139845607,13984560,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2020,Q2,Kussmaul respiration,,2020,Q2,7,F,,20200617.0,20170918,20200623,EXP,,PHHY2017AT137108,NOVARTIS,,71.0,YR,,M,Y,,,20200623.0,,HP,AT,AT,2020,Q2,Elderly
139845607,13984560,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2020,Q2,Lactic acidosis,,2020,Q2,7,F,,20200617.0,20170918,20200623,EXP,,PHHY2017AT137108,NOVARTIS,,71.0,YR,,M,Y,,,20200623.0,,HP,AT,AT,2020,Q2,Elderly
139845607,13984560,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2020,Q2,Nausea,,2020,Q2,7,F,,20200617.0,20170918,20200623,EXP,,PHHY2017AT137108,NOVARTIS,,71.0,YR,,M,Y,,,20200623.0,,HP,AT,AT,2020,Q2,Elderly
139845607,13984560,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2020,Q2,PCO2 decreased,,2020,Q2,7,F,,20200617.0,20170918,20200623,EXP,,PHHY2017AT137108,NOVARTIS,,71.0,YR,,M,Y,,,20200623.0,,HP,AT,AT,2020,Q2,Elderly
139845607,13984560,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2020,Q2,Pneumonia,,2020,Q2,7,F,,20200617.0,20170918,20200623,EXP,,PHHY2017AT137108,NOVARTIS,,71.0,YR,,M,Y,,,20200623.0,,HP,AT,AT,2020,Q2,Elderly
139845607,13984560,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2020,Q2,Somnolence,,2020,Q2,7,F,,20200617.0,20170918,20200623,EXP,,PHHY2017AT137108,NOVARTIS,,71.0,YR,,M,Y,,,20200623.0,,HP,AT,AT,2020,Q2,Elderly
139845607,13984560,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2020,Q2,Vomiting,,2020,Q2,7,F,,20200617.0,20170918,20200623,EXP,,PHHY2017AT137108,NOVARTIS,,71.0,YR,,M,Y,,,20200623.0,,HP,AT,AT,2020,Q2,Elderly
140337839,14033783,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q2,Acute kidney injury,,2020,Q2,9,F,,20200421.0,20171003,20200501,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20200502.0,,MD,AT,AT,2020,Q2,Elderly
140337839,14033783,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q2,Anion gap increased,,2020,Q2,9,F,,20200421.0,20171003,20200501,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20200502.0,,MD,AT,AT,2020,Q2,Elderly
140337839,14033783,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q2,Base excess decreased,,2020,Q2,9,F,,20200421.0,20171003,20200501,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20200502.0,,MD,AT,AT,2020,Q2,Elderly
140337839,14033783,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q2,Blood bicarbonate decreased,,2020,Q2,9,F,,20200421.0,20171003,20200501,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20200502.0,,MD,AT,AT,2020,Q2,Elderly
140337839,14033783,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q2,Blood lactic acid increased,,2020,Q2,9,F,,20200421.0,20171003,20200501,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20200502.0,,MD,AT,AT,2020,Q2,Elderly
140337839,14033783,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q2,Blood pH decreased,,2020,Q2,9,F,,20200421.0,20171003,20200501,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20200502.0,,MD,AT,AT,2020,Q2,Elderly
140337839,14033783,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q2,Body temperature decreased,,2020,Q2,9,F,,20200421.0,20171003,20200501,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20200502.0,,MD,AT,AT,2020,Q2,Elderly
140337839,14033783,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q2,Diabetic ketoacidosis,,2020,Q2,9,F,,20200421.0,20171003,20200501,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20200502.0,,MD,AT,AT,2020,Q2,Elderly
140337839,14033783,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q2,Hyperventilation,,2020,Q2,9,F,,20200421.0,20171003,20200501,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20200502.0,,MD,AT,AT,2020,Q2,Elderly
140337839,14033783,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q2,Hypotension,,2020,Q2,9,F,,20200421.0,20171003,20200501,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20200502.0,,MD,AT,AT,2020,Q2,Elderly
140337839,14033783,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q2,Ketoacidosis,,2020,Q2,9,F,,20200421.0,20171003,20200501,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20200502.0,,MD,AT,AT,2020,Q2,Elderly
140337839,14033783,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q2,Lactic acidosis,,2020,Q2,9,F,,20200421.0,20171003,20200501,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20200502.0,,MD,AT,AT,2020,Q2,Elderly
140337839,14033783,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q2,PCO2 decreased,,2020,Q2,9,F,,20200421.0,20171003,20200501,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20200502.0,,MD,AT,AT,2020,Q2,Elderly
140369185,14036918,11,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,TABLET,,2020,Q2,Arthralgia,,2020,Q2,5,F,201605.0,20180514.0,20171004,20200601,EXP,,US-UCBSA-2016020304,UCB,,65.0,YR,,F,Y,,,20200601.0,,PH,US,US,2020,Q2,Elderly
140369185,14036918,11,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,TABLET,,2020,Q2,Arthritis,,2020,Q2,5,F,201605.0,20180514.0,20171004,20200601,EXP,,US-UCBSA-2016020304,UCB,,65.0,YR,,F,Y,,,20200601.0,,PH,US,US,2020,Q2,Elderly
140369185,14036918,11,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,TABLET,,2020,Q2,Bronchitis,,2020,Q2,5,F,201605.0,20180514.0,20171004,20200601,EXP,,US-UCBSA-2016020304,UCB,,65.0,YR,,F,Y,,,20200601.0,,PH,US,US,2020,Q2,Elderly
140369185,14036918,11,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,TABLET,,2020,Q2,Pneumonia,,2020,Q2,5,F,201605.0,20180514.0,20171004,20200601,EXP,,US-UCBSA-2016020304,UCB,,65.0,YR,,F,Y,,,20200601.0,,PH,US,US,2020,Q2,Elderly
140369185,14036918,11,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,TABLET,,2020,Q2,Rheumatoid arthritis,,2020,Q2,5,F,201605.0,20180514.0,20171004,20200601,EXP,,US-UCBSA-2016020304,UCB,,65.0,YR,,F,Y,,,20200601.0,,PH,US,US,2020,Q2,Elderly
140369185,14036918,11,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,TABLET,,2020,Q2,Sinusitis,,2020,Q2,5,F,201605.0,20180514.0,20171004,20200601,EXP,,US-UCBSA-2016020304,UCB,,65.0,YR,,F,Y,,,20200601.0,,PH,US,US,2020,Q2,Elderly
142924636,14292463,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Hypoacusis,,2020,Q2,6,F,20171016.0,20200507.0,20171215,20200512,EXP,,US-ROCHE-2035495,ROCHE,,64.0,YR,,F,Y,73.1,KG,20200512.0,,MD,US,US,2020,Q2,Adult
155286192,15528619,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,300.0,MG,FILM-COATED TABLET,QD,2020,Q2,Acute kidney injury,,2020,Q2,2,F,2018.0,20200519.0,20181018,20200528,EXP,,US-JNJFOC-20181018748,JOHNSON AND JOHNSON,"PHADKE G, A, TOLAN D, HAHN K, JENSEN T, BJORNSTAD P. OSMOTIC NEPHROSIS AND ACUTE KIDNEY INJURY ASSOCIATED WITH SGLT2 INHIBITOR USE: A CASE REPORT.. AM J KIDNEY DIS. 2020;.",66.0,YR,,M,Y,175.0,KG,20200528.0,,MD,US,US,2020,Q2,Elderly
155286192,15528619,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,300.0,MG,FILM-COATED TABLET,QD,2020,Q2,Nephrotic syndrome,,2020,Q2,2,F,2018.0,20200519.0,20181018,20200528,EXP,,US-JNJFOC-20181018748,JOHNSON AND JOHNSON,"PHADKE G, A, TOLAN D, HAHN K, JENSEN T, BJORNSTAD P. OSMOTIC NEPHROSIS AND ACUTE KIDNEY INJURY ASSOCIATED WITH SGLT2 INHIBITOR USE: A CASE REPORT.. AM J KIDNEY DIS. 2020;.",66.0,YR,,M,Y,175.0,KG,20200528.0,,MD,US,US,2020,Q2,Elderly
155286192,15528619,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,300.0,MG,FILM-COATED TABLET,QD,2020,Q2,Renal impairment,,2020,Q2,2,F,2018.0,20200519.0,20181018,20200528,EXP,,US-JNJFOC-20181018748,JOHNSON AND JOHNSON,"PHADKE G, A, TOLAN D, HAHN K, JENSEN T, BJORNSTAD P. OSMOTIC NEPHROSIS AND ACUTE KIDNEY INJURY ASSOCIATED WITH SGLT2 INHIBITOR USE: A CASE REPORT.. AM J KIDNEY DIS. 2020;.",66.0,YR,,M,Y,175.0,KG,20200528.0,,MD,US,US,2020,Q2,Elderly
156798835,15679883,7,SS,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM DAILY;,,,U,,,,,300.0,MG,,QD,2020,Q2,Acute kidney injury,,2020,Q2,5,F,,20200615.0,20181203,20200622,EXP,,CA-TEVA-2018-CA-981537,TEVA,,37.0,YR,,F,Y,158.9,KG,20200623.0,,PH,CA,CA,2020,Q2,Adult
156798835,15679883,7,SS,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM DAILY;,,,U,,,,,300.0,MG,,QD,2020,Q2,Sepsis,,2020,Q2,5,F,,20200615.0,20181203,20200622,EXP,,CA-TEVA-2018-CA-981537,TEVA,,37.0,YR,,F,Y,158.9,KG,20200623.0,,PH,CA,CA,2020,Q2,Adult
168977068,16897706,3,C,Canagliflozin,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,TABLET,QD,2020,Q2,Abdominal pain upper,,2020,Q2,8,F,,20200502.0,20191009,20200512,EXP,,PT-AUROBINDO-AUR-APL-2019-064795,AUROBINDO,,76.0,YR,,M,Y,,,20200512.0,,HP,PT,PT,2020,Q2,Elderly
168977068,16897706,3,C,Canagliflozin,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,TABLET,QD,2020,Q2,Acute kidney injury,,2020,Q2,8,F,,20200502.0,20191009,20200512,EXP,,PT-AUROBINDO-AUR-APL-2019-064795,AUROBINDO,,76.0,YR,,M,Y,,,20200512.0,,HP,PT,PT,2020,Q2,Elderly
168977068,16897706,3,C,Canagliflozin,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,TABLET,QD,2020,Q2,Blood bicarbonate decreased,,2020,Q2,8,F,,20200502.0,20191009,20200512,EXP,,PT-AUROBINDO-AUR-APL-2019-064795,AUROBINDO,,76.0,YR,,M,Y,,,20200512.0,,HP,PT,PT,2020,Q2,Elderly
168977068,16897706,3,C,Canagliflozin,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,TABLET,QD,2020,Q2,Blood lactic acid increased,,2020,Q2,8,F,,20200502.0,20191009,20200512,EXP,,PT-AUROBINDO-AUR-APL-2019-064795,AUROBINDO,,76.0,YR,,M,Y,,,20200512.0,,HP,PT,PT,2020,Q2,Elderly
168977068,16897706,3,C,Canagliflozin,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,TABLET,QD,2020,Q2,Drug interaction,,2020,Q2,8,F,,20200502.0,20191009,20200512,EXP,,PT-AUROBINDO-AUR-APL-2019-064795,AUROBINDO,,76.0,YR,,M,Y,,,20200512.0,,HP,PT,PT,2020,Q2,Elderly
168977068,16897706,3,C,Canagliflozin,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,TABLET,QD,2020,Q2,Dyspnoea,,2020,Q2,8,F,,20200502.0,20191009,20200512,EXP,,PT-AUROBINDO-AUR-APL-2019-064795,AUROBINDO,,76.0,YR,,M,Y,,,20200512.0,,HP,PT,PT,2020,Q2,Elderly
168977068,16897706,3,C,Canagliflozin,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,TABLET,QD,2020,Q2,Emotional distress,,2020,Q2,8,F,,20200502.0,20191009,20200512,EXP,,PT-AUROBINDO-AUR-APL-2019-064795,AUROBINDO,,76.0,YR,,M,Y,,,20200512.0,,HP,PT,PT,2020,Q2,Elderly
168977068,16897706,3,C,Canagliflozin,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,TABLET,QD,2020,Q2,Fatigue,,2020,Q2,8,F,,20200502.0,20191009,20200512,EXP,,PT-AUROBINDO-AUR-APL-2019-064795,AUROBINDO,,76.0,YR,,M,Y,,,20200512.0,,HP,PT,PT,2020,Q2,Elderly
168977068,16897706,3,C,Canagliflozin,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,TABLET,QD,2020,Q2,Feeling abnormal,,2020,Q2,8,F,,20200502.0,20191009,20200512,EXP,,PT-AUROBINDO-AUR-APL-2019-064795,AUROBINDO,,76.0,YR,,M,Y,,,20200512.0,,HP,PT,PT,2020,Q2,Elderly
168977068,16897706,3,C,Canagliflozin,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,TABLET,QD,2020,Q2,Hyperhidrosis,,2020,Q2,8,F,,20200502.0,20191009,20200512,EXP,,PT-AUROBINDO-AUR-APL-2019-064795,AUROBINDO,,76.0,YR,,M,Y,,,20200512.0,,HP,PT,PT,2020,Q2,Elderly
168977068,16897706,3,C,Canagliflozin,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,TABLET,QD,2020,Q2,Hypotension,,2020,Q2,8,F,,20200502.0,20191009,20200512,EXP,,PT-AUROBINDO-AUR-APL-2019-064795,AUROBINDO,,76.0,YR,,M,Y,,,20200512.0,,HP,PT,PT,2020,Q2,Elderly
168977068,16897706,3,C,Canagliflozin,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,TABLET,QD,2020,Q2,Lactic acidosis,,2020,Q2,8,F,,20200502.0,20191009,20200512,EXP,,PT-AUROBINDO-AUR-APL-2019-064795,AUROBINDO,,76.0,YR,,M,Y,,,20200512.0,,HP,PT,PT,2020,Q2,Elderly
168977068,16897706,3,C,Canagliflozin,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,TABLET,QD,2020,Q2,Metabolic acidosis,,2020,Q2,8,F,,20200502.0,20191009,20200512,EXP,,PT-AUROBINDO-AUR-APL-2019-064795,AUROBINDO,,76.0,YR,,M,Y,,,20200512.0,,HP,PT,PT,2020,Q2,Elderly
168977068,16897706,3,C,Canagliflozin,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,TABLET,QD,2020,Q2,Pallor,,2020,Q2,8,F,,20200502.0,20191009,20200512,EXP,,PT-AUROBINDO-AUR-APL-2019-064795,AUROBINDO,,76.0,YR,,M,Y,,,20200512.0,,HP,PT,PT,2020,Q2,Elderly
168977068,16897706,3,C,Canagliflozin,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,TABLET,QD,2020,Q2,Palpitations,,2020,Q2,8,F,,20200502.0,20191009,20200512,EXP,,PT-AUROBINDO-AUR-APL-2019-064795,AUROBINDO,,76.0,YR,,M,Y,,,20200512.0,,HP,PT,PT,2020,Q2,Elderly
168977068,16897706,3,C,Canagliflozin,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,TABLET,QD,2020,Q2,Renal impairment,,2020,Q2,8,F,,20200502.0,20191009,20200512,EXP,,PT-AUROBINDO-AUR-APL-2019-064795,AUROBINDO,,76.0,YR,,M,Y,,,20200512.0,,HP,PT,PT,2020,Q2,Elderly
168977068,16897706,3,C,Canagliflozin,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,TABLET,QD,2020,Q2,Vomiting,,2020,Q2,8,F,,20200502.0,20191009,20200512,EXP,,PT-AUROBINDO-AUR-APL-2019-064795,AUROBINDO,,76.0,YR,,M,Y,,,20200512.0,,HP,PT,PT,2020,Q2,Elderly
169004803,16900480,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,1.0,DF,TABLET,QD,2020,Q2,Acute kidney injury,,2020,Q2,3,F,,20200428.0,20191009,20200501,EXP,,PT-MYLANLABS-2019M1094528,MYLAN,,76.0,YR,,M,Y,,,20200501.0,,MD,PT,PT,2020,Q2,Elderly
169004803,16900480,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,1.0,DF,TABLET,QD,2020,Q2,Blood bicarbonate decreased,,2020,Q2,3,F,,20200428.0,20191009,20200501,EXP,,PT-MYLANLABS-2019M1094528,MYLAN,,76.0,YR,,M,Y,,,20200501.0,,MD,PT,PT,2020,Q2,Elderly
169004803,16900480,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,1.0,DF,TABLET,QD,2020,Q2,Blood lactic acid increased,,2020,Q2,3,F,,20200428.0,20191009,20200501,EXP,,PT-MYLANLABS-2019M1094528,MYLAN,,76.0,YR,,M,Y,,,20200501.0,,MD,PT,PT,2020,Q2,Elderly
169004803,16900480,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,1.0,DF,TABLET,QD,2020,Q2,Drug interaction,,2020,Q2,3,F,,20200428.0,20191009,20200501,EXP,,PT-MYLANLABS-2019M1094528,MYLAN,,76.0,YR,,M,Y,,,20200501.0,,MD,PT,PT,2020,Q2,Elderly
169004803,16900480,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,1.0,DF,TABLET,QD,2020,Q2,Dyspnoea,,2020,Q2,3,F,,20200428.0,20191009,20200501,EXP,,PT-MYLANLABS-2019M1094528,MYLAN,,76.0,YR,,M,Y,,,20200501.0,,MD,PT,PT,2020,Q2,Elderly
169004803,16900480,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,1.0,DF,TABLET,QD,2020,Q2,Emotional distress,,2020,Q2,3,F,,20200428.0,20191009,20200501,EXP,,PT-MYLANLABS-2019M1094528,MYLAN,,76.0,YR,,M,Y,,,20200501.0,,MD,PT,PT,2020,Q2,Elderly
169004803,16900480,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,1.0,DF,TABLET,QD,2020,Q2,Fatigue,,2020,Q2,3,F,,20200428.0,20191009,20200501,EXP,,PT-MYLANLABS-2019M1094528,MYLAN,,76.0,YR,,M,Y,,,20200501.0,,MD,PT,PT,2020,Q2,Elderly
169004803,16900480,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,1.0,DF,TABLET,QD,2020,Q2,Hyperhidrosis,,2020,Q2,3,F,,20200428.0,20191009,20200501,EXP,,PT-MYLANLABS-2019M1094528,MYLAN,,76.0,YR,,M,Y,,,20200501.0,,MD,PT,PT,2020,Q2,Elderly
169004803,16900480,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,1.0,DF,TABLET,QD,2020,Q2,Hypotension,,2020,Q2,3,F,,20200428.0,20191009,20200501,EXP,,PT-MYLANLABS-2019M1094528,MYLAN,,76.0,YR,,M,Y,,,20200501.0,,MD,PT,PT,2020,Q2,Elderly
169004803,16900480,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,1.0,DF,TABLET,QD,2020,Q2,Lactic acidosis,,2020,Q2,3,F,,20200428.0,20191009,20200501,EXP,,PT-MYLANLABS-2019M1094528,MYLAN,,76.0,YR,,M,Y,,,20200501.0,,MD,PT,PT,2020,Q2,Elderly
169004803,16900480,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,1.0,DF,TABLET,QD,2020,Q2,Metabolic acidosis,,2020,Q2,3,F,,20200428.0,20191009,20200501,EXP,,PT-MYLANLABS-2019M1094528,MYLAN,,76.0,YR,,M,Y,,,20200501.0,,MD,PT,PT,2020,Q2,Elderly
169004803,16900480,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,1.0,DF,TABLET,QD,2020,Q2,Pallor,,2020,Q2,3,F,,20200428.0,20191009,20200501,EXP,,PT-MYLANLABS-2019M1094528,MYLAN,,76.0,YR,,M,Y,,,20200501.0,,MD,PT,PT,2020,Q2,Elderly
169004803,16900480,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,1.0,DF,TABLET,QD,2020,Q2,Palpitations,,2020,Q2,3,F,,20200428.0,20191009,20200501,EXP,,PT-MYLANLABS-2019M1094528,MYLAN,,76.0,YR,,M,Y,,,20200501.0,,MD,PT,PT,2020,Q2,Elderly
169004803,16900480,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,1.0,DF,TABLET,QD,2020,Q2,Vomiting,,2020,Q2,3,F,,20200428.0,20191009,20200501,EXP,,PT-MYLANLABS-2019M1094528,MYLAN,,76.0,YR,,M,Y,,,20200501.0,,MD,PT,PT,2020,Q2,Elderly
171190232,17119023,4,C,Canagliflozin,CANAGLIFLOZIN,1,,100 MG,,,U,U,,,,,,TABLET,,2020,Q2,Abdominal distension,,2020,Q2,2,F,2017.0,20171103.0,20191206,20200528,PER,,US-UCBSA-2017032095,UCB,,36.0,YR,,M,Y,,,20200528.0,,PH,US,US,2020,Q2,Adult
171190232,17119023,4,C,Canagliflozin,CANAGLIFLOZIN,1,,100 MG,,,U,U,,,,,,TABLET,,2020,Q2,Constipation,,2020,Q2,2,F,2017.0,20171103.0,20191206,20200528,PER,,US-UCBSA-2017032095,UCB,,36.0,YR,,M,Y,,,20200528.0,,PH,US,US,2020,Q2,Adult
171190232,17119023,4,C,Canagliflozin,CANAGLIFLOZIN,1,,100 MG,,,U,U,,,,,,TABLET,,2020,Q2,Crohn's disease,,2020,Q2,2,F,2017.0,20171103.0,20191206,20200528,PER,,US-UCBSA-2017032095,UCB,,36.0,YR,,M,Y,,,20200528.0,,PH,US,US,2020,Q2,Adult
171190232,17119023,4,C,Canagliflozin,CANAGLIFLOZIN,1,,100 MG,,,U,U,,,,,,TABLET,,2020,Q2,Diarrhoea,,2020,Q2,2,F,2017.0,20171103.0,20191206,20200528,PER,,US-UCBSA-2017032095,UCB,,36.0,YR,,M,Y,,,20200528.0,,PH,US,US,2020,Q2,Adult
171190232,17119023,4,C,Canagliflozin,CANAGLIFLOZIN,1,,100 MG,,,U,U,,,,,,TABLET,,2020,Q2,Pain,,2020,Q2,2,F,2017.0,20171103.0,20191206,20200528,PER,,US-UCBSA-2017032095,UCB,,36.0,YR,,M,Y,,,20200528.0,,PH,US,US,2020,Q2,Adult
171427576,17142757,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY,,,U,U,,,,100.0,MG,,QD,2020,Q2,Abdominal pain upper,,2020,Q2,6,F,,20200622.0,20191211,20200628,EXP,,NVSC2019PT057912,NOVARTIS,"SANTOS MB, GARCA M, COTA P, AVILA P, SANTOS A. METFORMIN-ASSOCIATED LACTIC ACIDOSIS, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION. MEDICINA INTERNA-CONGRESSO NACIONAL. 2019",76.0,YR,,M,Y,,,20200628.0,,HP,PT,PT,2020,Q2,Elderly
171427576,17142757,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY,,,U,U,,,,100.0,MG,,QD,2020,Q2,Acidosis,,2020,Q2,6,F,,20200622.0,20191211,20200628,EXP,,NVSC2019PT057912,NOVARTIS,"SANTOS MB, GARCA M, COTA P, AVILA P, SANTOS A. METFORMIN-ASSOCIATED LACTIC ACIDOSIS, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION. MEDICINA INTERNA-CONGRESSO NACIONAL. 2019",76.0,YR,,M,Y,,,20200628.0,,HP,PT,PT,2020,Q2,Elderly
171427576,17142757,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY,,,U,U,,,,100.0,MG,,QD,2020,Q2,Acute kidney injury,,2020,Q2,6,F,,20200622.0,20191211,20200628,EXP,,NVSC2019PT057912,NOVARTIS,"SANTOS MB, GARCA M, COTA P, AVILA P, SANTOS A. METFORMIN-ASSOCIATED LACTIC ACIDOSIS, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION. MEDICINA INTERNA-CONGRESSO NACIONAL. 2019",76.0,YR,,M,Y,,,20200628.0,,HP,PT,PT,2020,Q2,Elderly
171427576,17142757,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY,,,U,U,,,,100.0,MG,,QD,2020,Q2,Blood bicarbonate decreased,,2020,Q2,6,F,,20200622.0,20191211,20200628,EXP,,NVSC2019PT057912,NOVARTIS,"SANTOS MB, GARCA M, COTA P, AVILA P, SANTOS A. METFORMIN-ASSOCIATED LACTIC ACIDOSIS, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION. MEDICINA INTERNA-CONGRESSO NACIONAL. 2019",76.0,YR,,M,Y,,,20200628.0,,HP,PT,PT,2020,Q2,Elderly
171427576,17142757,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY,,,U,U,,,,100.0,MG,,QD,2020,Q2,Blood lactic acid increased,,2020,Q2,6,F,,20200622.0,20191211,20200628,EXP,,NVSC2019PT057912,NOVARTIS,"SANTOS MB, GARCA M, COTA P, AVILA P, SANTOS A. METFORMIN-ASSOCIATED LACTIC ACIDOSIS, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION. MEDICINA INTERNA-CONGRESSO NACIONAL. 2019",76.0,YR,,M,Y,,,20200628.0,,HP,PT,PT,2020,Q2,Elderly
171427576,17142757,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY,,,U,U,,,,100.0,MG,,QD,2020,Q2,Drug interaction,,2020,Q2,6,F,,20200622.0,20191211,20200628,EXP,,NVSC2019PT057912,NOVARTIS,"SANTOS MB, GARCA M, COTA P, AVILA P, SANTOS A. METFORMIN-ASSOCIATED LACTIC ACIDOSIS, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION. MEDICINA INTERNA-CONGRESSO NACIONAL. 2019",76.0,YR,,M,Y,,,20200628.0,,HP,PT,PT,2020,Q2,Elderly
171427576,17142757,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY,,,U,U,,,,100.0,MG,,QD,2020,Q2,Dyspnoea,,2020,Q2,6,F,,20200622.0,20191211,20200628,EXP,,NVSC2019PT057912,NOVARTIS,"SANTOS MB, GARCA M, COTA P, AVILA P, SANTOS A. METFORMIN-ASSOCIATED LACTIC ACIDOSIS, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION. MEDICINA INTERNA-CONGRESSO NACIONAL. 2019",76.0,YR,,M,Y,,,20200628.0,,HP,PT,PT,2020,Q2,Elderly
171427576,17142757,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY,,,U,U,,,,100.0,MG,,QD,2020,Q2,Emotional distress,,2020,Q2,6,F,,20200622.0,20191211,20200628,EXP,,NVSC2019PT057912,NOVARTIS,"SANTOS MB, GARCA M, COTA P, AVILA P, SANTOS A. METFORMIN-ASSOCIATED LACTIC ACIDOSIS, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION. MEDICINA INTERNA-CONGRESSO NACIONAL. 2019",76.0,YR,,M,Y,,,20200628.0,,HP,PT,PT,2020,Q2,Elderly
171427576,17142757,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY,,,U,U,,,,100.0,MG,,QD,2020,Q2,Fatigue,,2020,Q2,6,F,,20200622.0,20191211,20200628,EXP,,NVSC2019PT057912,NOVARTIS,"SANTOS MB, GARCA M, COTA P, AVILA P, SANTOS A. METFORMIN-ASSOCIATED LACTIC ACIDOSIS, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION. MEDICINA INTERNA-CONGRESSO NACIONAL. 2019",76.0,YR,,M,Y,,,20200628.0,,HP,PT,PT,2020,Q2,Elderly
171427576,17142757,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY,,,U,U,,,,100.0,MG,,QD,2020,Q2,Feeling abnormal,,2020,Q2,6,F,,20200622.0,20191211,20200628,EXP,,NVSC2019PT057912,NOVARTIS,"SANTOS MB, GARCA M, COTA P, AVILA P, SANTOS A. METFORMIN-ASSOCIATED LACTIC ACIDOSIS, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION. MEDICINA INTERNA-CONGRESSO NACIONAL. 2019",76.0,YR,,M,Y,,,20200628.0,,HP,PT,PT,2020,Q2,Elderly
171427576,17142757,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY,,,U,U,,,,100.0,MG,,QD,2020,Q2,Hyperhidrosis,,2020,Q2,6,F,,20200622.0,20191211,20200628,EXP,,NVSC2019PT057912,NOVARTIS,"SANTOS MB, GARCA M, COTA P, AVILA P, SANTOS A. METFORMIN-ASSOCIATED LACTIC ACIDOSIS, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION. MEDICINA INTERNA-CONGRESSO NACIONAL. 2019",76.0,YR,,M,Y,,,20200628.0,,HP,PT,PT,2020,Q2,Elderly
171427576,17142757,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY,,,U,U,,,,100.0,MG,,QD,2020,Q2,Hypotension,,2020,Q2,6,F,,20200622.0,20191211,20200628,EXP,,NVSC2019PT057912,NOVARTIS,"SANTOS MB, GARCA M, COTA P, AVILA P, SANTOS A. METFORMIN-ASSOCIATED LACTIC ACIDOSIS, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION. MEDICINA INTERNA-CONGRESSO NACIONAL. 2019",76.0,YR,,M,Y,,,20200628.0,,HP,PT,PT,2020,Q2,Elderly
171427576,17142757,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY,,,U,U,,,,100.0,MG,,QD,2020,Q2,Lactic acidosis,,2020,Q2,6,F,,20200622.0,20191211,20200628,EXP,,NVSC2019PT057912,NOVARTIS,"SANTOS MB, GARCA M, COTA P, AVILA P, SANTOS A. METFORMIN-ASSOCIATED LACTIC ACIDOSIS, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION. MEDICINA INTERNA-CONGRESSO NACIONAL. 2019",76.0,YR,,M,Y,,,20200628.0,,HP,PT,PT,2020,Q2,Elderly
171427576,17142757,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY,,,U,U,,,,100.0,MG,,QD,2020,Q2,Metabolic acidosis,,2020,Q2,6,F,,20200622.0,20191211,20200628,EXP,,NVSC2019PT057912,NOVARTIS,"SANTOS MB, GARCA M, COTA P, AVILA P, SANTOS A. METFORMIN-ASSOCIATED LACTIC ACIDOSIS, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION. MEDICINA INTERNA-CONGRESSO NACIONAL. 2019",76.0,YR,,M,Y,,,20200628.0,,HP,PT,PT,2020,Q2,Elderly
171427576,17142757,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY,,,U,U,,,,100.0,MG,,QD,2020,Q2,Pallor,,2020,Q2,6,F,,20200622.0,20191211,20200628,EXP,,NVSC2019PT057912,NOVARTIS,"SANTOS MB, GARCA M, COTA P, AVILA P, SANTOS A. METFORMIN-ASSOCIATED LACTIC ACIDOSIS, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION. MEDICINA INTERNA-CONGRESSO NACIONAL. 2019",76.0,YR,,M,Y,,,20200628.0,,HP,PT,PT,2020,Q2,Elderly
171427576,17142757,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY,,,U,U,,,,100.0,MG,,QD,2020,Q2,Palpitations,,2020,Q2,6,F,,20200622.0,20191211,20200628,EXP,,NVSC2019PT057912,NOVARTIS,"SANTOS MB, GARCA M, COTA P, AVILA P, SANTOS A. METFORMIN-ASSOCIATED LACTIC ACIDOSIS, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION. MEDICINA INTERNA-CONGRESSO NACIONAL. 2019",76.0,YR,,M,Y,,,20200628.0,,HP,PT,PT,2020,Q2,Elderly
171427576,17142757,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY,,,U,U,,,,100.0,MG,,QD,2020,Q2,Renal impairment,,2020,Q2,6,F,,20200622.0,20191211,20200628,EXP,,NVSC2019PT057912,NOVARTIS,"SANTOS MB, GARCA M, COTA P, AVILA P, SANTOS A. METFORMIN-ASSOCIATED LACTIC ACIDOSIS, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION. MEDICINA INTERNA-CONGRESSO NACIONAL. 2019",76.0,YR,,M,Y,,,20200628.0,,HP,PT,PT,2020,Q2,Elderly
171427576,17142757,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY,,,U,U,,,,100.0,MG,,QD,2020,Q2,Vomiting,,2020,Q2,6,F,,20200622.0,20191211,20200628,EXP,,NVSC2019PT057912,NOVARTIS,"SANTOS MB, GARCA M, COTA P, AVILA P, SANTOS A. METFORMIN-ASSOCIATED LACTIC ACIDOSIS, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION. MEDICINA INTERNA-CONGRESSO NACIONAL. 2019",76.0,YR,,M,Y,,,20200628.0,,HP,PT,PT,2020,Q2,Elderly
172247582,17224758,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,QD,2020,Q2,Acute kidney injury,,2020,Q2,2,F,,20200406.0,20200102,20200414,EXP,,PT-EMD SERONO-E2B_90073609,EMD SERONO INC,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. LACTIC ACIDOSIS ASSOCIATED TO METFORMIN, WITH ACUTE RENAL INJURY BY IATROGENIC HYPOTENSION.. THE ENDOCRINE AND METABOLIC DISEASES. 2019 MAY;.",76.0,YR,,M,Y,,,20200414.0,,HP,PT,PT,2020,Q2,Elderly
172247582,17224758,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,QD,2020,Q2,Blood bicarbonate decreased,,2020,Q2,2,F,,20200406.0,20200102,20200414,EXP,,PT-EMD SERONO-E2B_90073609,EMD SERONO INC,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. LACTIC ACIDOSIS ASSOCIATED TO METFORMIN, WITH ACUTE RENAL INJURY BY IATROGENIC HYPOTENSION.. THE ENDOCRINE AND METABOLIC DISEASES. 2019 MAY;.",76.0,YR,,M,Y,,,20200414.0,,HP,PT,PT,2020,Q2,Elderly
172247582,17224758,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,QD,2020,Q2,Blood lactic acid increased,,2020,Q2,2,F,,20200406.0,20200102,20200414,EXP,,PT-EMD SERONO-E2B_90073609,EMD SERONO INC,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. LACTIC ACIDOSIS ASSOCIATED TO METFORMIN, WITH ACUTE RENAL INJURY BY IATROGENIC HYPOTENSION.. THE ENDOCRINE AND METABOLIC DISEASES. 2019 MAY;.",76.0,YR,,M,Y,,,20200414.0,,HP,PT,PT,2020,Q2,Elderly
172247582,17224758,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,QD,2020,Q2,Dyspnoea,,2020,Q2,2,F,,20200406.0,20200102,20200414,EXP,,PT-EMD SERONO-E2B_90073609,EMD SERONO INC,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. LACTIC ACIDOSIS ASSOCIATED TO METFORMIN, WITH ACUTE RENAL INJURY BY IATROGENIC HYPOTENSION.. THE ENDOCRINE AND METABOLIC DISEASES. 2019 MAY;.",76.0,YR,,M,Y,,,20200414.0,,HP,PT,PT,2020,Q2,Elderly
172247582,17224758,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,QD,2020,Q2,Emotional distress,,2020,Q2,2,F,,20200406.0,20200102,20200414,EXP,,PT-EMD SERONO-E2B_90073609,EMD SERONO INC,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. LACTIC ACIDOSIS ASSOCIATED TO METFORMIN, WITH ACUTE RENAL INJURY BY IATROGENIC HYPOTENSION.. THE ENDOCRINE AND METABOLIC DISEASES. 2019 MAY;.",76.0,YR,,M,Y,,,20200414.0,,HP,PT,PT,2020,Q2,Elderly
172247582,17224758,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,QD,2020,Q2,Fatigue,,2020,Q2,2,F,,20200406.0,20200102,20200414,EXP,,PT-EMD SERONO-E2B_90073609,EMD SERONO INC,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. LACTIC ACIDOSIS ASSOCIATED TO METFORMIN, WITH ACUTE RENAL INJURY BY IATROGENIC HYPOTENSION.. THE ENDOCRINE AND METABOLIC DISEASES. 2019 MAY;.",76.0,YR,,M,Y,,,20200414.0,,HP,PT,PT,2020,Q2,Elderly
172247582,17224758,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,QD,2020,Q2,Hyperhidrosis,,2020,Q2,2,F,,20200406.0,20200102,20200414,EXP,,PT-EMD SERONO-E2B_90073609,EMD SERONO INC,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. LACTIC ACIDOSIS ASSOCIATED TO METFORMIN, WITH ACUTE RENAL INJURY BY IATROGENIC HYPOTENSION.. THE ENDOCRINE AND METABOLIC DISEASES. 2019 MAY;.",76.0,YR,,M,Y,,,20200414.0,,HP,PT,PT,2020,Q2,Elderly
172247582,17224758,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,QD,2020,Q2,Hypotension,,2020,Q2,2,F,,20200406.0,20200102,20200414,EXP,,PT-EMD SERONO-E2B_90073609,EMD SERONO INC,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. LACTIC ACIDOSIS ASSOCIATED TO METFORMIN, WITH ACUTE RENAL INJURY BY IATROGENIC HYPOTENSION.. THE ENDOCRINE AND METABOLIC DISEASES. 2019 MAY;.",76.0,YR,,M,Y,,,20200414.0,,HP,PT,PT,2020,Q2,Elderly
172247582,17224758,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,QD,2020,Q2,Lactic acidosis,,2020,Q2,2,F,,20200406.0,20200102,20200414,EXP,,PT-EMD SERONO-E2B_90073609,EMD SERONO INC,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. LACTIC ACIDOSIS ASSOCIATED TO METFORMIN, WITH ACUTE RENAL INJURY BY IATROGENIC HYPOTENSION.. THE ENDOCRINE AND METABOLIC DISEASES. 2019 MAY;.",76.0,YR,,M,Y,,,20200414.0,,HP,PT,PT,2020,Q2,Elderly
172247582,17224758,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,QD,2020,Q2,Metabolic acidosis,,2020,Q2,2,F,,20200406.0,20200102,20200414,EXP,,PT-EMD SERONO-E2B_90073609,EMD SERONO INC,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. LACTIC ACIDOSIS ASSOCIATED TO METFORMIN, WITH ACUTE RENAL INJURY BY IATROGENIC HYPOTENSION.. THE ENDOCRINE AND METABOLIC DISEASES. 2019 MAY;.",76.0,YR,,M,Y,,,20200414.0,,HP,PT,PT,2020,Q2,Elderly
172247582,17224758,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,QD,2020,Q2,Pallor,,2020,Q2,2,F,,20200406.0,20200102,20200414,EXP,,PT-EMD SERONO-E2B_90073609,EMD SERONO INC,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. LACTIC ACIDOSIS ASSOCIATED TO METFORMIN, WITH ACUTE RENAL INJURY BY IATROGENIC HYPOTENSION.. THE ENDOCRINE AND METABOLIC DISEASES. 2019 MAY;.",76.0,YR,,M,Y,,,20200414.0,,HP,PT,PT,2020,Q2,Elderly
172247582,17224758,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,QD,2020,Q2,Palpitations,,2020,Q2,2,F,,20200406.0,20200102,20200414,EXP,,PT-EMD SERONO-E2B_90073609,EMD SERONO INC,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. LACTIC ACIDOSIS ASSOCIATED TO METFORMIN, WITH ACUTE RENAL INJURY BY IATROGENIC HYPOTENSION.. THE ENDOCRINE AND METABOLIC DISEASES. 2019 MAY;.",76.0,YR,,M,Y,,,20200414.0,,HP,PT,PT,2020,Q2,Elderly
172247582,17224758,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,QD,2020,Q2,Vomiting,,2020,Q2,2,F,,20200406.0,20200102,20200414,EXP,,PT-EMD SERONO-E2B_90073609,EMD SERONO INC,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. LACTIC ACIDOSIS ASSOCIATED TO METFORMIN, WITH ACUTE RENAL INJURY BY IATROGENIC HYPOTENSION.. THE ENDOCRINE AND METABOLIC DISEASES. 2019 MAY;.",76.0,YR,,M,Y,,,20200414.0,,HP,PT,PT,2020,Q2,Elderly
173552802,17355280,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",1300.0,MG,Y,,,,204042.0,100.0,MG,TABLET,QD,2020,Q2,Erythema multiforme,,2020,Q2,2,F,20190127.0,20200420.0,20200131,20200424,EXP,,JP-JNJFOC-20200148227,JOHNSON AND JOHNSON,,86.0,YR,,F,Y,,,20200424.0,,MD,JP,JP,2020,Q2,Elderly
174731452,17473145,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q2,Bradycardia,,2020,Q2,2,F,,20200520.0,20200228,20200528,EXP,,NVSC2020PL055027,NOVARTIS,,74.0,YR,,F,Y,,,20200528.0,,HP,PL,PL,2020,Q2,Elderly
174731452,17473145,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q2,Drug interaction,,2020,Q2,2,F,,20200520.0,20200228,20200528,EXP,,NVSC2020PL055027,NOVARTIS,,74.0,YR,,F,Y,,,20200528.0,,HP,PL,PL,2020,Q2,Elderly
174731452,17473145,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q2,Hypotension,,2020,Q2,2,F,,20200520.0,20200228,20200528,EXP,,NVSC2020PL055027,NOVARTIS,,74.0,YR,,F,Y,,,20200528.0,,HP,PL,PL,2020,Q2,Elderly
174731452,17473145,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q2,Myalgia,,2020,Q2,2,F,,20200520.0,20200228,20200528,EXP,,NVSC2020PL055027,NOVARTIS,,74.0,YR,,F,Y,,,20200528.0,,HP,PL,PL,2020,Q2,Elderly
174731452,17473145,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q2,Polyuria,,2020,Q2,2,F,,20200520.0,20200228,20200528,EXP,,NVSC2020PL055027,NOVARTIS,,74.0,YR,,F,Y,,,20200528.0,,HP,PL,PL,2020,Q2,Elderly
175112853,17511285,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNKNOWN,,2020,Q2,Blood creatinine decreased,,2020,Q2,3,F,,20200504.0,20200306,20200514,EXP,,CA-JNJFOC-20200240192,JOHNSON AND JOHNSON,,47.0,YR,,F,Y,,,20200514.0,,MD,CA,CA,2020,Q2,Adult
175112853,17511285,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNKNOWN,,2020,Q2,Blood uric acid decreased,,2020,Q2,3,F,,20200504.0,20200306,20200514,EXP,,CA-JNJFOC-20200240192,JOHNSON AND JOHNSON,,47.0,YR,,F,Y,,,20200514.0,,MD,CA,CA,2020,Q2,Adult
175112853,17511285,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNKNOWN,,2020,Q2,Drug ineffective,,2020,Q2,3,F,,20200504.0,20200306,20200514,EXP,,CA-JNJFOC-20200240192,JOHNSON AND JOHNSON,,47.0,YR,,F,Y,,,20200514.0,,MD,CA,CA,2020,Q2,Adult
175112853,17511285,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNKNOWN,,2020,Q2,Gastrointestinal haemorrhage,,2020,Q2,3,F,,20200504.0,20200306,20200514,EXP,,CA-JNJFOC-20200240192,JOHNSON AND JOHNSON,,47.0,YR,,F,Y,,,20200514.0,,MD,CA,CA,2020,Q2,Adult
175112853,17511285,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNKNOWN,,2020,Q2,Hepatic cirrhosis,,2020,Q2,3,F,,20200504.0,20200306,20200514,EXP,,CA-JNJFOC-20200240192,JOHNSON AND JOHNSON,,47.0,YR,,F,Y,,,20200514.0,,MD,CA,CA,2020,Q2,Adult
175112853,17511285,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNKNOWN,,2020,Q2,Hepatosplenomegaly,,2020,Q2,3,F,,20200504.0,20200306,20200514,EXP,,CA-JNJFOC-20200240192,JOHNSON AND JOHNSON,,47.0,YR,,F,Y,,,20200514.0,,MD,CA,CA,2020,Q2,Adult
175112853,17511285,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNKNOWN,,2020,Q2,Liver disorder,,2020,Q2,3,F,,20200504.0,20200306,20200514,EXP,,CA-JNJFOC-20200240192,JOHNSON AND JOHNSON,,47.0,YR,,F,Y,,,20200514.0,,MD,CA,CA,2020,Q2,Adult
175112853,17511285,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNKNOWN,,2020,Q2,Low density lipoprotein increased,,2020,Q2,3,F,,20200504.0,20200306,20200514,EXP,,CA-JNJFOC-20200240192,JOHNSON AND JOHNSON,,47.0,YR,,F,Y,,,20200514.0,,MD,CA,CA,2020,Q2,Adult
175112853,17511285,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNKNOWN,,2020,Q2,Nonalcoholic fatty liver disease,,2020,Q2,3,F,,20200504.0,20200306,20200514,EXP,,CA-JNJFOC-20200240192,JOHNSON AND JOHNSON,,47.0,YR,,F,Y,,,20200514.0,,MD,CA,CA,2020,Q2,Adult
175112853,17511285,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNKNOWN,,2020,Q2,Psoriasis,,2020,Q2,3,F,,20200504.0,20200306,20200514,EXP,,CA-JNJFOC-20200240192,JOHNSON AND JOHNSON,,47.0,YR,,F,Y,,,20200514.0,,MD,CA,CA,2020,Q2,Adult
175112853,17511285,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNKNOWN,,2020,Q2,Psoriatic arthropathy,,2020,Q2,3,F,,20200504.0,20200306,20200514,EXP,,CA-JNJFOC-20200240192,JOHNSON AND JOHNSON,,47.0,YR,,F,Y,,,20200514.0,,MD,CA,CA,2020,Q2,Adult
175112853,17511285,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNKNOWN,,2020,Q2,Rheumatoid arthritis,,2020,Q2,3,F,,20200504.0,20200306,20200514,EXP,,CA-JNJFOC-20200240192,JOHNSON AND JOHNSON,,47.0,YR,,F,Y,,,20200514.0,,MD,CA,CA,2020,Q2,Adult
175112853,17511285,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNKNOWN,,2020,Q2,Type 2 diabetes mellitus,,2020,Q2,3,F,,20200504.0,20200306,20200514,EXP,,CA-JNJFOC-20200240192,JOHNSON AND JOHNSON,,47.0,YR,,F,Y,,,20200514.0,,MD,CA,CA,2020,Q2,Adult
175112853,17511285,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNKNOWN,,2020,Q2,Varices oesophageal,,2020,Q2,3,F,,20200504.0,20200306,20200514,EXP,,CA-JNJFOC-20200240192,JOHNSON AND JOHNSON,,47.0,YR,,F,Y,,,20200514.0,,MD,CA,CA,2020,Q2,Adult
175663032,17566303,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,,,FILM-COATED TABLET,,2020,Q2,Pollakiuria,,2020,Q2,2,F,,20200325.0,20200320,20200407,EXP,,JP-JNJFOC-20200321277,JOHNSON AND JOHNSON,,9.0,DEC,,M,Y,,,20200407.0,,HP,JP,JP,2020,Q2,Child
175663032,17566303,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,,,FILM-COATED TABLET,,2020,Q2,Urinary retention,,2020,Q2,2,F,,20200325.0,20200320,20200407,EXP,,JP-JNJFOC-20200321277,JOHNSON AND JOHNSON,,9.0,DEC,,M,Y,,,20200407.0,,HP,JP,JP,2020,Q2,Child
176284121,17628412,3,C,Canagliflozin,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY;,,,,,,,,,,TABLET,QD,2020,Q2,Acute kidney injury,,2020,Q2,1,I,,20200330.0,20200406,20200406,EXP,,PT-TEVA-2020-PT-1218339,TEVA,"SANTOS M. LACTIC ACIDOSIS ASSOCIATED WITH METFORMIN, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION. REVISTA DE MEDICINA INTERNA - 25 CONGRESSO DE MEDICINA INTERNA 2019. 2019;.",76.0,YR,,M,Y,,,20200406.0,,MD,PT,PT,2020,Q2,Elderly
176284121,17628412,3,C,Canagliflozin,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY;,,,,,,,,,,TABLET,QD,2020,Q2,Drug interaction,,2020,Q2,1,I,,20200330.0,20200406,20200406,EXP,,PT-TEVA-2020-PT-1218339,TEVA,"SANTOS M. LACTIC ACIDOSIS ASSOCIATED WITH METFORMIN, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION. REVISTA DE MEDICINA INTERNA - 25 CONGRESSO DE MEDICINA INTERNA 2019. 2019;.",76.0,YR,,M,Y,,,20200406.0,,MD,PT,PT,2020,Q2,Elderly
176284121,17628412,3,C,Canagliflozin,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY;,,,,,,,,,,TABLET,QD,2020,Q2,Hypotension,,2020,Q2,1,I,,20200330.0,20200406,20200406,EXP,,PT-TEVA-2020-PT-1218339,TEVA,"SANTOS M. LACTIC ACIDOSIS ASSOCIATED WITH METFORMIN, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION. REVISTA DE MEDICINA INTERNA - 25 CONGRESSO DE MEDICINA INTERNA 2019. 2019;.",76.0,YR,,M,Y,,,20200406.0,,MD,PT,PT,2020,Q2,Elderly
176284121,17628412,3,C,Canagliflozin,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY;,,,,,,,,,,TABLET,QD,2020,Q2,Lactic acidosis,,2020,Q2,1,I,,20200330.0,20200406,20200406,EXP,,PT-TEVA-2020-PT-1218339,TEVA,"SANTOS M. LACTIC ACIDOSIS ASSOCIATED WITH METFORMIN, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION. REVISTA DE MEDICINA INTERNA - 25 CONGRESSO DE MEDICINA INTERNA 2019. 2019;.",76.0,YR,,M,Y,,,20200406.0,,MD,PT,PT,2020,Q2,Elderly
176285112,17628511,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,TABLET,,2020,Q2,Adverse drug reaction,,2020,Q2,2,F,,20200420.0,20200406,20200428,EXP,,CA-APOTEX-2020AP009293,APOTEX,,37.0,YR,,F,Y,,,20200428.0,,CN,CA,CA,2020,Q2,Adult
176285112,17628511,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,TABLET,,2020,Q2,Arthralgia,,2020,Q2,2,F,,20200420.0,20200406,20200428,EXP,,CA-APOTEX-2020AP009293,APOTEX,,37.0,YR,,F,Y,,,20200428.0,,CN,CA,CA,2020,Q2,Adult
176285112,17628511,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,TABLET,,2020,Q2,Arthritis,,2020,Q2,2,F,,20200420.0,20200406,20200428,EXP,,CA-APOTEX-2020AP009293,APOTEX,,37.0,YR,,F,Y,,,20200428.0,,CN,CA,CA,2020,Q2,Adult
176285112,17628511,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,TABLET,,2020,Q2,Blood creatinine decreased,,2020,Q2,2,F,,20200420.0,20200406,20200428,EXP,,CA-APOTEX-2020AP009293,APOTEX,,37.0,YR,,F,Y,,,20200428.0,,CN,CA,CA,2020,Q2,Adult
176285112,17628511,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,TABLET,,2020,Q2,Blood uric acid decreased,,2020,Q2,2,F,,20200420.0,20200406,20200428,EXP,,CA-APOTEX-2020AP009293,APOTEX,,37.0,YR,,F,Y,,,20200428.0,,CN,CA,CA,2020,Q2,Adult
176285112,17628511,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,TABLET,,2020,Q2,Drug ineffective,,2020,Q2,2,F,,20200420.0,20200406,20200428,EXP,,CA-APOTEX-2020AP009293,APOTEX,,37.0,YR,,F,Y,,,20200428.0,,CN,CA,CA,2020,Q2,Adult
176285112,17628511,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,TABLET,,2020,Q2,Gastrointestinal haemorrhage,,2020,Q2,2,F,,20200420.0,20200406,20200428,EXP,,CA-APOTEX-2020AP009293,APOTEX,,37.0,YR,,F,Y,,,20200428.0,,CN,CA,CA,2020,Q2,Adult
176285112,17628511,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,TABLET,,2020,Q2,Glycosylated haemoglobin increased,,2020,Q2,2,F,,20200420.0,20200406,20200428,EXP,,CA-APOTEX-2020AP009293,APOTEX,,37.0,YR,,F,Y,,,20200428.0,,CN,CA,CA,2020,Q2,Adult
176285112,17628511,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,TABLET,,2020,Q2,Haemoglobin decreased,,2020,Q2,2,F,,20200420.0,20200406,20200428,EXP,,CA-APOTEX-2020AP009293,APOTEX,,37.0,YR,,F,Y,,,20200428.0,,CN,CA,CA,2020,Q2,Adult
176285112,17628511,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,TABLET,,2020,Q2,Hepatic cirrhosis,,2020,Q2,2,F,,20200420.0,20200406,20200428,EXP,,CA-APOTEX-2020AP009293,APOTEX,,37.0,YR,,F,Y,,,20200428.0,,CN,CA,CA,2020,Q2,Adult
176285112,17628511,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,TABLET,,2020,Q2,Hepatosplenomegaly,,2020,Q2,2,F,,20200420.0,20200406,20200428,EXP,,CA-APOTEX-2020AP009293,APOTEX,,37.0,YR,,F,Y,,,20200428.0,,CN,CA,CA,2020,Q2,Adult
176285112,17628511,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,TABLET,,2020,Q2,Hypertrophy,,2020,Q2,2,F,,20200420.0,20200406,20200428,EXP,,CA-APOTEX-2020AP009293,APOTEX,,37.0,YR,,F,Y,,,20200428.0,,CN,CA,CA,2020,Q2,Adult
176285112,17628511,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,TABLET,,2020,Q2,Inflammatory marker increased,,2020,Q2,2,F,,20200420.0,20200406,20200428,EXP,,CA-APOTEX-2020AP009293,APOTEX,,37.0,YR,,F,Y,,,20200428.0,,CN,CA,CA,2020,Q2,Adult
176285112,17628511,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,TABLET,,2020,Q2,Joint effusion,,2020,Q2,2,F,,20200420.0,20200406,20200428,EXP,,CA-APOTEX-2020AP009293,APOTEX,,37.0,YR,,F,Y,,,20200428.0,,CN,CA,CA,2020,Q2,Adult
176285112,17628511,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,TABLET,,2020,Q2,Joint swelling,,2020,Q2,2,F,,20200420.0,20200406,20200428,EXP,,CA-APOTEX-2020AP009293,APOTEX,,37.0,YR,,F,Y,,,20200428.0,,CN,CA,CA,2020,Q2,Adult
176285112,17628511,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,TABLET,,2020,Q2,Liver disorder,,2020,Q2,2,F,,20200420.0,20200406,20200428,EXP,,CA-APOTEX-2020AP009293,APOTEX,,37.0,YR,,F,Y,,,20200428.0,,CN,CA,CA,2020,Q2,Adult
176285112,17628511,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,TABLET,,2020,Q2,Low density lipoprotein increased,,2020,Q2,2,F,,20200420.0,20200406,20200428,EXP,,CA-APOTEX-2020AP009293,APOTEX,,37.0,YR,,F,Y,,,20200428.0,,CN,CA,CA,2020,Q2,Adult
176285112,17628511,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,TABLET,,2020,Q2,Nausea,,2020,Q2,2,F,,20200420.0,20200406,20200428,EXP,,CA-APOTEX-2020AP009293,APOTEX,,37.0,YR,,F,Y,,,20200428.0,,CN,CA,CA,2020,Q2,Adult
176285112,17628511,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,TABLET,,2020,Q2,Nonalcoholic fatty liver disease,,2020,Q2,2,F,,20200420.0,20200406,20200428,EXP,,CA-APOTEX-2020AP009293,APOTEX,,37.0,YR,,F,Y,,,20200428.0,,CN,CA,CA,2020,Q2,Adult
176285112,17628511,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,TABLET,,2020,Q2,Pain in extremity,,2020,Q2,2,F,,20200420.0,20200406,20200428,EXP,,CA-APOTEX-2020AP009293,APOTEX,,37.0,YR,,F,Y,,,20200428.0,,CN,CA,CA,2020,Q2,Adult
176285112,17628511,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,TABLET,,2020,Q2,Psoriasis,,2020,Q2,2,F,,20200420.0,20200406,20200428,EXP,,CA-APOTEX-2020AP009293,APOTEX,,37.0,YR,,F,Y,,,20200428.0,,CN,CA,CA,2020,Q2,Adult
176285112,17628511,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,TABLET,,2020,Q2,Psoriatic arthropathy,,2020,Q2,2,F,,20200420.0,20200406,20200428,EXP,,CA-APOTEX-2020AP009293,APOTEX,,37.0,YR,,F,Y,,,20200428.0,,CN,CA,CA,2020,Q2,Adult
176285112,17628511,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,TABLET,,2020,Q2,Red blood cell sedimentation rate increased,,2020,Q2,2,F,,20200420.0,20200406,20200428,EXP,,CA-APOTEX-2020AP009293,APOTEX,,37.0,YR,,F,Y,,,20200428.0,,CN,CA,CA,2020,Q2,Adult
176285112,17628511,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,TABLET,,2020,Q2,Rheumatoid arthritis,,2020,Q2,2,F,,20200420.0,20200406,20200428,EXP,,CA-APOTEX-2020AP009293,APOTEX,,37.0,YR,,F,Y,,,20200428.0,,CN,CA,CA,2020,Q2,Adult
176285112,17628511,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,TABLET,,2020,Q2,Therapeutic product effect decreased,,2020,Q2,2,F,,20200420.0,20200406,20200428,EXP,,CA-APOTEX-2020AP009293,APOTEX,,37.0,YR,,F,Y,,,20200428.0,,CN,CA,CA,2020,Q2,Adult
176285112,17628511,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,TABLET,,2020,Q2,Therapeutic product effect incomplete,,2020,Q2,2,F,,20200420.0,20200406,20200428,EXP,,CA-APOTEX-2020AP009293,APOTEX,,37.0,YR,,F,Y,,,20200428.0,,CN,CA,CA,2020,Q2,Adult
176285112,17628511,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,TABLET,,2020,Q2,Type 2 diabetes mellitus,,2020,Q2,2,F,,20200420.0,20200406,20200428,EXP,,CA-APOTEX-2020AP009293,APOTEX,,37.0,YR,,F,Y,,,20200428.0,,CN,CA,CA,2020,Q2,Adult
176285112,17628511,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,TABLET,,2020,Q2,Varices oesophageal,,2020,Q2,2,F,,20200420.0,20200406,20200428,EXP,,CA-APOTEX-2020AP009293,APOTEX,,37.0,YR,,F,Y,,,20200428.0,,CN,CA,CA,2020,Q2,Adult
176312072,17631207,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Lower respiratory tract infection,,2020,Q2,2,F,201912.0,20200609.0,20200406,20200622,EXP,,GB-JNJFOC-20200339413,JOHNSON AND JOHNSON,,6.0,DEC,,M,Y,,,20200622.0,,CN,GB,GB,2020,Q2,Child
176312072,17631207,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Psoriasis,,2020,Q2,2,F,201912.0,20200609.0,20200406,20200622,EXP,,GB-JNJFOC-20200339413,JOHNSON AND JOHNSON,,6.0,DEC,,M,Y,,,20200622.0,,CN,GB,GB,2020,Q2,Child
176383212,17638321,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q2,Adverse drug reaction,,2020,Q2,2,F,,20200420.0,20200407,20200424,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20200424.0,,CN,CA,CA,2020,Q2,Adult
176383212,17638321,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q2,Arthralgia,,2020,Q2,2,F,,20200420.0,20200407,20200424,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20200424.0,,CN,CA,CA,2020,Q2,Adult
176383212,17638321,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q2,Arthritis,,2020,Q2,2,F,,20200420.0,20200407,20200424,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20200424.0,,CN,CA,CA,2020,Q2,Adult
176383212,17638321,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q2,Blood creatinine decreased,,2020,Q2,2,F,,20200420.0,20200407,20200424,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20200424.0,,CN,CA,CA,2020,Q2,Adult
176383212,17638321,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q2,Blood uric acid decreased,,2020,Q2,2,F,,20200420.0,20200407,20200424,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20200424.0,,CN,CA,CA,2020,Q2,Adult
176383212,17638321,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q2,Drug ineffective,,2020,Q2,2,F,,20200420.0,20200407,20200424,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20200424.0,,CN,CA,CA,2020,Q2,Adult
176383212,17638321,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q2,Gastrointestinal haemorrhage,,2020,Q2,2,F,,20200420.0,20200407,20200424,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20200424.0,,CN,CA,CA,2020,Q2,Adult
176383212,17638321,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q2,Glycosylated haemoglobin increased,,2020,Q2,2,F,,20200420.0,20200407,20200424,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20200424.0,,CN,CA,CA,2020,Q2,Adult
176383212,17638321,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q2,Haemoglobin decreased,,2020,Q2,2,F,,20200420.0,20200407,20200424,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20200424.0,,CN,CA,CA,2020,Q2,Adult
176383212,17638321,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q2,Hepatic cirrhosis,,2020,Q2,2,F,,20200420.0,20200407,20200424,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20200424.0,,CN,CA,CA,2020,Q2,Adult
176383212,17638321,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q2,Hepatosplenomegaly,,2020,Q2,2,F,,20200420.0,20200407,20200424,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20200424.0,,CN,CA,CA,2020,Q2,Adult
176383212,17638321,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q2,Hypertrophy,,2020,Q2,2,F,,20200420.0,20200407,20200424,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20200424.0,,CN,CA,CA,2020,Q2,Adult
176383212,17638321,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q2,Inflammatory marker increased,,2020,Q2,2,F,,20200420.0,20200407,20200424,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20200424.0,,CN,CA,CA,2020,Q2,Adult
176383212,17638321,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q2,Joint effusion,,2020,Q2,2,F,,20200420.0,20200407,20200424,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20200424.0,,CN,CA,CA,2020,Q2,Adult
176383212,17638321,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q2,Joint swelling,,2020,Q2,2,F,,20200420.0,20200407,20200424,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20200424.0,,CN,CA,CA,2020,Q2,Adult
176383212,17638321,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q2,Liver disorder,,2020,Q2,2,F,,20200420.0,20200407,20200424,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20200424.0,,CN,CA,CA,2020,Q2,Adult
176383212,17638321,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q2,Low density lipoprotein increased,,2020,Q2,2,F,,20200420.0,20200407,20200424,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20200424.0,,CN,CA,CA,2020,Q2,Adult
176383212,17638321,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q2,Nausea,,2020,Q2,2,F,,20200420.0,20200407,20200424,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20200424.0,,CN,CA,CA,2020,Q2,Adult
176383212,17638321,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q2,Nonalcoholic fatty liver disease,,2020,Q2,2,F,,20200420.0,20200407,20200424,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20200424.0,,CN,CA,CA,2020,Q2,Adult
176383212,17638321,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q2,Pain in extremity,,2020,Q2,2,F,,20200420.0,20200407,20200424,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20200424.0,,CN,CA,CA,2020,Q2,Adult
176383212,17638321,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q2,Psoriasis,,2020,Q2,2,F,,20200420.0,20200407,20200424,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20200424.0,,CN,CA,CA,2020,Q2,Adult
176383212,17638321,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q2,Red blood cell sedimentation rate increased,,2020,Q2,2,F,,20200420.0,20200407,20200424,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20200424.0,,CN,CA,CA,2020,Q2,Adult
176383212,17638321,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q2,Therapeutic product effect decreased,,2020,Q2,2,F,,20200420.0,20200407,20200424,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20200424.0,,CN,CA,CA,2020,Q2,Adult
176383212,17638321,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q2,Therapeutic product effect incomplete,,2020,Q2,2,F,,20200420.0,20200407,20200424,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20200424.0,,CN,CA,CA,2020,Q2,Adult
176383212,17638321,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q2,Varices oesophageal,,2020,Q2,2,F,,20200420.0,20200407,20200424,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20200424.0,,CN,CA,CA,2020,Q2,Adult
176569732,17656973,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q2,Retinal detachment,,2020,Q2,2,F,20190517.0,20200407.0,20200410,20200416,EXP,,JP-JNJFOC-20200413169,JOHNSON AND JOHNSON,,59.0,YR,,M,Y,,,20200416.0,,MD,JP,JP,2020,Q2,Adult
176623981,17662398,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q2,Sinusitis,,2020,Q2,1,I,,20200409.0,20200413,20200413,EXP,,NVSC2020CA098655,NOVARTIS,,67.0,YR,,M,Y,,,20200413.0,,HP,CA,CA,2020,Q2,Elderly
176623981,17662398,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q2,Tooth abscess,,2020,Q2,1,I,,20200409.0,20200413,20200413,EXP,,NVSC2020CA098655,NOVARTIS,,67.0,YR,,M,Y,,,20200413.0,,HP,CA,CA,2020,Q2,Elderly
176672911,17667291,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2020,Q2,Rash,,2020,Q2,1,I,20200204.0,20200410.0,20200414,20200414,EXP,GB-MHRA-EYC 00219887,GB-MYLANLABS-2020M1037501,MYLAN,,73.0,YR,,M,Y,,,20200414.0,,CN,GB,GB,2020,Q2,Elderly
176672911,17667291,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2020,Q2,Skin disorder,,2020,Q2,1,I,20200204.0,20200410.0,20200414,20200414,EXP,GB-MHRA-EYC 00219887,GB-MYLANLABS-2020M1037501,MYLAN,,73.0,YR,,M,Y,,,20200414.0,,CN,GB,GB,2020,Q2,Elderly
176672911,17667291,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2020,Q2,Skin ulcer,,2020,Q2,1,I,20200204.0,20200410.0,20200414,20200414,EXP,GB-MHRA-EYC 00219887,GB-MYLANLABS-2020M1037501,MYLAN,,73.0,YR,,M,Y,,,20200414.0,,CN,GB,GB,2020,Q2,Elderly
176672911,17667291,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2020,Q2,Swelling,,2020,Q2,1,I,20200204.0,20200410.0,20200414,20200414,EXP,GB-MHRA-EYC 00219887,GB-MYLANLABS-2020M1037501,MYLAN,,73.0,YR,,M,Y,,,20200414.0,,CN,GB,GB,2020,Q2,Elderly
176721921,17672192,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,300 MG,,,U,,,,,300.0,MG,,,2020,Q2,Asthenia,,2020,Q2,1,I,201907.0,20200414.0,20200415,20200415,EXP,GB-MHRA-EYC 00215589,NVSC2020GB100744,NOVARTIS,,82.0,YR,,M,Y,86.9,KG,20200415.0,,HP,GB,GB,2020,Q2,Elderly
176721921,17672192,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,300 MG,,,U,,,,,300.0,MG,,,2020,Q2,Blood creatine phosphokinase increased,,2020,Q2,1,I,201907.0,20200414.0,20200415,20200415,EXP,GB-MHRA-EYC 00215589,NVSC2020GB100744,NOVARTIS,,82.0,YR,,M,Y,86.9,KG,20200415.0,,HP,GB,GB,2020,Q2,Elderly
176721921,17672192,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,300 MG,,,U,,,,,300.0,MG,,,2020,Q2,Dyspepsia,,2020,Q2,1,I,201907.0,20200414.0,20200415,20200415,EXP,GB-MHRA-EYC 00215589,NVSC2020GB100744,NOVARTIS,,82.0,YR,,M,Y,86.9,KG,20200415.0,,HP,GB,GB,2020,Q2,Elderly
176721921,17672192,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,300 MG,,,U,,,,,300.0,MG,,,2020,Q2,Flatulence,,2020,Q2,1,I,201907.0,20200414.0,20200415,20200415,EXP,GB-MHRA-EYC 00215589,NVSC2020GB100744,NOVARTIS,,82.0,YR,,M,Y,86.9,KG,20200415.0,,HP,GB,GB,2020,Q2,Elderly
176721921,17672192,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,300 MG,,,U,,,,,300.0,MG,,,2020,Q2,Gastrooesophageal reflux disease,,2020,Q2,1,I,201907.0,20200414.0,20200415,20200415,EXP,GB-MHRA-EYC 00215589,NVSC2020GB100744,NOVARTIS,,82.0,YR,,M,Y,86.9,KG,20200415.0,,HP,GB,GB,2020,Q2,Elderly
176721921,17672192,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,300 MG,,,U,,,,,300.0,MG,,,2020,Q2,Hypersensitivity,,2020,Q2,1,I,201907.0,20200414.0,20200415,20200415,EXP,GB-MHRA-EYC 00215589,NVSC2020GB100744,NOVARTIS,,82.0,YR,,M,Y,86.9,KG,20200415.0,,HP,GB,GB,2020,Q2,Elderly
176721921,17672192,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,300 MG,,,U,,,,,300.0,MG,,,2020,Q2,Myalgia,,2020,Q2,1,I,201907.0,20200414.0,20200415,20200415,EXP,GB-MHRA-EYC 00215589,NVSC2020GB100744,NOVARTIS,,82.0,YR,,M,Y,86.9,KG,20200415.0,,HP,GB,GB,2020,Q2,Elderly
176721921,17672192,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,300 MG,,,U,,,,,300.0,MG,,,2020,Q2,Rash,,2020,Q2,1,I,201907.0,20200414.0,20200415,20200415,EXP,GB-MHRA-EYC 00215589,NVSC2020GB100744,NOVARTIS,,82.0,YR,,M,Y,86.9,KG,20200415.0,,HP,GB,GB,2020,Q2,Elderly
176732367,17673236,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,1.0,DF,TABLETS,,2020,Q2,Tumour lysis syndrome,,2020,Q2,7,F,20200407.0,20200616.0,20200415,20200619,EXP,,JP-EISAI MEDICAL RESEARCH-EC-2020-073278,EISAI,,75.0,YR,E,M,Y,83.3,KG,20200619.0,,MD,JP,JP,2020,Q2,Elderly
176900641,17690064,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,300.0,MG,FILM-COATED TABLET,,2020,Q2,Diabetic ketoacidosis,,2020,Q2,1,I,20191029.0,20200414.0,20200421,20200421,EXP,GB-MHRA-MIDB-3D36C4F4-0412-4D06-848A-790E8DF2E36D,GB-JNJFOC-20200417764,JOHNSON AND JOHNSON,,59.0,YR,,M,Y,,,20200421.0,,PH,GB,GB,2020,Q2,Adult
176995631,17699563,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,TABLET,,2020,Q2,Acute respiratory failure,,2020,Q2,1,I,20191215.0,20200409.0,20200423,20200423,EXP,,US-AJANTA PHARMA USA INC.-2083076,AJANTA PHARMA,,71.0,YR,,F,Y,73.64,KG,20200423.0,,HP,US,US,2020,Q2,Elderly
176995631,17699563,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,TABLET,,2020,Q2,Chronic obstructive pulmonary disease,,2020,Q2,1,I,20191215.0,20200409.0,20200423,20200423,EXP,,US-AJANTA PHARMA USA INC.-2083076,AJANTA PHARMA,,71.0,YR,,F,Y,73.64,KG,20200423.0,,HP,US,US,2020,Q2,Elderly
176995631,17699563,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,TABLET,,2020,Q2,Idiopathic pulmonary fibrosis,,2020,Q2,1,I,20191215.0,20200409.0,20200423,20200423,EXP,,US-AJANTA PHARMA USA INC.-2083076,AJANTA PHARMA,,71.0,YR,,F,Y,73.64,KG,20200423.0,,HP,US,US,2020,Q2,Elderly
177234511,17723451,5,C,Canagliflozin,CANAGLIFLOZIN,1,,ONE TABLET BY MOUTH ONCE A DAY,,,D,,,,,1.0,DF,TABLET,QD,2020,Q2,Chronic obstructive pulmonary disease,,2020,Q2,1,I,201912.0,20200420.0,20200429,20200429,EXP,,US-TORRENT-00010185,TORRENT,,71.0,YR,E,F,Y,73.0,KG,20200429.0,,CN,US,US,2020,Q2,Elderly
177234511,17723451,5,C,Canagliflozin,CANAGLIFLOZIN,1,,ONE TABLET BY MOUTH ONCE A DAY,,,D,,,,,1.0,DF,TABLET,QD,2020,Q2,Idiopathic pulmonary fibrosis,,2020,Q2,1,I,201912.0,20200420.0,20200429,20200429,EXP,,US-TORRENT-00010185,TORRENT,,71.0,YR,E,F,Y,73.0,KG,20200429.0,,CN,US,US,2020,Q2,Elderly
177234511,17723451,5,C,Canagliflozin,CANAGLIFLOZIN,1,,ONE TABLET BY MOUTH ONCE A DAY,,,D,,,,,1.0,DF,TABLET,QD,2020,Q2,Respiratory failure,,2020,Q2,1,I,201912.0,20200420.0,20200429,20200429,EXP,,US-TORRENT-00010185,TORRENT,,71.0,YR,E,F,Y,73.0,KG,20200429.0,,CN,US,US,2020,Q2,Elderly
177291661,17729166,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,,,2020,Q2,Euglycaemic diabetic ketoacidosis,,2020,Q2,1,I,,20200428.0,20200430,20200430,EXP,,GB-EMD SERONO-9160577,EMD SERONO INC,"MILNE L, BRYANT C. SEVERE EUGLYCAEMIC KETOACIDOSIS WITH SGLT2 INHIBITOR USE IN THE PERIOPERATIVE PERIOD.. ANAESTHESIA.. 2019 SEP 01;74(SUPPLEMENT 4):12.",64.0,YR,,F,Y,,,20200430.0,,MD,GB,GB,2020,Q2,Adult
177370501,17737050,13,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,UNK,,,D,, UNK,,,,,,,2020,Q2,Suspected suicide,,2020,Q2,1,I,,20200421.0,20200502,20200502,EXP,,"US-INGENUS PHARMACEUTICALS, LLC-2020INF000071",INGENUS,,47.0,YR,,M,Y,,,20200502.0,,HP,US,US,2020,Q2,Adult
177461881,17746188,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q2,Acute kidney injury,,2020,Q2,1,I,,20200427.0,20200505,20200505,EXP,,AT-PFIZER INC-2020174950,PFIZER,"SCHWETZ, V.. COMBINED METFORMIN-ASSOCIATED LACTIC ACIDOSIS AND EUGLYCEMIC KETOACIDOSIS. THE CENTRAL EUROPEAN JOURNAL OF MEDICINE. 2017;129:649-9",71.0,YR,,M,Y,,,20200505.0,,HP,AT,AT,2020,Q2,Elderly
177496862,17749686,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,TABLET,QD,2020,Q2,Chronic obstructive pulmonary disease,,2020,Q2,2,F,,20200429.0,20200506,20200516,EXP,,US-NVP-000129,NOVITIUM PHARMA,,71.0,YR,E,,Y,73.48,KG,20200516.0,,CN,US,US,2020,Q2,Elderly
177496862,17749686,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,TABLET,QD,2020,Q2,Idiopathic pulmonary fibrosis,,2020,Q2,2,F,,20200429.0,20200506,20200516,EXP,,US-NVP-000129,NOVITIUM PHARMA,,71.0,YR,E,,Y,73.48,KG,20200516.0,,CN,US,US,2020,Q2,Elderly
177496862,17749686,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,TABLET,QD,2020,Q2,Respiratory failure,,2020,Q2,2,F,,20200429.0,20200506,20200516,EXP,,US-NVP-000129,NOVITIUM PHARMA,,71.0,YR,E,,Y,73.48,KG,20200516.0,,CN,US,US,2020,Q2,Elderly
177496862,17749686,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,TABLET,QD,2020,Q2,Ventilation perfusion mismatch,,2020,Q2,2,F,,20200429.0,20200506,20200516,EXP,,US-NVP-000129,NOVITIUM PHARMA,,71.0,YR,E,,Y,73.48,KG,20200516.0,,CN,US,US,2020,Q2,Elderly
177518761,17751876,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, EACH MORNING",,,U,,,,,100.0,MG,,QD,2020,Q2,Blood glucose increased,,2020,Q2,1,I,20200414.0,20200423.0,20200506,20200506,PER,,US-ELI_LILLY_AND_COMPANY-US202004010537,ELI LILLY AND CO,,61.0,YR,,F,Y,,,20200506.0,,CN,US,US,2020,Q2,Adult
177518761,17751876,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, EACH MORNING",,,U,,,,,100.0,MG,,QD,2020,Q2,Injection site pain,,2020,Q2,1,I,20200414.0,20200423.0,20200506,20200506,PER,,US-ELI_LILLY_AND_COMPANY-US202004010537,ELI LILLY AND CO,,61.0,YR,,F,Y,,,20200506.0,,CN,US,US,2020,Q2,Adult
177518761,17751876,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, EACH MORNING",,,U,,,,,100.0,MG,,QD,2020,Q2,Product dose omission,,2020,Q2,1,I,20200414.0,20200423.0,20200506,20200506,PER,,US-ELI_LILLY_AND_COMPANY-US202004010537,ELI LILLY AND CO,,61.0,YR,,F,Y,,,20200506.0,,CN,US,US,2020,Q2,Adult
177589123,17758912,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q2,Breast cancer metastatic,,2020,Q2,3,F,20200207.0,20200612.0,20200508,20200619,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-036212,BRISTOL MYERS SQUIBB,,44.0,YR,,F,Y,143.76,KG,20200619.0,,HP,US,US,2020,Q2,Adult
177589123,17758912,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q2,Neck pain,,2020,Q2,3,F,20200207.0,20200612.0,20200508,20200619,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-036212,BRISTOL MYERS SQUIBB,,44.0,YR,,F,Y,143.76,KG,20200619.0,,HP,US,US,2020,Q2,Adult
177589123,17758912,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q2,Peripheral swelling,,2020,Q2,3,F,20200207.0,20200612.0,20200508,20200619,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-036212,BRISTOL MYERS SQUIBB,,44.0,YR,,F,Y,143.76,KG,20200619.0,,HP,US,US,2020,Q2,Adult
177589123,17758912,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q2,Therapeutic response decreased,,2020,Q2,3,F,20200207.0,20200612.0,20200508,20200619,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-036212,BRISTOL MYERS SQUIBB,,44.0,YR,,F,Y,143.76,KG,20200619.0,,HP,US,US,2020,Q2,Adult
177617851,17761785,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,U,,,,,100.0,MG,,QD,2020,Q2,Drug interaction,,2020,Q2,1,I,,20200504.0,20200508,20200508,EXP,,PT-MYLANLABS-2020M1045421,MYLAN,"SANTOS MB, GAR?A M, COTA P, ?VILA P, SANTOS A. ACIDOSE L?TICA ASSOCIADA ? METFORMINA, COM LES?O RENAL AGUDA POR HIPOTENS?O IATROG?NICA.. MEDICINA INTERNA. 2019;25",76.0,YR,,M,Y,,,20200508.0,,MD,PT,PT,2020,Q2,Elderly
177617851,17761785,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,U,,,,,100.0,MG,,QD,2020,Q2,Lactic acidosis,,2020,Q2,1,I,,20200504.0,20200508,20200508,EXP,,PT-MYLANLABS-2020M1045421,MYLAN,"SANTOS MB, GAR?A M, COTA P, ?VILA P, SANTOS A. ACIDOSE L?TICA ASSOCIADA ? METFORMINA, COM LES?O RENAL AGUDA POR HIPOTENS?O IATROG?NICA.. MEDICINA INTERNA. 2019;25",76.0,YR,,M,Y,,,20200508.0,,MD,PT,PT,2020,Q2,Elderly
177623561,17762356,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,FILM-COATED TABLET,,2020,Q2,Diabetic ketoacidosis,,2020,Q2,1,I,201904.0,20200430.0,20200508,20200508,EXP,,US-JNJFOC-20200438864,JOHNSON AND JOHNSON,,24.0,YR,,M,Y,,,20200508.0,,MD,US,US,2020,Q2,Young Adult
177623561,17762356,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,FILM-COATED TABLET,,2020,Q2,Pulmonary embolism,,2020,Q2,1,I,201904.0,20200430.0,20200508,20200508,EXP,,US-JNJFOC-20200438864,JOHNSON AND JOHNSON,,24.0,YR,,M,Y,,,20200508.0,,MD,US,US,2020,Q2,Young Adult
177695671,17769567,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,204042.0,,,FILM-COATED TABLET,,2020,Q2,Asthma,,2020,Q2,1,I,,20200425.0,20200512,20200512,EXP,,CA-JNJFOC-20200509442,JOHNSON AND JOHNSON,,76.0,YR,,F,Y,,,20200512.0,,MD,CA,CA,2020,Q2,Elderly
177695671,17769567,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,204042.0,,,FILM-COATED TABLET,,2020,Q2,Blood count abnormal,,2020,Q2,1,I,,20200425.0,20200512,20200512,EXP,,CA-JNJFOC-20200509442,JOHNSON AND JOHNSON,,76.0,YR,,F,Y,,,20200512.0,,MD,CA,CA,2020,Q2,Elderly
177695671,17769567,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,204042.0,,,FILM-COATED TABLET,,2020,Q2,Gastrooesophageal reflux disease,,2020,Q2,1,I,,20200425.0,20200512,20200512,EXP,,CA-JNJFOC-20200509442,JOHNSON AND JOHNSON,,76.0,YR,,F,Y,,,20200512.0,,MD,CA,CA,2020,Q2,Elderly
177695671,17769567,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,204042.0,,,FILM-COATED TABLET,,2020,Q2,Hyperglycaemia,,2020,Q2,1,I,,20200425.0,20200512,20200512,EXP,,CA-JNJFOC-20200509442,JOHNSON AND JOHNSON,,76.0,YR,,F,Y,,,20200512.0,,MD,CA,CA,2020,Q2,Elderly
177695671,17769567,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,204042.0,,,FILM-COATED TABLET,,2020,Q2,Type 2 diabetes mellitus,,2020,Q2,1,I,,20200425.0,20200512,20200512,EXP,,CA-JNJFOC-20200509442,JOHNSON AND JOHNSON,,76.0,YR,,F,Y,,,20200512.0,,MD,CA,CA,2020,Q2,Elderly
177883731,17788373,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,U,U,,,,100.0,MG,,QD,2020,Q2,Drug interaction,,2020,Q2,1,I,,20200507.0,20200514,20200514,EXP,,PT-MYLANLABS-2020M1046521,MYLAN,"SANTOS MB, GAR?A M, COTA P, ?VILA P, SANTOS A. ET AL.. ACIDOSE L?TICA ASSOCIADA ? METFORMINA, COM LES?O RENAL AGUDA POR HIPOTENS?O IATROG?NICA.. MEDICINA INTERNA.. 2019;25(CONGRESSO)",76.0,YR,,M,Y,,,20200514.0,,MD,PT,PT,2020,Q2,Elderly
177883731,17788373,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,U,U,,,,100.0,MG,,QD,2020,Q2,Lactic acidosis,,2020,Q2,1,I,,20200507.0,20200514,20200514,EXP,,PT-MYLANLABS-2020M1046521,MYLAN,"SANTOS MB, GAR?A M, COTA P, ?VILA P, SANTOS A. ET AL.. ACIDOSE L?TICA ASSOCIADA ? METFORMINA, COM LES?O RENAL AGUDA POR HIPOTENS?O IATROG?NICA.. MEDICINA INTERNA.. 2019;25(CONGRESSO)",76.0,YR,,M,Y,,,20200514.0,,MD,PT,PT,2020,Q2,Elderly
177990662,17799066,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,(DAILY),,,Y,,,,,300.0,MG,,,2020,Q2,Acute kidney injury,,2020,Q2,2,F,2018.0,20200520.0,20200518,20200526,EXP,US-IBIGEN-2020.08777 (US-IBIGEN-2020.08777),US-IBIGEN-2020.08777,ISTITUTO BICHIMICO ITALIANO GIOVANNI LORENZINI (IBIGEN),"PHADKE G, KAUSHAL A, TOLAN DR, HAHN K, JENSEN T, BJORNSTAD P, RONCAL-JIMENEZ C, HERNANDO AA, LANASPA MA, ALEXANDER MP, KUKLA A, JOHNSON RJ. OSMOTIC NEPHROSIS AND ACUTE KIDNEY INJURY ASSOCIATED WITH SGLT2 INHIBITOR USE: A CASE REPORT. AM J KIDNEY DIS. 2020 MAY 5",66.0,YR,,M,Y,175.0,KG,20200520.0,,MD,US,US,2020,Q2,Elderly
177990662,17799066,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,(DAILY),,,Y,,,,,300.0,MG,,,2020,Q2,Blood creatinine increased,,2020,Q2,2,F,2018.0,20200520.0,20200518,20200526,EXP,US-IBIGEN-2020.08777 (US-IBIGEN-2020.08777),US-IBIGEN-2020.08777,ISTITUTO BICHIMICO ITALIANO GIOVANNI LORENZINI (IBIGEN),"PHADKE G, KAUSHAL A, TOLAN DR, HAHN K, JENSEN T, BJORNSTAD P, RONCAL-JIMENEZ C, HERNANDO AA, LANASPA MA, ALEXANDER MP, KUKLA A, JOHNSON RJ. OSMOTIC NEPHROSIS AND ACUTE KIDNEY INJURY ASSOCIATED WITH SGLT2 INHIBITOR USE: A CASE REPORT. AM J KIDNEY DIS. 2020 MAY 5",66.0,YR,,M,Y,175.0,KG,20200520.0,,MD,US,US,2020,Q2,Elderly
177990662,17799066,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,(DAILY),,,Y,,,,,300.0,MG,,,2020,Q2,Blood glucose increased,,2020,Q2,2,F,2018.0,20200520.0,20200518,20200526,EXP,US-IBIGEN-2020.08777 (US-IBIGEN-2020.08777),US-IBIGEN-2020.08777,ISTITUTO BICHIMICO ITALIANO GIOVANNI LORENZINI (IBIGEN),"PHADKE G, KAUSHAL A, TOLAN DR, HAHN K, JENSEN T, BJORNSTAD P, RONCAL-JIMENEZ C, HERNANDO AA, LANASPA MA, ALEXANDER MP, KUKLA A, JOHNSON RJ. OSMOTIC NEPHROSIS AND ACUTE KIDNEY INJURY ASSOCIATED WITH SGLT2 INHIBITOR USE: A CASE REPORT. AM J KIDNEY DIS. 2020 MAY 5",66.0,YR,,M,Y,175.0,KG,20200520.0,,MD,US,US,2020,Q2,Elderly
177990662,17799066,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,(DAILY),,,Y,,,,,300.0,MG,,,2020,Q2,Blood potassium increased,,2020,Q2,2,F,2018.0,20200520.0,20200518,20200526,EXP,US-IBIGEN-2020.08777 (US-IBIGEN-2020.08777),US-IBIGEN-2020.08777,ISTITUTO BICHIMICO ITALIANO GIOVANNI LORENZINI (IBIGEN),"PHADKE G, KAUSHAL A, TOLAN DR, HAHN K, JENSEN T, BJORNSTAD P, RONCAL-JIMENEZ C, HERNANDO AA, LANASPA MA, ALEXANDER MP, KUKLA A, JOHNSON RJ. OSMOTIC NEPHROSIS AND ACUTE KIDNEY INJURY ASSOCIATED WITH SGLT2 INHIBITOR USE: A CASE REPORT. AM J KIDNEY DIS. 2020 MAY 5",66.0,YR,,M,Y,175.0,KG,20200520.0,,MD,US,US,2020,Q2,Elderly
177990662,17799066,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,(DAILY),,,Y,,,,,300.0,MG,,,2020,Q2,Blood sodium decreased,,2020,Q2,2,F,2018.0,20200520.0,20200518,20200526,EXP,US-IBIGEN-2020.08777 (US-IBIGEN-2020.08777),US-IBIGEN-2020.08777,ISTITUTO BICHIMICO ITALIANO GIOVANNI LORENZINI (IBIGEN),"PHADKE G, KAUSHAL A, TOLAN DR, HAHN K, JENSEN T, BJORNSTAD P, RONCAL-JIMENEZ C, HERNANDO AA, LANASPA MA, ALEXANDER MP, KUKLA A, JOHNSON RJ. OSMOTIC NEPHROSIS AND ACUTE KIDNEY INJURY ASSOCIATED WITH SGLT2 INHIBITOR USE: A CASE REPORT. AM J KIDNEY DIS. 2020 MAY 5",66.0,YR,,M,Y,175.0,KG,20200520.0,,MD,US,US,2020,Q2,Elderly
177990662,17799066,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,(DAILY),,,Y,,,,,300.0,MG,,,2020,Q2,Blood urea increased,,2020,Q2,2,F,2018.0,20200520.0,20200518,20200526,EXP,US-IBIGEN-2020.08777 (US-IBIGEN-2020.08777),US-IBIGEN-2020.08777,ISTITUTO BICHIMICO ITALIANO GIOVANNI LORENZINI (IBIGEN),"PHADKE G, KAUSHAL A, TOLAN DR, HAHN K, JENSEN T, BJORNSTAD P, RONCAL-JIMENEZ C, HERNANDO AA, LANASPA MA, ALEXANDER MP, KUKLA A, JOHNSON RJ. OSMOTIC NEPHROSIS AND ACUTE KIDNEY INJURY ASSOCIATED WITH SGLT2 INHIBITOR USE: A CASE REPORT. AM J KIDNEY DIS. 2020 MAY 5",66.0,YR,,M,Y,175.0,KG,20200520.0,,MD,US,US,2020,Q2,Elderly
177990662,17799066,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,(DAILY),,,Y,,,,,300.0,MG,,,2020,Q2,Diarrhoea,,2020,Q2,2,F,2018.0,20200520.0,20200518,20200526,EXP,US-IBIGEN-2020.08777 (US-IBIGEN-2020.08777),US-IBIGEN-2020.08777,ISTITUTO BICHIMICO ITALIANO GIOVANNI LORENZINI (IBIGEN),"PHADKE G, KAUSHAL A, TOLAN DR, HAHN K, JENSEN T, BJORNSTAD P, RONCAL-JIMENEZ C, HERNANDO AA, LANASPA MA, ALEXANDER MP, KUKLA A, JOHNSON RJ. OSMOTIC NEPHROSIS AND ACUTE KIDNEY INJURY ASSOCIATED WITH SGLT2 INHIBITOR USE: A CASE REPORT. AM J KIDNEY DIS. 2020 MAY 5",66.0,YR,,M,Y,175.0,KG,20200520.0,,MD,US,US,2020,Q2,Elderly
177990662,17799066,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,(DAILY),,,Y,,,,,300.0,MG,,,2020,Q2,Glucose urine present,,2020,Q2,2,F,2018.0,20200520.0,20200518,20200526,EXP,US-IBIGEN-2020.08777 (US-IBIGEN-2020.08777),US-IBIGEN-2020.08777,ISTITUTO BICHIMICO ITALIANO GIOVANNI LORENZINI (IBIGEN),"PHADKE G, KAUSHAL A, TOLAN DR, HAHN K, JENSEN T, BJORNSTAD P, RONCAL-JIMENEZ C, HERNANDO AA, LANASPA MA, ALEXANDER MP, KUKLA A, JOHNSON RJ. OSMOTIC NEPHROSIS AND ACUTE KIDNEY INJURY ASSOCIATED WITH SGLT2 INHIBITOR USE: A CASE REPORT. AM J KIDNEY DIS. 2020 MAY 5",66.0,YR,,M,Y,175.0,KG,20200520.0,,MD,US,US,2020,Q2,Elderly
177990662,17799066,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,(DAILY),,,Y,,,,,300.0,MG,,,2020,Q2,Haematuria,,2020,Q2,2,F,2018.0,20200520.0,20200518,20200526,EXP,US-IBIGEN-2020.08777 (US-IBIGEN-2020.08777),US-IBIGEN-2020.08777,ISTITUTO BICHIMICO ITALIANO GIOVANNI LORENZINI (IBIGEN),"PHADKE G, KAUSHAL A, TOLAN DR, HAHN K, JENSEN T, BJORNSTAD P, RONCAL-JIMENEZ C, HERNANDO AA, LANASPA MA, ALEXANDER MP, KUKLA A, JOHNSON RJ. OSMOTIC NEPHROSIS AND ACUTE KIDNEY INJURY ASSOCIATED WITH SGLT2 INHIBITOR USE: A CASE REPORT. AM J KIDNEY DIS. 2020 MAY 5",66.0,YR,,M,Y,175.0,KG,20200520.0,,MD,US,US,2020,Q2,Elderly
177990662,17799066,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,(DAILY),,,Y,,,,,300.0,MG,,,2020,Q2,Nephrotic syndrome,,2020,Q2,2,F,2018.0,20200520.0,20200518,20200526,EXP,US-IBIGEN-2020.08777 (US-IBIGEN-2020.08777),US-IBIGEN-2020.08777,ISTITUTO BICHIMICO ITALIANO GIOVANNI LORENZINI (IBIGEN),"PHADKE G, KAUSHAL A, TOLAN DR, HAHN K, JENSEN T, BJORNSTAD P, RONCAL-JIMENEZ C, HERNANDO AA, LANASPA MA, ALEXANDER MP, KUKLA A, JOHNSON RJ. OSMOTIC NEPHROSIS AND ACUTE KIDNEY INJURY ASSOCIATED WITH SGLT2 INHIBITOR USE: A CASE REPORT. AM J KIDNEY DIS. 2020 MAY 5",66.0,YR,,M,Y,175.0,KG,20200520.0,,MD,US,US,2020,Q2,Elderly
177990662,17799066,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,(DAILY),,,Y,,,,,300.0,MG,,,2020,Q2,Oliguria,,2020,Q2,2,F,2018.0,20200520.0,20200518,20200526,EXP,US-IBIGEN-2020.08777 (US-IBIGEN-2020.08777),US-IBIGEN-2020.08777,ISTITUTO BICHIMICO ITALIANO GIOVANNI LORENZINI (IBIGEN),"PHADKE G, KAUSHAL A, TOLAN DR, HAHN K, JENSEN T, BJORNSTAD P, RONCAL-JIMENEZ C, HERNANDO AA, LANASPA MA, ALEXANDER MP, KUKLA A, JOHNSON RJ. OSMOTIC NEPHROSIS AND ACUTE KIDNEY INJURY ASSOCIATED WITH SGLT2 INHIBITOR USE: A CASE REPORT. AM J KIDNEY DIS. 2020 MAY 5",66.0,YR,,M,Y,175.0,KG,20200520.0,,MD,US,US,2020,Q2,Elderly
177990662,17799066,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,(DAILY),,,Y,,,,,300.0,MG,,,2020,Q2,Urine sodium decreased,,2020,Q2,2,F,2018.0,20200520.0,20200518,20200526,EXP,US-IBIGEN-2020.08777 (US-IBIGEN-2020.08777),US-IBIGEN-2020.08777,ISTITUTO BICHIMICO ITALIANO GIOVANNI LORENZINI (IBIGEN),"PHADKE G, KAUSHAL A, TOLAN DR, HAHN K, JENSEN T, BJORNSTAD P, RONCAL-JIMENEZ C, HERNANDO AA, LANASPA MA, ALEXANDER MP, KUKLA A, JOHNSON RJ. OSMOTIC NEPHROSIS AND ACUTE KIDNEY INJURY ASSOCIATED WITH SGLT2 INHIBITOR USE: A CASE REPORT. AM J KIDNEY DIS. 2020 MAY 5",66.0,YR,,M,Y,175.0,KG,20200520.0,,MD,US,US,2020,Q2,Elderly
177991751,17799175,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,300.0,MG,FILM-COATED TABLET,,2020,Q2,Accidental overdose,,2020,Q2,1,I,,20200505.0,20200518,20200518,EXP,GB-MHRA-EYC 00221967,GB-JNJFOC-20200503809,JOHNSON AND JOHNSON,,56.0,YR,,F,Y,,,20200518.0,,HP,GB,GB,2020,Q2,Adult
177991751,17799175,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,300.0,MG,FILM-COATED TABLET,,2020,Q2,Blood urine present,,2020,Q2,1,I,,20200505.0,20200518,20200518,EXP,GB-MHRA-EYC 00221967,GB-JNJFOC-20200503809,JOHNSON AND JOHNSON,,56.0,YR,,F,Y,,,20200518.0,,HP,GB,GB,2020,Q2,Adult
177991751,17799175,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,300.0,MG,FILM-COATED TABLET,,2020,Q2,Medication error,,2020,Q2,1,I,,20200505.0,20200518,20200518,EXP,GB-MHRA-EYC 00221967,GB-JNJFOC-20200503809,JOHNSON AND JOHNSON,,56.0,YR,,F,Y,,,20200518.0,,HP,GB,GB,2020,Q2,Adult
177991751,17799175,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2020,Q2,Accidental overdose,,2020,Q2,1,I,,20200505.0,20200518,20200518,EXP,GB-MHRA-EYC 00221967,GB-JNJFOC-20200503809,JOHNSON AND JOHNSON,,56.0,YR,,F,Y,,,20200518.0,,HP,GB,GB,2020,Q2,Adult
177991751,17799175,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2020,Q2,Blood urine present,,2020,Q2,1,I,,20200505.0,20200518,20200518,EXP,GB-MHRA-EYC 00221967,GB-JNJFOC-20200503809,JOHNSON AND JOHNSON,,56.0,YR,,F,Y,,,20200518.0,,HP,GB,GB,2020,Q2,Adult
177991751,17799175,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2020,Q2,Medication error,,2020,Q2,1,I,,20200505.0,20200518,20200518,EXP,GB-MHRA-EYC 00221967,GB-JNJFOC-20200503809,JOHNSON AND JOHNSON,,56.0,YR,,F,Y,,,20200518.0,,HP,GB,GB,2020,Q2,Adult
178037151,17803715,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2020,Q2,Abdominal pain upper,,2020,Q2,1,I,,20200512.0,20200519,20200519,EXP,,PT-MYLANLABS-2020M1048333,MYLAN,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A.. METFORMIN-ASSOCIATED LACTIC ACIDOSIS, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION.. MEDICINA INTERNA ? CONGRESSO NACIONAL. 2019;25CNMI19",76.0,YR,,M,Y,,,20200519.0,,MD,PT,PT,2020,Q2,Elderly
178037151,17803715,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2020,Q2,Acidosis,,2020,Q2,1,I,,20200512.0,20200519,20200519,EXP,,PT-MYLANLABS-2020M1048333,MYLAN,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A.. METFORMIN-ASSOCIATED LACTIC ACIDOSIS, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION.. MEDICINA INTERNA ? CONGRESSO NACIONAL. 2019;25CNMI19",76.0,YR,,M,Y,,,20200519.0,,MD,PT,PT,2020,Q2,Elderly
178037151,17803715,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2020,Q2,Dyspnoea,,2020,Q2,1,I,,20200512.0,20200519,20200519,EXP,,PT-MYLANLABS-2020M1048333,MYLAN,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A.. METFORMIN-ASSOCIATED LACTIC ACIDOSIS, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION.. MEDICINA INTERNA ? CONGRESSO NACIONAL. 2019;25CNMI19",76.0,YR,,M,Y,,,20200519.0,,MD,PT,PT,2020,Q2,Elderly
178037151,17803715,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2020,Q2,Fatigue,,2020,Q2,1,I,,20200512.0,20200519,20200519,EXP,,PT-MYLANLABS-2020M1048333,MYLAN,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A.. METFORMIN-ASSOCIATED LACTIC ACIDOSIS, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION.. MEDICINA INTERNA ? CONGRESSO NACIONAL. 2019;25CNMI19",76.0,YR,,M,Y,,,20200519.0,,MD,PT,PT,2020,Q2,Elderly
178037151,17803715,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2020,Q2,Feeling abnormal,,2020,Q2,1,I,,20200512.0,20200519,20200519,EXP,,PT-MYLANLABS-2020M1048333,MYLAN,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A.. METFORMIN-ASSOCIATED LACTIC ACIDOSIS, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION.. MEDICINA INTERNA ? CONGRESSO NACIONAL. 2019;25CNMI19",76.0,YR,,M,Y,,,20200519.0,,MD,PT,PT,2020,Q2,Elderly
178037151,17803715,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2020,Q2,Hyperhidrosis,,2020,Q2,1,I,,20200512.0,20200519,20200519,EXP,,PT-MYLANLABS-2020M1048333,MYLAN,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A.. METFORMIN-ASSOCIATED LACTIC ACIDOSIS, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION.. MEDICINA INTERNA ? CONGRESSO NACIONAL. 2019;25CNMI19",76.0,YR,,M,Y,,,20200519.0,,MD,PT,PT,2020,Q2,Elderly
178037151,17803715,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2020,Q2,Hypotension,,2020,Q2,1,I,,20200512.0,20200519,20200519,EXP,,PT-MYLANLABS-2020M1048333,MYLAN,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A.. METFORMIN-ASSOCIATED LACTIC ACIDOSIS, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION.. MEDICINA INTERNA ? CONGRESSO NACIONAL. 2019;25CNMI19",76.0,YR,,M,Y,,,20200519.0,,MD,PT,PT,2020,Q2,Elderly
178037151,17803715,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2020,Q2,Lactic acidosis,,2020,Q2,1,I,,20200512.0,20200519,20200519,EXP,,PT-MYLANLABS-2020M1048333,MYLAN,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A.. METFORMIN-ASSOCIATED LACTIC ACIDOSIS, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION.. MEDICINA INTERNA ? CONGRESSO NACIONAL. 2019;25CNMI19",76.0,YR,,M,Y,,,20200519.0,,MD,PT,PT,2020,Q2,Elderly
178037151,17803715,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2020,Q2,Renal impairment,,2020,Q2,1,I,,20200512.0,20200519,20200519,EXP,,PT-MYLANLABS-2020M1048333,MYLAN,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A.. METFORMIN-ASSOCIATED LACTIC ACIDOSIS, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION.. MEDICINA INTERNA ? CONGRESSO NACIONAL. 2019;25CNMI19",76.0,YR,,M,Y,,,20200519.0,,MD,PT,PT,2020,Q2,Elderly
178037151,17803715,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2020,Q2,Vomiting,,2020,Q2,1,I,,20200512.0,20200519,20200519,EXP,,PT-MYLANLABS-2020M1048333,MYLAN,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A.. METFORMIN-ASSOCIATED LACTIC ACIDOSIS, WITH ACUTE KIDNEY INJURY DUE TO IATROGENIC HYPOTENSION.. MEDICINA INTERNA ? CONGRESSO NACIONAL. 2019;25CNMI19",76.0,YR,,M,Y,,,20200519.0,,MD,PT,PT,2020,Q2,Elderly
178091901,17809190,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,,,,,100.0,MG,,QD,2020,Q2,Abdominal discomfort,,2020,Q2,1,I,,20181205.0,20200520,20200520,EXP,,ES-SAKK-2018SA334374AA,SANOFI AVENTIS,,59.0,YR,A,M,Y,,,20200520.0,,CN,ES,ES,2020,Q2,Adult
178091901,17809190,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,,,,,100.0,MG,,QD,2020,Q2,Asthenia,,2020,Q2,1,I,,20181205.0,20200520,20200520,EXP,,ES-SAKK-2018SA334374AA,SANOFI AVENTIS,,59.0,YR,A,M,Y,,,20200520.0,,CN,ES,ES,2020,Q2,Adult
178091901,17809190,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,,,,,100.0,MG,,QD,2020,Q2,Blood glucose increased,,2020,Q2,1,I,,20181205.0,20200520,20200520,EXP,,ES-SAKK-2018SA334374AA,SANOFI AVENTIS,,59.0,YR,A,M,Y,,,20200520.0,,CN,ES,ES,2020,Q2,Adult
178091901,17809190,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,,,,,100.0,MG,,QD,2020,Q2,Diabetic ketoacidosis,,2020,Q2,1,I,,20181205.0,20200520,20200520,EXP,,ES-SAKK-2018SA334374AA,SANOFI AVENTIS,,59.0,YR,A,M,Y,,,20200520.0,,CN,ES,ES,2020,Q2,Adult
178091901,17809190,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,,,,,100.0,MG,,QD,2020,Q2,Glycosylated haemoglobin increased,,2020,Q2,1,I,,20181205.0,20200520,20200520,EXP,,ES-SAKK-2018SA334374AA,SANOFI AVENTIS,,59.0,YR,A,M,Y,,,20200520.0,,CN,ES,ES,2020,Q2,Adult
178091901,17809190,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,,,,,100.0,MG,,QD,2020,Q2,Ketonuria,,2020,Q2,1,I,,20181205.0,20200520,20200520,EXP,,ES-SAKK-2018SA334374AA,SANOFI AVENTIS,,59.0,YR,A,M,Y,,,20200520.0,,CN,ES,ES,2020,Q2,Adult
178091901,17809190,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,,,,,100.0,MG,,QD,2020,Q2,Metabolic acidosis,,2020,Q2,1,I,,20181205.0,20200520,20200520,EXP,,ES-SAKK-2018SA334374AA,SANOFI AVENTIS,,59.0,YR,A,M,Y,,,20200520.0,,CN,ES,ES,2020,Q2,Adult
178091901,17809190,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,,,,,100.0,MG,,QD,2020,Q2,Metabolic disorder,,2020,Q2,1,I,,20181205.0,20200520,20200520,EXP,,ES-SAKK-2018SA334374AA,SANOFI AVENTIS,,59.0,YR,A,M,Y,,,20200520.0,,CN,ES,ES,2020,Q2,Adult
178091901,17809190,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,,,,,100.0,MG,,QD,2020,Q2,Nausea,,2020,Q2,1,I,,20181205.0,20200520,20200520,EXP,,ES-SAKK-2018SA334374AA,SANOFI AVENTIS,,59.0,YR,A,M,Y,,,20200520.0,,CN,ES,ES,2020,Q2,Adult
178091901,17809190,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,,,,,100.0,MG,,QD,2020,Q2,Vomiting,,2020,Q2,1,I,,20181205.0,20200520,20200520,EXP,,ES-SAKK-2018SA334374AA,SANOFI AVENTIS,,59.0,YR,A,M,Y,,,20200520.0,,CN,ES,ES,2020,Q2,Adult
178093511,17809351,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q2,Neoplasm recurrence,,2020,Q2,1,I,,20200514.0,20200521,20200521,EXP,,CA-ROCHE-2601339,ROCHE,,36.0,YR,,M,Y,,,20200521.0,,HP,CA,CA,2020,Q2,Adult
178093511,17809351,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q2,Pyrexia,,2020,Q2,1,I,,20200514.0,20200521,20200521,EXP,,CA-ROCHE-2601339,ROCHE,,36.0,YR,,M,Y,,,20200521.0,,HP,CA,CA,2020,Q2,Adult
178101744,17810174,5,C,CANAGLIFLOZIN;TENELIGLIPTIN,,2,Oral,BEGINNING OF DOSAGE DAY: TRIAL PREINITIATION,,,,,,,,1.0,DF,TABLET,QD,2020,Q2,Adrenocorticotropic hormone deficiency,,2020,Q2,4,F,20200506.0,20200604.0,20200521,20200612,EXP,,JP-ROCHE-2602163,ROCHE,,68.0,YR,,M,Y,80.7,KG,20200612.0,,MD,JP,JP,2020,Q2,Elderly
178128032,17812803,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, 1X/DAY",,,Y,, UNKNOWN,,,300.0,MG,,QD,2020,Q2,Acute kidney injury,,2020,Q2,2,F,2018.0,20200525.0,20200521,20200528,EXP,,US-PFIZER INC-2020201619,PFIZER,"PHADKE, G.. OSMOTIC NEPHROSIS AND ACUTE KIDNEY INJURY ASSOCIATED WITH SGLT2 INHIBITOR USE: A CASE REPORT. AMERICAN JOURNAL OF KIDNEY DISEASES. 2020;10.1053/J.AJKD.2020.01.015",66.0,YR,,M,Y,175.0,KG,20200528.0,,MD,US,US,2020,Q2,Elderly
178128032,17812803,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, 1X/DAY",,,Y,, UNKNOWN,,,300.0,MG,,QD,2020,Q2,Nephrotic syndrome,,2020,Q2,2,F,2018.0,20200525.0,20200521,20200528,EXP,,US-PFIZER INC-2020201619,PFIZER,"PHADKE, G.. OSMOTIC NEPHROSIS AND ACUTE KIDNEY INJURY ASSOCIATED WITH SGLT2 INHIBITOR USE: A CASE REPORT. AMERICAN JOURNAL OF KIDNEY DISEASES. 2020;10.1053/J.AJKD.2020.01.015",66.0,YR,,M,Y,175.0,KG,20200528.0,,MD,US,US,2020,Q2,Elderly
178128032,17812803,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, 1X/DAY",,,Y,, UNKNOWN,,,300.0,MG,,QD,2020,Q2,Renal impairment,,2020,Q2,2,F,2018.0,20200525.0,20200521,20200528,EXP,,US-PFIZER INC-2020201619,PFIZER,"PHADKE, G.. OSMOTIC NEPHROSIS AND ACUTE KIDNEY INJURY ASSOCIATED WITH SGLT2 INHIBITOR USE: A CASE REPORT. AMERICAN JOURNAL OF KIDNEY DISEASES. 2020;10.1053/J.AJKD.2020.01.015",66.0,YR,,M,Y,175.0,KG,20200528.0,,MD,US,US,2020,Q2,Elderly
178200901,17820090,3,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM DAILY,,,Y,,,,,300.0,MG,,,2020,Q2,Acute kidney injury,,2020,Q2,1,I,2018.0,20200512.0,20200525,20200525,EXP,,US-EMCURE PHARMACEUTICALS LTD-2020-EPL-000628,EMCURE,,66.0,YR,,M,Y,175.06,KG,20200524.0,,MD,US,US,2020,Q2,Elderly
178254291,17825429,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,,,,,,,,,2020,Q2,Anal fistula,,2020,Q2,1,I,,20200518.0,20200526,20200526,EXP,,CA-TEVA-2020-CA-1239294,TEVA,"ELBEDDINI A, GALLINGER J, DAVEY M, BRASSARD S, GAZARIN M, PLOURDE F, ET AL. A CASE OF FOURNIER^S GANGRENE IN A PATIENT TAKING CANAGLIFLOZIN FOR THE TREATMENT OF TYPE II DIABETES MELLITUS. AM-J-CASE-REP 2020;:.",72.0,YR,,M,Y,,,20200526.0,,HP,CA,CA,2020,Q2,Elderly
178254291,17825429,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,,,,,,,,,2020,Q2,Diarrhoea,,2020,Q2,1,I,,20200518.0,20200526,20200526,EXP,,CA-TEVA-2020-CA-1239294,TEVA,"ELBEDDINI A, GALLINGER J, DAVEY M, BRASSARD S, GAZARIN M, PLOURDE F, ET AL. A CASE OF FOURNIER^S GANGRENE IN A PATIENT TAKING CANAGLIFLOZIN FOR THE TREATMENT OF TYPE II DIABETES MELLITUS. AM-J-CASE-REP 2020;:.",72.0,YR,,M,Y,,,20200526.0,,HP,CA,CA,2020,Q2,Elderly
178254291,17825429,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,,,,,,,,,2020,Q2,Fournier's gangrene,,2020,Q2,1,I,,20200518.0,20200526,20200526,EXP,,CA-TEVA-2020-CA-1239294,TEVA,"ELBEDDINI A, GALLINGER J, DAVEY M, BRASSARD S, GAZARIN M, PLOURDE F, ET AL. A CASE OF FOURNIER^S GANGRENE IN A PATIENT TAKING CANAGLIFLOZIN FOR THE TREATMENT OF TYPE II DIABETES MELLITUS. AM-J-CASE-REP 2020;:.",72.0,YR,,M,Y,,,20200526.0,,HP,CA,CA,2020,Q2,Elderly
178254291,17825429,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,,,,,,,,,2020,Q2,Rectal abscess,,2020,Q2,1,I,,20200518.0,20200526,20200526,EXP,,CA-TEVA-2020-CA-1239294,TEVA,"ELBEDDINI A, GALLINGER J, DAVEY M, BRASSARD S, GAZARIN M, PLOURDE F, ET AL. A CASE OF FOURNIER^S GANGRENE IN A PATIENT TAKING CANAGLIFLOZIN FOR THE TREATMENT OF TYPE II DIABETES MELLITUS. AM-J-CASE-REP 2020;:.",72.0,YR,,M,Y,,,20200526.0,,HP,CA,CA,2020,Q2,Elderly
178277101,17827710,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q2,Aphonia,,2020,Q2,1,I,,20200515.0,20200527,20200527,EXP,,CA-ROCHE-2602575,ROCHE,,67.0,YR,,F,Y,71.0,KG,20200527.0,,HP,CA,CA,2020,Q2,Elderly
178277101,17827710,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q2,Arthralgia,,2020,Q2,1,I,,20200515.0,20200527,20200527,EXP,,CA-ROCHE-2602575,ROCHE,,67.0,YR,,F,Y,71.0,KG,20200527.0,,HP,CA,CA,2020,Q2,Elderly
178277101,17827710,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q2,Blood glucose increased,,2020,Q2,1,I,,20200515.0,20200527,20200527,EXP,,CA-ROCHE-2602575,ROCHE,,67.0,YR,,F,Y,71.0,KG,20200527.0,,HP,CA,CA,2020,Q2,Elderly
178277101,17827710,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q2,Blood pressure increased,,2020,Q2,1,I,,20200515.0,20200527,20200527,EXP,,CA-ROCHE-2602575,ROCHE,,67.0,YR,,F,Y,71.0,KG,20200527.0,,HP,CA,CA,2020,Q2,Elderly
178277101,17827710,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q2,Blood pressure systolic increased,,2020,Q2,1,I,,20200515.0,20200527,20200527,EXP,,CA-ROCHE-2602575,ROCHE,,67.0,YR,,F,Y,71.0,KG,20200527.0,,HP,CA,CA,2020,Q2,Elderly
178277101,17827710,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q2,C-reactive protein increased,,2020,Q2,1,I,,20200515.0,20200527,20200527,EXP,,CA-ROCHE-2602575,ROCHE,,67.0,YR,,F,Y,71.0,KG,20200527.0,,HP,CA,CA,2020,Q2,Elderly
178277101,17827710,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q2,Cough,,2020,Q2,1,I,,20200515.0,20200527,20200527,EXP,,CA-ROCHE-2602575,ROCHE,,67.0,YR,,F,Y,71.0,KG,20200527.0,,HP,CA,CA,2020,Q2,Elderly
178277101,17827710,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q2,Diabetes mellitus,,2020,Q2,1,I,,20200515.0,20200527,20200527,EXP,,CA-ROCHE-2602575,ROCHE,,67.0,YR,,F,Y,71.0,KG,20200527.0,,HP,CA,CA,2020,Q2,Elderly
178277101,17827710,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q2,Diarrhoea,,2020,Q2,1,I,,20200515.0,20200527,20200527,EXP,,CA-ROCHE-2602575,ROCHE,,67.0,YR,,F,Y,71.0,KG,20200527.0,,HP,CA,CA,2020,Q2,Elderly
178277101,17827710,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q2,Dizziness,,2020,Q2,1,I,,20200515.0,20200527,20200527,EXP,,CA-ROCHE-2602575,ROCHE,,67.0,YR,,F,Y,71.0,KG,20200527.0,,HP,CA,CA,2020,Q2,Elderly
178277101,17827710,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q2,Drug ineffective,,2020,Q2,1,I,,20200515.0,20200527,20200527,EXP,,CA-ROCHE-2602575,ROCHE,,67.0,YR,,F,Y,71.0,KG,20200527.0,,HP,CA,CA,2020,Q2,Elderly
178277101,17827710,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q2,Dry mouth,,2020,Q2,1,I,,20200515.0,20200527,20200527,EXP,,CA-ROCHE-2602575,ROCHE,,67.0,YR,,F,Y,71.0,KG,20200527.0,,HP,CA,CA,2020,Q2,Elderly
178277101,17827710,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q2,Dyspepsia,,2020,Q2,1,I,,20200515.0,20200527,20200527,EXP,,CA-ROCHE-2602575,ROCHE,,67.0,YR,,F,Y,71.0,KG,20200527.0,,HP,CA,CA,2020,Q2,Elderly
178277101,17827710,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q2,Ear infection viral,,2020,Q2,1,I,,20200515.0,20200527,20200527,EXP,,CA-ROCHE-2602575,ROCHE,,67.0,YR,,F,Y,71.0,KG,20200527.0,,HP,CA,CA,2020,Q2,Elderly
178277101,17827710,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q2,Feeling hot,,2020,Q2,1,I,,20200515.0,20200527,20200527,EXP,,CA-ROCHE-2602575,ROCHE,,67.0,YR,,F,Y,71.0,KG,20200527.0,,HP,CA,CA,2020,Q2,Elderly
178277101,17827710,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q2,Hyperhidrosis,,2020,Q2,1,I,,20200515.0,20200527,20200527,EXP,,CA-ROCHE-2602575,ROCHE,,67.0,YR,,F,Y,71.0,KG,20200527.0,,HP,CA,CA,2020,Q2,Elderly
178277101,17827710,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q2,Infection,,2020,Q2,1,I,,20200515.0,20200527,20200527,EXP,,CA-ROCHE-2602575,ROCHE,,67.0,YR,,F,Y,71.0,KG,20200527.0,,HP,CA,CA,2020,Q2,Elderly
178277101,17827710,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q2,Inflammation,,2020,Q2,1,I,,20200515.0,20200527,20200527,EXP,,CA-ROCHE-2602575,ROCHE,,67.0,YR,,F,Y,71.0,KG,20200527.0,,HP,CA,CA,2020,Q2,Elderly
178277101,17827710,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q2,Infusion related reaction,,2020,Q2,1,I,,20200515.0,20200527,20200527,EXP,,CA-ROCHE-2602575,ROCHE,,67.0,YR,,F,Y,71.0,KG,20200527.0,,HP,CA,CA,2020,Q2,Elderly
178277101,17827710,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q2,Joint swelling,,2020,Q2,1,I,,20200515.0,20200527,20200527,EXP,,CA-ROCHE-2602575,ROCHE,,67.0,YR,,F,Y,71.0,KG,20200527.0,,HP,CA,CA,2020,Q2,Elderly
178277101,17827710,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q2,Malaise,,2020,Q2,1,I,,20200515.0,20200527,20200527,EXP,,CA-ROCHE-2602575,ROCHE,,67.0,YR,,F,Y,71.0,KG,20200527.0,,HP,CA,CA,2020,Q2,Elderly
178277101,17827710,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q2,Musculoskeletal stiffness,,2020,Q2,1,I,,20200515.0,20200527,20200527,EXP,,CA-ROCHE-2602575,ROCHE,,67.0,YR,,F,Y,71.0,KG,20200527.0,,HP,CA,CA,2020,Q2,Elderly
178277101,17827710,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q2,Myocardial infarction,,2020,Q2,1,I,,20200515.0,20200527,20200527,EXP,,CA-ROCHE-2602575,ROCHE,,67.0,YR,,F,Y,71.0,KG,20200527.0,,HP,CA,CA,2020,Q2,Elderly
178277101,17827710,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q2,Respiratory rate increased,,2020,Q2,1,I,,20200515.0,20200527,20200527,EXP,,CA-ROCHE-2602575,ROCHE,,67.0,YR,,F,Y,71.0,KG,20200527.0,,HP,CA,CA,2020,Q2,Elderly
178277101,17827710,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q2,Sneezing,,2020,Q2,1,I,,20200515.0,20200527,20200527,EXP,,CA-ROCHE-2602575,ROCHE,,67.0,YR,,F,Y,71.0,KG,20200527.0,,HP,CA,CA,2020,Q2,Elderly
178277101,17827710,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q2,Vomiting,,2020,Q2,1,I,,20200515.0,20200527,20200527,EXP,,CA-ROCHE-2602575,ROCHE,,67.0,YR,,F,Y,71.0,KG,20200527.0,,HP,CA,CA,2020,Q2,Elderly
178277101,17827710,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q2,Weight increased,,2020,Q2,1,I,,20200515.0,20200527,20200527,EXP,,CA-ROCHE-2602575,ROCHE,,67.0,YR,,F,Y,71.0,KG,20200527.0,,HP,CA,CA,2020,Q2,Elderly
178294951,17829495,1,PS,CANAGLIFLOZIN 100MG,CANAGLIFLOZIN,1,,,,,,Y,,,,,,,,2020,Q2,Osteomyelitis,,2020,Q2,1,I,20200525.0,,20200527,20200527,DIR,,,FDA-CTU,,69.0,YR,,M,N,169.0,KG,20200527.0,N,PH,US,US,2020,Q2,Elderly
178294951,17829495,1,PS,CANAGLIFLOZIN 100MG,CANAGLIFLOZIN,1,,,,,,Y,,,,,,,,2020,Q2,Toe amputation,,2020,Q2,1,I,20200525.0,,20200527,20200527,DIR,,,FDA-CTU,,69.0,YR,,M,N,169.0,KG,20200527.0,N,PH,US,US,2020,Q2,Elderly
178353771,17835377,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,,300.0,MG,,,2020,Q2,Acute kidney injury,,2020,Q2,1,I,2018.0,20200519.0,20200528,20200528,EXP,,US-ACCORD-183470,ACCORD,"PHADKE G, KAUSHAL A, TOLAN DR, HAHN K, JENSEN T, BJORNSTAD P ET AL. OSMOTIC NEPHROSIS AND ACUTE KIDNEY INJURY ASSOCIATED WITH SGLT2 INHIBITOR USE: A CASE REPORT. AM J KIDNEY DIS. 2020. DOI: 10.1053/J.AJKD.2020.01.015.",66.0,YR,,M,Y,175.0,KG,20200528.0,,MD,US,US,2020,Q2,Elderly
178353771,17835377,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,,300.0,MG,,,2020,Q2,Nephrotic syndrome,,2020,Q2,1,I,2018.0,20200519.0,20200528,20200528,EXP,,US-ACCORD-183470,ACCORD,"PHADKE G, KAUSHAL A, TOLAN DR, HAHN K, JENSEN T, BJORNSTAD P ET AL. OSMOTIC NEPHROSIS AND ACUTE KIDNEY INJURY ASSOCIATED WITH SGLT2 INHIBITOR USE: A CASE REPORT. AM J KIDNEY DIS. 2020. DOI: 10.1053/J.AJKD.2020.01.015.",66.0,YR,,M,Y,175.0,KG,20200528.0,,MD,US,US,2020,Q2,Elderly
178353771,17835377,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,,300.0,MG,,,2020,Q2,Renal impairment,,2020,Q2,1,I,2018.0,20200519.0,20200528,20200528,EXP,,US-ACCORD-183470,ACCORD,"PHADKE G, KAUSHAL A, TOLAN DR, HAHN K, JENSEN T, BJORNSTAD P ET AL. OSMOTIC NEPHROSIS AND ACUTE KIDNEY INJURY ASSOCIATED WITH SGLT2 INHIBITOR USE: A CASE REPORT. AM J KIDNEY DIS. 2020. DOI: 10.1053/J.AJKD.2020.01.015.",66.0,YR,,M,Y,175.0,KG,20200528.0,,MD,US,US,2020,Q2,Elderly
178390391,17839039,3,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,"300 MILLIGRAM, ONCE A DAY",,,Y,U,,,,300.0,MG,,QD,2020,Q2,Acute kidney injury,,2020,Q2,1,I,2018.0,20200519.0,20200529,20200529,EXP,,US-AUROBINDO-AUR-APL-2020-026000,AUROBINDO,,66.0,YR,,M,Y,175.0,KG,20200529.0,,HP,US,US,2020,Q2,Elderly
178390391,17839039,3,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,"300 MILLIGRAM, ONCE A DAY",,,Y,U,,,,300.0,MG,,QD,2020,Q2,Nephrotic syndrome,,2020,Q2,1,I,2018.0,20200519.0,20200529,20200529,EXP,,US-AUROBINDO-AUR-APL-2020-026000,AUROBINDO,,66.0,YR,,M,Y,175.0,KG,20200529.0,,HP,US,US,2020,Q2,Elderly
178390391,17839039,3,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,"300 MILLIGRAM, ONCE A DAY",,,Y,U,,,,300.0,MG,,QD,2020,Q2,Renal impairment,,2020,Q2,1,I,2018.0,20200519.0,20200529,20200529,EXP,,US-AUROBINDO-AUR-APL-2020-026000,AUROBINDO,,66.0,YR,,M,Y,175.0,KG,20200529.0,,HP,US,US,2020,Q2,Elderly
178394361,17839436,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",,,D,,,,,,,TABLET,,2020,Q2,Idiopathic pulmonary fibrosis,,2020,Q2,1,I,20191215.0,20200518.0,20200529,20200529,EXP,,US-HETERO-HET2020US00567,HETERO,,71.0,YR,,F,Y,73.0,KG,20200529.0,,CN,US,US,2020,Q2,Elderly
178394361,17839436,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",,,D,,,,,,,TABLET,,2020,Q2,Respiratory failure,,2020,Q2,1,I,20191215.0,20200518.0,20200529,20200529,EXP,,US-HETERO-HET2020US00567,HETERO,,71.0,YR,,F,Y,73.0,KG,20200529.0,,CN,US,US,2020,Q2,Elderly
178411861,17841186,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,FILM-COATED TABLET,,2020,Q2,Dyspnoea,,2020,Q2,1,I,20200309.0,20200520.0,20200529,20200529,EXP,GB-MHRA-INP79A6FC7E-1D36-447F-BCC0-464B50E29CCD,GB-JNJFOC-20200525228,JOHNSON AND JOHNSON,,71.0,YR,,M,Y,78.0,KG,20200529.0,,PH,GB,GB,2020,Q2,Elderly
178424181,17842418,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Acute kidney injury,,2020,Q2,1,I,20200508.0,20200520.0,20200529,20200529,EXP,GB-MHRA-WEBRADR-20200508180145,GB-ELI_LILLY_AND_COMPANY-GB202005008125,ELI LILLY AND CO,,66.0,YR,,M,Y,81.0,KG,20200529.0,,PH,GB,GB,2020,Q2,Elderly
178424181,17842418,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Blood calcium decreased,,2020,Q2,1,I,20200508.0,20200520.0,20200529,20200529,EXP,GB-MHRA-WEBRADR-20200508180145,GB-ELI_LILLY_AND_COMPANY-GB202005008125,ELI LILLY AND CO,,66.0,YR,,M,Y,81.0,KG,20200529.0,,PH,GB,GB,2020,Q2,Elderly
178424181,17842418,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Blood creatinine increased,,2020,Q2,1,I,20200508.0,20200520.0,20200529,20200529,EXP,GB-MHRA-WEBRADR-20200508180145,GB-ELI_LILLY_AND_COMPANY-GB202005008125,ELI LILLY AND CO,,66.0,YR,,M,Y,81.0,KG,20200529.0,,PH,GB,GB,2020,Q2,Elderly
178424181,17842418,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Blood magnesium decreased,,2020,Q2,1,I,20200508.0,20200520.0,20200529,20200529,EXP,GB-MHRA-WEBRADR-20200508180145,GB-ELI_LILLY_AND_COMPANY-GB202005008125,ELI LILLY AND CO,,66.0,YR,,M,Y,81.0,KG,20200529.0,,PH,GB,GB,2020,Q2,Elderly
178424181,17842418,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Gastrointestinal disorder,,2020,Q2,1,I,20200508.0,20200520.0,20200529,20200529,EXP,GB-MHRA-WEBRADR-20200508180145,GB-ELI_LILLY_AND_COMPANY-GB202005008125,ELI LILLY AND CO,,66.0,YR,,M,Y,81.0,KG,20200529.0,,PH,GB,GB,2020,Q2,Elderly
178435001,17843500,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,,300.0,MG,UNKNOWN,,2020,Q2,Acute kidney injury,,2020,Q2,1,I,2018.0,20200519.0,20200531,20200531,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-51387,HIKMA,"PHADKE G, KAUSHAL A, TOLAN D, HAHN K, JENSEN T, BJORNSTAD P, RONCAL-JIMENEZ C, HERNANDO A, LANASPA M, ALEXANDER M, KUKLA A, JOHNSON R. OSMOTIC NEPHROSIS AND ACUTE KIDNEY INJURY ASSOCIATED WITH SGLT2 INHIBITOR USE: A CASE REPORT. THE AMERICAN JOURNAL OF KIDNEY DISEASES; DOI: 10.1053/J.AJKD.2020.01.015. 2020 MAY;.",66.0,YR,,M,Y,175.0,KG,20200527.0,,MD,US,US,2020,Q2,Elderly
178435001,17843500,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,,300.0,MG,UNKNOWN,,2020,Q2,Nephrotic syndrome,,2020,Q2,1,I,2018.0,20200519.0,20200531,20200531,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-51387,HIKMA,"PHADKE G, KAUSHAL A, TOLAN D, HAHN K, JENSEN T, BJORNSTAD P, RONCAL-JIMENEZ C, HERNANDO A, LANASPA M, ALEXANDER M, KUKLA A, JOHNSON R. OSMOTIC NEPHROSIS AND ACUTE KIDNEY INJURY ASSOCIATED WITH SGLT2 INHIBITOR USE: A CASE REPORT. THE AMERICAN JOURNAL OF KIDNEY DISEASES; DOI: 10.1053/J.AJKD.2020.01.015. 2020 MAY;.",66.0,YR,,M,Y,175.0,KG,20200527.0,,MD,US,US,2020,Q2,Elderly
178435001,17843500,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,,300.0,MG,UNKNOWN,,2020,Q2,Renal impairment,,2020,Q2,1,I,2018.0,20200519.0,20200531,20200531,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-51387,HIKMA,"PHADKE G, KAUSHAL A, TOLAN D, HAHN K, JENSEN T, BJORNSTAD P, RONCAL-JIMENEZ C, HERNANDO A, LANASPA M, ALEXANDER M, KUKLA A, JOHNSON R. OSMOTIC NEPHROSIS AND ACUTE KIDNEY INJURY ASSOCIATED WITH SGLT2 INHIBITOR USE: A CASE REPORT. THE AMERICAN JOURNAL OF KIDNEY DISEASES; DOI: 10.1053/J.AJKD.2020.01.015. 2020 MAY;.",66.0,YR,,M,Y,175.0,KG,20200527.0,,MD,US,US,2020,Q2,Elderly
178553351,17855335,21,C,INVOKANA[CANAGLIFLOZIN],,2,Unknown,,,,,,,,,,,,,2020,Q2,Arrhythmia,,2020,Q2,1,I,,20200526.0,20200603,20200603,EXP,,CA-TEVA-2020-CA-1241719,TEVA,,69.0,YR,,M,Y,,,20200603.0,,MD,CA,CA,2020,Q2,Elderly
178553351,17855335,21,C,INVOKANA[CANAGLIFLOZIN],,2,Unknown,,,,,,,,,,,,,2020,Q2,Cataract,,2020,Q2,1,I,,20200526.0,20200603,20200603,EXP,,CA-TEVA-2020-CA-1241719,TEVA,,69.0,YR,,M,Y,,,20200603.0,,MD,CA,CA,2020,Q2,Elderly
178553351,17855335,21,C,INVOKANA[CANAGLIFLOZIN],,2,Unknown,,,,,,,,,,,,,2020,Q2,Hypoaesthesia,,2020,Q2,1,I,,20200526.0,20200603,20200603,EXP,,CA-TEVA-2020-CA-1241719,TEVA,,69.0,YR,,M,Y,,,20200603.0,,MD,CA,CA,2020,Q2,Elderly
178553351,17855335,21,C,INVOKANA[CANAGLIFLOZIN],,2,Unknown,,,,,,,,,,,,,2020,Q2,Mass,,2020,Q2,1,I,,20200526.0,20200603,20200603,EXP,,CA-TEVA-2020-CA-1241719,TEVA,,69.0,YR,,M,Y,,,20200603.0,,MD,CA,CA,2020,Q2,Elderly
178553351,17855335,21,C,INVOKANA[CANAGLIFLOZIN],,2,Unknown,,,,,,,,,,,,,2020,Q2,Pneumonia,,2020,Q2,1,I,,20200526.0,20200603,20200603,EXP,,CA-TEVA-2020-CA-1241719,TEVA,,69.0,YR,,M,Y,,,20200603.0,,MD,CA,CA,2020,Q2,Elderly
178610223,17861022,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",2400.0,MG,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q2,Drug eruption,,2020,Q2,3,F,20200501.0,20200615.0,20200604,20200625,EXP,,JP-JNJFOC-20200603877,JOHNSON AND JOHNSON,,88.0,YR,,M,Y,,,20200625.0,,MD,JP,JP,2020,Q2,Elderly
178834021,17883402,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q2,Dizziness,,2020,Q2,1,I,,20200605.0,20200611,20200611,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-028589",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,,,20200611.0,,MD,CA,CA,2020,Q2,Elderly
178834021,17883402,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q2,Drug ineffective,,2020,Q2,1,I,,20200605.0,20200611,20200611,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-028589",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,,,20200611.0,,MD,CA,CA,2020,Q2,Elderly
178834021,17883402,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q2,Dyspnoea,,2020,Q2,1,I,,20200605.0,20200611,20200611,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-028589",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,,,20200611.0,,MD,CA,CA,2020,Q2,Elderly
178834021,17883402,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q2,Fatigue,,2020,Q2,1,I,,20200605.0,20200611,20200611,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-028589",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,,,20200611.0,,MD,CA,CA,2020,Q2,Elderly
178834021,17883402,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q2,Flushing,,2020,Q2,1,I,,20200605.0,20200611,20200611,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-028589",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,,,20200611.0,,MD,CA,CA,2020,Q2,Elderly
178834021,17883402,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q2,Headache,,2020,Q2,1,I,,20200605.0,20200611,20200611,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-028589",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,,,20200611.0,,MD,CA,CA,2020,Q2,Elderly
178834021,17883402,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q2,Hypoxia,,2020,Q2,1,I,,20200605.0,20200611,20200611,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-028589",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,,,20200611.0,,MD,CA,CA,2020,Q2,Elderly
178834021,17883402,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q2,Muscular weakness,,2020,Q2,1,I,,20200605.0,20200611,20200611,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-028589",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,,,20200611.0,,MD,CA,CA,2020,Q2,Elderly
178834021,17883402,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q2,Nausea,,2020,Q2,1,I,,20200605.0,20200611,20200611,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-028589",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,,,20200611.0,,MD,CA,CA,2020,Q2,Elderly
178997601,17899760,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,Y,,,,300.0,MG,,QD,2020,Q2,Balance disorder,,2020,Q2,1,I,20200326.0,,20200615,20200615,DIR,,,FDA-CTU,,66.0,YR,,M,N,92.0,KG,20200615.0,N,PH,US,US,2020,Q2,Elderly
178997601,17899760,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,Y,,,,300.0,MG,,QD,2020,Q2,Dizziness,,2020,Q2,1,I,20200326.0,,20200615,20200615,DIR,,,FDA-CTU,,66.0,YR,,M,N,92.0,KG,20200615.0,N,PH,US,US,2020,Q2,Elderly
178997601,17899760,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,Y,,,,300.0,MG,,QD,2020,Q2,Dysarthria,,2020,Q2,1,I,20200326.0,,20200615,20200615,DIR,,,FDA-CTU,,66.0,YR,,M,N,92.0,KG,20200615.0,N,PH,US,US,2020,Q2,Elderly
178997601,17899760,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,Y,,,,300.0,MG,,QD,2020,Q2,Euglycaemic diabetic ketoacidosis,,2020,Q2,1,I,20200326.0,,20200615,20200615,DIR,,,FDA-CTU,,66.0,YR,,M,N,92.0,KG,20200615.0,N,PH,US,US,2020,Q2,Elderly
178997601,17899760,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,Y,,,,300.0,MG,,QD,2020,Q2,Lacunar infarction,,2020,Q2,1,I,20200326.0,,20200615,20200615,DIR,,,FDA-CTU,,66.0,YR,,M,N,92.0,KG,20200615.0,N,PH,US,US,2020,Q2,Elderly
178997601,17899760,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,Y,,,,300.0,MG,,QD,2020,Q2,Nausea,,2020,Q2,1,I,20200326.0,,20200615,20200615,DIR,,,FDA-CTU,,66.0,YR,,M,N,92.0,KG,20200615.0,N,PH,US,US,2020,Q2,Elderly
178997601,17899760,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,Y,,,,300.0,MG,,QD,2020,Q2,Vomiting,,2020,Q2,1,I,20200326.0,,20200615,20200615,DIR,,,FDA-CTU,,66.0,YR,,M,N,92.0,KG,20200615.0,N,PH,US,US,2020,Q2,Elderly
179072091,17907209,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Bronchitis,,2020,Q2,1,I,,20200610.0,20200617,20200617,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20200617.0,,HP,CA,CA,2020,Q2,Elderly
179072091,17907209,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Constipation,,2020,Q2,1,I,,20200610.0,20200617,20200617,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20200617.0,,HP,CA,CA,2020,Q2,Elderly
179072091,17907209,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Cough,,2020,Q2,1,I,,20200610.0,20200617,20200617,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20200617.0,,HP,CA,CA,2020,Q2,Elderly
179072091,17907209,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Dyspnoea,,2020,Q2,1,I,,20200610.0,20200617,20200617,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20200617.0,,HP,CA,CA,2020,Q2,Elderly
179072091,17907209,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Ear disorder,,2020,Q2,1,I,,20200610.0,20200617,20200617,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20200617.0,,HP,CA,CA,2020,Q2,Elderly
179072091,17907209,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Ear infection,,2020,Q2,1,I,,20200610.0,20200617,20200617,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20200617.0,,HP,CA,CA,2020,Q2,Elderly
179072091,17907209,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Eyelid infection,,2020,Q2,1,I,,20200610.0,20200617,20200617,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20200617.0,,HP,CA,CA,2020,Q2,Elderly
179072091,17907209,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Heart rate increased,,2020,Q2,1,I,,20200610.0,20200617,20200617,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20200617.0,,HP,CA,CA,2020,Q2,Elderly
179072091,17907209,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Hypotension,,2020,Q2,1,I,,20200610.0,20200617,20200617,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20200617.0,,HP,CA,CA,2020,Q2,Elderly
179072091,17907209,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Influenza,,2020,Q2,1,I,,20200610.0,20200617,20200617,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20200617.0,,HP,CA,CA,2020,Q2,Elderly
179072091,17907209,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Localised infection,,2020,Q2,1,I,,20200610.0,20200617,20200617,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20200617.0,,HP,CA,CA,2020,Q2,Elderly
179072091,17907209,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Malaise,,2020,Q2,1,I,,20200610.0,20200617,20200617,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20200617.0,,HP,CA,CA,2020,Q2,Elderly
179072091,17907209,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Neuralgia,,2020,Q2,1,I,,20200610.0,20200617,20200617,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20200617.0,,HP,CA,CA,2020,Q2,Elderly
179072091,17907209,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Paranasal cyst,,2020,Q2,1,I,,20200610.0,20200617,20200617,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20200617.0,,HP,CA,CA,2020,Q2,Elderly
179072091,17907209,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Polyp,,2020,Q2,1,I,,20200610.0,20200617,20200617,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20200617.0,,HP,CA,CA,2020,Q2,Elderly
179072091,17907209,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Sinusitis,,2020,Q2,1,I,,20200610.0,20200617,20200617,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20200617.0,,HP,CA,CA,2020,Q2,Elderly
179072091,17907209,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Tinnitus,,2020,Q2,1,I,,20200610.0,20200617,20200617,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20200617.0,,HP,CA,CA,2020,Q2,Elderly
179072091,17907209,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Tympanic membrane perforation,,2020,Q2,1,I,,20200610.0,20200617,20200617,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20200617.0,,HP,CA,CA,2020,Q2,Elderly
179072091,17907209,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Viral infection,,2020,Q2,1,I,,20200610.0,20200617,20200617,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20200617.0,,HP,CA,CA,2020,Q2,Elderly
179072091,17907209,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Weight increased,,2020,Q2,1,I,,20200610.0,20200617,20200617,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20200617.0,,HP,CA,CA,2020,Q2,Elderly
179248201,17924820,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,U,,,204042.0,300.0,MG,FILM-COATED TABLET,,2020,Q2,Diabetic ketoacidosis,,2020,Q2,1,I,20200601.0,20200612.0,20200622,20200622,EXP,GB-MHRA-EYC 00223813,GB-JNJFOC-20200619384,JOHNSON AND JOHNSON,,55.0,YR,,F,Y,,,20200622.0,,PH,GB,GB,2020,Q2,Adult
179427191,17942719,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,UNKNOWN,,2020,Q2,Blood lactic acid increased,,2020,Q2,1,I,,20200622.0,20200625,20200625,EXP,,CA-DRREDDYS-USA/CAN/20/0124509,DR REDDYS,,54.0,YR,A,M,Y,66.28,KG,20200625.0,,PH,CA,CA,2020,Q2,Adult
179427191,17942719,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,UNKNOWN,,2020,Q2,Dyspnoea exertional,,2020,Q2,1,I,,20200622.0,20200625,20200625,EXP,,CA-DRREDDYS-USA/CAN/20/0124509,DR REDDYS,,54.0,YR,A,M,Y,66.28,KG,20200625.0,,PH,CA,CA,2020,Q2,Adult
179427191,17942719,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,UNKNOWN,,2020,Q2,Haemoglobin decreased,,2020,Q2,1,I,,20200622.0,20200625,20200625,EXP,,CA-DRREDDYS-USA/CAN/20/0124509,DR REDDYS,,54.0,YR,A,M,Y,66.28,KG,20200625.0,,PH,CA,CA,2020,Q2,Adult
179427191,17942719,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,UNKNOWN,,2020,Q2,Heart rate increased,,2020,Q2,1,I,,20200622.0,20200625,20200625,EXP,,CA-DRREDDYS-USA/CAN/20/0124509,DR REDDYS,,54.0,YR,A,M,Y,66.28,KG,20200625.0,,PH,CA,CA,2020,Q2,Adult
179427191,17942719,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,UNKNOWN,,2020,Q2,Malaise,,2020,Q2,1,I,,20200622.0,20200625,20200625,EXP,,CA-DRREDDYS-USA/CAN/20/0124509,DR REDDYS,,54.0,YR,A,M,Y,66.28,KG,20200625.0,,PH,CA,CA,2020,Q2,Adult
179427191,17942719,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,UNKNOWN,,2020,Q2,Neutrophil count decreased,,2020,Q2,1,I,,20200622.0,20200625,20200625,EXP,,CA-DRREDDYS-USA/CAN/20/0124509,DR REDDYS,,54.0,YR,A,M,Y,66.28,KG,20200625.0,,PH,CA,CA,2020,Q2,Adult
179427191,17942719,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,UNKNOWN,,2020,Q2,Platelet count decreased,,2020,Q2,1,I,,20200622.0,20200625,20200625,EXP,,CA-DRREDDYS-USA/CAN/20/0124509,DR REDDYS,,54.0,YR,A,M,Y,66.28,KG,20200625.0,,PH,CA,CA,2020,Q2,Adult
179427191,17942719,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,UNKNOWN,,2020,Q2,Pyoderma gangrenosum,,2020,Q2,1,I,,20200622.0,20200625,20200625,EXP,,CA-DRREDDYS-USA/CAN/20/0124509,DR REDDYS,,54.0,YR,A,M,Y,66.28,KG,20200625.0,,PH,CA,CA,2020,Q2,Adult
179427191,17942719,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,UNKNOWN,,2020,Q2,Pyrexia,,2020,Q2,1,I,,20200622.0,20200625,20200625,EXP,,CA-DRREDDYS-USA/CAN/20/0124509,DR REDDYS,,54.0,YR,A,M,Y,66.28,KG,20200625.0,,PH,CA,CA,2020,Q2,Adult
179427191,17942719,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,UNKNOWN,,2020,Q2,Rash,,2020,Q2,1,I,,20200622.0,20200625,20200625,EXP,,CA-DRREDDYS-USA/CAN/20/0124509,DR REDDYS,,54.0,YR,A,M,Y,66.28,KG,20200625.0,,PH,CA,CA,2020,Q2,Adult
179427191,17942719,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,UNKNOWN,,2020,Q2,Respiratory rate increased,,2020,Q2,1,I,,20200622.0,20200625,20200625,EXP,,CA-DRREDDYS-USA/CAN/20/0124509,DR REDDYS,,54.0,YR,A,M,Y,66.28,KG,20200625.0,,PH,CA,CA,2020,Q2,Adult
179427191,17942719,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,UNKNOWN,,2020,Q2,White blood cell count decreased,,2020,Q2,1,I,,20200622.0,20200625,20200625,EXP,,CA-DRREDDYS-USA/CAN/20/0124509,DR REDDYS,,54.0,YR,A,M,Y,66.28,KG,20200625.0,,PH,CA,CA,2020,Q2,Adult
179607421,17960742,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, QD",,,U,,,,,300.0,MG,,QD,2020,Q2,Angina pectoris,,2020,Q2,1,I,,20200624.0,20200630,20200630,EXP,,NVSC2020US179715,NOVARTIS,"SETHI P, CHANG GV, GOWDA SN, ELNAIR R, FENNER R, LAMFERS R. RECURRENT CATECHOLAMINE-INDUCED CARDIOMYOPATHY AND HYPERTENSIVE EMERGENCIES: A PRESENTATION OF PHEOCHROMOCYTOMA AND RELATED CONCERNS. SOUTH DAKOTA MEDICINE. 2020;73(2):78-80",51.0,YR,,F,Y,,,20200630.0,,HP,US,US,2020,Q2,Adult
179607421,17960742,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, QD",,,U,,,,,300.0,MG,,QD,2020,Q2,Chest pain,,2020,Q2,1,I,,20200624.0,20200630,20200630,EXP,,NVSC2020US179715,NOVARTIS,"SETHI P, CHANG GV, GOWDA SN, ELNAIR R, FENNER R, LAMFERS R. RECURRENT CATECHOLAMINE-INDUCED CARDIOMYOPATHY AND HYPERTENSIVE EMERGENCIES: A PRESENTATION OF PHEOCHROMOCYTOMA AND RELATED CONCERNS. SOUTH DAKOTA MEDICINE. 2020;73(2):78-80",51.0,YR,,F,Y,,,20200630.0,,HP,US,US,2020,Q2,Adult
179607421,17960742,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, QD",,,U,,,,,300.0,MG,,QD,2020,Q2,Dizziness,,2020,Q2,1,I,,20200624.0,20200630,20200630,EXP,,NVSC2020US179715,NOVARTIS,"SETHI P, CHANG GV, GOWDA SN, ELNAIR R, FENNER R, LAMFERS R. RECURRENT CATECHOLAMINE-INDUCED CARDIOMYOPATHY AND HYPERTENSIVE EMERGENCIES: A PRESENTATION OF PHEOCHROMOCYTOMA AND RELATED CONCERNS. SOUTH DAKOTA MEDICINE. 2020;73(2):78-80",51.0,YR,,F,Y,,,20200630.0,,HP,US,US,2020,Q2,Adult
179607421,17960742,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, QD",,,U,,,,,300.0,MG,,QD,2020,Q2,Headache,,2020,Q2,1,I,,20200624.0,20200630,20200630,EXP,,NVSC2020US179715,NOVARTIS,"SETHI P, CHANG GV, GOWDA SN, ELNAIR R, FENNER R, LAMFERS R. RECURRENT CATECHOLAMINE-INDUCED CARDIOMYOPATHY AND HYPERTENSIVE EMERGENCIES: A PRESENTATION OF PHEOCHROMOCYTOMA AND RELATED CONCERNS. SOUTH DAKOTA MEDICINE. 2020;73(2):78-80",51.0,YR,,F,Y,,,20200630.0,,HP,US,US,2020,Q2,Adult
179607421,17960742,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, QD",,,U,,,,,300.0,MG,,QD,2020,Q2,Hypertensive emergency,,2020,Q2,1,I,,20200624.0,20200630,20200630,EXP,,NVSC2020US179715,NOVARTIS,"SETHI P, CHANG GV, GOWDA SN, ELNAIR R, FENNER R, LAMFERS R. RECURRENT CATECHOLAMINE-INDUCED CARDIOMYOPATHY AND HYPERTENSIVE EMERGENCIES: A PRESENTATION OF PHEOCHROMOCYTOMA AND RELATED CONCERNS. SOUTH DAKOTA MEDICINE. 2020;73(2):78-80",51.0,YR,,F,Y,,,20200630.0,,HP,US,US,2020,Q2,Adult
179607421,17960742,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, QD",,,U,,,,,300.0,MG,,QD,2020,Q2,Labile blood pressure,,2020,Q2,1,I,,20200624.0,20200630,20200630,EXP,,NVSC2020US179715,NOVARTIS,"SETHI P, CHANG GV, GOWDA SN, ELNAIR R, FENNER R, LAMFERS R. RECURRENT CATECHOLAMINE-INDUCED CARDIOMYOPATHY AND HYPERTENSIVE EMERGENCIES: A PRESENTATION OF PHEOCHROMOCYTOMA AND RELATED CONCERNS. SOUTH DAKOTA MEDICINE. 2020;73(2):78-80",51.0,YR,,F,Y,,,20200630.0,,HP,US,US,2020,Q2,Adult
179607421,17960742,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, QD",,,U,,,,,300.0,MG,,QD,2020,Q2,Nausea,,2020,Q2,1,I,,20200624.0,20200630,20200630,EXP,,NVSC2020US179715,NOVARTIS,"SETHI P, CHANG GV, GOWDA SN, ELNAIR R, FENNER R, LAMFERS R. RECURRENT CATECHOLAMINE-INDUCED CARDIOMYOPATHY AND HYPERTENSIVE EMERGENCIES: A PRESENTATION OF PHEOCHROMOCYTOMA AND RELATED CONCERNS. SOUTH DAKOTA MEDICINE. 2020;73(2):78-80",51.0,YR,,F,Y,,,20200630.0,,HP,US,US,2020,Q2,Adult
179607421,17960742,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, QD",,,U,,,,,300.0,MG,,QD,2020,Q2,Vomiting,,2020,Q2,1,I,,20200624.0,20200630,20200630,EXP,,NVSC2020US179715,NOVARTIS,"SETHI P, CHANG GV, GOWDA SN, ELNAIR R, FENNER R, LAMFERS R. RECURRENT CATECHOLAMINE-INDUCED CARDIOMYOPATHY AND HYPERTENSIVE EMERGENCIES: A PRESENTATION OF PHEOCHROMOCYTOMA AND RELATED CONCERNS. SOUTH DAKOTA MEDICINE. 2020;73(2):78-80",51.0,YR,,F,Y,,,20200630.0,,HP,US,US,2020,Q2,Adult
115181232,11518123,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 4370268,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Angina unstable,,2020,Q3,2,F,20150701.0,20150911.0,20150917,20150921,EXP,,JP-JNJFOC-20150905964,JANSSEN,,64.0,YR,A,M,Y,97.0,KG,20150921.0,,MD,JP,JP,2020,Q3,Adult
115181232,11518123,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 4370268,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Angina unstable,,2020,Q3,2,F,20150701.0,20150911.0,20150917,20150921,EXP,,JP-JNJFOC-20150905964,JANSSEN,,64.0,YR,A,M,Y,97.0,KG,20150921.0,,MD,JP,JP,2020,Q3,Adult
122632292,12263229,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 020494,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Atrial fibrillation,,2020,Q3,2,F,20160204.0,20160727.0,20160413,20160803,EXP,,CA-JNJFOC-20160404287,JANSSEN,,75.0,YR,E,M,Y,95.0,KG,20160803.0,,MD,CA,CA,2020,Q3,Elderly
122632292,12263229,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 020494,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Renal injury,,2020,Q3,2,F,20160204.0,20160727.0,20160413,20160803,EXP,,CA-JNJFOC-20160404287,JANSSEN,,75.0,YR,E,M,Y,95.0,KG,20160803.0,,MD,CA,CA,2020,Q3,Elderly
122632292,12263229,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 020494,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Atrial fibrillation,,2020,Q3,2,F,20160204.0,20160727.0,20160413,20160803,EXP,,CA-JNJFOC-20160404287,JANSSEN,,75.0,YR,E,M,Y,95.0,KG,20160803.0,,MD,CA,CA,2020,Q3,Elderly
122632292,12263229,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 020494,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Renal injury,,2020,Q3,2,F,20160204.0,20160727.0,20160413,20160803,EXP,,CA-JNJFOC-20160404287,JANSSEN,,75.0,YR,E,M,Y,95.0,KG,20160803.0,,MD,CA,CA,2020,Q3,Elderly
122911005,12291100,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNSPECIFIED,QD,2020,Q3,Cough,,2020,Q3,5,F,20160412.0,20160615.0,20160421,20160627,EXP,,US-JNJFOC-20160418100,PHARMACYCLICS,,31.0,YR,A,M,Y,128.2,KG,20160627.0,,MD,US,US,2020,Q3,Young Adult
122911005,12291100,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNSPECIFIED,QD,2020,Q3,Influenza,,2020,Q3,5,F,20160412.0,20160615.0,20160421,20160627,EXP,,US-JNJFOC-20160418100,PHARMACYCLICS,,31.0,YR,A,M,Y,128.2,KG,20160627.0,,MD,US,US,2020,Q3,Young Adult
122911005,12291100,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNSPECIFIED,QD,2020,Q3,Pyrexia,,2020,Q3,5,F,20160412.0,20160615.0,20160421,20160627,EXP,,US-JNJFOC-20160418100,PHARMACYCLICS,,31.0,YR,A,M,Y,128.2,KG,20160627.0,,MD,US,US,2020,Q3,Young Adult
122911005,12291100,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,UNSPECIFIED,QD,2020,Q3,Rectal haemorrhage,,2020,Q3,5,F,20160412.0,20160615.0,20160421,20160627,EXP,,US-JNJFOC-20160418100,PHARMACYCLICS,,31.0,YR,A,M,Y,128.2,KG,20160627.0,,MD,US,US,2020,Q3,Young Adult
122911005,12291100,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,QD,2020,Q3,Cough,,2020,Q3,5,F,20160412.0,20160615.0,20160421,20160627,EXP,,US-JNJFOC-20160418100,PHARMACYCLICS,,31.0,YR,A,M,Y,128.2,KG,20160627.0,,MD,US,US,2020,Q3,Young Adult
122911005,12291100,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,QD,2020,Q3,Influenza,,2020,Q3,5,F,20160412.0,20160615.0,20160421,20160627,EXP,,US-JNJFOC-20160418100,PHARMACYCLICS,,31.0,YR,A,M,Y,128.2,KG,20160627.0,,MD,US,US,2020,Q3,Young Adult
122911005,12291100,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,QD,2020,Q3,Pyrexia,,2020,Q3,5,F,20160412.0,20160615.0,20160421,20160627,EXP,,US-JNJFOC-20160418100,PHARMACYCLICS,,31.0,YR,A,M,Y,128.2,KG,20160627.0,,MD,US,US,2020,Q3,Young Adult
122911005,12291100,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,QD,2020,Q3,Rectal haemorrhage,,2020,Q3,5,F,20160412.0,20160615.0,20160421,20160627,EXP,,US-JNJFOC-20160418100,PHARMACYCLICS,,31.0,YR,A,M,Y,128.2,KG,20160627.0,,MD,US,US,2020,Q3,Young Adult
123527884,12352788,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Nephrolithiasis,,2020,Q3,4,F,20160225.0,20180523.0,20160510,20180525,EXP,,FR-JNJFOC-20160501649,JANSSEN,,73.0,YR,E,M,Y,72.0,KG,20180525.0,,MD,FR,FR,2020,Q3,Elderly
123527884,12352788,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Nephrolithiasis,,2020,Q3,4,F,20160225.0,20180523.0,20160510,20180525,EXP,,FR-JNJFOC-20160501649,JANSSEN,,73.0,YR,E,M,Y,72.0,KG,20180525.0,,MD,FR,FR,2020,Q3,Elderly
124117712,12411771,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Cellulitis,,2020,Q3,2,F,20160501.0,20160524.0,20160527,20160601,EXP,,US-JNJFOC-20160520233,JANSSEN,,68.0,YR,E,M,Y,104.3,KG,20160601.0,,MD,US,US,2020,Q3,Elderly
124117712,12411771,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Cellulitis,,2020,Q3,2,F,20160501.0,20160524.0,20160527,20160601,EXP,,US-JNJFOC-20160520233,JANSSEN,,68.0,YR,E,M,Y,104.3,KG,20160601.0,,MD,US,US,2020,Q3,Elderly
1252230616,12522306,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, T206450,,,100.0,MG,CAPSULE,QD,2020,Q3,Anaphylactic reaction,,2020,Q3,16,F,20160611.0,20180308.0,20160701,20180312,EXP,,NZ-JNJFOC-20160625031,JANSSEN,,58.0,YR,A,M,Y,112.0,KG,20180312.0,,MD,NZ,NZ,2020,Q3,Adult
1252230616,12522306,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, T206450,,,100.0,MG,CAPSULE,QD,2020,Q3,Cellulitis,,2020,Q3,16,F,20160611.0,20180308.0,20160701,20180312,EXP,,NZ-JNJFOC-20160625031,JANSSEN,,58.0,YR,A,M,Y,112.0,KG,20180312.0,,MD,NZ,NZ,2020,Q3,Adult
1252230616,12522306,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, T206450,,,100.0,MG,CAPSULE,QD,2020,Q3,Diabetic foot,,2020,Q3,16,F,20160611.0,20180308.0,20160701,20180312,EXP,,NZ-JNJFOC-20160625031,JANSSEN,,58.0,YR,A,M,Y,112.0,KG,20180312.0,,MD,NZ,NZ,2020,Q3,Adult
1252230616,12522306,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, T206450,,,100.0,MG,CAPSULE,QD,2020,Q3,Osteomyelitis,,2020,Q3,16,F,20160611.0,20180308.0,20160701,20180312,EXP,,NZ-JNJFOC-20160625031,JANSSEN,,58.0,YR,A,M,Y,112.0,KG,20180312.0,,MD,NZ,NZ,2020,Q3,Adult
1252230616,12522306,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, T206450,,,100.0,MG,CAPSULE,QD,2020,Q3,Anaphylactic reaction,,2020,Q3,16,F,20160611.0,20180308.0,20160701,20180312,EXP,,NZ-JNJFOC-20160625031,JANSSEN,,58.0,YR,A,M,Y,112.0,KG,20180312.0,,MD,NZ,NZ,2020,Q3,Adult
1252230616,12522306,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, T206450,,,100.0,MG,CAPSULE,QD,2020,Q3,Cellulitis,,2020,Q3,16,F,20160611.0,20180308.0,20160701,20180312,EXP,,NZ-JNJFOC-20160625031,JANSSEN,,58.0,YR,A,M,Y,112.0,KG,20180312.0,,MD,NZ,NZ,2020,Q3,Adult
1252230616,12522306,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, T206450,,,100.0,MG,CAPSULE,QD,2020,Q3,Diabetic foot,,2020,Q3,16,F,20160611.0,20180308.0,20160701,20180312,EXP,,NZ-JNJFOC-20160625031,JANSSEN,,58.0,YR,A,M,Y,112.0,KG,20180312.0,,MD,NZ,NZ,2020,Q3,Adult
1252230616,12522306,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, T206450,,,100.0,MG,CAPSULE,QD,2020,Q3,Osteomyelitis,,2020,Q3,16,F,20160611.0,20180308.0,20160701,20180312,EXP,,NZ-JNJFOC-20160625031,JANSSEN,,58.0,YR,A,M,Y,112.0,KG,20180312.0,,MD,NZ,NZ,2020,Q3,Adult
1252230616,12522306,3,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, T206450,,204042.0,,,CAPSULE,,2020,Q3,Anaphylactic reaction,,2020,Q3,16,F,20160611.0,20180308.0,20160701,20180312,EXP,,NZ-JNJFOC-20160625031,JANSSEN,,58.0,YR,A,M,Y,112.0,KG,20180312.0,,MD,NZ,NZ,2020,Q3,Adult
1252230616,12522306,3,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, T206450,,204042.0,,,CAPSULE,,2020,Q3,Cellulitis,,2020,Q3,16,F,20160611.0,20180308.0,20160701,20180312,EXP,,NZ-JNJFOC-20160625031,JANSSEN,,58.0,YR,A,M,Y,112.0,KG,20180312.0,,MD,NZ,NZ,2020,Q3,Adult
1252230616,12522306,3,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, T206450,,204042.0,,,CAPSULE,,2020,Q3,Diabetic foot,,2020,Q3,16,F,20160611.0,20180308.0,20160701,20180312,EXP,,NZ-JNJFOC-20160625031,JANSSEN,,58.0,YR,A,M,Y,112.0,KG,20180312.0,,MD,NZ,NZ,2020,Q3,Adult
1252230616,12522306,3,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, T206450,,204042.0,,,CAPSULE,,2020,Q3,Osteomyelitis,,2020,Q3,16,F,20160611.0,20180308.0,20160701,20180312,EXP,,NZ-JNJFOC-20160625031,JANSSEN,,58.0,YR,A,M,Y,112.0,KG,20180312.0,,MD,NZ,NZ,2020,Q3,Adult
1252230616,12522306,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, T206450,,119255.0,,,CAPSULE,,2020,Q3,Anaphylactic reaction,,2020,Q3,16,F,20160611.0,20180308.0,20160701,20180312,EXP,,NZ-JNJFOC-20160625031,JANSSEN,,58.0,YR,A,M,Y,112.0,KG,20180312.0,,MD,NZ,NZ,2020,Q3,Adult
1252230616,12522306,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, T206450,,119255.0,,,CAPSULE,,2020,Q3,Cellulitis,,2020,Q3,16,F,20160611.0,20180308.0,20160701,20180312,EXP,,NZ-JNJFOC-20160625031,JANSSEN,,58.0,YR,A,M,Y,112.0,KG,20180312.0,,MD,NZ,NZ,2020,Q3,Adult
1252230616,12522306,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, T206450,,119255.0,,,CAPSULE,,2020,Q3,Diabetic foot,,2020,Q3,16,F,20160611.0,20180308.0,20160701,20180312,EXP,,NZ-JNJFOC-20160625031,JANSSEN,,58.0,YR,A,M,Y,112.0,KG,20180312.0,,MD,NZ,NZ,2020,Q3,Adult
1252230616,12522306,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, T206450,,119255.0,,,CAPSULE,,2020,Q3,Osteomyelitis,,2020,Q3,16,F,20160611.0,20180308.0,20160701,20180312,EXP,,NZ-JNJFOC-20160625031,JANSSEN,,58.0,YR,A,M,Y,112.0,KG,20180312.0,,MD,NZ,NZ,2020,Q3,Adult
128073883,12807388,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, T206450,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Diabetic foot infection,,2020,Q3,3,F,20160912.0,20170112.0,20161004,20170119,EXP,,NZ-JNJFOC-20160930478,JANSSEN,,58.0,YR,A,M,Y,112.5,KG,20170119.0,,MD,NZ,NZ,2020,Q3,Adult
128073883,12807388,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, T206450,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Diabetic foot infection,,2020,Q3,3,F,20160912.0,20170112.0,20161004,20170119,EXP,,NZ-JNJFOC-20160930478,JANSSEN,,58.0,YR,A,M,Y,112.5,KG,20170119.0,,MD,NZ,NZ,2020,Q3,Adult
128889275,12888927,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,N, T209990,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Skin ulcer,,2020,Q3,5,F,20161012.0,20171117.0,20161027,20171123,EXP,,BR-JNJFOC-20161016067,JANSSEN,,68.0,YR,E,F,Y,43.5,KG,20171123.0,,MD,BR,BR,2020,Q3,Elderly
128889275,12888927,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,N, T209990,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Skin ulcer,,2020,Q3,5,F,20161012.0,20171117.0,20161027,20171123,EXP,,BR-JNJFOC-20161016067,JANSSEN,,68.0,YR,E,F,Y,43.5,KG,20171123.0,,MD,BR,BR,2020,Q3,Elderly
131333062,13133306,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 4343034,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Angina pectoris,,2020,Q3,2,F,20161223.0,20170201.0,20170120,20170206,EXP,,US-JNJFOC-20170110566,JANSSEN,,65.0,YR,A,M,Y,113.4,KG,20170206.0,,MD,US,US,2020,Q3,Elderly
131333062,13133306,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 4343034,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Renal injury,,2020,Q3,2,F,20161223.0,20170201.0,20170120,20170206,EXP,,US-JNJFOC-20170110566,JANSSEN,,65.0,YR,A,M,Y,113.4,KG,20170206.0,,MD,US,US,2020,Q3,Elderly
131333062,13133306,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 4343034,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Angina pectoris,,2020,Q3,2,F,20161223.0,20170201.0,20170120,20170206,EXP,,US-JNJFOC-20170110566,JANSSEN,,65.0,YR,A,M,Y,113.4,KG,20170206.0,,MD,US,US,2020,Q3,Elderly
131333062,13133306,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 4343034,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Renal injury,,2020,Q3,2,F,20161223.0,20170201.0,20170120,20170206,EXP,,US-JNJFOC-20170110566,JANSSEN,,65.0,YR,A,M,Y,113.4,KG,20170206.0,,MD,US,US,2020,Q3,Elderly
133558135,13355813,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, T221132,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Hypoglycaemia,,2020,Q3,5,F,20170224.0,20170425.0,20170321,20170428,EXP,,BR-JNJFOC-20170318447,JANSSEN,,68.0,YR,E,M,Y,69.0,KG,20170428.0,,MD,BR,BR,2020,Q3,Elderly
133558135,13355813,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, T221132,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Hypoglycaemia,,2020,Q3,5,F,20170224.0,20170425.0,20170321,20170428,EXP,,BR-JNJFOC-20170318447,JANSSEN,,68.0,YR,E,M,Y,69.0,KG,20170428.0,,MD,BR,BR,2020,Q3,Elderly
134928367,13492836,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N, B215519,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Laryngeal squamous cell carcinoma,,2020,Q3,7,F,20170412.0,20171103.0,20170427,20171110,EXP,,US-JNJFOC-20170422242,JANSSEN,,61.0,YR,A,M,Y,70.1,KG,20171110.0,,MD,US,US,2020,Q3,Adult
134928367,13492836,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N, B215519,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Lymphadenopathy,,2020,Q3,7,F,20170412.0,20171103.0,20170427,20171110,EXP,,US-JNJFOC-20170422242,JANSSEN,,61.0,YR,A,M,Y,70.1,KG,20171110.0,,MD,US,US,2020,Q3,Adult
134928367,13492836,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N, B215519,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Laryngeal squamous cell carcinoma,,2020,Q3,7,F,20170412.0,20171103.0,20170427,20171110,EXP,,US-JNJFOC-20170422242,JANSSEN,,61.0,YR,A,M,Y,70.1,KG,20171110.0,,MD,US,US,2020,Q3,Adult
134928367,13492836,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N, B215519,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Lymphadenopathy,,2020,Q3,7,F,20170412.0,20171103.0,20170427,20171110,EXP,,US-JNJFOC-20170422242,JANSSEN,,61.0,YR,A,M,Y,70.1,KG,20171110.0,,MD,US,US,2020,Q3,Adult
135143966,13514396,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, B215519,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Eczema,,2020,Q3,6,F,20170421.0,20181018.0,20170504,20181023,EXP,,CN-JNJFOC-20170429222,JANSSEN,,76.0,YR,E,M,Y,80.0,KG,20181023.0,,MD,CN,CN,2020,Q3,Elderly
135143966,13514396,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, B215519,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Eczema,,2020,Q3,6,F,20170421.0,20181018.0,20170504,20181023,EXP,,CN-JNJFOC-20170429222,JANSSEN,,76.0,YR,E,M,Y,80.0,KG,20181023.0,,MD,CN,CN,2020,Q3,Elderly
135466063,13546606,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, B215519;T221132,,,100.0,MG,CAPSULE,QD,2020,Q3,Angina unstable,,2020,Q3,3,F,20170102.0,20170824.0,20170515,20170901,EXP,,MY-JNJFOC-20170104631,JANSSEN,,68.0,YR,E,M,Y,79.0,KG,20170901.0,,MD,MY,MY,2020,Q3,Elderly
135466063,13546606,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, B215519;T221132,,,100.0,MG,CAPSULE,QD,2020,Q3,Ischaemic stroke,,2020,Q3,3,F,20170102.0,20170824.0,20170515,20170901,EXP,,MY-JNJFOC-20170104631,JANSSEN,,68.0,YR,E,M,Y,79.0,KG,20170901.0,,MD,MY,MY,2020,Q3,Elderly
135466063,13546606,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, B215519;T221132,,,100.0,MG,CAPSULE,QD,2020,Q3,Angina unstable,,2020,Q3,3,F,20170102.0,20170824.0,20170515,20170901,EXP,,MY-JNJFOC-20170104631,JANSSEN,,68.0,YR,E,M,Y,79.0,KG,20170901.0,,MD,MY,MY,2020,Q3,Elderly
135466063,13546606,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, B215519;T221132,,,100.0,MG,CAPSULE,QD,2020,Q3,Ischaemic stroke,,2020,Q3,3,F,20170102.0,20170824.0,20170515,20170901,EXP,,MY-JNJFOC-20170104631,JANSSEN,,68.0,YR,E,M,Y,79.0,KG,20170901.0,,MD,MY,MY,2020,Q3,Elderly
135466063,13546606,3,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, B215519;T221132,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Angina unstable,,2020,Q3,3,F,20170102.0,20170824.0,20170515,20170901,EXP,,MY-JNJFOC-20170104631,JANSSEN,,68.0,YR,E,M,Y,79.0,KG,20170901.0,,MD,MY,MY,2020,Q3,Elderly
135466063,13546606,3,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, B215519;T221132,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Ischaemic stroke,,2020,Q3,3,F,20170102.0,20170824.0,20170515,20170901,EXP,,MY-JNJFOC-20170104631,JANSSEN,,68.0,YR,E,M,Y,79.0,KG,20170901.0,,MD,MY,MY,2020,Q3,Elderly
135466063,13546606,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, B215519;T221132,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Angina unstable,,2020,Q3,3,F,20170102.0,20170824.0,20170515,20170901,EXP,,MY-JNJFOC-20170104631,JANSSEN,,68.0,YR,E,M,Y,79.0,KG,20170901.0,,MD,MY,MY,2020,Q3,Elderly
135466063,13546606,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, B215519;T221132,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Ischaemic stroke,,2020,Q3,3,F,20170102.0,20170824.0,20170515,20170901,EXP,,MY-JNJFOC-20170104631,JANSSEN,,68.0,YR,E,M,Y,79.0,KG,20170901.0,,MD,MY,MY,2020,Q3,Elderly
137719663,13771966,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, T221132,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Peripheral vascular disorder,,2020,Q3,3,F,20170212.0,20170913.0,20170720,20170918,EXP,,BR-JNJFOC-20170329641,JANSSEN,,58.0,YR,A,F,Y,85.0,KG,20170918.0,,MD,BR,BR,2020,Q3,Adult
137719663,13771966,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, T221132,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Peripheral vascular disorder,,2020,Q3,3,F,20170212.0,20170913.0,20170720,20170918,EXP,,BR-JNJFOC-20170329641,JANSSEN,,58.0,YR,A,F,Y,85.0,KG,20170918.0,,MD,BR,BR,2020,Q3,Adult
137931315,13793131,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 022076,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Vertigo,,2020,Q3,5,F,20170712.0,20171023.0,20170726,20171030,EXP,,CA-JNJFOC-20170715514,JANSSEN,,69.0,YR,E,M,Y,74.0,KG,20171030.0,,MD,CA,CA,2020,Q3,Elderly
137931315,13793131,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 022076,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Vertigo,,2020,Q3,5,F,20170712.0,20171023.0,20170726,20171030,EXP,,CA-JNJFOC-20170715514,JANSSEN,,69.0,YR,E,M,Y,74.0,KG,20171030.0,,MD,CA,CA,2020,Q3,Elderly
140747214,14074721,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 022537,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Diabetic hyperosmolar coma,,2020,Q3,4,F,20170908.0,20171221.0,20171011,20171229,EXP,,CA-JNJFOC-20171002576,JANSSEN,,77.0,YR,E,M,Y,72.7,KG,20171229.0,,MD,CA,CA,2020,Q3,Elderly
140747214,14074721,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 022537,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Diabetic hyperosmolar coma,,2020,Q3,4,F,20170908.0,20171221.0,20171011,20171229,EXP,,CA-JNJFOC-20171002576,JANSSEN,,77.0,YR,E,M,Y,72.7,KG,20171229.0,,MD,CA,CA,2020,Q3,Elderly
141496822,14149682,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, T228084,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Anal haemorrhage,,2020,Q3,2,F,20170727.0,20171226.0,20171101,20180102,EXP,,AR-JNJFOC-20171000005,JANSSEN,,83.0,YR,E,M,Y,73.1,KG,20180102.0,,MD,AR,AR,2020,Q3,Elderly
141496822,14149682,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, T228084,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Infected skin ulcer,,2020,Q3,2,F,20170727.0,20171226.0,20171101,20180102,EXP,,AR-JNJFOC-20171000005,JANSSEN,,83.0,YR,E,M,Y,73.1,KG,20180102.0,,MD,AR,AR,2020,Q3,Elderly
141496822,14149682,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, T228084,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Anal haemorrhage,,2020,Q3,2,F,20170727.0,20171226.0,20171101,20180102,EXP,,AR-JNJFOC-20171000005,JANSSEN,,83.0,YR,E,M,Y,73.1,KG,20180102.0,,MD,AR,AR,2020,Q3,Elderly
141496822,14149682,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, T228084,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Infected skin ulcer,,2020,Q3,2,F,20170727.0,20171226.0,20171101,20180102,EXP,,AR-JNJFOC-20171000005,JANSSEN,,83.0,YR,E,M,Y,73.1,KG,20180102.0,,MD,AR,AR,2020,Q3,Elderly
142156586,14215658,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, GLZS01M;T234331,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Fluid overload,,2020,Q3,6,F,20170909.0,20180330.0,20171122,20180404,EXP,,MY-JNJFOC-20171114824,JANSSEN,,57.0,YR,A,F,Y,97.0,KG,20180404.0,,MD,MY,MY,2020,Q3,Adult
142156586,14215658,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, GLZS01M;T234331,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Nephrogenic anaemia,,2020,Q3,6,F,20170909.0,20180330.0,20171122,20180404,EXP,,MY-JNJFOC-20171114824,JANSSEN,,57.0,YR,A,F,Y,97.0,KG,20180404.0,,MD,MY,MY,2020,Q3,Adult
142156586,14215658,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, GLZS01M;T234331,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Fluid overload,,2020,Q3,6,F,20170909.0,20180330.0,20171122,20180404,EXP,,MY-JNJFOC-20171114824,JANSSEN,,57.0,YR,A,F,Y,97.0,KG,20180404.0,,MD,MY,MY,2020,Q3,Adult
142156586,14215658,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, GLZS01M;T234331,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Nephrogenic anaemia,,2020,Q3,6,F,20170909.0,20180330.0,20171122,20180404,EXP,,MY-JNJFOC-20171114824,JANSSEN,,57.0,YR,A,F,Y,97.0,KG,20180404.0,,MD,MY,MY,2020,Q3,Adult
142557686,14255768,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, B215519,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Coronary artery disease,,2020,Q3,6,F,20171103.0,20180720.0,20171206,20180726,EXP,,US-JNJFOC-20171135010,JANSSEN,,67.0,YR,E,M,Y,118.5,KG,20180726.0,,MD,US,US,2020,Q3,Elderly
142557686,14255768,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, B215519,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Sepsis,,2020,Q3,6,F,20171103.0,20180720.0,20171206,20180726,EXP,,US-JNJFOC-20171135010,JANSSEN,,67.0,YR,E,M,Y,118.5,KG,20180726.0,,MD,US,US,2020,Q3,Elderly
142557686,14255768,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, B215519,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Wound infection,,2020,Q3,6,F,20171103.0,20180720.0,20171206,20180726,EXP,,US-JNJFOC-20171135010,JANSSEN,,67.0,YR,E,M,Y,118.5,KG,20180726.0,,MD,US,US,2020,Q3,Elderly
142557686,14255768,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, B215519,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Coronary artery disease,,2020,Q3,6,F,20171103.0,20180720.0,20171206,20180726,EXP,,US-JNJFOC-20171135010,JANSSEN,,67.0,YR,E,M,Y,118.5,KG,20180726.0,,MD,US,US,2020,Q3,Elderly
142557686,14255768,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, B215519,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Sepsis,,2020,Q3,6,F,20171103.0,20180720.0,20171206,20180726,EXP,,US-JNJFOC-20171135010,JANSSEN,,67.0,YR,E,M,Y,118.5,KG,20180726.0,,MD,US,US,2020,Q3,Elderly
142557686,14255768,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, B215519,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Wound infection,,2020,Q3,6,F,20171103.0,20180720.0,20171206,20180726,EXP,,US-JNJFOC-20171135010,JANSSEN,,67.0,YR,E,M,Y,118.5,KG,20180726.0,,MD,US,US,2020,Q3,Elderly
143726408,14372640,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N, T238539,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Pneumonia,,2020,Q3,8,F,20171230.0,20180322.0,20180110,20180330,EXP,,PH-JNJFOC-20180101820,JANSSEN,,48.0,YR,A,M,Y,86.0,KG,20180330.0,,MD,PH,PH,2020,Q3,Adult
143726408,14372640,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N, T238539,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Pulmonary congestion,,2020,Q3,8,F,20171230.0,20180322.0,20180110,20180330,EXP,,PH-JNJFOC-20180101820,JANSSEN,,48.0,YR,A,M,Y,86.0,KG,20180330.0,,MD,PH,PH,2020,Q3,Adult
143726408,14372640,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N, T238539,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Pneumonia,,2020,Q3,8,F,20171230.0,20180322.0,20180110,20180330,EXP,,PH-JNJFOC-20180101820,JANSSEN,,48.0,YR,A,M,Y,86.0,KG,20180330.0,,MD,PH,PH,2020,Q3,Adult
143726408,14372640,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N, T238539,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Pulmonary congestion,,2020,Q3,8,F,20171230.0,20180322.0,20180110,20180330,EXP,,PH-JNJFOC-20180101820,JANSSEN,,48.0,YR,A,M,Y,86.0,KG,20180330.0,,MD,PH,PH,2020,Q3,Adult
143801387,14380138,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,N,,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Osteomyelitis chronic,,2020,Q3,7,F,20171123.0,20180517.0,20180112,20180523,EXP,,BR-JNJFOC-20171231595,JANSSEN,,67.0,YR,E,M,Y,,,20180523.0,,MD,BR,BR,2020,Q3,Elderly
143801387,14380138,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,N,,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Osteomyelitis chronic,,2020,Q3,7,F,20171123.0,20180517.0,20180112,20180523,EXP,,BR-JNJFOC-20171231595,JANSSEN,,67.0,YR,E,M,Y,,,20180523.0,,MD,BR,BR,2020,Q3,Elderly
143801408,14380140,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,,100.0,MG,CAPSULE,QD,2020,Q3,Extremity necrosis,,2020,Q3,8,F,20170816.0,20180517.0,20180112,20180523,EXP,,BR-JNJFOC-20171229828,JANSSEN,,67.0,YR,E,M,Y,,,20180523.0,,MD,BR,BR,2020,Q3,Elderly
143801408,14380140,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,,100.0,MG,CAPSULE,QD,2020,Q3,Extremity necrosis,,2020,Q3,8,F,20170816.0,20180517.0,20180112,20180523,EXP,,BR-JNJFOC-20171229828,JANSSEN,,67.0,YR,E,M,Y,,,20180523.0,,MD,BR,BR,2020,Q3,Elderly
143801408,14380140,3,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Extremity necrosis,,2020,Q3,8,F,20170816.0,20180517.0,20180112,20180523,EXP,,BR-JNJFOC-20171229828,JANSSEN,,67.0,YR,E,M,Y,,,20180523.0,,MD,BR,BR,2020,Q3,Elderly
143801408,14380140,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Extremity necrosis,,2020,Q3,8,F,20170816.0,20180517.0,20180112,20180523,EXP,,BR-JNJFOC-20171229828,JANSSEN,,67.0,YR,E,M,Y,,,20180523.0,,MD,BR,BR,2020,Q3,Elderly
144174342,14417434,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,N,,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Femur fracture,,2020,Q3,2,F,20180113.0,20180122.0,20180122,20180129,EXP,,UA-JNJFOC-20180120773,JANSSEN,,60.0,YR,A,M,Y,89.0,KG,20180129.0,,MD,UA,UA,2020,Q3,Adult
144174342,14417434,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,N,,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Femur fracture,,2020,Q3,2,F,20180113.0,20180122.0,20180122,20180129,EXP,,UA-JNJFOC-20180120773,JANSSEN,,60.0,YR,A,M,Y,89.0,KG,20180129.0,,MD,UA,UA,2020,Q3,Adult
146548282,14654828,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 129723870,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Prostate cancer,,2020,Q3,2,F,20170621.0,20180320.0,20180319,20180327,EXP,,US-JNJFOC-20170928652,JANSSEN,,66.0,YR,E,M,Y,102.0,KG,20180327.0,,MD,US,US,2020,Q3,Elderly
146548282,14654828,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 129723870,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Prostate cancer,,2020,Q3,2,F,20170621.0,20180320.0,20180319,20180327,EXP,,US-JNJFOC-20170928652,JANSSEN,,66.0,YR,E,M,Y,102.0,KG,20180327.0,,MD,US,US,2020,Q3,Elderly
149736687,14973668,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,N, HDZS00N,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Acute kidney injury,,2020,Q3,7,F,20180414.0,20181121.0,20180605,20181122,EXP,,MY-JNJFOC-20180600194,JANSSEN,,66.0,YR,E,M,Y,,,20181122.0,,MD,MY,MY,2020,Q3,Elderly
149736687,14973668,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,N, HDZS00N,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Pulmonary embolism,,2020,Q3,7,F,20180414.0,20181121.0,20180605,20181122,EXP,,MY-JNJFOC-20180600194,JANSSEN,,66.0,YR,E,M,Y,,,20181122.0,,MD,MY,MY,2020,Q3,Elderly
149736687,14973668,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,N, HDZS00N,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Acute kidney injury,,2020,Q3,7,F,20180414.0,20181121.0,20180605,20181122,EXP,,MY-JNJFOC-20180600194,JANSSEN,,66.0,YR,E,M,Y,,,20181122.0,,MD,MY,MY,2020,Q3,Elderly
149736687,14973668,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,N, HDZS00N,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Pulmonary embolism,,2020,Q3,7,F,20180414.0,20181121.0,20180605,20181122,EXP,,MY-JNJFOC-20180600194,JANSSEN,,66.0,YR,E,M,Y,,,20181122.0,,MD,MY,MY,2020,Q3,Elderly
155242834,15524283,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, T245862,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Deep vein thrombosis,,2020,Q3,4,F,201806.0,20181024.0,20181019,20181031,EXP,,CN-JNJFOC-20180821804,JANSSEN,,68.0,YR,E,F,Y,82.0,KG,20181031.0,,MD,CN,CN,2020,Q3,Elderly
155242834,15524283,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, T245862,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Deep vein thrombosis,,2020,Q3,4,F,201806.0,20181024.0,20181019,20181031,EXP,,CN-JNJFOC-20180821804,JANSSEN,,68.0,YR,E,F,Y,82.0,KG,20181031.0,,MD,CN,CN,2020,Q3,Elderly
156763981,15676398,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, T195187,,204042.0,,,CAPSULE,,2020,Q3,Chronic kidney disease,,2020,Q3,1,I,20150919.0,20150922.0,20181130,20181130,EXP,,ES-JNJFOC-20150920531,JANSSEN,,59.0,YR,A,M,Y,107.9,KG,20181130.0,,MD,ES,ES,2020,Q3,Adult
156763981,15676398,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, T195187,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Chronic kidney disease,,2020,Q3,1,I,20150919.0,20150922.0,20181130,20181130,EXP,,ES-JNJFOC-20150920531,JANSSEN,,59.0,YR,A,M,Y,107.9,KG,20181130.0,,MD,ES,ES,2020,Q3,Adult
156891181,15689118,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 129723870,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Delirium,,2020,Q3,1,I,20180311.0,20180312.0,20181205,20181205,EXP,,US-JNJFOC-20180317540,JANSSEN,,67.0,YR,E,M,Y,99.6,KG,20181205.0,,MD,US,US,2020,Q3,Elderly
156891181,15689118,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 129723870,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Lactic acidosis,,2020,Q3,1,I,20180311.0,20180312.0,20181205,20181205,EXP,,US-JNJFOC-20180317540,JANSSEN,,67.0,YR,E,M,Y,99.6,KG,20181205.0,,MD,US,US,2020,Q3,Elderly
156891181,15689118,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 129723870,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Respiratory failure,,2020,Q3,1,I,20180311.0,20180312.0,20181205,20181205,EXP,,US-JNJFOC-20180317540,JANSSEN,,67.0,YR,E,M,Y,99.6,KG,20181205.0,,MD,US,US,2020,Q3,Elderly
156891181,15689118,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 129723870,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Delirium,,2020,Q3,1,I,20180311.0,20180312.0,20181205,20181205,EXP,,US-JNJFOC-20180317540,JANSSEN,,67.0,YR,E,M,Y,99.6,KG,20181205.0,,MD,US,US,2020,Q3,Elderly
156891181,15689118,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 129723870,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Lactic acidosis,,2020,Q3,1,I,20180311.0,20180312.0,20181205,20181205,EXP,,US-JNJFOC-20180317540,JANSSEN,,67.0,YR,E,M,Y,99.6,KG,20181205.0,,MD,US,US,2020,Q3,Elderly
156891181,15689118,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 129723870,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Respiratory failure,,2020,Q3,1,I,20180311.0,20180312.0,20181205,20181205,EXP,,US-JNJFOC-20180317540,JANSSEN,,67.0,YR,E,M,Y,99.6,KG,20181205.0,,MD,US,US,2020,Q3,Elderly
157469811,15746981,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 4282696,,204042.0,100.0,MG,CAPSULE,QD,2020,Q3,Fournier's gangrene,,2020,Q3,1,I,20160526.0,20160606.0,20181220,20181220,EXP,,HU-JNJFOC-20160726866,JANSSEN,,49.0,YR,A,M,Y,154.2,KG,20181220.0,,MD,HU,HU,2020,Q3,Adult
157469811,15746981,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 4282696,,119255.0,100.0,MG,CAPSULE,QD,2020,Q3,Fournier's gangrene,,2020,Q3,1,I,20160526.0,20160606.0,20181220,20181220,EXP,,HU-JNJFOC-20160726866,JANSSEN,,49.0,YR,A,M,Y,154.2,KG,20181220.0,,MD,HU,HU,2020,Q3,Adult
163850044,16385004,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,,,,,,2020,Q3,Myocardial infarction,,2020,Q3,4,F,20190515.0,20190612.0,20190603,20190620,EXP,,CA-JNJFOC-20190538025,JOHNSON AND JOHNSON,,63.0,YR,,M,Y,101.8,KG,20190621.0,,MD,CA,CA,2020,Q3,Adult
164811114,16481111,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2020,Q3,Cystitis,,2020,Q3,4,F,201908.0,20200825.0,20190626,20200828,EXP,,US-JAZZ-2019-US-008758,JAZZ,,48.0,YR,,F,Y,,,20200828.0,,MD,US,US,2020,Q3,Adult
164811114,16481111,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2020,Q3,Electroconvulsive therapy,,2020,Q3,4,F,201908.0,20200825.0,20190626,20200828,EXP,,US-JAZZ-2019-US-008758,JAZZ,,48.0,YR,,F,Y,,,20200828.0,,MD,US,US,2020,Q3,Adult
164811114,16481111,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2020,Q3,Hospitalisation,,2020,Q3,4,F,201908.0,20200825.0,20190626,20200828,EXP,,US-JAZZ-2019-US-008758,JAZZ,,48.0,YR,,F,Y,,,20200828.0,,MD,US,US,2020,Q3,Adult
164811114,16481111,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2020,Q3,Memory impairment,,2020,Q3,4,F,201908.0,20200825.0,20190626,20200828,EXP,,US-JAZZ-2019-US-008758,JAZZ,,48.0,YR,,F,Y,,,20200828.0,,MD,US,US,2020,Q3,Adult
164811114,16481111,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2020,Q3,Spinal fusion surgery,,2020,Q3,4,F,201908.0,20200825.0,20190626,20200828,EXP,,US-JAZZ-2019-US-008758,JAZZ,,48.0,YR,,F,Y,,,20200828.0,,MD,US,US,2020,Q3,Adult
170322014,17032201,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2020,Q3,Metastatic renal cell carcinoma,,2020,Q3,4,F,,20200811.0,20191114,20200821,EXP,,US-JNJFOC-20191106071,JOHNSON AND JOHNSON,,78.0,YR,E,M,Y,67.65,KG,20200821.0,,HP,US,US,2020,Q3,Elderly
172433412,17243341,20,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2020,Q3,Myocarditis,,2020,Q3,2,F,20191218.0,20200124.0,20200107,20200129,EXP,,CA-CELGENEUS-CAN-20200100192,CELGENE,,61.0,YR,,M,Y,,,20200129.0,,HP,CA,CA,2020,Q3,Adult
175233482,17523348,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",300.0,MG,Y,,,,204042.0,100.0,MG,TABLET,QD,2020,Q3,Toxic epidermal necrolysis,,2020,Q3,2,F,20200131.0,20200717.0,20200310,20200730,EXP,,JP-JNJFOC-20200303902,JOHNSON AND JOHNSON,,87.0,YR,E,F,Y,,,20200730.0,,PH,JP,JP,2020,Q3,Elderly
1767323610,17673236,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,1.0,DF,TABLETS,,2020,Q3,Tumour lysis syndrome,,2020,Q3,10,F,20200407.0,20200814.0,20200415,20200820,EXP,,JP-EISAI MEDICAL RESEARCH-EC-2020-073278,EISAI,,75.0,YR,E,M,Y,83.3,KG,20200820.0,,MD,JP,JP,2020,Q3,Elderly
178155652,17815565,20,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2020,Q3,Sinusitis,,2020,Q3,2,F,,20200911.0,20200522,20200922,EXP,,CA-APOTEX-2020AP011141,APOTEX,,67.0,YR,,M,Y,,,20200922.0,,CN,CA,CA,2020,Q3,Elderly
178155652,17815565,20,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2020,Q3,Tooth abscess,,2020,Q3,2,F,,20200911.0,20200522,20200922,EXP,,CA-APOTEX-2020AP011141,APOTEX,,67.0,YR,,M,Y,,,20200922.0,,CN,CA,CA,2020,Q3,Elderly
179688171,17968817,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q3,Pemphigoid,,2020,Q3,1,I,,20200622.0,20200701,20200701,EXP,,JP-JNJFOC-20200636375,JOHNSON AND JOHNSON,,9.0,DEC,,M,Y,,,20200701.0,,MD,JP,JP,2020,Q3,Child
179721234,17972123,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM,,,,,,,,100.0,MG,TABLET,,2020,Q3,Hepatic failure,,2020,Q3,4,F,20200627.0,20200916.0,20200701,20200917,EXP,,US-TAKEDA-2020TUS028352,TAKEDA,,67.0,YR,,M,Y,,,20200917.0,,MD,US,US,2020,Q3,Elderly
179721234,17972123,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM,,,,,,,,100.0,MG,TABLET,,2020,Q3,Hepatitis,,2020,Q3,4,F,20200627.0,20200916.0,20200701,20200917,EXP,,US-TAKEDA-2020TUS028352,TAKEDA,,67.0,YR,,M,Y,,,20200917.0,,MD,US,US,2020,Q3,Elderly
179721234,17972123,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM,,,,,,,,100.0,MG,TABLET,,2020,Q3,Sepsis,,2020,Q3,4,F,20200627.0,20200916.0,20200701,20200917,EXP,,US-TAKEDA-2020TUS028352,TAKEDA,,67.0,YR,,M,Y,,,20200917.0,,MD,US,US,2020,Q3,Elderly
179741083,17974108,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,,,,204042.0,100.0,MG,TABLET,QD,2020,Q3,Suicide attempt,,2020,Q3,3,F,202004.0,20200721.0,20200702,20200731,EXP,,JP-JNJFOC-20200636377,JOHNSON AND JOHNSON,,43.0,YR,A,M,Y,,,20200731.0,,MD,JP,JP,2020,Q3,Adult
179745711,17974571,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q3,Pemphigoid,,2020,Q3,1,I,201805.0,20200619.0,20200702,20200702,EXP,,JP-JNJFOC-20200632285,JOHNSON AND JOHNSON,,9.0,DEC,,M,Y,,,20200702.0,,MD,JP,JP,2020,Q3,Child
179751281,17975128,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MILLIGRAM, QD",,,U,U,,,,300.0,MG,,QD,2020,Q3,Labile blood pressure,,2020,Q3,1,I,,20200622.0,20200702,20200702,EXP,,US-MYLANLABS-2020M1060789,MYLAN,"SETHI P, CHANG GV, GOWDA SN, ELNAIR R, FENNER R, LAMFERS R. RECURRENT CATECHOLAMINE?INDUCED CARDIOMYOPATHY AND HYPERTENSIVE EMERGENCIES: A PRESENTATION OF PHEOCHROMOCYTOMA AND RELATED CONCERNS. S?D?MED 2020?73(2):78?80.",51.0,YR,,F,Y,,,20200702.0,,MD,US,US,2020,Q3,Adult
179861521,17986152,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Blood lactic acid increased,,2020,Q3,1,I,,20200704.0,20200707,20200707,EXP,,CA-ABBVIE-20K-028-3472183-00,ABBVIE,,54.0,YR,,M,Y,66.28,KG,20200707.0,,PH,CA,CA,2020,Q3,Adult
179861521,17986152,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Dyspnoea exertional,,2020,Q3,1,I,,20200704.0,20200707,20200707,EXP,,CA-ABBVIE-20K-028-3472183-00,ABBVIE,,54.0,YR,,M,Y,66.28,KG,20200707.0,,PH,CA,CA,2020,Q3,Adult
179861521,17986152,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Haemoglobin abnormal,,2020,Q3,1,I,,20200704.0,20200707,20200707,EXP,,CA-ABBVIE-20K-028-3472183-00,ABBVIE,,54.0,YR,,M,Y,66.28,KG,20200707.0,,PH,CA,CA,2020,Q3,Adult
179861521,17986152,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Heart rate increased,,2020,Q3,1,I,,20200704.0,20200707,20200707,EXP,,CA-ABBVIE-20K-028-3472183-00,ABBVIE,,54.0,YR,,M,Y,66.28,KG,20200707.0,,PH,CA,CA,2020,Q3,Adult
179861521,17986152,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Malaise,,2020,Q3,1,I,,20200704.0,20200707,20200707,EXP,,CA-ABBVIE-20K-028-3472183-00,ABBVIE,,54.0,YR,,M,Y,66.28,KG,20200707.0,,PH,CA,CA,2020,Q3,Adult
179861521,17986152,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Neutrophil count decreased,,2020,Q3,1,I,,20200704.0,20200707,20200707,EXP,,CA-ABBVIE-20K-028-3472183-00,ABBVIE,,54.0,YR,,M,Y,66.28,KG,20200707.0,,PH,CA,CA,2020,Q3,Adult
179861521,17986152,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Platelet count decreased,,2020,Q3,1,I,,20200704.0,20200707,20200707,EXP,,CA-ABBVIE-20K-028-3472183-00,ABBVIE,,54.0,YR,,M,Y,66.28,KG,20200707.0,,PH,CA,CA,2020,Q3,Adult
179861521,17986152,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Pyoderma gangrenosum,,2020,Q3,1,I,,20200704.0,20200707,20200707,EXP,,CA-ABBVIE-20K-028-3472183-00,ABBVIE,,54.0,YR,,M,Y,66.28,KG,20200707.0,,PH,CA,CA,2020,Q3,Adult
179861521,17986152,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Pyrexia,,2020,Q3,1,I,,20200704.0,20200707,20200707,EXP,,CA-ABBVIE-20K-028-3472183-00,ABBVIE,,54.0,YR,,M,Y,66.28,KG,20200707.0,,PH,CA,CA,2020,Q3,Adult
179861521,17986152,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Rash,,2020,Q3,1,I,,20200704.0,20200707,20200707,EXP,,CA-ABBVIE-20K-028-3472183-00,ABBVIE,,54.0,YR,,M,Y,66.28,KG,20200707.0,,PH,CA,CA,2020,Q3,Adult
179861521,17986152,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Respiratory rate increased,,2020,Q3,1,I,,20200704.0,20200707,20200707,EXP,,CA-ABBVIE-20K-028-3472183-00,ABBVIE,,54.0,YR,,M,Y,66.28,KG,20200707.0,,PH,CA,CA,2020,Q3,Adult
179861521,17986152,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,White blood cell count decreased,,2020,Q3,1,I,,20200704.0,20200707,20200707,EXP,,CA-ABBVIE-20K-028-3472183-00,ABBVIE,,54.0,YR,,M,Y,66.28,KG,20200707.0,,PH,CA,CA,2020,Q3,Adult
179886772,17988677,7,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,300 MILLIGRAM DAILY;,,,U,,,,,300.0,MG,,QD,2020,Q3,Labile blood pressure,,2020,Q3,2,F,,20200721.0,20200707,20200723,EXP,,US-TEVA-2020-US-1796955,TEVA,"SETHI P, CHANG GV, GOWDA SN, ELNAIR R, FENNER R, LAMFERS R. RECURRENT CATECHOLAMINE?INDUCED CARDIOMYOPATHY AND HYPERTENSIVE EMERGENCIES: A PRESENTATION OF PHEOCHROMOCYTOMA AND RELATED CONCERNS. S?D?MED 2020?73(2):78?80.",51.0,YR,,F,Y,,,20200723.0,,MD,US,US,2020,Q3,Adult
180026312,18002631,11,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"300 MILLIGRAM, DAILY",,,U,,,,,300.0,MG,,,2020,Q3,Angina pectoris,,2020,Q3,2,F,,20200727.0,20200710,20200804,EXP,,US-AUROBINDO-AUR-APL-2020-033455,AUROBINDO,,51.0,YR,,F,Y,,,20200805.0,,MD,US,US,2020,Q3,Adult
180026312,18002631,11,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"300 MILLIGRAM, DAILY",,,U,,,,,300.0,MG,,,2020,Q3,Blood pressure increased,,2020,Q3,2,F,,20200727.0,20200710,20200804,EXP,,US-AUROBINDO-AUR-APL-2020-033455,AUROBINDO,,51.0,YR,,F,Y,,,20200805.0,,MD,US,US,2020,Q3,Adult
180026312,18002631,11,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"300 MILLIGRAM, DAILY",,,U,,,,,300.0,MG,,,2020,Q3,Chest pain,,2020,Q3,2,F,,20200727.0,20200710,20200804,EXP,,US-AUROBINDO-AUR-APL-2020-033455,AUROBINDO,,51.0,YR,,F,Y,,,20200805.0,,MD,US,US,2020,Q3,Adult
180026312,18002631,11,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"300 MILLIGRAM, DAILY",,,U,,,,,300.0,MG,,,2020,Q3,Dizziness,,2020,Q3,2,F,,20200727.0,20200710,20200804,EXP,,US-AUROBINDO-AUR-APL-2020-033455,AUROBINDO,,51.0,YR,,F,Y,,,20200805.0,,MD,US,US,2020,Q3,Adult
180026312,18002631,11,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"300 MILLIGRAM, DAILY",,,U,,,,,300.0,MG,,,2020,Q3,Headache,,2020,Q3,2,F,,20200727.0,20200710,20200804,EXP,,US-AUROBINDO-AUR-APL-2020-033455,AUROBINDO,,51.0,YR,,F,Y,,,20200805.0,,MD,US,US,2020,Q3,Adult
180026312,18002631,11,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"300 MILLIGRAM, DAILY",,,U,,,,,300.0,MG,,,2020,Q3,Hypertensive emergency,,2020,Q3,2,F,,20200727.0,20200710,20200804,EXP,,US-AUROBINDO-AUR-APL-2020-033455,AUROBINDO,,51.0,YR,,F,Y,,,20200805.0,,MD,US,US,2020,Q3,Adult
180026312,18002631,11,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"300 MILLIGRAM, DAILY",,,U,,,,,300.0,MG,,,2020,Q3,Labile blood pressure,,2020,Q3,2,F,,20200727.0,20200710,20200804,EXP,,US-AUROBINDO-AUR-APL-2020-033455,AUROBINDO,,51.0,YR,,F,Y,,,20200805.0,,MD,US,US,2020,Q3,Adult
180026312,18002631,11,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"300 MILLIGRAM, DAILY",,,U,,,,,300.0,MG,,,2020,Q3,Nausea,,2020,Q3,2,F,,20200727.0,20200710,20200804,EXP,,US-AUROBINDO-AUR-APL-2020-033455,AUROBINDO,,51.0,YR,,F,Y,,,20200805.0,,MD,US,US,2020,Q3,Adult
180026312,18002631,11,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"300 MILLIGRAM, DAILY",,,U,,,,,300.0,MG,,,2020,Q3,Vomiting,,2020,Q3,2,F,,20200727.0,20200710,20200804,EXP,,US-AUROBINDO-AUR-APL-2020-033455,AUROBINDO,,51.0,YR,,F,Y,,,20200805.0,,MD,US,US,2020,Q3,Adult
180134491,18013449,13,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2020,Q3,Completed suicide,,2020,Q3,1,I,,20200630.0,20200713,20200713,EXP,,US-AUROBINDO-AUR-APL-2020-032863,AUROBINDO,,47.0,YR,,M,Y,,,20200713.0,,HP,US,US,2020,Q3,Adult
180211434,18021143,7,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q3,Concomitant disease aggravated,,2020,Q3,4,F,20200710.0,20200806.0,20200714,20200812,EXP,,NVSC2020JP195846,NOVARTIS,,66.0,YR,,M,Y,62.0,KG,20200812.0,,HP,JP,JP,2020,Q3,Elderly
180211434,18021143,7,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q3,Diabetic nephropathy,,2020,Q3,4,F,20200710.0,20200806.0,20200714,20200812,EXP,,NVSC2020JP195846,NOVARTIS,,66.0,YR,,M,Y,62.0,KG,20200812.0,,HP,JP,JP,2020,Q3,Elderly
180271801,18027180,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q3,Myocarditis,,2020,Q3,1,I,,20200707.0,20200716,20200716,EXP,E2B_03047664,CA-ACCORD-190344,ACCORD,,61.0,YR,,M,Y,,,20200716.0,,HP,CA,CA,2020,Q3,Adult
180566711,18056671,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM,,,U,,,,,100.0,MG,TABLET,,2020,Q3,Decreased appetite,,2020,Q3,1,I,,20200713.0,20200722,20200722,EXP,,CA-APOTEX-2020AP013970,APOTEX,,53.0,YR,,M,Y,,,20200722.0,,CN,CA,CA,2020,Q3,Adult
180566711,18056671,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM,,,U,,,,,100.0,MG,TABLET,,2020,Q3,Glomerular filtration rate decreased,,2020,Q3,1,I,,20200713.0,20200722,20200722,EXP,,CA-APOTEX-2020AP013970,APOTEX,,53.0,YR,,M,Y,,,20200722.0,,CN,CA,CA,2020,Q3,Adult
180566711,18056671,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM,,,U,,,,,100.0,MG,TABLET,,2020,Q3,Polydipsia,,2020,Q3,1,I,,20200713.0,20200722,20200722,EXP,,CA-APOTEX-2020AP013970,APOTEX,,53.0,YR,,M,Y,,,20200722.0,,CN,CA,CA,2020,Q3,Adult
180566711,18056671,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM,,,U,,,,,100.0,MG,TABLET,,2020,Q3,Urinary tract infection,,2020,Q3,1,I,,20200713.0,20200722,20200722,EXP,,CA-APOTEX-2020AP013970,APOTEX,,53.0,YR,,M,Y,,,20200722.0,,CN,CA,CA,2020,Q3,Adult
180566711,18056671,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM,,,U,,,,,100.0,MG,TABLET,,2020,Q3,Urine output increased,,2020,Q3,1,I,,20200713.0,20200722,20200722,EXP,,CA-APOTEX-2020AP013970,APOTEX,,53.0,YR,,M,Y,,,20200722.0,,CN,CA,CA,2020,Q3,Adult
180566711,18056671,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM,,,U,,,,,100.0,MG,TABLET,,2020,Q3,Weight decreased,,2020,Q3,1,I,,20200713.0,20200722,20200722,EXP,,CA-APOTEX-2020AP013970,APOTEX,,53.0,YR,,M,Y,,,20200722.0,,CN,CA,CA,2020,Q3,Adult
180616791,18061679,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2020,Q3,Drug hypersensitivity,,2020,Q3,1,I,,20200720.0,20200723,20200723,PER,,US-PFIZER INC-2020278335,PFIZER,,65.0,YR,,M,Y,,,20200723.0,,HP,US,US,2020,Q3,Elderly
181045961,18104596,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100MG X 1 TABLET,,,U,,,,204042.0,,,TABLET,,2020,Q3,Abdominal distension,,2020,Q3,1,I,20200719.0,20200724.0,20200803,20200803,EXP,,TW-JNJFOC-20200743876,JOHNSON AND JOHNSON,,34.0,YR,A,F,Y,,,20200803.0,,MD,TW,TW,2020,Q3,Young Adult
181045961,18104596,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100MG X 1 TABLET,,,U,,,,204042.0,,,TABLET,,2020,Q3,Pyrexia,,2020,Q3,1,I,20200719.0,20200724.0,20200803,20200803,EXP,,TW-JNJFOC-20200743876,JOHNSON AND JOHNSON,,34.0,YR,A,F,Y,,,20200803.0,,MD,TW,TW,2020,Q3,Young Adult
181045961,18104596,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100MG X 1 TABLET,,,U,,,,204042.0,,,TABLET,,2020,Q3,Urinary tract infection,,2020,Q3,1,I,20200719.0,20200724.0,20200803,20200803,EXP,,TW-JNJFOC-20200743876,JOHNSON AND JOHNSON,,34.0,YR,A,F,Y,,,20200803.0,,MD,TW,TW,2020,Q3,Young Adult
181045961,18104596,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,204042.0,,,TABLET,,2020,Q3,Abdominal distension,,2020,Q3,1,I,20200719.0,20200724.0,20200803,20200803,EXP,,TW-JNJFOC-20200743876,JOHNSON AND JOHNSON,,34.0,YR,A,F,Y,,,20200803.0,,MD,TW,TW,2020,Q3,Young Adult
181045961,18104596,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,204042.0,,,TABLET,,2020,Q3,Pyrexia,,2020,Q3,1,I,20200719.0,20200724.0,20200803,20200803,EXP,,TW-JNJFOC-20200743876,JOHNSON AND JOHNSON,,34.0,YR,A,F,Y,,,20200803.0,,MD,TW,TW,2020,Q3,Young Adult
181045961,18104596,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,204042.0,,,TABLET,,2020,Q3,Urinary tract infection,,2020,Q3,1,I,20200719.0,20200724.0,20200803,20200803,EXP,,TW-JNJFOC-20200743876,JOHNSON AND JOHNSON,,34.0,YR,A,F,Y,,,20200803.0,,MD,TW,TW,2020,Q3,Young Adult
181046321,18104632,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,D,D,,,,100.0,UG,,QD,2020,Q3,Bacteraemia,,2020,Q3,1,I,20200728.0,,20200803,20200803,DIR,,,FDA-CTU,,54.0,YR,,M,N,179.0,KG,20200803.0,N,PH,US,US,2020,Q3,Adult
181046321,18104632,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,D,D,,,,100.0,UG,,QD,2020,Q3,Necrotising fasciitis,,2020,Q3,1,I,20200728.0,,20200803,20200803,DIR,,,FDA-CTU,,54.0,YR,,M,N,179.0,KG,20200803.0,N,PH,US,US,2020,Q3,Adult
181046321,18104632,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,D,D,,,,100.0,UG,,QD,2020,Q3,Septic shock,,2020,Q3,1,I,20200728.0,,20200803,20200803,DIR,,,FDA-CTU,,54.0,YR,,M,N,179.0,KG,20200803.0,N,PH,US,US,2020,Q3,Adult
181086841,18108684,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,U,,,204042.0,300.0,MG,TABLET,,2020,Q3,Blood ketone body increased,,2020,Q3,1,I,20200714.0,20200729.0,20200804,20200804,EXP,GB-MHRA-EYC 00226157,GB-JNJFOC-20200745056,JOHNSON AND JOHNSON,,43.0,YR,A,F,Y,63.2,KG,20200804.0,,HP,GB,GB,2020,Q3,Adult
181086841,18108684,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,U,,,204042.0,300.0,MG,TABLET,,2020,Q3,Diabetic ketoacidosis,,2020,Q3,1,I,20200714.0,20200729.0,20200804,20200804,EXP,GB-MHRA-EYC 00226157,GB-JNJFOC-20200745056,JOHNSON AND JOHNSON,,43.0,YR,A,F,Y,63.2,KG,20200804.0,,HP,GB,GB,2020,Q3,Adult
181086841,18108684,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,U,,,204042.0,300.0,MG,TABLET,,2020,Q3,Malaise,,2020,Q3,1,I,20200714.0,20200729.0,20200804,20200804,EXP,GB-MHRA-EYC 00226157,GB-JNJFOC-20200745056,JOHNSON AND JOHNSON,,43.0,YR,A,F,Y,63.2,KG,20200804.0,,HP,GB,GB,2020,Q3,Adult
181086841,18108684,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,U,,,204042.0,300.0,MG,TABLET,,2020,Q3,Respiratory rate increased,,2020,Q3,1,I,20200714.0,20200729.0,20200804,20200804,EXP,GB-MHRA-EYC 00226157,GB-JNJFOC-20200745056,JOHNSON AND JOHNSON,,43.0,YR,A,F,Y,63.2,KG,20200804.0,,HP,GB,GB,2020,Q3,Adult
181228852,18122885,6,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q3,Condition aggravated,,2020,Q3,2,F,20200628.0,20200807.0,20200807,20200817,EXP,,NVSC2020JP218905,NOVARTIS,,66.0,YR,,M,Y,62.0,KG,20200817.0,,HP,JP,JP,2020,Q3,Elderly
181228852,18122885,6,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q3,Diabetic retinopathy,,2020,Q3,2,F,20200628.0,20200807.0,20200807,20200817,EXP,,NVSC2020JP218905,NOVARTIS,,66.0,YR,,M,Y,62.0,KG,20200817.0,,HP,JP,JP,2020,Q3,Elderly
181294631,18129463,1,PS,CANAGLIFLOZIN 100MG QDAY,CANAGLIFLOZIN,1,Oral,,,,D,D,,,,100.0,MG,,QD,2020,Q3,Fournier's gangrene,,2020,Q3,1,I,20200728.0,,20200807,20200807,DIR,,,FDA-CTU,,54.0,YR,,M,N,179.0,KG,20200807.0,N,MD,US,US,2020,Q3,Adult
181294631,18129463,1,PS,CANAGLIFLOZIN 100MG QDAY,CANAGLIFLOZIN,1,Oral,,,,D,D,,,,100.0,MG,,QD,2020,Q3,Illness,,2020,Q3,1,I,20200728.0,,20200807,20200807,DIR,,,FDA-CTU,,54.0,YR,,M,N,179.0,KG,20200807.0,N,MD,US,US,2020,Q3,Adult
181331631,18133163,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,, NOT SURE,,204042.0,300.0,MG,TABLET,,2020,Q3,Euglycaemic diabetic ketoacidosis,,2020,Q3,1,I,20200719.0,20200804.0,20200811,20200811,EXP,GB-MHRA-EYC 00226484,GB-JNJFOC-20200803367,JOHNSON AND JOHNSON,,58.0,YR,A,M,Y,,,20200811.0,,HP,GB,GB,2020,Q3,Adult
181338281,18133828,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q3,Arthralgia,,2020,Q3,1,I,,20200804.0,20200811,20200811,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040325",BOEHRINGER INGELHEIM,,60.0,YR,,F,Y,120.0,KG,20200811.0,,MD,CA,CA,2020,Q3,Adult
181338281,18133828,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q3,Bronchitis,,2020,Q3,1,I,,20200804.0,20200811,20200811,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040325",BOEHRINGER INGELHEIM,,60.0,YR,,F,Y,120.0,KG,20200811.0,,MD,CA,CA,2020,Q3,Adult
181338281,18133828,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q3,Constipation,,2020,Q3,1,I,,20200804.0,20200811,20200811,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040325",BOEHRINGER INGELHEIM,,60.0,YR,,F,Y,120.0,KG,20200811.0,,MD,CA,CA,2020,Q3,Adult
181338281,18133828,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q3,Cough,,2020,Q3,1,I,,20200804.0,20200811,20200811,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040325",BOEHRINGER INGELHEIM,,60.0,YR,,F,Y,120.0,KG,20200811.0,,MD,CA,CA,2020,Q3,Adult
181338281,18133828,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q3,Dyspnoea,,2020,Q3,1,I,,20200804.0,20200811,20200811,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040325",BOEHRINGER INGELHEIM,,60.0,YR,,F,Y,120.0,KG,20200811.0,,MD,CA,CA,2020,Q3,Adult
181338281,18133828,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q3,Ear disorder,,2020,Q3,1,I,,20200804.0,20200811,20200811,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040325",BOEHRINGER INGELHEIM,,60.0,YR,,F,Y,120.0,KG,20200811.0,,MD,CA,CA,2020,Q3,Adult
181338281,18133828,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q3,Ear infection,,2020,Q3,1,I,,20200804.0,20200811,20200811,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040325",BOEHRINGER INGELHEIM,,60.0,YR,,F,Y,120.0,KG,20200811.0,,MD,CA,CA,2020,Q3,Adult
181338281,18133828,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q3,Eyelid infection,,2020,Q3,1,I,,20200804.0,20200811,20200811,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040325",BOEHRINGER INGELHEIM,,60.0,YR,,F,Y,120.0,KG,20200811.0,,MD,CA,CA,2020,Q3,Adult
181338281,18133828,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q3,Heart rate increased,,2020,Q3,1,I,,20200804.0,20200811,20200811,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040325",BOEHRINGER INGELHEIM,,60.0,YR,,F,Y,120.0,KG,20200811.0,,MD,CA,CA,2020,Q3,Adult
181338281,18133828,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q3,Hypotension,,2020,Q3,1,I,,20200804.0,20200811,20200811,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040325",BOEHRINGER INGELHEIM,,60.0,YR,,F,Y,120.0,KG,20200811.0,,MD,CA,CA,2020,Q3,Adult
181338281,18133828,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q3,Influenza,,2020,Q3,1,I,,20200804.0,20200811,20200811,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040325",BOEHRINGER INGELHEIM,,60.0,YR,,F,Y,120.0,KG,20200811.0,,MD,CA,CA,2020,Q3,Adult
181338281,18133828,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q3,Localised infection,,2020,Q3,1,I,,20200804.0,20200811,20200811,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040325",BOEHRINGER INGELHEIM,,60.0,YR,,F,Y,120.0,KG,20200811.0,,MD,CA,CA,2020,Q3,Adult
181338281,18133828,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q3,Malaise,,2020,Q3,1,I,,20200804.0,20200811,20200811,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040325",BOEHRINGER INGELHEIM,,60.0,YR,,F,Y,120.0,KG,20200811.0,,MD,CA,CA,2020,Q3,Adult
181338281,18133828,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q3,Musculoskeletal pain,,2020,Q3,1,I,,20200804.0,20200811,20200811,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040325",BOEHRINGER INGELHEIM,,60.0,YR,,F,Y,120.0,KG,20200811.0,,MD,CA,CA,2020,Q3,Adult
181338281,18133828,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q3,Neck pain,,2020,Q3,1,I,,20200804.0,20200811,20200811,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040325",BOEHRINGER INGELHEIM,,60.0,YR,,F,Y,120.0,KG,20200811.0,,MD,CA,CA,2020,Q3,Adult
181338281,18133828,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q3,Neuralgia,,2020,Q3,1,I,,20200804.0,20200811,20200811,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040325",BOEHRINGER INGELHEIM,,60.0,YR,,F,Y,120.0,KG,20200811.0,,MD,CA,CA,2020,Q3,Adult
181338281,18133828,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q3,Pain in extremity,,2020,Q3,1,I,,20200804.0,20200811,20200811,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040325",BOEHRINGER INGELHEIM,,60.0,YR,,F,Y,120.0,KG,20200811.0,,MD,CA,CA,2020,Q3,Adult
181338281,18133828,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q3,Paranasal cyst,,2020,Q3,1,I,,20200804.0,20200811,20200811,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040325",BOEHRINGER INGELHEIM,,60.0,YR,,F,Y,120.0,KG,20200811.0,,MD,CA,CA,2020,Q3,Adult
181338281,18133828,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q3,Polyp,,2020,Q3,1,I,,20200804.0,20200811,20200811,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040325",BOEHRINGER INGELHEIM,,60.0,YR,,F,Y,120.0,KG,20200811.0,,MD,CA,CA,2020,Q3,Adult
181338281,18133828,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q3,Sinusitis,,2020,Q3,1,I,,20200804.0,20200811,20200811,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040325",BOEHRINGER INGELHEIM,,60.0,YR,,F,Y,120.0,KG,20200811.0,,MD,CA,CA,2020,Q3,Adult
181338281,18133828,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q3,Tinnitus,,2020,Q3,1,I,,20200804.0,20200811,20200811,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040325",BOEHRINGER INGELHEIM,,60.0,YR,,F,Y,120.0,KG,20200811.0,,MD,CA,CA,2020,Q3,Adult
181338281,18133828,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q3,Tympanic membrane perforation,,2020,Q3,1,I,,20200804.0,20200811,20200811,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040325",BOEHRINGER INGELHEIM,,60.0,YR,,F,Y,120.0,KG,20200811.0,,MD,CA,CA,2020,Q3,Adult
181338281,18133828,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q3,Viral infection,,2020,Q3,1,I,,20200804.0,20200811,20200811,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040325",BOEHRINGER INGELHEIM,,60.0,YR,,F,Y,120.0,KG,20200811.0,,MD,CA,CA,2020,Q3,Adult
181338281,18133828,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q3,Weight increased,,2020,Q3,1,I,,20200804.0,20200811,20200811,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040325",BOEHRINGER INGELHEIM,,60.0,YR,,F,Y,120.0,KG,20200811.0,,MD,CA,CA,2020,Q3,Adult
181351201,18135120,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Pancreatitis,,2020,Q3,1,I,20200722.0,,20200811,20200811,DIR,,,FDA-CTU,,64.0,YR,,M,N,86.4,KG,20200811.0,N,PH,US,US,2020,Q3,Adult
181365451,18136545,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q3,Myocarditis,,2020,Q3,1,I,,20200803.0,20200811,20200811,EXP,,CA-TEVA-2020-CA-1812017,TEVA,,61.0,YR,A,M,Y,,,20200811.0,,HP,CA,CA,2020,Q3,Adult
181457921,18145792,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,,U,,,,100.0,MG,,QD,2020,Q3,Drug ineffective,,2020,Q3,1,I,,20200804.0,20200813,20200813,EXP,,US-MYLANLABS-2020M1070644,MYLAN,,37.0,YR,,F,Y,,,20200813.0,,HP,NL,US,2020,Q3,Adult
181462661,18146266,6,SS,CANAGLIOZIN [CANAGLIFLOZIN],CANAGLIFLOZIN,1,Unknown,100.0MG UNKNOWN,,,Y,,,,,100.0,MG,,,2020,Q3,Hepatocellular injury,,2020,Q3,1,I,,20200805.0,20200813,20200813,EXP,,TW-ASTRAZENECA-2020SE98962,ASTRAZENECA,,76.0,YR,,F,Y,,,20200813.0,,MD,TW,TW,2020,Q3,Elderly
181462661,18146266,6,SS,CANAGLIOZIN [CANAGLIFLOZIN],CANAGLIFLOZIN,1,Unknown,100.0MG UNKNOWN,,,Y,,,,,100.0,MG,,,2020,Q3,Muscular weakness,,2020,Q3,1,I,,20200805.0,20200813,20200813,EXP,,TW-ASTRAZENECA-2020SE98962,ASTRAZENECA,,76.0,YR,,F,Y,,,20200813.0,,MD,TW,TW,2020,Q3,Elderly
181462661,18146266,6,SS,CANAGLIOZIN [CANAGLIFLOZIN],CANAGLIFLOZIN,1,Unknown,100.0MG UNKNOWN,,,Y,,,,,100.0,MG,,,2020,Q3,Pain in extremity,,2020,Q3,1,I,,20200805.0,20200813,20200813,EXP,,TW-ASTRAZENECA-2020SE98962,ASTRAZENECA,,76.0,YR,,F,Y,,,20200813.0,,MD,TW,TW,2020,Q3,Elderly
181462661,18146266,6,SS,CANAGLIOZIN [CANAGLIFLOZIN],CANAGLIFLOZIN,1,Unknown,100.0MG UNKNOWN,,,Y,,,,,100.0,MG,,,2020,Q3,Rhabdomyolysis,,2020,Q3,1,I,,20200805.0,20200813,20200813,EXP,,TW-ASTRAZENECA-2020SE98962,ASTRAZENECA,,76.0,YR,,F,Y,,,20200813.0,,MD,TW,TW,2020,Q3,Elderly
181462661,18146266,6,SS,CANAGLIOZIN [CANAGLIFLOZIN],CANAGLIFLOZIN,1,Unknown,100.0MG UNKNOWN,,,Y,,,,,100.0,MG,,,2020,Q3,Toxicity to various agents,,2020,Q3,1,I,,20200805.0,20200813,20200813,EXP,,TW-ASTRAZENECA-2020SE98962,ASTRAZENECA,,76.0,YR,,F,Y,,,20200813.0,,MD,TW,TW,2020,Q3,Elderly
181522301,18152230,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,TABLET,QD,2020,Q3,Diabetic ketoacidosis,,2020,Q3,1,I,,20200804.0,20200814,20200814,EXP,,US-JNJFOC-20200807308,JOHNSON AND JOHNSON,"TITLE: FOURNIER^S GANGRENE AND DIABETIC KETOACIDOSIS ASSOCIATED WITH SODIUM GLUCOSE CO?TRANSPORTER 2 (SGLT2) INHIBITORS: LIFE?THREATENING COMPLICATIONS YEAR: 2020 VOLUME: 21 ISSUE:  AUTHOR AFFILIATION: (KASBAWALA) SCHOOL OF MEDICINE, SABA UNIVERSITY, SABA, NETHERLANDS(STAMATIADES, MAJUMDAR) DEPARTMENT OF MEDICINE, YALE NEW HAVEN HEALTH, BRIDGEPORT HOSPITAL, BRIDGEPORT, CT, UNITED STATES(STAMATIADES) SCHOOL OF MEDICINE, UNIVERSITY OF CRETE, HERAKLION, GREECE JOURNAL NAME: AMERICAN JOURNAL OF C...",37.0,YR,A,F,Y,,,20200814.0,,HP,US,NL,2020,Q3,Adult
181522301,18152230,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,TABLET,QD,2020,Q3,Fournier's gangrene,,2020,Q3,1,I,,20200804.0,20200814,20200814,EXP,,US-JNJFOC-20200807308,JOHNSON AND JOHNSON,"TITLE: FOURNIER^S GANGRENE AND DIABETIC KETOACIDOSIS ASSOCIATED WITH SODIUM GLUCOSE CO?TRANSPORTER 2 (SGLT2) INHIBITORS: LIFE?THREATENING COMPLICATIONS YEAR: 2020 VOLUME: 21 ISSUE:  AUTHOR AFFILIATION: (KASBAWALA) SCHOOL OF MEDICINE, SABA UNIVERSITY, SABA, NETHERLANDS(STAMATIADES, MAJUMDAR) DEPARTMENT OF MEDICINE, YALE NEW HAVEN HEALTH, BRIDGEPORT HOSPITAL, BRIDGEPORT, CT, UNITED STATES(STAMATIADES) SCHOOL OF MEDICINE, UNIVERSITY OF CRETE, HERAKLION, GREECE JOURNAL NAME: AMERICAN JOURNAL OF C...",37.0,YR,A,F,Y,,,20200814.0,,HP,US,NL,2020,Q3,Adult
181525152,18152515,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,,,,,100.0,MG,,QD,2020,Q3,Drug interaction,,2020,Q3,2,F,,20200812.0,20200814,20200819,EXP,,CA-ASTRAZENECA-2020SF02220,ASTRAZENECA,"NOT REPORTED. ROSUVASTATIN?CANAGLIFLOZIN COMBO MAY BE TOXIC, CASE SUGGESTS: A 76?YEAR?OLD WOMAN HAD A SPIKE IN ROSUVASTATIN PLASMA CONCENTRATIONS AFTER STARTING THE SGLT2 INHIBITOR. TCTMD 2020?",76.0,YR,,F,Y,,,20200819.0,,HP,CA,CA,2020,Q3,Elderly
181525152,18152515,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,,,,,100.0,MG,,QD,2020,Q3,Drug level increased,,2020,Q3,2,F,,20200812.0,20200814,20200819,EXP,,CA-ASTRAZENECA-2020SF02220,ASTRAZENECA,"NOT REPORTED. ROSUVASTATIN?CANAGLIFLOZIN COMBO MAY BE TOXIC, CASE SUGGESTS: A 76?YEAR?OLD WOMAN HAD A SPIKE IN ROSUVASTATIN PLASMA CONCENTRATIONS AFTER STARTING THE SGLT2 INHIBITOR. TCTMD 2020?",76.0,YR,,F,Y,,,20200819.0,,HP,CA,CA,2020,Q3,Elderly
181525152,18152515,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,,,,,100.0,MG,,QD,2020,Q3,Gait disturbance,,2020,Q3,2,F,,20200812.0,20200814,20200819,EXP,,CA-ASTRAZENECA-2020SF02220,ASTRAZENECA,"NOT REPORTED. ROSUVASTATIN?CANAGLIFLOZIN COMBO MAY BE TOXIC, CASE SUGGESTS: A 76?YEAR?OLD WOMAN HAD A SPIKE IN ROSUVASTATIN PLASMA CONCENTRATIONS AFTER STARTING THE SGLT2 INHIBITOR. TCTMD 2020?",76.0,YR,,F,Y,,,20200819.0,,HP,CA,CA,2020,Q3,Elderly
181525152,18152515,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,,,,,100.0,MG,,QD,2020,Q3,Hepatocellular injury,,2020,Q3,2,F,,20200812.0,20200814,20200819,EXP,,CA-ASTRAZENECA-2020SF02220,ASTRAZENECA,"NOT REPORTED. ROSUVASTATIN?CANAGLIFLOZIN COMBO MAY BE TOXIC, CASE SUGGESTS: A 76?YEAR?OLD WOMAN HAD A SPIKE IN ROSUVASTATIN PLASMA CONCENTRATIONS AFTER STARTING THE SGLT2 INHIBITOR. TCTMD 2020?",76.0,YR,,F,Y,,,20200819.0,,HP,CA,CA,2020,Q3,Elderly
181525152,18152515,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,,,,,100.0,MG,,QD,2020,Q3,Laboratory test abnormal,,2020,Q3,2,F,,20200812.0,20200814,20200819,EXP,,CA-ASTRAZENECA-2020SF02220,ASTRAZENECA,"NOT REPORTED. ROSUVASTATIN?CANAGLIFLOZIN COMBO MAY BE TOXIC, CASE SUGGESTS: A 76?YEAR?OLD WOMAN HAD A SPIKE IN ROSUVASTATIN PLASMA CONCENTRATIONS AFTER STARTING THE SGLT2 INHIBITOR. TCTMD 2020?",76.0,YR,,F,Y,,,20200819.0,,HP,CA,CA,2020,Q3,Elderly
181525152,18152515,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,,,,,100.0,MG,,QD,2020,Q3,Rhabdomyolysis,,2020,Q3,2,F,,20200812.0,20200814,20200819,EXP,,CA-ASTRAZENECA-2020SF02220,ASTRAZENECA,"NOT REPORTED. ROSUVASTATIN?CANAGLIFLOZIN COMBO MAY BE TOXIC, CASE SUGGESTS: A 76?YEAR?OLD WOMAN HAD A SPIKE IN ROSUVASTATIN PLASMA CONCENTRATIONS AFTER STARTING THE SGLT2 INHIBITOR. TCTMD 2020?",76.0,YR,,F,Y,,,20200819.0,,HP,CA,CA,2020,Q3,Elderly
181525152,18152515,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,,,,,100.0,MG,,QD,2020,Q3,Toxicity to various agents,,2020,Q3,2,F,,20200812.0,20200814,20200819,EXP,,CA-ASTRAZENECA-2020SF02220,ASTRAZENECA,"NOT REPORTED. ROSUVASTATIN?CANAGLIFLOZIN COMBO MAY BE TOXIC, CASE SUGGESTS: A 76?YEAR?OLD WOMAN HAD A SPIKE IN ROSUVASTATIN PLASMA CONCENTRATIONS AFTER STARTING THE SGLT2 INHIBITOR. TCTMD 2020?",76.0,YR,,F,Y,,,20200819.0,,HP,CA,CA,2020,Q3,Elderly
181561271,18156127,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2020,Q3,Drug interaction,,2020,Q3,1,I,,20200806.0,20200817,20200817,EXP,,CA-CPL-001896,CADILA,"BRAILOVSKI E, KIM RB, JUURLINK D. ROSUVASTATIN MYOTOXICITY AFTER STARTING CANAGLIFLOZIN TREATMENT: A CASE REPORT. ANN INTERN MED. 2020 AUG 4",76.0,YR,,F,Y,,,20200817.0,,MD,CA,CA,2020,Q3,Elderly
181561271,18156127,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2020,Q3,Hepatocellular injury,,2020,Q3,1,I,,20200806.0,20200817,20200817,EXP,,CA-CPL-001896,CADILA,"BRAILOVSKI E, KIM RB, JUURLINK D. ROSUVASTATIN MYOTOXICITY AFTER STARTING CANAGLIFLOZIN TREATMENT: A CASE REPORT. ANN INTERN MED. 2020 AUG 4",76.0,YR,,F,Y,,,20200817.0,,MD,CA,CA,2020,Q3,Elderly
181561271,18156127,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2020,Q3,Rhabdomyolysis,,2020,Q3,1,I,,20200806.0,20200817,20200817,EXP,,CA-CPL-001896,CADILA,"BRAILOVSKI E, KIM RB, JUURLINK D. ROSUVASTATIN MYOTOXICITY AFTER STARTING CANAGLIFLOZIN TREATMENT: A CASE REPORT. ANN INTERN MED. 2020 AUG 4",76.0,YR,,F,Y,,,20200817.0,,MD,CA,CA,2020,Q3,Elderly
181569282,18156928,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2020,Q3,Drug interaction,,2020,Q3,2,F,,20200821.0,20200817,20200831,EXP,,CA-ACCORD-195666,ACCORD,"BRAILOVSKI E, KIM RB, JUURLINK D. ROSUVASTATIN MYOTOXICITY AFTER STARTING CANAGLIFLOZIN TREATMENT: A CASE REPORT. ANN INTERN MED. 2020 AUG 4",76.0,YR,,F,Y,,,20200831.0,,MD,CA,CA,2020,Q3,Elderly
181569282,18156928,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2020,Q3,Hepatocellular injury,,2020,Q3,2,F,,20200821.0,20200817,20200831,EXP,,CA-ACCORD-195666,ACCORD,"BRAILOVSKI E, KIM RB, JUURLINK D. ROSUVASTATIN MYOTOXICITY AFTER STARTING CANAGLIFLOZIN TREATMENT: A CASE REPORT. ANN INTERN MED. 2020 AUG 4",76.0,YR,,F,Y,,,20200831.0,,MD,CA,CA,2020,Q3,Elderly
181569282,18156928,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2020,Q3,Rhabdomyolysis,,2020,Q3,2,F,,20200821.0,20200817,20200831,EXP,,CA-ACCORD-195666,ACCORD,"BRAILOVSKI E, KIM RB, JUURLINK D. ROSUVASTATIN MYOTOXICITY AFTER STARTING CANAGLIFLOZIN TREATMENT: A CASE REPORT. ANN INTERN MED. 2020 AUG 4",76.0,YR,,F,Y,,,20200831.0,,MD,CA,CA,2020,Q3,Elderly
181632131,18163213,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,100 MG DAILY,,,Y,,,,,100.0,MG,,,2020,Q3,Drug interaction,Drug interaction,2020,Q3,1,I,,20200809.0,20200818,20200818,EXP,,CA-UMEDICA-000014,UMEDICA LABS,,76.0,YR,E,F,Y,,,20200818.0,,MD,CA,CA,2020,Q3,Elderly
181632131,18163213,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,100 MG DAILY,,,Y,,,,,100.0,MG,,,2020,Q3,Drug level increased,Drug level increased,2020,Q3,1,I,,20200809.0,20200818,20200818,EXP,,CA-UMEDICA-000014,UMEDICA LABS,,76.0,YR,E,F,Y,,,20200818.0,,MD,CA,CA,2020,Q3,Elderly
181632131,18163213,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,100 MG DAILY,,,Y,,,,,100.0,MG,,,2020,Q3,Hepatotoxicity,Hepatotoxicity,2020,Q3,1,I,,20200809.0,20200818,20200818,EXP,,CA-UMEDICA-000014,UMEDICA LABS,,76.0,YR,E,F,Y,,,20200818.0,,MD,CA,CA,2020,Q3,Elderly
181632131,18163213,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,100 MG DAILY,,,Y,,,,,100.0,MG,,,2020,Q3,Rhabdomyolysis,Rhabdomyolysis,2020,Q3,1,I,,20200809.0,20200818,20200818,EXP,,CA-UMEDICA-000014,UMEDICA LABS,,76.0,YR,E,F,Y,,,20200818.0,,MD,CA,CA,2020,Q3,Elderly
181632131,18163213,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,100 MG DAILY,,,Y,,,,,100.0,MG,,,2020,Q3,Toxicity to various agents,Toxicity to various agents,2020,Q3,1,I,,20200809.0,20200818,20200818,EXP,,CA-UMEDICA-000014,UMEDICA LABS,,76.0,YR,E,F,Y,,,20200818.0,,MD,CA,CA,2020,Q3,Elderly
181710601,18171060,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2020,Q3,Blood lactic acid increased,,2020,Q3,1,I,,20200811.0,20200819,20200819,EXP,,CA-CELGENEUS-CAN-20200803441,CELGENE,,54.0,YR,,M,Y,66.28,KG,20200819.0,,PH,CA,CA,2020,Q3,Adult
181710601,18171060,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2020,Q3,Dyspnoea exertional,,2020,Q3,1,I,,20200811.0,20200819,20200819,EXP,,CA-CELGENEUS-CAN-20200803441,CELGENE,,54.0,YR,,M,Y,66.28,KG,20200819.0,,PH,CA,CA,2020,Q3,Adult
181710601,18171060,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2020,Q3,Haemoglobin abnormal,,2020,Q3,1,I,,20200811.0,20200819,20200819,EXP,,CA-CELGENEUS-CAN-20200803441,CELGENE,,54.0,YR,,M,Y,66.28,KG,20200819.0,,PH,CA,CA,2020,Q3,Adult
181710601,18171060,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2020,Q3,Heart rate increased,,2020,Q3,1,I,,20200811.0,20200819,20200819,EXP,,CA-CELGENEUS-CAN-20200803441,CELGENE,,54.0,YR,,M,Y,66.28,KG,20200819.0,,PH,CA,CA,2020,Q3,Adult
181710601,18171060,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2020,Q3,Malaise,,2020,Q3,1,I,,20200811.0,20200819,20200819,EXP,,CA-CELGENEUS-CAN-20200803441,CELGENE,,54.0,YR,,M,Y,66.28,KG,20200819.0,,PH,CA,CA,2020,Q3,Adult
181710601,18171060,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2020,Q3,Neutrophil count decreased,,2020,Q3,1,I,,20200811.0,20200819,20200819,EXP,,CA-CELGENEUS-CAN-20200803441,CELGENE,,54.0,YR,,M,Y,66.28,KG,20200819.0,,PH,CA,CA,2020,Q3,Adult
181710601,18171060,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2020,Q3,Platelet count decreased,,2020,Q3,1,I,,20200811.0,20200819,20200819,EXP,,CA-CELGENEUS-CAN-20200803441,CELGENE,,54.0,YR,,M,Y,66.28,KG,20200819.0,,PH,CA,CA,2020,Q3,Adult
181710601,18171060,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2020,Q3,Pyoderma gangrenosum,,2020,Q3,1,I,,20200811.0,20200819,20200819,EXP,,CA-CELGENEUS-CAN-20200803441,CELGENE,,54.0,YR,,M,Y,66.28,KG,20200819.0,,PH,CA,CA,2020,Q3,Adult
181710601,18171060,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2020,Q3,Pyrexia,,2020,Q3,1,I,,20200811.0,20200819,20200819,EXP,,CA-CELGENEUS-CAN-20200803441,CELGENE,,54.0,YR,,M,Y,66.28,KG,20200819.0,,PH,CA,CA,2020,Q3,Adult
181710601,18171060,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2020,Q3,Rash,,2020,Q3,1,I,,20200811.0,20200819,20200819,EXP,,CA-CELGENEUS-CAN-20200803441,CELGENE,,54.0,YR,,M,Y,66.28,KG,20200819.0,,PH,CA,CA,2020,Q3,Adult
181710601,18171060,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2020,Q3,Respiratory rate increased,,2020,Q3,1,I,,20200811.0,20200819,20200819,EXP,,CA-CELGENEUS-CAN-20200803441,CELGENE,,54.0,YR,,M,Y,66.28,KG,20200819.0,,PH,CA,CA,2020,Q3,Adult
181710601,18171060,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2020,Q3,White blood cell count decreased,,2020,Q3,1,I,,20200811.0,20200819,20200819,EXP,,CA-CELGENEUS-CAN-20200803441,CELGENE,,54.0,YR,,M,Y,66.28,KG,20200819.0,,PH,CA,CA,2020,Q3,Adult
181713782,18171378,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,Y,,,,,100.0,MG,,QD,2020,Q3,Diabetic ketoacidosis,,2020,Q3,2,F,,20200825.0,20200819,20200827,EXP,,US-TEVA-2020-US-1815023,TEVA,"KASBAWALA K, STAMATIADES GA, MAJUMDAR SK. FOURNIER^S GANGRENE AND DIABETIC KETOACIDOSIS ASSOCIATED WITH SODIUM GLUCOSE CO?TRANSPORTER 2 (SGLT2) INHIBITORS: LIFE?THREATENING COMPLICATIONS. AM?J?CASE?REP 2020?21:E921536?1?E921536?4.",37.0,YR,A,F,Y,,,20200827.0,,HP,US,US,2020,Q3,Adult
181713782,18171378,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,Y,,,,,100.0,MG,,QD,2020,Q3,Drug ineffective,,2020,Q3,2,F,,20200825.0,20200819,20200827,EXP,,US-TEVA-2020-US-1815023,TEVA,"KASBAWALA K, STAMATIADES GA, MAJUMDAR SK. FOURNIER^S GANGRENE AND DIABETIC KETOACIDOSIS ASSOCIATED WITH SODIUM GLUCOSE CO?TRANSPORTER 2 (SGLT2) INHIBITORS: LIFE?THREATENING COMPLICATIONS. AM?J?CASE?REP 2020?21:E921536?1?E921536?4.",37.0,YR,A,F,Y,,,20200827.0,,HP,US,US,2020,Q3,Adult
181713782,18171378,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,Y,,,,,100.0,MG,,QD,2020,Q3,Fournier's gangrene,,2020,Q3,2,F,,20200825.0,20200819,20200827,EXP,,US-TEVA-2020-US-1815023,TEVA,"KASBAWALA K, STAMATIADES GA, MAJUMDAR SK. FOURNIER^S GANGRENE AND DIABETIC KETOACIDOSIS ASSOCIATED WITH SODIUM GLUCOSE CO?TRANSPORTER 2 (SGLT2) INHIBITORS: LIFE?THREATENING COMPLICATIONS. AM?J?CASE?REP 2020?21:E921536?1?E921536?4.",37.0,YR,A,F,Y,,,20200827.0,,HP,US,US,2020,Q3,Adult
181713782,18171378,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,Y,,,,,100.0,MG,,QD,2020,Q3,Sepsis,,2020,Q3,2,F,,20200825.0,20200819,20200827,EXP,,US-TEVA-2020-US-1815023,TEVA,"KASBAWALA K, STAMATIADES GA, MAJUMDAR SK. FOURNIER^S GANGRENE AND DIABETIC KETOACIDOSIS ASSOCIATED WITH SODIUM GLUCOSE CO?TRANSPORTER 2 (SGLT2) INHIBITORS: LIFE?THREATENING COMPLICATIONS. AM?J?CASE?REP 2020?21:E921536?1?E921536?4.",37.0,YR,A,F,Y,,,20200827.0,,HP,US,US,2020,Q3,Adult
181713782,18171378,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,Y,,,,,100.0,MG,,QD,2020,Q3,Urinary tract infection,,2020,Q3,2,F,,20200825.0,20200819,20200827,EXP,,US-TEVA-2020-US-1815023,TEVA,"KASBAWALA K, STAMATIADES GA, MAJUMDAR SK. FOURNIER^S GANGRENE AND DIABETIC KETOACIDOSIS ASSOCIATED WITH SODIUM GLUCOSE CO?TRANSPORTER 2 (SGLT2) INHIBITORS: LIFE?THREATENING COMPLICATIONS. AM?J?CASE?REP 2020?21:E921536?1?E921536?4.",37.0,YR,A,F,Y,,,20200827.0,,HP,US,US,2020,Q3,Adult
181824071,18182407,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Acute kidney injury,,2020,Q3,1,I,20200710.0,20200819.0,20200821,20200821,EXP,,IT-EMD SERONO-9181903,EMD SERONO INC,,86.0,YR,E,F,Y,,,20200821.0,,MD,IT,IT,2020,Q3,Elderly
181824071,18182407,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Lactic acidosis,,2020,Q3,1,I,20200710.0,20200819.0,20200821,20200821,EXP,,IT-EMD SERONO-9181903,EMD SERONO INC,,86.0,YR,E,F,Y,,,20200821.0,,MD,IT,IT,2020,Q3,Elderly
181906801,18190680,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,Y,, UNKNOWN,,,100.0,MG,,QD,2020,Q3,Drug interaction,,2020,Q3,1,I,,20200810.0,20200825,20200825,EXP,,CA-ALKEM LABORATORIES LIMITED-CA-ALKEM-2020-05133,ALKEM,,76.0,YR,,F,Y,,,20200825.0,,MD,CA,CA,2020,Q3,Elderly
181906801,18190680,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,Y,, UNKNOWN,,,100.0,MG,,QD,2020,Q3,Hepatocellular injury,,2020,Q3,1,I,,20200810.0,20200825,20200825,EXP,,CA-ALKEM LABORATORIES LIMITED-CA-ALKEM-2020-05133,ALKEM,,76.0,YR,,F,Y,,,20200825.0,,MD,CA,CA,2020,Q3,Elderly
181906801,18190680,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,Y,, UNKNOWN,,,100.0,MG,,QD,2020,Q3,Musculoskeletal toxicity,,2020,Q3,1,I,,20200810.0,20200825,20200825,EXP,,CA-ALKEM LABORATORIES LIMITED-CA-ALKEM-2020-05133,ALKEM,,76.0,YR,,F,Y,,,20200825.0,,MD,CA,CA,2020,Q3,Elderly
181986691,18198669,5,C,CANAGLIFLOZIN W/METFORMIN,,2,,,,,,,,,,,,,,2020,Q3,Aggression,,2020,Q3,1,I,202007.0,20200815.0,20200826,20200826,EXP,,US-JNJFOC-20200824697,JOHNSON AND JOHNSON,,82.0,YR,E,F,Y,40.86,KG,20200826.0,,CN,US,US,2020,Q3,Elderly
181986691,18198669,5,C,CANAGLIFLOZIN W/METFORMIN,,2,,,,,,,,,,,,,,2020,Q3,Dementia,,2020,Q3,1,I,202007.0,20200815.0,20200826,20200826,EXP,,US-JNJFOC-20200824697,JOHNSON AND JOHNSON,,82.0,YR,E,F,Y,40.86,KG,20200826.0,,CN,US,US,2020,Q3,Elderly
181986691,18198669,5,C,CANAGLIFLOZIN W/METFORMIN,,2,,,,,,,,,,,,,,2020,Q3,Fatigue,,2020,Q3,1,I,202007.0,20200815.0,20200826,20200826,EXP,,US-JNJFOC-20200824697,JOHNSON AND JOHNSON,,82.0,YR,E,F,Y,40.86,KG,20200826.0,,CN,US,US,2020,Q3,Elderly
181986691,18198669,5,C,CANAGLIFLOZIN W/METFORMIN,,2,,,,,,,,,,,,,,2020,Q3,Gait disturbance,,2020,Q3,1,I,202007.0,20200815.0,20200826,20200826,EXP,,US-JNJFOC-20200824697,JOHNSON AND JOHNSON,,82.0,YR,E,F,Y,40.86,KG,20200826.0,,CN,US,US,2020,Q3,Elderly
181986691,18198669,5,C,CANAGLIFLOZIN W/METFORMIN,,2,,,,,,,,,,,,,,2020,Q3,Sedation,,2020,Q3,1,I,202007.0,20200815.0,20200826,20200826,EXP,,US-JNJFOC-20200824697,JOHNSON AND JOHNSON,,82.0,YR,E,F,Y,40.86,KG,20200826.0,,CN,US,US,2020,Q3,Elderly
181986691,18198669,5,C,CANAGLIFLOZIN W/METFORMIN,,2,,,,,,,,,,,,,,2020,Q3,Speech disorder,,2020,Q3,1,I,202007.0,20200815.0,20200826,20200826,EXP,,US-JNJFOC-20200824697,JOHNSON AND JOHNSON,,82.0,YR,E,F,Y,40.86,KG,20200826.0,,CN,US,US,2020,Q3,Elderly
181986691,18198669,5,C,CANAGLIFLOZIN W/METFORMIN,,2,,,,,,,,,,,,,,2020,Q3,Tremor,,2020,Q3,1,I,202007.0,20200815.0,20200826,20200826,EXP,,US-JNJFOC-20200824697,JOHNSON AND JOHNSON,,82.0,YR,E,F,Y,40.86,KG,20200826.0,,CN,US,US,2020,Q3,Elderly
182003121,18200312,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Acute kidney injury,,2020,Q3,1,I,20200710.0,20200821.0,20200826,20200826,EXP,IT-MINISAL02-631306,IT-BAUSCH-BL-2020-024172,BAUSCH AND LOMB,,86.0,YR,,F,Y,80.0,KG,20200826.0,,MD,IT,IT,2020,Q3,Elderly
182003121,18200312,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Lactic acidosis,,2020,Q3,1,I,20200710.0,20200821.0,20200826,20200826,EXP,IT-MINISAL02-631306,IT-BAUSCH-BL-2020-024172,BAUSCH AND LOMB,,86.0,YR,,F,Y,80.0,KG,20200826.0,,MD,IT,IT,2020,Q3,Elderly
182034192,18203419,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,U,,,,100.0,MG,,,2020,Q3,Drug ineffective,,2020,Q3,2,F,,20200827.0,20200818,20200904,EXP,,US-VISTA PHARMACEUTICALS INC.-2088729,VISTAPHARM,,37.0,YR,,F,Y,,,20200904.0,,,US,US,2020,Q3,Adult
182035901,18203590,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q3,Acute kidney injury,,2020,Q3,1,I,20200710.0,20200824.0,20200827,20200827,EXP,IT-MINISAL02-631306,NVSC2020IT234103,NOVARTIS,,86.0,YR,,F,Y,80.0,KG,20200827.0,,HP,IT,IT,2020,Q3,Elderly
182035901,18203590,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q3,Lactic acidosis,,2020,Q3,1,I,20200710.0,20200824.0,20200827,20200827,EXP,IT-MINISAL02-631306,NVSC2020IT234103,NOVARTIS,,86.0,YR,,F,Y,80.0,KG,20200827.0,,HP,IT,IT,2020,Q3,Elderly
182082821,18208282,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,, UNKNOWN,,,,,,,2020,Q3,Acute kidney injury,,2020,Q3,1,I,,20200818.0,20200828,20200828,EXP,,US-LUPIN PHARMACEUTICALS INC.-2020-05147,LUPIN,,52.0,YR,,F,Y,,,20200828.0,,MD,US,US,2020,Q3,Adult
182100482,18210048,2,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q3,Acute kidney injury,,2020,Q3,2,F,20200710.0,20200904.0,20200829,20200911,EXP,,IT-AUROBINDO-AUR-APL-2020-045295,AUROBINDO,,86.0,YR,,F,Y,80.0,KG,20200911.0,,MD,IT,IT,2020,Q3,Elderly
182100482,18210048,2,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q3,Lactic acidosis,,2020,Q3,2,F,20200710.0,20200904.0,20200829,20200911,EXP,,IT-AUROBINDO-AUR-APL-2020-045295,AUROBINDO,,86.0,YR,,F,Y,80.0,KG,20200911.0,,MD,IT,IT,2020,Q3,Elderly
182120542,18212054,2,I,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,Y,,,,,100.0,MG,,QD,2020,Q3,Drug interaction,,2020,Q3,2,F,,20200831.0,20200831,20200909,EXP,,CA-AUROBINDO-AUR-APL-2020-045004,AUROBINDO,,76.0,YR,,F,Y,,,20200909.0,,HP,CA,CA,2020,Q3,Elderly
182120542,18212054,2,I,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,Y,,,,,100.0,MG,,QD,2020,Q3,Drug-induced liver injury,,2020,Q3,2,F,,20200831.0,20200831,20200909,EXP,,CA-AUROBINDO-AUR-APL-2020-045004,AUROBINDO,,76.0,YR,,F,Y,,,20200909.0,,HP,CA,CA,2020,Q3,Elderly
182120542,18212054,2,I,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,Y,,,,,100.0,MG,,QD,2020,Q3,Hepatocellular injury,,2020,Q3,2,F,,20200831.0,20200831,20200909,EXP,,CA-AUROBINDO-AUR-APL-2020-045004,AUROBINDO,,76.0,YR,,F,Y,,,20200909.0,,HP,CA,CA,2020,Q3,Elderly
182120542,18212054,2,I,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,Y,,,,,100.0,MG,,QD,2020,Q3,Musculoskeletal toxicity,,2020,Q3,2,F,,20200831.0,20200831,20200909,EXP,,CA-AUROBINDO-AUR-APL-2020-045004,AUROBINDO,,76.0,YR,,F,Y,,,20200909.0,,HP,CA,CA,2020,Q3,Elderly
182120542,18212054,2,I,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,Y,,,,,100.0,MG,,QD,2020,Q3,Rhabdomyolysis,,2020,Q3,2,F,,20200831.0,20200831,20200909,EXP,,CA-AUROBINDO-AUR-APL-2020-045004,AUROBINDO,,76.0,YR,,F,Y,,,20200909.0,,HP,CA,CA,2020,Q3,Elderly
182120542,18212054,2,I,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,Y,,,,,100.0,MG,,QD,2020,Q3,Toxicity to various agents,,2020,Q3,2,F,,20200831.0,20200831,20200909,EXP,,CA-AUROBINDO-AUR-APL-2020-045004,AUROBINDO,,76.0,YR,,F,Y,,,20200909.0,,HP,CA,CA,2020,Q3,Elderly
182176011,18217601,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",200.0,MG,U,U,,,204042.0,100.0,MG,TABLET,QD,2020,Q3,Dizziness,,2020,Q3,1,I,20200515.0,20200819.0,20200901,20200901,EXP,,JP-JNJFOC-20200844855,JOHNSON AND JOHNSON,,48.0,YR,A,M,Y,,,20200901.0,,HP,JP,JP,2020,Q3,Adult
182176011,18217601,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",200.0,MG,U,U,,,204042.0,100.0,MG,TABLET,QD,2020,Q3,Dyshidrotic eczema,,2020,Q3,1,I,20200515.0,20200819.0,20200901,20200901,EXP,,JP-JNJFOC-20200844855,JOHNSON AND JOHNSON,,48.0,YR,A,M,Y,,,20200901.0,,HP,JP,JP,2020,Q3,Adult
182176011,18217601,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",200.0,MG,U,U,,,204042.0,100.0,MG,TABLET,QD,2020,Q3,Erythema multiforme,,2020,Q3,1,I,20200515.0,20200819.0,20200901,20200901,EXP,,JP-JNJFOC-20200844855,JOHNSON AND JOHNSON,,48.0,YR,A,M,Y,,,20200901.0,,HP,JP,JP,2020,Q3,Adult
182176011,18217601,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",200.0,MG,U,U,,,204042.0,100.0,MG,TABLET,QD,2020,Q3,Nasopharyngitis,,2020,Q3,1,I,20200515.0,20200819.0,20200901,20200901,EXP,,JP-JNJFOC-20200844855,JOHNSON AND JOHNSON,,48.0,YR,A,M,Y,,,20200901.0,,HP,JP,JP,2020,Q3,Adult
182235201,18223520,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,STRENGTH :300MG,230400.0,MG,,U, UNKNOWN,,204042.0,300.0,MG,TABLET,,2020,Q3,Ketonuria,,2020,Q3,1,I,20200601.0,20200821.0,20200902,20200902,EXP,DK-DKMA-WBS-0026077,DK-JNJFOC-20200833340,JOHNSON AND JOHNSON,,73.0,YR,E,M,Y,100.0,KG,20200902.0,,MD,DK,DK,2020,Q3,Elderly
182236161,18223616,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,Y,, UNKNOWN,,,100.0,MG,,QD,2020,Q3,Drug interaction,,2020,Q3,1,I,,20200821.0,20200902,20200902,EXP,,CA-LUPIN PHARMACEUTICALS INC.-2020-05244,LUPIN,,76.0,YR,,F,Y,,,20200902.0,,CN,NL,CA,2020,Q3,Elderly
182236161,18223616,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,Y,, UNKNOWN,,,100.0,MG,,QD,2020,Q3,Drug-induced liver injury,,2020,Q3,1,I,,20200821.0,20200902,20200902,EXP,,CA-LUPIN PHARMACEUTICALS INC.-2020-05244,LUPIN,,76.0,YR,,F,Y,,,20200902.0,,CN,NL,CA,2020,Q3,Elderly
182236161,18223616,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,Y,, UNKNOWN,,,100.0,MG,,QD,2020,Q3,Hepatocellular injury,,2020,Q3,1,I,,20200821.0,20200902,20200902,EXP,,CA-LUPIN PHARMACEUTICALS INC.-2020-05244,LUPIN,,76.0,YR,,F,Y,,,20200902.0,,CN,NL,CA,2020,Q3,Elderly
182236161,18223616,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,Y,, UNKNOWN,,,100.0,MG,,QD,2020,Q3,Musculoskeletal toxicity,,2020,Q3,1,I,,20200821.0,20200902,20200902,EXP,,CA-LUPIN PHARMACEUTICALS INC.-2020-05244,LUPIN,,76.0,YR,,F,Y,,,20200902.0,,CN,NL,CA,2020,Q3,Elderly
182236161,18223616,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,Y,, UNKNOWN,,,100.0,MG,,QD,2020,Q3,Rhabdomyolysis,,2020,Q3,1,I,,20200821.0,20200902,20200902,EXP,,CA-LUPIN PHARMACEUTICALS INC.-2020-05244,LUPIN,,76.0,YR,,F,Y,,,20200902.0,,CN,NL,CA,2020,Q3,Elderly
182236161,18223616,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,Y,, UNKNOWN,,,100.0,MG,,QD,2020,Q3,Toxicity to various agents,,2020,Q3,1,I,,20200821.0,20200902,20200902,EXP,,CA-LUPIN PHARMACEUTICALS INC.-2020-05244,LUPIN,,76.0,YR,,F,Y,,,20200902.0,,CN,NL,CA,2020,Q3,Elderly
182275602,18227560,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MILLIGRAM, QD",,,Y,U,,,,300.0,MG,,QD,2020,Q3,Acute kidney injury,,2020,Q3,2,F,,20200903.0,20200903,20200910,EXP,,US-MYLANLABS-2020M1076069,MYLAN,,66.0,YR,,M,Y,,,20200910.0,,MD,US,US,2020,Q3,Elderly
182275602,18227560,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MILLIGRAM, QD",,,Y,U,,,,300.0,MG,,QD,2020,Q3,Diarrhoea,,2020,Q3,2,F,,20200903.0,20200903,20200910,EXP,,US-MYLANLABS-2020M1076069,MYLAN,,66.0,YR,,M,Y,,,20200910.0,,MD,US,US,2020,Q3,Elderly
182275602,18227560,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MILLIGRAM, QD",,,Y,U,,,,300.0,MG,,QD,2020,Q3,Nephrotic syndrome,,2020,Q3,2,F,,20200903.0,20200903,20200910,EXP,,US-MYLANLABS-2020M1076069,MYLAN,,66.0,YR,,M,Y,,,20200910.0,,MD,US,US,2020,Q3,Elderly
182349321,18234932,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,(),,,U,,,,,,,,,2020,Q3,Acute kidney injury,,2020,Q3,1,I,20200710.0,20200825.0,20200905,20200905,EXP,,IT-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-259987,RANBAXY,,86.0,YR,,F,Y,80.0,KG,20200905.0,,HP,NL,IT,2020,Q3,Elderly
182349321,18234932,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,(),,,U,,,,,,,,,2020,Q3,Lactic acidosis,,2020,Q3,1,I,20200710.0,20200825.0,20200905,20200905,EXP,,IT-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-259987,RANBAXY,,86.0,YR,,F,Y,80.0,KG,20200905.0,,HP,NL,IT,2020,Q3,Elderly
182370691,18237069,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,Y,,,,,100.0,MG,,,2020,Q3,Drug interaction,,2020,Q3,1,I,,20200827.0,20200907,20200907,EXP,,CA-APOTEX-2020AP017182,APOTEX,,76.0,YR,,F,Y,,,20200907.0,,MD,CA,CA,2020,Q3,Elderly
182370691,18237069,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,Y,,,,,100.0,MG,,,2020,Q3,Drug level above therapeutic,,2020,Q3,1,I,,20200827.0,20200907,20200907,EXP,,CA-APOTEX-2020AP017182,APOTEX,,76.0,YR,,F,Y,,,20200907.0,,MD,CA,CA,2020,Q3,Elderly
182370691,18237069,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,Y,,,,,100.0,MG,,,2020,Q3,Hepatocellular injury,,2020,Q3,1,I,,20200827.0,20200907,20200907,EXP,,CA-APOTEX-2020AP017182,APOTEX,,76.0,YR,,F,Y,,,20200907.0,,MD,CA,CA,2020,Q3,Elderly
182370691,18237069,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,Y,,,,,100.0,MG,,,2020,Q3,Rhabdomyolysis,,2020,Q3,1,I,,20200827.0,20200907,20200907,EXP,,CA-APOTEX-2020AP017182,APOTEX,,76.0,YR,,F,Y,,,20200907.0,,MD,CA,CA,2020,Q3,Elderly
182370691,18237069,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,Y,,,,,100.0,MG,,,2020,Q3,Toxicity to various agents,,2020,Q3,1,I,,20200827.0,20200907,20200907,EXP,,CA-APOTEX-2020AP017182,APOTEX,,76.0,YR,,F,Y,,,20200907.0,,MD,CA,CA,2020,Q3,Elderly
182546851,18254685,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q3,Acute kidney injury,,2020,Q3,1,I,20200710.0,20200902.0,20200910,20200910,EXP,IT-MINISAL02-631306,IT-MYLANLABS-2020M1076780,MYLAN,,86.0,YR,,F,Y,80.0,KG,20200910.0,,MD,IT,IT,2020,Q3,Elderly
182546851,18254685,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q3,Lactic acidosis,,2020,Q3,1,I,20200710.0,20200902.0,20200910,20200910,EXP,IT-MINISAL02-631306,IT-MYLANLABS-2020M1076780,MYLAN,,86.0,YR,,F,Y,80.0,KG,20200910.0,,MD,IT,IT,2020,Q3,Elderly
182620401,18262040,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,,,,,,2020,Q3,Asthma,,2020,Q3,1,I,,20200908.0,20200914,20200914,EXP,,NVSC2020CA249348,NOVARTIS,,76.0,YR,,F,Y,,,20200914.0,,HP,CA,CA,2020,Q3,Elderly
182620401,18262040,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,,,,,,2020,Q3,Blood count abnormal,,2020,Q3,1,I,,20200908.0,20200914,20200914,EXP,,NVSC2020CA249348,NOVARTIS,,76.0,YR,,F,Y,,,20200914.0,,HP,CA,CA,2020,Q3,Elderly
182620401,18262040,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,,,,,,2020,Q3,Gastrooesophageal reflux disease,,2020,Q3,1,I,,20200908.0,20200914,20200914,EXP,,NVSC2020CA249348,NOVARTIS,,76.0,YR,,F,Y,,,20200914.0,,HP,CA,CA,2020,Q3,Elderly
182620401,18262040,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,,,,,,2020,Q3,Hyperglycaemia,,2020,Q3,1,I,,20200908.0,20200914,20200914,EXP,,NVSC2020CA249348,NOVARTIS,,76.0,YR,,F,Y,,,20200914.0,,HP,CA,CA,2020,Q3,Elderly
182620401,18262040,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,,,,,,2020,Q3,Type 2 diabetes mellitus,,2020,Q3,1,I,,20200908.0,20200914,20200914,EXP,,NVSC2020CA249348,NOVARTIS,,76.0,YR,,F,Y,,,20200914.0,,HP,CA,CA,2020,Q3,Elderly
182678951,18267895,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q3,Myocarditis,,2020,Q3,1,I,,20200910.0,20200915,20200915,EXP,,CA-PFIZER INC-2020353109,PFIZER,,61.0,YR,,M,Y,,,20200915.0,,HP,CA,CA,2020,Q3,Adult
182697391,18269739,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2020,Q3,Anal fistula,,2020,Q3,1,I,,20200908.0,20200916,20200916,EXP,,CA-AUROBINDO-AUR-APL-2020-047762,AUROBINDO,,72.0,YR,,M,Y,,,20200916.0,,HP,CA,CA,2020,Q3,Elderly
182697391,18269739,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2020,Q3,Diarrhoea,,2020,Q3,1,I,,20200908.0,20200916,20200916,EXP,,CA-AUROBINDO-AUR-APL-2020-047762,AUROBINDO,,72.0,YR,,M,Y,,,20200916.0,,HP,CA,CA,2020,Q3,Elderly
182697391,18269739,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2020,Q3,Fournier's gangrene,,2020,Q3,1,I,,20200908.0,20200916,20200916,EXP,,CA-AUROBINDO-AUR-APL-2020-047762,AUROBINDO,,72.0,YR,,M,Y,,,20200916.0,,HP,CA,CA,2020,Q3,Elderly
182697391,18269739,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2020,Q3,Rectal abscess,,2020,Q3,1,I,,20200908.0,20200916,20200916,EXP,,CA-AUROBINDO-AUR-APL-2020-047762,AUROBINDO,,72.0,YR,,M,Y,,,20200916.0,,HP,CA,CA,2020,Q3,Elderly
182757771,18275777,2,I,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,Y,U,,,,100.0,MG,,,2020,Q3,Drug interaction,,2020,Q3,1,I,,20200908.0,20200917,20200917,EXP,,CA-CHANGZHOU PHARMACEUTICAL FACTORY-2090831,CHANGZHOU PHARMACEUTICAL FACTORY,"BRAILOVSKI E, KIM RB, JUURLINK D. ROSUVASTATIN MYOTOXICITY AFTER STARTING CANAGLIFLOZIN TREATMENT: A CASE REPORT. ANNALS OF INTERNAL MEDICINE: NO PAGINATION, 4 AUG 2020. URL: HTTP://DOI.ORG/10.7326/L20?0549",76.0,YR,,F,Y,,,20200917.0,,MD,CA,CA,2020,Q3,Elderly
182757771,18275777,2,I,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,Y,U,,,,100.0,MG,,,2020,Q3,Hepatocellular injury,,2020,Q3,1,I,,20200908.0,20200917,20200917,EXP,,CA-CHANGZHOU PHARMACEUTICAL FACTORY-2090831,CHANGZHOU PHARMACEUTICAL FACTORY,"BRAILOVSKI E, KIM RB, JUURLINK D. ROSUVASTATIN MYOTOXICITY AFTER STARTING CANAGLIFLOZIN TREATMENT: A CASE REPORT. ANNALS OF INTERNAL MEDICINE: NO PAGINATION, 4 AUG 2020. URL: HTTP://DOI.ORG/10.7326/L20?0549",76.0,YR,,F,Y,,,20200917.0,,MD,CA,CA,2020,Q3,Elderly
182757771,18275777,2,I,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,Y,U,,,,100.0,MG,,,2020,Q3,Rhabdomyolysis,,2020,Q3,1,I,,20200908.0,20200917,20200917,EXP,,CA-CHANGZHOU PHARMACEUTICAL FACTORY-2090831,CHANGZHOU PHARMACEUTICAL FACTORY,"BRAILOVSKI E, KIM RB, JUURLINK D. ROSUVASTATIN MYOTOXICITY AFTER STARTING CANAGLIFLOZIN TREATMENT: A CASE REPORT. ANNALS OF INTERNAL MEDICINE: NO PAGINATION, 4 AUG 2020. URL: HTTP://DOI.ORG/10.7326/L20?0549",76.0,YR,,F,Y,,,20200917.0,,MD,CA,CA,2020,Q3,Elderly
182798081,18279808,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,UNKNOWN,,2020,Q3,Thrombosis,,2020,Q3,1,I,20200806.0,20200907.0,20200917,20200917,EXP,GB-MHRA-EYC 00227455,GB-JNJFOC-20200919995,JOHNSON AND JOHNSON,,44.0,YR,A,M,Y,150.0,KG,20200917.0,,PH,GB,GB,2020,Q3,Adult
182803861,18280386,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U, UNKNOWN,,,,,,,2020,Q3,Asthma,,2020,Q3,1,I,,20200908.0,20200918,20200918,EXP,,CA-ROCHE-2677670,ROCHE,,76.0,YR,,F,Y,,,20200918.0,,HP,CA,CA,2020,Q3,Elderly
182803861,18280386,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U, UNKNOWN,,,,,,,2020,Q3,Blood count abnormal,,2020,Q3,1,I,,20200908.0,20200918,20200918,EXP,,CA-ROCHE-2677670,ROCHE,,76.0,YR,,F,Y,,,20200918.0,,HP,CA,CA,2020,Q3,Elderly
182803861,18280386,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U, UNKNOWN,,,,,,,2020,Q3,Gastrooesophageal reflux disease,,2020,Q3,1,I,,20200908.0,20200918,20200918,EXP,,CA-ROCHE-2677670,ROCHE,,76.0,YR,,F,Y,,,20200918.0,,HP,CA,CA,2020,Q3,Elderly
182803861,18280386,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U, UNKNOWN,,,,,,,2020,Q3,Hyperglycaemia,,2020,Q3,1,I,,20200908.0,20200918,20200918,EXP,,CA-ROCHE-2677670,ROCHE,,76.0,YR,,F,Y,,,20200918.0,,HP,CA,CA,2020,Q3,Elderly
182803861,18280386,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U, UNKNOWN,,,,,,,2020,Q3,Type 2 diabetes mellitus,,2020,Q3,1,I,,20200908.0,20200918,20200918,EXP,,CA-ROCHE-2677670,ROCHE,,76.0,YR,,F,Y,,,20200918.0,,HP,CA,CA,2020,Q3,Elderly
182815991,18281599,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Actinomyces test positive,,2020,Q3,1,I,20200903.0,,20200917,20200917,DIR,,,FDA-CTU,,56.0,YR,,F,N,127.5,KG,20200917.0,N,,US,US,2020,Q3,Adult
182815991,18281599,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Bacterial infection,,2020,Q3,1,I,20200903.0,,20200917,20200917,DIR,,,FDA-CTU,,56.0,YR,,F,N,127.5,KG,20200917.0,N,,US,US,2020,Q3,Adult
182815991,18281599,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Culture positive,,2020,Q3,1,I,20200903.0,,20200917,20200917,DIR,,,FDA-CTU,,56.0,YR,,F,N,127.5,KG,20200917.0,N,,US,US,2020,Q3,Adult
182815991,18281599,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Groin abscess,,2020,Q3,1,I,20200903.0,,20200917,20200917,DIR,,,FDA-CTU,,56.0,YR,,F,N,127.5,KG,20200917.0,N,,US,US,2020,Q3,Adult
182815991,18281599,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Necrosis,,2020,Q3,1,I,20200903.0,,20200917,20200917,DIR,,,FDA-CTU,,56.0,YR,,F,N,127.5,KG,20200917.0,N,,US,US,2020,Q3,Adult
182815991,18281599,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Necrotising fasciitis,,2020,Q3,1,I,20200903.0,,20200917,20200917,DIR,,,FDA-CTU,,56.0,YR,,F,N,127.5,KG,20200917.0,N,,US,US,2020,Q3,Adult
182815991,18281599,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Pain,,2020,Q3,1,I,20200903.0,,20200917,20200917,DIR,,,FDA-CTU,,56.0,YR,,F,N,127.5,KG,20200917.0,N,,US,US,2020,Q3,Adult
182822961,18282296,16,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2020,Q3,Asthma,,2020,Q3,1,I,,20200914.0,20200918,20200918,EXP,,CA-TEVA-2020-CA-1829694,TEVA,,76.0,YR,E,F,Y,,,20200918.0,,MD,CA,CA,2020,Q3,Elderly
182822961,18282296,16,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2020,Q3,Blood count abnormal,,2020,Q3,1,I,,20200914.0,20200918,20200918,EXP,,CA-TEVA-2020-CA-1829694,TEVA,,76.0,YR,E,F,Y,,,20200918.0,,MD,CA,CA,2020,Q3,Elderly
182822961,18282296,16,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2020,Q3,Gastrooesophageal reflux disease,,2020,Q3,1,I,,20200914.0,20200918,20200918,EXP,,CA-TEVA-2020-CA-1829694,TEVA,,76.0,YR,E,F,Y,,,20200918.0,,MD,CA,CA,2020,Q3,Elderly
182822961,18282296,16,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2020,Q3,Hyperglycaemia,,2020,Q3,1,I,,20200914.0,20200918,20200918,EXP,,CA-TEVA-2020-CA-1829694,TEVA,,76.0,YR,E,F,Y,,,20200918.0,,MD,CA,CA,2020,Q3,Elderly
182822961,18282296,16,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2020,Q3,Type 2 diabetes mellitus,,2020,Q3,1,I,,20200914.0,20200918,20200918,EXP,,CA-TEVA-2020-CA-1829694,TEVA,,76.0,YR,E,F,Y,,,20200918.0,,MD,CA,CA,2020,Q3,Elderly
182831401,18283140,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,100 MG DAILY,,,Y,, UNKNOWN,,,100.0,MG,UNKNOWN,,2020,Q3,Drug interaction,,2020,Q3,1,I,,20200910.0,20200918,20200918,EXP,,CA-SCIEGEN-2020SCILIT00282,SCIEGEN,E BRAILOVSKI.ROSUVASTATIN MYOTOXICITY AFTER STARTING CANAGLIFLOZIN TREATMENT: A CASE REPORT..ANNALS OF INTERNAL MEDICINE : NO PAGINATION.4 AUG 2020?NA:NA,76.0,YR,E,F,Y,,,20200918.0,,HP,CA,CA,2020,Q3,Elderly
182831401,18283140,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,100 MG DAILY,,,Y,, UNKNOWN,,,100.0,MG,UNKNOWN,,2020,Q3,Hepatocellular injury,,2020,Q3,1,I,,20200910.0,20200918,20200918,EXP,,CA-SCIEGEN-2020SCILIT00282,SCIEGEN,E BRAILOVSKI.ROSUVASTATIN MYOTOXICITY AFTER STARTING CANAGLIFLOZIN TREATMENT: A CASE REPORT..ANNALS OF INTERNAL MEDICINE : NO PAGINATION.4 AUG 2020?NA:NA,76.0,YR,E,F,Y,,,20200918.0,,HP,CA,CA,2020,Q3,Elderly
182831401,18283140,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,100 MG DAILY,,,Y,, UNKNOWN,,,100.0,MG,UNKNOWN,,2020,Q3,Rhabdomyolysis,,2020,Q3,1,I,,20200910.0,20200918,20200918,EXP,,CA-SCIEGEN-2020SCILIT00282,SCIEGEN,E BRAILOVSKI.ROSUVASTATIN MYOTOXICITY AFTER STARTING CANAGLIFLOZIN TREATMENT: A CASE REPORT..ANNALS OF INTERNAL MEDICINE : NO PAGINATION.4 AUG 2020?NA:NA,76.0,YR,E,F,Y,,,20200918.0,,HP,CA,CA,2020,Q3,Elderly
183047331,18304733,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Bone disorder,,2020,Q3,1,I,,20200917.0,20200924,20200924,EXP,GB-MHRA-ADR 24519756,GB-ACCORD-202333,ACCORD,,65.0,YR,,F,Y,68.94,KG,20200924.0,,CN,GB,GB,2020,Q3,Elderly
183047331,18304733,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Dupuytren's contracture,,2020,Q3,1,I,,20200917.0,20200924,20200924,EXP,GB-MHRA-ADR 24519756,GB-ACCORD-202333,ACCORD,,65.0,YR,,F,Y,68.94,KG,20200924.0,,CN,GB,GB,2020,Q3,Elderly
183047331,18304733,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Tenderness,,2020,Q3,1,I,,20200917.0,20200924,20200924,EXP,GB-MHRA-ADR 24519756,GB-ACCORD-202333,ACCORD,,65.0,YR,,F,Y,68.94,KG,20200924.0,,CN,GB,GB,2020,Q3,Elderly
183047331,18304733,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Trigger finger,,2020,Q3,1,I,,20200917.0,20200924,20200924,EXP,GB-MHRA-ADR 24519756,GB-ACCORD-202333,ACCORD,,65.0,YR,,F,Y,68.94,KG,20200924.0,,CN,GB,GB,2020,Q3,Elderly
183164741,18316474,9,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q3,Bone disorder,,2020,Q3,1,I,,20200917.0,20200927,20200927,EXP,,GB-AUROBINDO-AUR-APL-2020-048987,AUROBINDO,,65.0,YR,,F,Y,68.94,KG,20200928.0,,CN,GB,GB,2020,Q3,Elderly
183164741,18316474,9,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q3,Dupuytren's contracture,,2020,Q3,1,I,,20200917.0,20200927,20200927,EXP,,GB-AUROBINDO-AUR-APL-2020-048987,AUROBINDO,,65.0,YR,,F,Y,68.94,KG,20200928.0,,CN,GB,GB,2020,Q3,Elderly
183164741,18316474,9,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q3,Tenderness,,2020,Q3,1,I,,20200917.0,20200927,20200927,EXP,,GB-AUROBINDO-AUR-APL-2020-048987,AUROBINDO,,65.0,YR,,F,Y,68.94,KG,20200928.0,,CN,GB,GB,2020,Q3,Elderly
183164741,18316474,9,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q3,Trigger finger,,2020,Q3,1,I,,20200917.0,20200927,20200927,EXP,,GB-AUROBINDO-AUR-APL-2020-048987,AUROBINDO,,65.0,YR,,F,Y,68.94,KG,20200928.0,,CN,GB,GB,2020,Q3,Elderly
183187261,18318726,1,PS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,Y,U," 20GG150,20GG150",,204353.0,1000.0,MG/KG,TABLET,,2020,Q3,Diarrhoea,,2020,Q3,1,I,20190801.0,20200921.0,20200928,20200928,PER,,US-JNJFOC-20200939677,JOHNSON AND JOHNSON,,60.0,YR,A,F,Y,70.37,KG,20200928.0,,CN,US,UM,2020,Q3,Adult
183230631,18323063,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q3,Bone disorder,,2020,Q3,1,I,,20200921.0,20200928,20200928,EXP,GB-MHRA-EYC 00228798,NVSC2020GB257310,NOVARTIS,,65.0,YR,,F,Y,68.94,KG,20200928.0,,HP,GB,GB,2020,Q3,Elderly
183230631,18323063,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q3,Dupuytren's contracture,,2020,Q3,1,I,,20200921.0,20200928,20200928,EXP,GB-MHRA-EYC 00228798,NVSC2020GB257310,NOVARTIS,,65.0,YR,,F,Y,68.94,KG,20200928.0,,HP,GB,GB,2020,Q3,Elderly
183230631,18323063,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q3,Tenderness,,2020,Q3,1,I,,20200921.0,20200928,20200928,EXP,GB-MHRA-EYC 00228798,NVSC2020GB257310,NOVARTIS,,65.0,YR,,F,Y,68.94,KG,20200928.0,,HP,GB,GB,2020,Q3,Elderly
183230631,18323063,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q3,Trigger finger,,2020,Q3,1,I,,20200921.0,20200928,20200928,EXP,GB-MHRA-EYC 00228798,NVSC2020GB257310,NOVARTIS,,65.0,YR,,F,Y,68.94,KG,20200928.0,,HP,GB,GB,2020,Q3,Elderly
183253251,18325325,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q3,Bone disorder,,2020,Q3,1,I,,20200925.0,20200929,20200929,EXP,GB-MHRA-EYC 00228798,GB-PFIZER INC-2020371664,PFIZER,,65.0,YR,,F,Y,68.94,KG,20200929.0,,CN,GB,GB,2020,Q3,Elderly
183253251,18325325,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q3,Dupuytren's contracture,,2020,Q3,1,I,,20200925.0,20200929,20200929,EXP,GB-MHRA-EYC 00228798,GB-PFIZER INC-2020371664,PFIZER,,65.0,YR,,F,Y,68.94,KG,20200929.0,,CN,GB,GB,2020,Q3,Elderly
183253251,18325325,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q3,Tenderness,,2020,Q3,1,I,,20200925.0,20200929,20200929,EXP,GB-MHRA-EYC 00228798,GB-PFIZER INC-2020371664,PFIZER,,65.0,YR,,F,Y,68.94,KG,20200929.0,,CN,GB,GB,2020,Q3,Elderly
183253251,18325325,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q3,Trigger finger,,2020,Q3,1,I,,20200925.0,20200929,20200929,EXP,GB-MHRA-EYC 00228798,GB-PFIZER INC-2020371664,PFIZER,,65.0,YR,,F,Y,68.94,KG,20200929.0,,CN,GB,GB,2020,Q3,Elderly
183279561,18327956,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,(),,,U,,,,,,,,,2020,Q3,Bone disorder,,2020,Q3,1,I,,20200918.0,20200930,20200930,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-262181,RANBAXY,,65.0,YR,,F,Y,68.94,KG,20200930.0,,HP,NL,GB,2020,Q3,Elderly
183279561,18327956,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,(),,,U,,,,,,,,,2020,Q3,Dupuytren's contracture,,2020,Q3,1,I,,20200918.0,20200930,20200930,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-262181,RANBAXY,,65.0,YR,,F,Y,68.94,KG,20200930.0,,HP,NL,GB,2020,Q3,Elderly
183279561,18327956,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,(),,,U,,,,,,,,,2020,Q3,Tenderness,,2020,Q3,1,I,,20200918.0,20200930,20200930,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-262181,RANBAXY,,65.0,YR,,F,Y,68.94,KG,20200930.0,,HP,NL,GB,2020,Q3,Elderly
183279561,18327956,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,(),,,U,,,,,,,,,2020,Q3,Trigger finger,,2020,Q3,1,I,,20200918.0,20200930,20200930,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-262181,RANBAXY,,65.0,YR,,F,Y,68.94,KG,20200930.0,,HP,NL,GB,2020,Q3,Elderly
183315211,18331521,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q3,Bone disorder,,2020,Q3,1,I,,20200921.0,20200930,20200930,EXP,,GB-ANIPHARMA-2020-UK-000203,ANI,,65.0,YR,,F,Y,68.0,KG,20200930.0,,CN,GB,GB,2020,Q3,Elderly
183315211,18331521,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q3,Dupuytren's contracture,,2020,Q3,1,I,,20200921.0,20200930,20200930,EXP,,GB-ANIPHARMA-2020-UK-000203,ANI,,65.0,YR,,F,Y,68.0,KG,20200930.0,,CN,GB,GB,2020,Q3,Elderly
183315211,18331521,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q3,Tenderness,,2020,Q3,1,I,,20200921.0,20200930,20200930,EXP,,GB-ANIPHARMA-2020-UK-000203,ANI,,65.0,YR,,F,Y,68.0,KG,20200930.0,,CN,GB,GB,2020,Q3,Elderly
183315211,18331521,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q3,Trigger finger,,2020,Q3,1,I,,20200921.0,20200930,20200930,EXP,,GB-ANIPHARMA-2020-UK-000203,ANI,,65.0,YR,,F,Y,68.0,KG,20200930.0,,CN,GB,GB,2020,Q3,Elderly
92642123,9264212,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,,,CAPSULE,,2020,Q3,Adenocarcinoma of colon,,2020,Q3,3,F,20130219.0,20130702.0,20130430,20130710,PER,,NL-JNJFOC-20130212426,JANSSEN,,64.0,YR,A,M,Y,90.0,KG,20130710.0,,MD,NL,NL,2020,Q3,Adult
92642123,9264212,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,76479.0,100,MG,CAPSULE,,2020,Q3,Adenocarcinoma of colon,,2020,Q3,3,F,20130219.0,20130702.0,20130430,20130710,PER,,NL-JNJFOC-20130212426,JANSSEN,,64.0,YR,A,M,Y,90.0,KG,20130710.0,,MD,NL,NL,2020,Q3,Adult
93324344,9332434,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 365184,,204042.0,,,CAPSULE,,2020,Q3,Ocular myasthenia,,2020,Q3,4,F,20130409.0,20130701.0,20130606,20130709,EXP,,PL-JNJFOC-20130521205,JANSSEN,,74.0,YR,E,M,Y,98.5,KG,20130709.0,,MD,PL,PL,2020,Q3,Elderly
93324344,9332434,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 365184,,76479.0,100,MG,CAPSULE,QD,2020,Q3,Ocular myasthenia,,2020,Q3,4,F,20130409.0,20130701.0,20130606,20130709,EXP,,PL-JNJFOC-20130521205,JANSSEN,,74.0,YR,E,M,Y,98.5,KG,20130709.0,,MD,PL,PL,2020,Q3,Elderly
129499312,12949931,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Cellulitis,,2020,Q4,2,F,20161027.0,20201215.0,20161117,20201223,EXP,,JP-JNJFOC-20161116164,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,,,20201223.0,,MD,JP,JP,2020,Q4,Elderly
139165382,13916538,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Neoplasm malignant,,2020,Q4,2,F,201707.0,20201110.0,20170829,20201126,EXP,,JP-JNJFOC-20170822872,JOHNSON AND JOHNSON,,7.0,DEC,E,M,Y,,,20201126.0,,MD,JP,JP,2020,Q4,Child
161802985,16180298,24,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2020,Q4,Asthma,,2020,Q4,5,F,,20201125.0,20190410,20201130,EXP,,CA-009507513-1904CAN003813,MERCK,,76.0,YR,,F,Y,,,20201130.0,,MD,CA,CA,2020,Q4,Elderly
161802985,16180298,24,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2020,Q4,Blood count abnormal,,2020,Q4,5,F,,20201125.0,20190410,20201130,EXP,,CA-009507513-1904CAN003813,MERCK,,76.0,YR,,F,Y,,,20201130.0,,MD,CA,CA,2020,Q4,Elderly
161802985,16180298,24,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2020,Q4,Gastrooesophageal reflux disease,,2020,Q4,5,F,,20201125.0,20190410,20201130,EXP,,CA-009507513-1904CAN003813,MERCK,,76.0,YR,,F,Y,,,20201130.0,,MD,CA,CA,2020,Q4,Elderly
161802985,16180298,24,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2020,Q4,Hyperglycaemia,,2020,Q4,5,F,,20201125.0,20190410,20201130,EXP,,CA-009507513-1904CAN003813,MERCK,,76.0,YR,,F,Y,,,20201130.0,,MD,CA,CA,2020,Q4,Elderly
161802985,16180298,24,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2020,Q4,Type 2 diabetes mellitus,,2020,Q4,5,F,,20201125.0,20190410,20201130,EXP,,CA-009507513-1904CAN003813,MERCK,,76.0,YR,,F,Y,,,20201130.0,,MD,CA,CA,2020,Q4,Elderly
165728012,16572801,5,SS,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,"300 MILLIGRAM, QD",,,U,,,,,300.0,MG,,,2020,Q4,Acute kidney injury,,2020,Q4,2,F,,20200930.0,20190715,20201009,EXP,,CA-APOTEX-2019AP018006,APOTEX,,37.0,YR,,F,Y,158.0,KG,20201009.0,,CN,CA,CA,2020,Q4,Adult
165728012,16572801,5,SS,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,"300 MILLIGRAM, QD",,,U,,,,,300.0,MG,,,2020,Q4,Sepsis,,2020,Q4,2,F,,20200930.0,20190715,20201009,EXP,,CA-APOTEX-2019AP018006,APOTEX,,37.0,YR,,F,Y,158.0,KG,20201009.0,,CN,CA,CA,2020,Q4,Adult
166272812,16627281,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,TABLET,,2020,Q4,Abdominal distension,,2020,Q4,2,F,,20201104.0,20190724,20201118,EXP,,JP-JNJFOC-20190727511,JOHNSON AND JOHNSON,,57.0,YR,A,M,Y,,,20201118.0,,CN,JP,JP,2020,Q4,Adult
166272812,16627281,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,TABLET,,2020,Q4,Diarrhoea,,2020,Q4,2,F,,20201104.0,20190724,20201118,EXP,,JP-JNJFOC-20190727511,JOHNSON AND JOHNSON,,57.0,YR,A,M,Y,,,20201118.0,,CN,JP,JP,2020,Q4,Adult
166272812,16627281,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,TABLET,,2020,Q4,Eructation,,2020,Q4,2,F,,20201104.0,20190724,20201118,EXP,,JP-JNJFOC-20190727511,JOHNSON AND JOHNSON,,57.0,YR,A,M,Y,,,20201118.0,,CN,JP,JP,2020,Q4,Adult
166272812,16627281,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,TABLET,,2020,Q4,Intestinal obstruction,,2020,Q4,2,F,,20201104.0,20190724,20201118,EXP,,JP-JNJFOC-20190727511,JOHNSON AND JOHNSON,,57.0,YR,A,M,Y,,,20201118.0,,CN,JP,JP,2020,Q4,Adult
166272812,16627281,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,TABLET,,2020,Q4,Physical deconditioning,,2020,Q4,2,F,,20201104.0,20190724,20201118,EXP,,JP-JNJFOC-20190727511,JOHNSON AND JOHNSON,,57.0,YR,A,M,Y,,,20201118.0,,CN,JP,JP,2020,Q4,Adult
166272812,16627281,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,TABLET,,2020,Q4,Vomiting,,2020,Q4,2,F,,20201104.0,20190724,20201118,EXP,,JP-JNJFOC-20190727511,JOHNSON AND JOHNSON,,57.0,YR,A,M,Y,,,20201118.0,,CN,JP,JP,2020,Q4,Adult
168686303,16868630,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Toxic skin eruption,,2020,Q4,3,F,20190913.0,20191011.0,20190930,20201227,EXP,,JP-JNJFOC-20190936839,JOHNSON AND JOHNSON,,69.0,YR,E,M,Y,,,20201228.0,,MD,JP,JP,2020,Q4,Elderly
176383213,17638321,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q4,Adverse drug reaction,,2020,Q4,3,F,,20201207.0,20200407,20201216,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20201216.0,,CN,CA,CA,2020,Q4,Adult
176383213,17638321,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q4,Arthralgia,,2020,Q4,3,F,,20201207.0,20200407,20201216,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20201216.0,,CN,CA,CA,2020,Q4,Adult
176383213,17638321,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q4,Arthritis,,2020,Q4,3,F,,20201207.0,20200407,20201216,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20201216.0,,CN,CA,CA,2020,Q4,Adult
176383213,17638321,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q4,Blood creatinine decreased,,2020,Q4,3,F,,20201207.0,20200407,20201216,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20201216.0,,CN,CA,CA,2020,Q4,Adult
176383213,17638321,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q4,Blood uric acid decreased,,2020,Q4,3,F,,20201207.0,20200407,20201216,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20201216.0,,CN,CA,CA,2020,Q4,Adult
176383213,17638321,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q4,Drug ineffective,,2020,Q4,3,F,,20201207.0,20200407,20201216,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20201216.0,,CN,CA,CA,2020,Q4,Adult
176383213,17638321,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q4,Gastrointestinal haemorrhage,,2020,Q4,3,F,,20201207.0,20200407,20201216,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20201216.0,,CN,CA,CA,2020,Q4,Adult
176383213,17638321,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q4,Glycosylated haemoglobin increased,,2020,Q4,3,F,,20201207.0,20200407,20201216,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20201216.0,,CN,CA,CA,2020,Q4,Adult
176383213,17638321,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q4,Haemoglobin decreased,,2020,Q4,3,F,,20201207.0,20200407,20201216,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20201216.0,,CN,CA,CA,2020,Q4,Adult
176383213,17638321,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q4,Hepatic cirrhosis,,2020,Q4,3,F,,20201207.0,20200407,20201216,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20201216.0,,CN,CA,CA,2020,Q4,Adult
176383213,17638321,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q4,Hepatosplenomegaly,,2020,Q4,3,F,,20201207.0,20200407,20201216,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20201216.0,,CN,CA,CA,2020,Q4,Adult
176383213,17638321,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q4,Hypertrophy,,2020,Q4,3,F,,20201207.0,20200407,20201216,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20201216.0,,CN,CA,CA,2020,Q4,Adult
176383213,17638321,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q4,Inflammatory marker increased,,2020,Q4,3,F,,20201207.0,20200407,20201216,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20201216.0,,CN,CA,CA,2020,Q4,Adult
176383213,17638321,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q4,Joint effusion,,2020,Q4,3,F,,20201207.0,20200407,20201216,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20201216.0,,CN,CA,CA,2020,Q4,Adult
176383213,17638321,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q4,Joint swelling,,2020,Q4,3,F,,20201207.0,20200407,20201216,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20201216.0,,CN,CA,CA,2020,Q4,Adult
176383213,17638321,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q4,Liver disorder,,2020,Q4,3,F,,20201207.0,20200407,20201216,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20201216.0,,CN,CA,CA,2020,Q4,Adult
176383213,17638321,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q4,Low density lipoprotein increased,,2020,Q4,3,F,,20201207.0,20200407,20201216,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20201216.0,,CN,CA,CA,2020,Q4,Adult
176383213,17638321,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q4,Nausea,,2020,Q4,3,F,,20201207.0,20200407,20201216,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20201216.0,,CN,CA,CA,2020,Q4,Adult
176383213,17638321,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q4,Nonalcoholic fatty liver disease,,2020,Q4,3,F,,20201207.0,20200407,20201216,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20201216.0,,CN,CA,CA,2020,Q4,Adult
176383213,17638321,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q4,Pain in extremity,,2020,Q4,3,F,,20201207.0,20200407,20201216,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20201216.0,,CN,CA,CA,2020,Q4,Adult
176383213,17638321,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q4,Psoriasis,,2020,Q4,3,F,,20201207.0,20200407,20201216,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20201216.0,,CN,CA,CA,2020,Q4,Adult
176383213,17638321,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q4,Psoriatic arthropathy,,2020,Q4,3,F,,20201207.0,20200407,20201216,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20201216.0,,CN,CA,CA,2020,Q4,Adult
176383213,17638321,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q4,Red blood cell sedimentation rate increased,,2020,Q4,3,F,,20201207.0,20200407,20201216,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20201216.0,,CN,CA,CA,2020,Q4,Adult
176383213,17638321,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q4,Rheumatoid arthritis,,2020,Q4,3,F,,20201207.0,20200407,20201216,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20201216.0,,CN,CA,CA,2020,Q4,Adult
176383213,17638321,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q4,Therapeutic product effect decreased,,2020,Q4,3,F,,20201207.0,20200407,20201216,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20201216.0,,CN,CA,CA,2020,Q4,Adult
176383213,17638321,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q4,Therapeutic product effect incomplete,,2020,Q4,3,F,,20201207.0,20200407,20201216,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20201216.0,,CN,CA,CA,2020,Q4,Adult
176383213,17638321,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q4,Type 2 diabetes mellitus,,2020,Q4,3,F,,20201207.0,20200407,20201216,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20201216.0,,CN,CA,CA,2020,Q4,Adult
176383213,17638321,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,D,,,,,300.0,MG,,,2020,Q4,Varices oesophageal,,2020,Q4,3,F,,20201207.0,20200407,20201216,EXP,,CA-APOTEX-2020AP009255,APOTEX,,47.0,YR,,F,Y,,,20201216.0,,CN,CA,CA,2020,Q4,Adult
176569733,17656973,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q4,Retinal detachment,,2020,Q4,3,F,20190517.0,20200407.0,20200410,20201103,EXP,,JP-JNJFOC-20200413169,JOHNSON AND JOHNSON,,59.0,YR,A,M,Y,,,20201103.0,,MD,JP,JP,2020,Q4,Adult
178254294,17825429,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,,,,,,,,,2020,Q4,Anal fistula,,2020,Q4,4,F,,20201009.0,20200526,20201020,EXP,,CA-TEVA-2020-CA-1239294,TEVA,"ELBEDDINI A, GALLINGER J, DAVEY M, BRASSARD S, GAZARIN M, PLOURDE F, ET AL. A CASE OF FOURNIER^S GANGRENE IN A PATIENT TAKING CANAGLIFLOZIN FOR THE TREATMENT OF TYPE II DIABETES MELLITUS. AM-J-CASE-REP 2020;:.",72.0,YR,E,M,Y,,,20201020.0,,HP,CA,CA,2020,Q4,Elderly
178254294,17825429,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,,,,,,,,,2020,Q4,Diarrhoea,,2020,Q4,4,F,,20201009.0,20200526,20201020,EXP,,CA-TEVA-2020-CA-1239294,TEVA,"ELBEDDINI A, GALLINGER J, DAVEY M, BRASSARD S, GAZARIN M, PLOURDE F, ET AL. A CASE OF FOURNIER^S GANGRENE IN A PATIENT TAKING CANAGLIFLOZIN FOR THE TREATMENT OF TYPE II DIABETES MELLITUS. AM-J-CASE-REP 2020;:.",72.0,YR,E,M,Y,,,20201020.0,,HP,CA,CA,2020,Q4,Elderly
178254294,17825429,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,,,,,,,,,2020,Q4,Fournier's gangrene,,2020,Q4,4,F,,20201009.0,20200526,20201020,EXP,,CA-TEVA-2020-CA-1239294,TEVA,"ELBEDDINI A, GALLINGER J, DAVEY M, BRASSARD S, GAZARIN M, PLOURDE F, ET AL. A CASE OF FOURNIER^S GANGRENE IN A PATIENT TAKING CANAGLIFLOZIN FOR THE TREATMENT OF TYPE II DIABETES MELLITUS. AM-J-CASE-REP 2020;:.",72.0,YR,E,M,Y,,,20201020.0,,HP,CA,CA,2020,Q4,Elderly
178254294,17825429,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,,,,,,,,,2020,Q4,Rectal abscess,,2020,Q4,4,F,,20201009.0,20200526,20201020,EXP,,CA-TEVA-2020-CA-1239294,TEVA,"ELBEDDINI A, GALLINGER J, DAVEY M, BRASSARD S, GAZARIN M, PLOURDE F, ET AL. A CASE OF FOURNIER^S GANGRENE IN A PATIENT TAKING CANAGLIFLOZIN FOR THE TREATMENT OF TYPE II DIABETES MELLITUS. AM-J-CASE-REP 2020;:.",72.0,YR,E,M,Y,,,20201020.0,,HP,CA,CA,2020,Q4,Elderly
182377772,18237777,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,Y,,,,,100.0,MG,,QD,2020,Q4,Drug interaction,,2020,Q4,2,F,,20201006.0,20200907,20201007,EXP,,CA-TEVA-2020-CA-1824712,TEVA,"BRAILOVSKI E, KIM RB, JUURLINK D. ROSUVASTATIN MYOTOXICITY AFTER STARTING CANAGLIFLOZIN TREATMENT: A CASE REPORT. ANN-INTERN-MED 2020;:NO PAGINATION.",76.0,YR,E,F,Y,,,20201007.0,,MD,CA,CA,2020,Q4,Elderly
182377772,18237777,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,Y,,,,,100.0,MG,,QD,2020,Q4,Drug level increased,,2020,Q4,2,F,,20201006.0,20200907,20201007,EXP,,CA-TEVA-2020-CA-1824712,TEVA,"BRAILOVSKI E, KIM RB, JUURLINK D. ROSUVASTATIN MYOTOXICITY AFTER STARTING CANAGLIFLOZIN TREATMENT: A CASE REPORT. ANN-INTERN-MED 2020;:NO PAGINATION.",76.0,YR,E,F,Y,,,20201007.0,,MD,CA,CA,2020,Q4,Elderly
182377772,18237777,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,Y,,,,,100.0,MG,,QD,2020,Q4,Hepatocellular injury,,2020,Q4,2,F,,20201006.0,20200907,20201007,EXP,,CA-TEVA-2020-CA-1824712,TEVA,"BRAILOVSKI E, KIM RB, JUURLINK D. ROSUVASTATIN MYOTOXICITY AFTER STARTING CANAGLIFLOZIN TREATMENT: A CASE REPORT. ANN-INTERN-MED 2020;:NO PAGINATION.",76.0,YR,E,F,Y,,,20201007.0,,MD,CA,CA,2020,Q4,Elderly
182377772,18237777,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,Y,,,,,100.0,MG,,QD,2020,Q4,Rhabdomyolysis,,2020,Q4,2,F,,20201006.0,20200907,20201007,EXP,,CA-TEVA-2020-CA-1824712,TEVA,"BRAILOVSKI E, KIM RB, JUURLINK D. ROSUVASTATIN MYOTOXICITY AFTER STARTING CANAGLIFLOZIN TREATMENT: A CASE REPORT. ANN-INTERN-MED 2020;:NO PAGINATION.",76.0,YR,E,F,Y,,,20201007.0,,MD,CA,CA,2020,Q4,Elderly
182503672,18250367,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,, UNKNOWN,,,,,,,2020,Q4,Acute kidney injury,,2020,Q4,2,F,20200710.0,20201015.0,20200909,20201023,EXP,IT-MINISAL02-631306,IT-TEVA-2020-IT-1824490,TEVA,,86.0,YR,E,F,Y,80.0,KG,20201023.0,,MD,IT,IT,2020,Q4,Elderly
182503672,18250367,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,, UNKNOWN,,,,,,,2020,Q4,Lactic acidosis,,2020,Q4,2,F,20200710.0,20201015.0,20200909,20201023,EXP,IT-MINISAL02-631306,IT-TEVA-2020-IT-1824490,TEVA,,86.0,YR,E,F,Y,80.0,KG,20201023.0,,MD,IT,IT,2020,Q4,Elderly
183275472,18327547,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Cellulitis,,2020,Q4,2,F,20200810.0,20200926.0,20200929,20201006,EXP,,JP-JNJFOC-20200944755,JOHNSON AND JOHNSON,,80.0,YR,E,F,Y,,,20201006.0,,MD,JP,JP,2020,Q4,Elderly
183446521,18344652,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q4,Bone disorder,,2020,Q4,1,I,,20200928.0,20201005,20201005,EXP,GB-MHRA-EYC 00228798,GB-MYLANLABS-2020M1083218,MYLAN,,65.0,YR,,F,Y,68.94,KG,20201005.0,,CN,GB,GB,2020,Q4,Elderly
183446521,18344652,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q4,Dupuytren's contracture,,2020,Q4,1,I,,20200928.0,20201005,20201005,EXP,GB-MHRA-EYC 00228798,GB-MYLANLABS-2020M1083218,MYLAN,,65.0,YR,,F,Y,68.94,KG,20201005.0,,CN,GB,GB,2020,Q4,Elderly
183446521,18344652,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q4,Tenderness,,2020,Q4,1,I,,20200928.0,20201005,20201005,EXP,GB-MHRA-EYC 00228798,GB-MYLANLABS-2020M1083218,MYLAN,,65.0,YR,,F,Y,68.94,KG,20201005.0,,CN,GB,GB,2020,Q4,Elderly
183446521,18344652,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q4,Trigger finger,,2020,Q4,1,I,,20200928.0,20201005,20201005,EXP,GB-MHRA-EYC 00228798,GB-MYLANLABS-2020M1083218,MYLAN,,65.0,YR,,F,Y,68.94,KG,20201005.0,,CN,GB,GB,2020,Q4,Elderly
183447151,18344715,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,, UNKNOWN,,,,,,,2020,Q4,Bone disorder,,2020,Q4,1,I,,20200928.0,20201005,20201005,EXP,GB-MHRA-EYC 00228798,GB-TEVA-2020-GB-1834999,TEVA,,65.0,YR,E,F,Y,68.94,KG,20201005.0,,CN,GB,GB,2020,Q4,Elderly
183447151,18344715,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,, UNKNOWN,,,,,,,2020,Q4,Dupuytren's contracture,,2020,Q4,1,I,,20200928.0,20201005,20201005,EXP,GB-MHRA-EYC 00228798,GB-TEVA-2020-GB-1834999,TEVA,,65.0,YR,E,F,Y,68.94,KG,20201005.0,,CN,GB,GB,2020,Q4,Elderly
183447151,18344715,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,, UNKNOWN,,,,,,,2020,Q4,Tenderness,,2020,Q4,1,I,,20200928.0,20201005,20201005,EXP,GB-MHRA-EYC 00228798,GB-TEVA-2020-GB-1834999,TEVA,,65.0,YR,E,F,Y,68.94,KG,20201005.0,,CN,GB,GB,2020,Q4,Elderly
183447151,18344715,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,, UNKNOWN,,,,,,,2020,Q4,Trigger finger,,2020,Q4,1,I,,20200928.0,20201005,20201005,EXP,GB-MHRA-EYC 00228798,GB-TEVA-2020-GB-1834999,TEVA,,65.0,YR,E,F,Y,68.94,KG,20201005.0,,CN,GB,GB,2020,Q4,Elderly
183639741,18363974,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,,,TABLET,,2020,Q4,Torulopsis infection,,2020,Q4,1,I,,20200928.0,20201009,20201009,EXP,,PT-JNJFOC-20200953691,JOHNSON AND JOHNSON,"RODRIGUES R, ALVES T, SOUSA R, REIGOT R, GONCALVE J, FIGUEIREDO A, CARVALHO A, NOGUEIRA J. ATYPICAL FUNGUS WITH NEW ORAL ANTIDIABETICS. MEDICINA INTERNA. 2020;27(SPECIAL EDITION):527-528.",85.0,YR,E,M,Y,,,20201008.0,,MD,PT,PT,2020,Q4,Elderly
183682481,18368248,16,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNKNOWN,,,U,,,,,,,,,2020,Q4,Asthma,,2020,Q4,1,I,,20201001.0,20201009,20201009,EXP,,CA-ASTRAZENECA-2020SF27281,ASTRAZENECA,,76.0,YR,,F,Y,,,20201009.0,,CN,CA,CA,2020,Q4,Elderly
183682481,18368248,16,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNKNOWN,,,U,,,,,,,,,2020,Q4,Blood count abnormal,,2020,Q4,1,I,,20201001.0,20201009,20201009,EXP,,CA-ASTRAZENECA-2020SF27281,ASTRAZENECA,,76.0,YR,,F,Y,,,20201009.0,,CN,CA,CA,2020,Q4,Elderly
183682481,18368248,16,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNKNOWN,,,U,,,,,,,,,2020,Q4,Gastrooesophageal reflux disease,,2020,Q4,1,I,,20201001.0,20201009,20201009,EXP,,CA-ASTRAZENECA-2020SF27281,ASTRAZENECA,,76.0,YR,,F,Y,,,20201009.0,,CN,CA,CA,2020,Q4,Elderly
183682481,18368248,16,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNKNOWN,,,U,,,,,,,,,2020,Q4,Hyperglycaemia,,2020,Q4,1,I,,20201001.0,20201009,20201009,EXP,,CA-ASTRAZENECA-2020SF27281,ASTRAZENECA,,76.0,YR,,F,Y,,,20201009.0,,CN,CA,CA,2020,Q4,Elderly
183682481,18368248,16,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNKNOWN,,,U,,,,,,,,,2020,Q4,Type 2 diabetes mellitus,,2020,Q4,1,I,,20201001.0,20201009,20201009,EXP,,CA-ASTRAZENECA-2020SF27281,ASTRAZENECA,,76.0,YR,,F,Y,,,20201009.0,,CN,CA,CA,2020,Q4,Elderly
183711701,18371170,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2020,Q4,Asthma,,2020,Q4,1,I,,20201005.0,20201012,20201012,EXP,,CA-BAUSCH-BL-2020-029073,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20201012.0,,MD,CA,CA,2020,Q4,Elderly
183711701,18371170,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2020,Q4,Blood count abnormal,,2020,Q4,1,I,,20201005.0,20201012,20201012,EXP,,CA-BAUSCH-BL-2020-029073,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20201012.0,,MD,CA,CA,2020,Q4,Elderly
183711701,18371170,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2020,Q4,Gastrooesophageal reflux disease,,2020,Q4,1,I,,20201005.0,20201012,20201012,EXP,,CA-BAUSCH-BL-2020-029073,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20201012.0,,MD,CA,CA,2020,Q4,Elderly
183711701,18371170,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2020,Q4,Hyperglycaemia,,2020,Q4,1,I,,20201005.0,20201012,20201012,EXP,,CA-BAUSCH-BL-2020-029073,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20201012.0,,MD,CA,CA,2020,Q4,Elderly
183711701,18371170,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2020,Q4,Type 2 diabetes mellitus,,2020,Q4,1,I,,20201005.0,20201012,20201012,EXP,,CA-BAUSCH-BL-2020-029073,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20201012.0,,MD,CA,CA,2020,Q4,Elderly
183719961,18371996,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,1 DOSAGE FORMS,40.0,DF,,, UNKNOWN,,,1.0,DF,,,2020,Q4,Rash macular,,2020,Q4,1,I,20200908.0,20201004.0,20201012,20201012,EXP,GB-MHRA-TPP27338430C440242YC1599577101360,GB-TEVA-2020-GB-1836530,TEVA,,58.0,YR,A,F,Y,100.0,KG,20201012.0,,MD,GB,GB,2020,Q4,Adult
183763951,18376395,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,TABLET,,2020,Q4,Metabolic acidosis,,2020,Q4,1,I,,20201002.0,20201013,20201013,EXP,,JP-JNJFOC-20201006952,JOHNSON AND JOHNSON,,69.0,YR,E,F,Y,,,20201013.0,,PH,JP,JP,2020,Q4,Elderly
183878801,18387880,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,U,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Birth mark,,2020,Q4,1,I,202006.0,20201008.0,20201015,20201015,EXP,,JP-JNJFOC-20201020825,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,,,20201015.0,,CN,JP,JP,2020,Q4,Elderly
183878801,18387880,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,U,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Constipation,,2020,Q4,1,I,202006.0,20201008.0,20201015,20201015,EXP,,JP-JNJFOC-20201020825,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,,,20201015.0,,CN,JP,JP,2020,Q4,Elderly
183878801,18387880,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,U,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Functional gastrointestinal disorder,,2020,Q4,1,I,202006.0,20201008.0,20201015,20201015,EXP,,JP-JNJFOC-20201020825,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,,,20201015.0,,CN,JP,JP,2020,Q4,Elderly
183878801,18387880,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,U,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Gait disturbance,,2020,Q4,1,I,202006.0,20201008.0,20201015,20201015,EXP,,JP-JNJFOC-20201020825,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,,,20201015.0,,CN,JP,JP,2020,Q4,Elderly
183878801,18387880,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,U,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Intentional product misuse,,2020,Q4,1,I,202006.0,20201008.0,20201015,20201015,EXP,,JP-JNJFOC-20201020825,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,,,20201015.0,,CN,JP,JP,2020,Q4,Elderly
183878801,18387880,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,U,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Malaise,,2020,Q4,1,I,202006.0,20201008.0,20201015,20201015,EXP,,JP-JNJFOC-20201020825,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,,,20201015.0,,CN,JP,JP,2020,Q4,Elderly
183878801,18387880,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,U,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Movement disorder,,2020,Q4,1,I,202006.0,20201008.0,20201015,20201015,EXP,,JP-JNJFOC-20201020825,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,,,20201015.0,,CN,JP,JP,2020,Q4,Elderly
183878801,18387880,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,U,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,No adverse event,,2020,Q4,1,I,202006.0,20201008.0,20201015,20201015,EXP,,JP-JNJFOC-20201020825,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,,,20201015.0,,CN,JP,JP,2020,Q4,Elderly
183878801,18387880,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,U,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Pain in extremity,,2020,Q4,1,I,202006.0,20201008.0,20201015,20201015,EXP,,JP-JNJFOC-20201020825,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,,,20201015.0,,CN,JP,JP,2020,Q4,Elderly
183878801,18387880,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,U,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Pruritus,,2020,Q4,1,I,202006.0,20201008.0,20201015,20201015,EXP,,JP-JNJFOC-20201020825,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,,,20201015.0,,CN,JP,JP,2020,Q4,Elderly
183878801,18387880,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,U,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Therapeutic product effect incomplete,,2020,Q4,1,I,202006.0,20201008.0,20201015,20201015,EXP,,JP-JNJFOC-20201020825,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,,,20201015.0,,CN,JP,JP,2020,Q4,Elderly
183878801,18387880,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,U,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Urticaria,,2020,Q4,1,I,202006.0,20201008.0,20201015,20201015,EXP,,JP-JNJFOC-20201020825,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,,,20201015.0,,CN,JP,JP,2020,Q4,Elderly
183922881,18392288,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Blood creatinine increased,,2020,Q4,1,I,20200928.0,,20201016,20201016,DIR,,,FDA-CTU,,58.0,YR,,F,N,100.8,KG,20201016.0,N,CN,US,US,2020,Q4,Adult
184330431,18433043,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Diabetic gangrene,,2020,Q4,1,I,,20200218.0,20201027,20201027,EXP,,JP-JNJFOC-20200243889,JOHNSON AND JOHNSON,,51.0,YR,A,M,Y,76.1,KG,20201027.0,,MD,JP,JP,2020,Q4,Adult
184411891,18441189,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,30 MG,,,,, UNKNOWN,,,,,,,2020,Q4,Arteriosclerosis coronary artery,,2020,Q4,1,I,20201008.0,20201016.0,20201029,20201029,EXP,,BR-NOVOPROD-762119,NOVO NORDISK,,78.0,YR,,M,Y,81.0,KG,20201029.0,,MD,BR,BR,2020,Q4,Elderly
184411891,18441189,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,30 MG,,,,, UNKNOWN,,,,,,,2020,Q4,Hyperglycaemia,,2020,Q4,1,I,20201008.0,20201016.0,20201029,20201029,EXP,,BR-NOVOPROD-762119,NOVO NORDISK,,78.0,YR,,M,Y,81.0,KG,20201029.0,,MD,BR,BR,2020,Q4,Elderly
184411891,18441189,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,30 MG,,,,, UNKNOWN,,,,,,,2020,Q4,Hypoglycaemia,,2020,Q4,1,I,20201008.0,20201016.0,20201029,20201029,EXP,,BR-NOVOPROD-762119,NOVO NORDISK,,78.0,YR,,M,Y,81.0,KG,20201029.0,,MD,BR,BR,2020,Q4,Elderly
184451201,18445120,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2020,Q4,Acute kidney injury,,2020,Q4,1,I,,20201020.0,20201030,20201030,EXP,,CA-APOTEX-2020AP020594,APOTEX,,64.0,YR,,M,Y,,,20201030.0,,CN,CA,CA,2020,Q4,Adult
184451201,18445120,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2020,Q4,Extradural abscess,,2020,Q4,1,I,,20201020.0,20201030,20201030,EXP,,CA-APOTEX-2020AP020594,APOTEX,,64.0,YR,,M,Y,,,20201030.0,,CN,CA,CA,2020,Q4,Adult
184451201,18445120,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2020,Q4,Post streptococcal glomerulonephritis,,2020,Q4,1,I,,20201020.0,20201030,20201030,EXP,,CA-APOTEX-2020AP020594,APOTEX,,64.0,YR,,M,Y,,,20201030.0,,CN,CA,CA,2020,Q4,Adult
184528041,18452804,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,204042.0,,,TABLET,,2020,Q4,Asthma,,2020,Q4,1,I,,20201005.0,20201102,20201102,EXP,,CA-JNJFOC-20201050571,JOHNSON AND JOHNSON,,76.0,YR,E,F,Y,,,20201102.0,,MD,CA,CA,2020,Q4,Elderly
184528041,18452804,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,204042.0,,,TABLET,,2020,Q4,Blood count abnormal,,2020,Q4,1,I,,20201005.0,20201102,20201102,EXP,,CA-JNJFOC-20201050571,JOHNSON AND JOHNSON,,76.0,YR,E,F,Y,,,20201102.0,,MD,CA,CA,2020,Q4,Elderly
184528041,18452804,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,204042.0,,,TABLET,,2020,Q4,Gastrooesophageal reflux disease,,2020,Q4,1,I,,20201005.0,20201102,20201102,EXP,,CA-JNJFOC-20201050571,JOHNSON AND JOHNSON,,76.0,YR,E,F,Y,,,20201102.0,,MD,CA,CA,2020,Q4,Elderly
184528041,18452804,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,204042.0,,,TABLET,,2020,Q4,Hyperglycaemia,,2020,Q4,1,I,,20201005.0,20201102,20201102,EXP,,CA-JNJFOC-20201050571,JOHNSON AND JOHNSON,,76.0,YR,E,F,Y,,,20201102.0,,MD,CA,CA,2020,Q4,Elderly
184528041,18452804,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,204042.0,,,TABLET,,2020,Q4,Type 2 diabetes mellitus,,2020,Q4,1,I,,20201005.0,20201102,20201102,EXP,,CA-JNJFOC-20201050571,JOHNSON AND JOHNSON,,76.0,YR,E,F,Y,,,20201102.0,,MD,CA,CA,2020,Q4,Elderly
184731021,18473102,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,TABLET,,2020,Q4,Abdominal discomfort,,2020,Q4,1,I,20201018.0,20201026.0,20201106,20201106,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202010011488,ELI LILLY AND CO,,70.0,YR,,M,Y,77.5,KG,20201106.0,,CN,CN,CN,2020,Q4,Elderly
184731021,18473102,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,TABLET,,2020,Q4,Blood glucose increased,,2020,Q4,1,I,20201018.0,20201026.0,20201106,20201106,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202010011488,ELI LILLY AND CO,,70.0,YR,,M,Y,77.5,KG,20201106.0,,CN,CN,CN,2020,Q4,Elderly
184731021,18473102,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,TABLET,,2020,Q4,Dizziness,,2020,Q4,1,I,20201018.0,20201026.0,20201106,20201106,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202010011488,ELI LILLY AND CO,,70.0,YR,,M,Y,77.5,KG,20201106.0,,CN,CN,CN,2020,Q4,Elderly
184731021,18473102,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,TABLET,,2020,Q4,Dyspepsia,,2020,Q4,1,I,20201018.0,20201026.0,20201106,20201106,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202010011488,ELI LILLY AND CO,,70.0,YR,,M,Y,77.5,KG,20201106.0,,CN,CN,CN,2020,Q4,Elderly
184731021,18473102,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,TABLET,,2020,Q4,Glycosylated haemoglobin increased,,2020,Q4,1,I,20201018.0,20201026.0,20201106,20201106,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202010011488,ELI LILLY AND CO,,70.0,YR,,M,Y,77.5,KG,20201106.0,,CN,CN,CN,2020,Q4,Elderly
184731021,18473102,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,TABLET,,2020,Q4,Hypophagia,,2020,Q4,1,I,20201018.0,20201026.0,20201106,20201106,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202010011488,ELI LILLY AND CO,,70.0,YR,,M,Y,77.5,KG,20201106.0,,CN,CN,CN,2020,Q4,Elderly
184731021,18473102,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,TABLET,,2020,Q4,Vomiting,,2020,Q4,1,I,20201018.0,20201026.0,20201106,20201106,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202010011488,ELI LILLY AND CO,,70.0,YR,,M,Y,77.5,KG,20201106.0,,CN,CN,CN,2020,Q4,Elderly
184859011,18485901,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,D,,,,300.0,MG,,QD,2020,Q4,Fournier's gangrene,,2020,Q4,1,I,20200527.0,,20201110,20201110,DIR,,,FDA-CTU,,57.0,YR,,M,N,93.0,KG,20200718.0,N,PH,US,US,2020,Q4,Adult
184859011,18485901,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,D,,,,300.0,MG,,QD,2020,Q4,Necrotising soft tissue infection,,2020,Q4,1,I,20200527.0,,20201110,20201110,DIR,,,FDA-CTU,,57.0,YR,,M,N,93.0,KG,20200718.0,N,PH,US,US,2020,Q4,Adult
184891231,18489123,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Diabetic ketoacidosis,,2020,Q4,1,I,20190814.0,20200205.0,20201111,20201111,EXP,,JP-JNJFOC-20200216252,JOHNSON AND JOHNSON,"TANAKA S, MIWA Y, TAGUCHI Y, OGASAWARA J, MUROYA Y, HONJYO  SET AL., O-010 KETOACIDOSIS DEVELOPED IN 3 ELDERLY PATIENTS WITH TYPE 2 DIABETES MELLITUS WHILE ON ORAL SGLT2 INHIBITORS, THE 57TH KANTO KOUSHINETSU REGIONAL MEETING OF THE JAPAN DIABETES SOCIETY, 2020.1.18;71",77.0,YR,E,M,Y,,,20201111.0,,MD,JP,JP,2020,Q4,Elderly
184891231,18489123,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Pneumonia,,2020,Q4,1,I,20190814.0,20200205.0,20201111,20201111,EXP,,JP-JNJFOC-20200216252,JOHNSON AND JOHNSON,"TANAKA S, MIWA Y, TAGUCHI Y, OGASAWARA J, MUROYA Y, HONJYO  SET AL., O-010 KETOACIDOSIS DEVELOPED IN 3 ELDERLY PATIENTS WITH TYPE 2 DIABETES MELLITUS WHILE ON ORAL SGLT2 INHIBITORS, THE 57TH KANTO KOUSHINETSU REGIONAL MEETING OF THE JAPAN DIABETES SOCIETY, 2020.1.18;71",77.0,YR,E,M,Y,,,20201111.0,,MD,JP,JP,2020,Q4,Elderly
184891231,18489123,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Pulmonary artery thrombosis,,2020,Q4,1,I,20190814.0,20200205.0,20201111,20201111,EXP,,JP-JNJFOC-20200216252,JOHNSON AND JOHNSON,"TANAKA S, MIWA Y, TAGUCHI Y, OGASAWARA J, MUROYA Y, HONJYO  SET AL., O-010 KETOACIDOSIS DEVELOPED IN 3 ELDERLY PATIENTS WITH TYPE 2 DIABETES MELLITUS WHILE ON ORAL SGLT2 INHIBITORS, THE 57TH KANTO KOUSHINETSU REGIONAL MEETING OF THE JAPAN DIABETES SOCIETY, 2020.1.18;71",77.0,YR,E,M,Y,,,20201111.0,,MD,JP,JP,2020,Q4,Elderly
184891231,18489123,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Septic shock,,2020,Q4,1,I,20190814.0,20200205.0,20201111,20201111,EXP,,JP-JNJFOC-20200216252,JOHNSON AND JOHNSON,"TANAKA S, MIWA Y, TAGUCHI Y, OGASAWARA J, MUROYA Y, HONJYO  SET AL., O-010 KETOACIDOSIS DEVELOPED IN 3 ELDERLY PATIENTS WITH TYPE 2 DIABETES MELLITUS WHILE ON ORAL SGLT2 INHIBITORS, THE 57TH KANTO KOUSHINETSU REGIONAL MEETING OF THE JAPAN DIABETES SOCIETY, 2020.1.18;71",77.0,YR,E,M,Y,,,20201111.0,,MD,JP,JP,2020,Q4,Elderly
184892761,18489276,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"300 MILLIGRAM, DAILY",,,U,,,,,300.0,MG,,,2020,Q4,Increased insulin requirement,,2020,Q4,1,I,,20201027.0,20201111,20201111,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-267311,RANBAXY,"WEI ET, KOH E, KELLY MS, WRIGHT LA, TYLEE TS. PATIENT ERRORS IN USE OF INJECTABLE ANTIDIABETIC MEDICATIONS: A NEED FOR IMPROVED CLINIC-BASED EDUCATION. J AM PHARMACISTS ASSOC. 2020;60 (5), MAR 4:E76-E80",55.0,YR,,M,Y,,,20201111.0,,PH,US,US,2020,Q4,Adult
184966681,18496668,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,TABLET,,2020,Q4,Ketoacidosis,,2020,Q4,1,I,,20201103.0,20201112,20201112,EXP,,JP-JNJFOC-20201117015,JOHNSON AND JOHNSON,"TITLE: CASE REPORT OF SUPERIOR MESENTERIC ARTERY SYNDROME THAT DEVELOPED IN A LEAN TYPE 2 DIABETES PATIENT AND WAS ASSOCIATED WITH RAPID BODY WEIGHT LOSS AFTER SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITOR ADMINISTRATION YEAR: 2020 VOLUME: 11 ISSUE: 5 AUTHOR AFFILIATION: (HIRAI, KITADA, HAYASHI, MONNO, TAKAGAKI, SHIMADA, OGURA, FUJII, KONISHI, NAKAGAWA, KOYA) DEPARTMENT OF DIABETOLOGY AND ENDOCRINOLOGY, KANAZAWA MEDICAL UNIVERSITY, UCHINADA, JAPAN JOURNAL NAME: JOURNAL OF DIABETES INVESTIGATION",58.0,YR,A,F,Y,,,20201112.0,,HP,JP,JP,2020,Q4,Adult
184966681,18496668,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,TABLET,,2020,Q4,Superior mesenteric artery syndrome,,2020,Q4,1,I,,20201103.0,20201112,20201112,EXP,,JP-JNJFOC-20201117015,JOHNSON AND JOHNSON,"TITLE: CASE REPORT OF SUPERIOR MESENTERIC ARTERY SYNDROME THAT DEVELOPED IN A LEAN TYPE 2 DIABETES PATIENT AND WAS ASSOCIATED WITH RAPID BODY WEIGHT LOSS AFTER SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITOR ADMINISTRATION YEAR: 2020 VOLUME: 11 ISSUE: 5 AUTHOR AFFILIATION: (HIRAI, KITADA, HAYASHI, MONNO, TAKAGAKI, SHIMADA, OGURA, FUJII, KONISHI, NAKAGAWA, KOYA) DEPARTMENT OF DIABETOLOGY AND ENDOCRINOLOGY, KANAZAWA MEDICAL UNIVERSITY, UCHINADA, JAPAN JOURNAL NAME: JOURNAL OF DIABETES INVESTIGATION",58.0,YR,A,F,Y,,,20201112.0,,HP,JP,JP,2020,Q4,Adult
184966681,18496668,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,TABLET,,2020,Q4,Weight decreased,,2020,Q4,1,I,,20201103.0,20201112,20201112,EXP,,JP-JNJFOC-20201117015,JOHNSON AND JOHNSON,"TITLE: CASE REPORT OF SUPERIOR MESENTERIC ARTERY SYNDROME THAT DEVELOPED IN A LEAN TYPE 2 DIABETES PATIENT AND WAS ASSOCIATED WITH RAPID BODY WEIGHT LOSS AFTER SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITOR ADMINISTRATION YEAR: 2020 VOLUME: 11 ISSUE: 5 AUTHOR AFFILIATION: (HIRAI, KITADA, HAYASHI, MONNO, TAKAGAKI, SHIMADA, OGURA, FUJII, KONISHI, NAKAGAWA, KOYA) DEPARTMENT OF DIABETOLOGY AND ENDOCRINOLOGY, KANAZAWA MEDICAL UNIVERSITY, UCHINADA, JAPAN JOURNAL NAME: JOURNAL OF DIABETES INVESTIGATION",58.0,YR,A,F,Y,,,20201112.0,,HP,JP,JP,2020,Q4,Adult
184971391,18497139,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,TABLET,,2020,Q4,Altered state of consciousness,,2020,Q4,1,I,,20201104.0,20201112,20201112,EXP,,JP-JNJFOC-20201118175,JOHNSON AND JOHNSON,"AKANE HORI, SAYAKA TANAKA, KEIICHI KIMURA, FUSA TSUNETA, KENTO YAMAMOTO, ATSUSHI YOSHIKAWA, KOHEI OKITA. 8-19 A CASE OF MARKED HYPERGLYCAEMIA AND METABOLIC ACIDOSIS NOTED AFTER HOSPITAL ADMISSION FOR DISTURBED CONSCIOUSNESS DURING TREATMENT FOR DIABETES MELLITUS. THE 57TH KINKI REGIONAL MEETING OF THE JAPAN DIABETES SOCIETY [HELD ONLINE]. 2020.10.17,18,19,20,21,22,23,24,25,26,27,28,29,30,31;135",46.0,YR,A,M,Y,,,20201112.0,,MD,JP,JP,2020,Q4,Adult
184971391,18497139,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,TABLET,,2020,Q4,Metabolic acidosis,,2020,Q4,1,I,,20201104.0,20201112,20201112,EXP,,JP-JNJFOC-20201118175,JOHNSON AND JOHNSON,"AKANE HORI, SAYAKA TANAKA, KEIICHI KIMURA, FUSA TSUNETA, KENTO YAMAMOTO, ATSUSHI YOSHIKAWA, KOHEI OKITA. 8-19 A CASE OF MARKED HYPERGLYCAEMIA AND METABOLIC ACIDOSIS NOTED AFTER HOSPITAL ADMISSION FOR DISTURBED CONSCIOUSNESS DURING TREATMENT FOR DIABETES MELLITUS. THE 57TH KINKI REGIONAL MEETING OF THE JAPAN DIABETES SOCIETY [HELD ONLINE]. 2020.10.17,18,19,20,21,22,23,24,25,26,27,28,29,30,31;135",46.0,YR,A,M,Y,,,20201112.0,,MD,JP,JP,2020,Q4,Adult
184971391,18497139,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,TABLET,,2020,Q4,Seizure,,2020,Q4,1,I,,20201104.0,20201112,20201112,EXP,,JP-JNJFOC-20201118175,JOHNSON AND JOHNSON,"AKANE HORI, SAYAKA TANAKA, KEIICHI KIMURA, FUSA TSUNETA, KENTO YAMAMOTO, ATSUSHI YOSHIKAWA, KOHEI OKITA. 8-19 A CASE OF MARKED HYPERGLYCAEMIA AND METABOLIC ACIDOSIS NOTED AFTER HOSPITAL ADMISSION FOR DISTURBED CONSCIOUSNESS DURING TREATMENT FOR DIABETES MELLITUS. THE 57TH KINKI REGIONAL MEETING OF THE JAPAN DIABETES SOCIETY [HELD ONLINE]. 2020.10.17,18,19,20,21,22,23,24,25,26,27,28,29,30,31;135",46.0,YR,A,M,Y,,,20201112.0,,MD,JP,JP,2020,Q4,Adult
185058881,18505888,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2020,Q4,Completed suicide,,2020,Q4,1,I,2018.0,20201102.0,20201116,20201116,EXP,,US-NORTHSTAR HEALTHCARE HOLDINGS-US-2020NSR000062,NORTHSTAR,"GUMMIN DD, MOWRY JB, SPYKER DA, BROOKS DE, BEUHLER MC, RIVERS LJ, ET AL. 2018 ANNUAL REPORT OF THE AMERICAN ASSOCIATION OF POISON CONTROL CENTERS^ NATIONAL POISON DATA SYSTEM (NPDS): 36TH ANNUAL REPORT. CLINICAL TOXICOLOGY. 2019;57(12):1220-1413",47.0,YR,,M,Y,,,20201116.0,,MD,US,US,2020,Q4,Adult
185058881,18505888,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2020,Q4,Toxicity to various agents,,2020,Q4,1,I,2018.0,20201102.0,20201116,20201116,EXP,,US-NORTHSTAR HEALTHCARE HOLDINGS-US-2020NSR000062,NORTHSTAR,"GUMMIN DD, MOWRY JB, SPYKER DA, BROOKS DE, BEUHLER MC, RIVERS LJ, ET AL. 2018 ANNUAL REPORT OF THE AMERICAN ASSOCIATION OF POISON CONTROL CENTERS^ NATIONAL POISON DATA SYSTEM (NPDS): 36TH ANNUAL REPORT. CLINICAL TOXICOLOGY. 2019;57(12):1220-1413",47.0,YR,,M,Y,,,20201116.0,,MD,US,US,2020,Q4,Adult
185063591,18506359,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2020,Q4,Completed suicide,,2020,Q4,1,I,2018.0,20201102.0,20201116,20201116,EXP,,US-VALIDUS PHARMACEUTICALS LLC-US-2020VAL000897,VALIDUS,"GUMMIN DD, MOWRY JB, SPYKER DA, BROOKS DE, BEUHLER MC, RIVERS LJ, ET AL. 2018 ANNUAL REPORT OF THE AMERICAN ASSOCIATION OF POISON CONTROL CENTERS? NATIONAL POISON DATA SYSTEM (NPDS): 36TH ANNUAL REPORT. CLINICAL TOXICOLOGY. 2019;57(12):1220-1413",47.0,YR,,M,Y,,,20201116.0,,MD,US,US,2020,Q4,Adult
185063591,18506359,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2020,Q4,Toxicity to various agents,,2020,Q4,1,I,2018.0,20201102.0,20201116,20201116,EXP,,US-VALIDUS PHARMACEUTICALS LLC-US-2020VAL000897,VALIDUS,"GUMMIN DD, MOWRY JB, SPYKER DA, BROOKS DE, BEUHLER MC, RIVERS LJ, ET AL. 2018 ANNUAL REPORT OF THE AMERICAN ASSOCIATION OF POISON CONTROL CENTERS? NATIONAL POISON DATA SYSTEM (NPDS): 36TH ANNUAL REPORT. CLINICAL TOXICOLOGY. 2019;57(12):1220-1413",47.0,YR,,M,Y,,,20201116.0,,MD,US,US,2020,Q4,Adult
185109151,18510915,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,U,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Cerebral infarction,,2020,Q4,1,I,20200914.0,20201013.0,20201117,20201117,EXP,,JP-JNJFOC-20201031214,JOHNSON AND JOHNSON,,68.0,YR,E,M,Y,,,20201117.0,,PH,JP,JP,2020,Q4,Elderly
185109151,18510915,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,U,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Euglycaemic diabetic ketoacidosis,,2020,Q4,1,I,20200914.0,20201013.0,20201117,20201117,EXP,,JP-JNJFOC-20201031214,JOHNSON AND JOHNSON,,68.0,YR,E,M,Y,,,20201117.0,,PH,JP,JP,2020,Q4,Elderly
185127691,18512769,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,, NOT AVAILABLE,,,,,,,2020,Q4,Completed suicide,,2020,Q4,1,I,,20201112.0,20201117,20201117,EXP,,US-ABBVIE-20K-163-3651395-00,ABBVIE,"GUMMIN D, MOWRY J, SPYKER D, ET AL. 2018 ANNUAL REPORT OF THE AMERICAN ASSOCIATION OF POISON CONTROL CENTERS NATIONAL POISON DATA SYSTEM (NPDS): 36TH ANNUAL REPORT. CLINICAL TOXICOLOGY. 2019;57 (12):1220-1413.",47.0,YR,,M,Y,,,20201117.0,,HP,COUNTRY NOT SPECIFIED,US,2020,Q4,Adult
185152201,18515220,1,PS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,Y,U, -,,204353.0,,,TABLET,,2020,Q4,Euglycaemic diabetic ketoacidosis,,2020,Q4,1,I,20201028.0,20201109.0,20201118,20201118,EXP,IT-MINISAL02-642034,IT-JNJFOC-20201114030,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,,,20201118.0,,MD,IT,IT,2020,Q4,Elderly
185152201,18515220,1,PS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,Y,U, -,,204353.0,,,TABLET,,2020,Q4,SARS-CoV-2 test positive,,2020,Q4,1,I,20201028.0,20201109.0,20201118,20201118,EXP,IT-MINISAL02-642034,IT-JNJFOC-20201114030,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,,,20201118.0,,MD,IT,IT,2020,Q4,Elderly
185262863,18526286,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,U,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Dehydration,,2020,Q4,3,F,20181117.0,20201209.0,20201120,20201219,EXP,,JP-JNJFOC-20201132246,JOHNSON AND JOHNSON,"PRIVACY, HIRAI T, MUNEHIRO K, YOSHIHIRO H, MONNO I, TAKAGAKI Y, SHIMADA.",58.0,YR,A,F,Y,,,20201219.0,,MD,JP,JP,2020,Q4,Adult
185262863,18526286,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,U,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Ketoacidosis,,2020,Q4,3,F,20181117.0,20201209.0,20201120,20201219,EXP,,JP-JNJFOC-20201132246,JOHNSON AND JOHNSON,"PRIVACY, HIRAI T, MUNEHIRO K, YOSHIHIRO H, MONNO I, TAKAGAKI Y, SHIMADA.",58.0,YR,A,F,Y,,,20201219.0,,MD,JP,JP,2020,Q4,Adult
185262863,18526286,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,U,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Superior mesenteric artery syndrome,,2020,Q4,3,F,20181117.0,20201209.0,20201120,20201219,EXP,,JP-JNJFOC-20201132246,JOHNSON AND JOHNSON,"PRIVACY, HIRAI T, MUNEHIRO K, YOSHIHIRO H, MONNO I, TAKAGAKI Y, SHIMADA.",58.0,YR,A,F,Y,,,20201219.0,,MD,JP,JP,2020,Q4,Adult
185262863,18526286,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,U,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Weight decreased,,2020,Q4,3,F,20181117.0,20201209.0,20201120,20201219,EXP,,JP-JNJFOC-20201132246,JOHNSON AND JOHNSON,"PRIVACY, HIRAI T, MUNEHIRO K, YOSHIHIRO H, MONNO I, TAKAGAKI Y, SHIMADA.",58.0,YR,A,F,Y,,,20201219.0,,MD,JP,JP,2020,Q4,Adult
185320392,18532039,4,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q4,Superior mesenteric artery syndrome,,2020,Q4,2,F,,20201125.0,20201123,20201207,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-268286,RANBAXY,,58.0,YR,,F,Y,,,20201207.0,,HP,JP,JP,2020,Q4,Adult
185372441,18537244,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,DAILY,,,,,,,,40.0,MG,,,2020,Q4,Nasopharyngitis,Nasopharyngitis,2020,Q4,1,I,,20191002.0,20201124,20201124,PER,,US-ALVOGEN-2019-ALVOGEN-101771,ALVOGEN,,70.0,YR,,M,Y,,,20201124.0,,CN,US,US,2020,Q4,Elderly
185390641,18539064,6,C,canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q4,Vulvovaginal mycotic infection,,2020,Q4,1,I,,20201109.0,20201124,20201124,EXP,,CA-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-268645,RANBAXY,,55.0,YR,,F,Y,,,20201124.0,,HP,CA,CA,2020,Q4,Adult
185440941,18544094,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,TABLET,,2020,Q4,Diabetic ketoacidosis,,2020,Q4,1,I,,20201116.0,20201125,20201125,EXP,,GB-JNJFOC-20201134480,JOHNSON AND JOHNSON,"MUSSO G, SABA F, CASSADER M, GAMBINO R. DIABETIC KETOACIDOSIS WITH SGLT2 INHIBITORS. BRITISH MEDICAL JOURNAL. 2020;371:.",45.0,YR,A,F,Y,,,20201125.0,,HP,GB,GB,2020,Q4,Adult
185578191,18557819,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Cerebral infarction,,2020,Q4,1,I,20160812.0,20201118.0,20201130,20201130,EXP,,JP-JNJFOC-20201149933,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20201130.0,,MD,JP,JP,2020,Q4,Elderly
185578191,18557819,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Dementia Alzheimer's type,,2020,Q4,1,I,20160812.0,20201118.0,20201130,20201130,EXP,,JP-JNJFOC-20201149933,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20201130.0,,MD,JP,JP,2020,Q4,Elderly
185578191,18557819,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Osteoporosis,,2020,Q4,1,I,20160812.0,20201118.0,20201130,20201130,EXP,,JP-JNJFOC-20201149933,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20201130.0,,MD,JP,JP,2020,Q4,Elderly
185732262,18573226,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,204042.0,,,TABLET,,2020,Q4,Prostatic operation,,2020,Q4,2,F,,20201201.0,20201203,20201214,EXP,,JP-JNJFOC-20201152678,JOHNSON AND JOHNSON,,68.0,YR,E,M,Y,,,20201214.0,,PH,JP,JP,2020,Q4,Elderly
185773261,18577326,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,IN THE MORNING,193187.5,MG,Y,U, UNKNOWN,,204042.0,300.0,MG,TABLET,,2020,Q4,Diabetic foot infection,,2020,Q4,1,I,20200810.0,20201201.0,20201203,20201203,EXP,GB-MHRA-EYC 00233324,GB-JNJFOC-20201201920,JOHNSON AND JOHNSON,,56.0,YR,A,F,Y,86.4,KG,20201204.0,,HP,GB,GB,2020,Q4,Adult
185773261,18577326,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,IN THE MORNING,193187.5,MG,Y,U, UNKNOWN,,204042.0,300.0,MG,TABLET,,2020,Q4,Skin ulcer,,2020,Q4,1,I,20200810.0,20201201.0,20201203,20201203,EXP,GB-MHRA-EYC 00233324,GB-JNJFOC-20201201920,JOHNSON AND JOHNSON,,56.0,YR,A,F,Y,86.4,KG,20201204.0,,HP,GB,GB,2020,Q4,Adult
185777771,18577777,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U, UNKNOWN,,204042.0,300.0,MG,TABLET,,2020,Q4,Diabetic foot,,2020,Q4,1,I,20200101.0,20201130.0,20201204,20201204,EXP,GB-MHRA-EYC 00233325,GB-JNJFOC-20201153010,JOHNSON AND JOHNSON,,71.0,YR,E,M,Y,120.0,KG,20201204.0,,HP,GB,GB,2020,Q4,Elderly
185777771,18577777,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U, UNKNOWN,,204042.0,300.0,MG,TABLET,,2020,Q4,Localised infection,,2020,Q4,1,I,20200101.0,20201130.0,20201204,20201204,EXP,GB-MHRA-EYC 00233325,GB-JNJFOC-20201153010,JOHNSON AND JOHNSON,,71.0,YR,E,M,Y,120.0,KG,20201204.0,,HP,GB,GB,2020,Q4,Elderly
185886841,18588684,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",19700.0,MG,Y,U,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Cerebral infarction,,2020,Q4,1,I,20201014.0,20201127.0,20201207,20201207,EXP,,JP-JNJFOC-20201207649,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,,,20201208.0,,PH,JP,JP,2020,Q4,Elderly
186108811,18610881,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,U,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Nephritis bacterial,,2020,Q4,1,I,20201125.0,20201203.0,20201214,20201214,EXP,,JP-JNJFOC-20201216273,JOHNSON AND JOHNSON,,60.0,YR,A,F,Y,,,20201214.0,,MD,JP,JP,2020,Q4,Adult
186110541,18611054,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,1604.1666,MG,Y,,,,204042.0,100.0,MG,TABLET,,2020,Q4,Hypocalcaemia,,2020,Q4,1,I,20201106.0,20201210.0,20201214,20201214,EXP,GB-MHRA-EYC 00233851,GB-JNJFOC-20201219199,JOHNSON AND JOHNSON,,60.0,YR,A,F,Y,,,20201214.0,,PH,GB,GB,2020,Q4,Adult
186110541,18611054,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,1604.1666,MG,Y,,,,204042.0,100.0,MG,TABLET,,2020,Q4,Hypomagnesaemia,,2020,Q4,1,I,20201106.0,20201210.0,20201214,20201214,EXP,GB-MHRA-EYC 00233851,GB-JNJFOC-20201219199,JOHNSON AND JOHNSON,,60.0,YR,A,F,Y,,,20201214.0,,PH,GB,GB,2020,Q4,Adult
186110541,18611054,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,1604.1666,MG,Y,,,,204042.0,100.0,MG,TABLET,,2020,Q4,Hypotension,,2020,Q4,1,I,20201106.0,20201210.0,20201214,20201214,EXP,GB-MHRA-EYC 00233851,GB-JNJFOC-20201219199,JOHNSON AND JOHNSON,,60.0,YR,A,F,Y,,,20201214.0,,PH,GB,GB,2020,Q4,Adult
186183991,18618399,5,C,canagliflozin 300mg,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,COVID-19,,2020,Q4,1,I,20201211.0,,20201215,20201215,DIR,,,FDA-CTU,,83.0,YR,,M,N,84.4,KG,20201215.0,N,PH,US,US,2020,Q4,Elderly
186183991,18618399,5,C,canagliflozin 300mg,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Drug hypersensitivity,,2020,Q4,1,I,20201211.0,,20201215,20201215,DIR,,,FDA-CTU,,83.0,YR,,M,N,84.4,KG,20201215.0,N,PH,US,US,2020,Q4,Elderly
186222941,18622294,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MG,,,U,,,,,100.0,MG,,,2020,Q4,Dehydration,,2020,Q4,1,I,,20201203.0,20201216,20201216,EXP,,NVSJ2020JP013671,NOVARTIS,,96.0,YR,,F,Y,,,20201216.0,,MD,JP,JP,2020,Q4,Elderly
186222941,18622294,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MG,,,U,,,,,100.0,MG,,,2020,Q4,Delirium,,2020,Q4,1,I,,20201203.0,20201216,20201216,EXP,,NVSJ2020JP013671,NOVARTIS,,96.0,YR,,F,Y,,,20201216.0,,MD,JP,JP,2020,Q4,Elderly
186222941,18622294,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MG,,,U,,,,,100.0,MG,,,2020,Q4,Weight decreased,,2020,Q4,1,I,,20201203.0,20201216,20201216,EXP,,NVSJ2020JP013671,NOVARTIS,,96.0,YR,,F,Y,,,20201216.0,,MD,JP,JP,2020,Q4,Elderly
186251741,18625174,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",70400.0,MG,,U,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Eczema,,2020,Q4,1,I,20201106.0,20201208.0,20201217,20201217,EXP,,JP-JNJFOC-20201225437,JOHNSON AND JOHNSON,,76.0,YR,E,F,Y,,,20201217.0,,MD,JP,JP,2020,Q4,Elderly
186261851,18626185,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,200 MILLILITRE(S) UNCHECKED UNITS,,,U,U,,,204042.0,1.0,DF,TABLET,,2020,Q4,Ketosis,,2020,Q4,1,I,20201119.0,20201214.0,20201216,20201216,EXP,GB-MHRA-TPP49374561C23951YC1605801057723,GB-JNJFOC-20201225776,JOHNSON AND JOHNSON,,82.0,YR,E,F,Y,45.0,KG,20201217.0,,MD,GB,GB,2020,Q4,Elderly
186385682,18638568,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,300 MILLIGRAM,,,U,,,,,300.0,MG,,,2020,Q4,Autoimmune colitis,,2020,Q4,2,F,20201209.0,20201219.0,20201218,20201228,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-106690,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,107.6,KG,20201228.0,,HP,CA,CA,2020,Q4,Adult
186401841,18640184,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,U,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Hepatic function abnormal,,2020,Q4,1,I,202012.0,20201210.0,20201220,20201220,EXP,,JP-JNJFOC-20201233398,JOHNSON AND JOHNSON,,42.0,YR,A,M,Y,,,20201221.0,,MD,JP,JP,2020,Q4,Adult
186401841,18640184,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,U,,,204042.0,100.0,MG,TABLET,QD,2020,Q4,Pyrexia,,2020,Q4,1,I,202012.0,20201210.0,20201220,20201220,EXP,,JP-JNJFOC-20201233398,JOHNSON AND JOHNSON,,42.0,YR,A,M,Y,,,20201221.0,,MD,JP,JP,2020,Q4,Adult
186416841,18641684,4,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,100 MG,,,U,,,,,100.0,MG,,,2020,Q4,Blood pressure decreased,,2020,Q4,1,I,,20201208.0,20201221,20201221,EXP,,NVSJ2020JP013917,NOVARTIS,,65.0,YR,,M,Y,90.0,KG,20201221.0,,MD,JP,JP,2020,Q4,Elderly
186416841,18641684,4,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,100 MG,,,U,,,,,100.0,MG,,,2020,Q4,Low cardiac output syndrome,,2020,Q4,1,I,,20201208.0,20201221,20201221,EXP,,NVSJ2020JP013917,NOVARTIS,,65.0,YR,,M,Y,90.0,KG,20201221.0,,MD,JP,JP,2020,Q4,Elderly
186416841,18641684,4,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,100 MG,,,U,,,,,100.0,MG,,,2020,Q4,Sepsis,,2020,Q4,1,I,,20201208.0,20201221,20201221,EXP,,NVSJ2020JP013917,NOVARTIS,,65.0,YR,,M,Y,90.0,KG,20201221.0,,MD,JP,JP,2020,Q4,Elderly
186716191,18671619,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q4,Disorientation,,2020,Q4,1,I,20200614.0,20201223.0,20201229,20201229,EXP,IT-MINISAL02-648268,IT-JNJFOC-20201242866,JOHNSON AND JOHNSON,,66.0,YR,E,M,Y,109.0,KG,20201229.0,,PH,IT,IT,2020,Q4,Elderly
186716191,18671619,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2020,Q4,Dysentery,,2020,Q4,1,I,20200614.0,20201223.0,20201229,20201229,EXP,IT-MINISAL02-648268,IT-JNJFOC-20201242866,JOHNSON AND JOHNSON,,66.0,YR,E,M,Y,109.0,KG,20201229.0,,PH,IT,IT,2020,Q4,Elderly
186893001,18689300,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"1 DOSAGE FORM, QD",,,,,,,,1.0,DF,TABLET,QD,2020,Q4,Diarrhoea,,2020,Q4,1,I,20201019.0,20201030.0,20201231,20201231,PER,GB-MHRA-TPP25163780C4486669YC1603109364216,GB-LUPIN PHARMACEUTICALS INC.-2020-08433,LUPIN,,54.0,YR,,F,Y,81.0,KG,20201231.0,,CN,NL,GB,2020,Q4,Adult
